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Abstract
Meta-analysis is now commonly used in medical research. However there are statis-
tical issues relating to the subject that require investigation and some are considered
here, from both a methodological and a practical perspective.
Each of the fixed effect and the random effects models for meta-analysis are
based on certain assumptions and the validity of these is investigated. A formal test of
the homogeneity assumption made in the lixed effect model may be performed. Since
the test has low power, simulation was used to investigate the power under various
conditions. The random effects model incorporates a between-study component of
variance into the model. A likelihood based method was used to obtain a confidence
interval for this variance and also to provide an interval for the overall treatment
effect which takes into account the fact that the between-study variance is estimated,
rather than assuming it to be known.
In order to obtain confidence intervals for the treatment effect for both the
fixed effect and the random effects models, distributional assumptions of normality
are usually made. Such assumptions may be checked using q-q plots of the residu-
als obtained for each trial in the meta-analysis. In both meta-analysis models it is
assumed that the weight allocated to each study is known, when in fact it must be
estimated from the data. The effect of estimating the weights on the overall treat-
ment effect estimate, its confidence intervals, the between-study variance estimate
and the test statistic for homogeneity, is investigated by both analytic and simulation
methods.
It is shown how meta-analysis methods may be used to analyse multicentre
trials of a paired cluster randomised design. Meta-analysis techniques are found to
be preferable to previously published methods specifically developed for the analysis
of such designs, which produce biased and potentially misleading results when a large
treatment effect is present.
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1 Existing Statistical Methods in Meta-Analysis
Chapter 1 provides an introduction to standard meta-analysis techniques and sets the
scene for the subsequent research described in later chapters. Section 1.1 contains
a review of the current meta-analysis literature and provides general background
information. Section 1.2 outlines the structure and the aims of the thesis, while
Section 1.3 introduces two data sets which are used in the thesis as examples. The
standard meta-analysis methods are then introduced, with Section 1.4 considering the
issue of hypothesis testing and the next three sections that of estimation. Section 1.5
describes the different fixed effect methods of meta-analysis, Section 1.6 considers
the issue of heterogeneity and Section 1.7 outlines the random effects method of
meta-analysis. The question of how to display meta-analysis data is addressed in
Section 1.8 and finally, Section 1.9 contains a discussion and comparison of the two
different meta-analysis approaches, those of the fixed effect and the random effects
models.
1.1 Background
Meta-analysis can be defined as the statistical evaluation of a collection of analytic
results for the purpose of integrating the findings [1]. Researchers in psychology and
education were the first, in the 1970s, to define meta-analysis and begin to develop the
statistical methodology. Meta-analyses were, however, rare in the medical literature
until the early 1980s, but have proliferated in the last few years [2], although one of
the first medical meta-analyses was performed as far back as 1977 [3].
The aim of such an analysis is "to obtain information that cannot be ascer-
tamed from any of the studies alone" [4]. Peto discussed the importance of meta-
analysis, indicating that while moderate differences in mortality rates may be humanly
30
worthwhile, in many circumstances it is very difficult to detect a 10% - or even 20%
- reduction in risk of death [5]. Studies involving at least 1000 deaths may often be
required to detect such effects reliably. Lack of money, resources and time may limit
the size of a single trial, and so while it is generally emphasized that meta-analysis
should never be a substitute for the single, large well-designed study [6, 7, 8], it is
clear that the combining of results from different trials is a desirable and necessary
technique in the field of medical research. However, there is considerable debate as
to when and how the data should be combined in a formal manner.
In the past, clinicians have relied heavily on narrative reviews of literature
to define the current state of knowledge on any particular therapy. However, it is
common for similar trials on the same treatment to produce apparently conflicting
results. The situation becomes even more confused when these trials differ in terms
of the treatment regimen, treatment duration and patient characteristics. Hence,
interpretation of all the information available is difficult and the conclusions reached
will be highly subjective and may depend greatly on the perspective of the individual
reviewer. Indeed, such reviews have been criticised as being haphazard and biased
[91 . Meta-analysis can simply be thought of as a more structured approach to this
traditional literature review which attempts to produce an objective measure of the
overall benefit of the therapy being considered [10]. Nevertheless, there is still scope
for differing conclusions to be reached.
Chalmers et al. [11] carried out a study looking at the reproducibility of meta-
analysis and found that there were cases where meta-analyses on the same therapy
arrived at different conclusions. However, encouragement may be gained from the
fact that these observed disagreements were usually in terms of degree rather than
direction. A recent example in the literature has been the disagreement regarding
meta-analyses of the trials of serum cholesterol reduction [12]. Such discrepancies
may arise owing to different investigators including a different collection of studies in
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their meta-analysis because of, for example, different literature search strategies or
different inclusion criteria. A great deal of attention has been focused on the problem
of which studies to include in a meta-analysis and Naylor [13] holds the opinion that
"methodology is less important than determining which results are to be aggregated".
It is generally agreed that there is a need for scientific rigour throughout the whole
meta-analysis process, including the initial literature search [6, 14]. The use of a meta-
analysis protocol specifying all procedures, especially those related to the selection
of trials, has been advocated [6]. The possibility of "publication bias" [15], whereby
published studies differ systematically from unpublished ones is a widely recognised
problem in meta-analysis [14]. Hence, it is advised that efforts should be made to
minimise this potential bias by tracking down relevant unpublished material [101.
Furthermore, guidelines have been proposed which were designed to help to minimise
bias in meta-analyses [2]. Meta-analyses usually combine only the information directly
available from the literature and so are reliant on the validity of the analysis in the
original trials. Hence, it has recently been advocated that meta-analyses should be
based on the reanalysis of individual patient data, as this provides the least biased
and most reliable results [16].
Considerable research has also been carried out on how the quality of each
study included in a meta-analysis may iafiuence the results [17, 18, 19] and, fur-
thermore, of ways to incorporate this quality assessment into the statistical analysis
[17]. This may involve the use of a specific quality score threshold meaning that poor
quality studies are excluded, or the incorporation of the quality scores as weights
[20]. Greenland [211 however, describes quality scoring as "the most insidious form of
subjectivity masquerading as objectivity" and states that it can obscure important
sources of heterogeneity.
Thacker [22) was concerned that using sophisticated meta-analysis techniques
could lead to "unwarranted comfort with one's conclusions" if the initial data used is
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of a poor standard. However, O'Rourke [14] views meta-analysis as an ideal means
for uncovering and correcting inadequacies in previous research. It has even been
suggested [8] that all clinical trials should be started with the notion of meta-analysis
in mind in order to help future reviewers. In this way, evidence in the form of a
meta-analysis would keep accumulating as the results of each new study became
available [23]. Specifically, it has been shown that continuously updated literature
reviews, as exemplified by the Oxford Database of Perinatal Trials, can shorten the
time between research discoveries and clinical implementation of treatment strategies
[24]. This database has been extended to include results of meta-analyses and will be
updated as each relevant new trial is published. As well as the formation of databases,
there is also a move to generate user-friendly meta-analysis computer packages [25],
such as that produced by the Cochrane Collaboration [26]. These developments will
allow more meta-analyses to be carried out, but it should be emphasised that care and
thought should still go into each analysis and data should never be fed blindly into
a program to obtain a result [25]. There is also the need for emphasis in computer
software on the issue of heterogeneity and how it should be investigated [27].
Issues relating to the identification, selection and quality of trials for a meta-
analysis have been widely discussed in the literature and will not be pursued in this
thesis. Concentration is, instead, focused on the methodological issues relating to the
statistical methods used in meta-analysis. The majority of the work on meta-analysis
in the medical field has been with regards to randomised clinical trials, and this is
where the emphasis will lie here. There has been some work relating to epidemiological
studies [28, 29], but the results of such studies are even more problematic to combine
than those of clinical trials owing to the additional variations in design and the greater
scope for the existence of biases in individual studies.
Many of the statistical techniques applied to meta-analysis have been long
established for the purpose of combining various forms of experimental data. It is
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only much more recently that these methods have been applied to the problem of
combining the results of completely separate studies. For example, methodology has
been extracted from the work of Cochran in the 1950s [301 relating to the combination
of estimates from different experiments. The statistical aspect of meta-analysis can
be split into two components; hypothesis testing and estimation. In the case of
hypothesis testing, the null hypothesis is that all individual studies in the meta-
analysis have in truth zero treatment effect. Estimation deals with the calculation of
an overall treatment effect together with a relevant confidence interval. The issue of
estimation is the more problematic of the two and is therefore considered in greater
detail in this thesis. Most meta-analyses in the medical field have concentrated on
estimating and testing the common treatment effect, which is assumed to be equal
for all trials [31]. This is the fixed effect approach, which makes the assumption that
the true treatment effect is the same in all of the individual studies included in the
meta-analysis, that is the treatment effects are homogeneous. Several estimates have
been proposed and these are described in Section 1.5.
It is nearly always unreasonable to assume homogeneity in medical contexts,
and the combining of heterogeneous material is a commonly cited threat to the validity
of meta-analysis [32]. There has been concern about the practice of merely publishing
the numerical results of a fixed effect analysis, where "little attention is paid to
possible heterogeneity in effect sizes between trials" [31]. Thompson and Pocock [33]
stress that a single weighted average of the separate treatment effects is difficult to
interpret, as it is not clear as to what treatment or what population of patients it
applies. This interpretational problem means that clinicians may find it difficult to
apply the results of a meta-analysis to a practical situation, since they must decide
whether the results are generalisable to their own specific case [34]. On the other hand,
it has been argued [13] that since a broader range of patients and practices has been
incorporated into the data, the generalisability of the results from the combination of
several small trials may be superior to that of a single large trial. Hence, it is possible
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to argue that the results of a meta-analysis of small trials are more applicable to the
practice of medicine, in which the patients encountered are rarely homogeneous [32].
Various formal tests of heterogeneity exist (Section 1.6), but they lack power
and so a negative result should not be interpreted as implying that the treatment
effects are homogeneous [35]. Therefore, L'Abb et. al. [10] suggest that in the case
of a non-significant result, the investigators should "resort to informed judgement
and examine a graphic display of heterogeneity...". It has generally been stressed in
the literature that the investigation of heterogeneity and its possible causes are of the
utmost importance when carrying out a meta-analysis. An investigation of subgroups
of the studies can be carried out whereby further important questions, such as for
whom and under what circumstances the treatment works best, may be considered
[10]. In fact the ability to explore such questions can be viewed as a great advantage
of meta-analysis [36]. However, care should be taken when such an investigation of
heterogeneity is undertaken, since such investigations will tend to be post-hoc and
hence the problems are similar to those which occur when undertaking subgroup
analyses in a single clinical trial [27, 37]. Furthermore, it is generally not a simple
matter to isolate a single source of heterogeneity, and it may be that a number of
possibilities exist or there may be no explanation apparent at all.
DerSimonian and Laird [38] proposed an alternative to the fixed effect ap-
proach which does take account of the between-study variation in the true treatment
effects. This is known as the random effects model (Section 1.7), since it incorporates
a between-study component of variance. The random effects model allows for the
extra uncertainty in a set of heterogeneous data and produces an overall estimate of
treatment effect with a suitably widened confidence interval. However, the model has
been criticised as unrealistic for making the assumption that the trials included in the
meta-analysis are a random sample taken from some hypothetical universe of trials.
It has also been criticised as being an easy option and an excuse for not investigating
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the causes of heterogeneity fully [211.
As well as these standard approaches to meta-analysis, further methods have
recently been developed. The use of empirical Bayes methods for meta-analysis has
been proposed [31, 39], whereby shrunken estimates of the treatment effect for each
trial are obtained. These empirical Bayes estimates incorporate the information from
the full set of data in order to provide a more precise estimate for each trial. A fully
Bayesian approach has been adopted by other researchers. Carlin [40] and Skene
and Wakefield [41] based methods on three-stage hierarchical models and then used
Monte-Carlo type methods in order to obtain the solutions. Malec and Sedransk [421
used a prior distribution which reflected the belief that there are subsets of trials
in the data such that within each subset each trial produces a similar result. The
composition of these subsets was, however, considered to be uncertain. In addition,
Eddy, Hasselblad and Shachter [43] proposed a Bayesian approach to meta-analysis
which they called the "conlidence profile method".
An alternative development in meta-analysis has been the use of likelihood
theory. Goodman [44] produced plots of the "support curves" in order to obtain
the parameter values which received the most "support" from the available data.
Within this likelihood framework he proposed both a fixed effect and a random effects
model. A further likelihood based approach, for binary outcomes, proposed by van
Houwelingen et al. [45] uses the exact conditional distribution of each 2x2 table. The
likelihood approach to meta-analysis will be considered further in Chapter 2.
1.2 Aims and Objectives of the Thesis
Meta-analysis, as an objective way of reviewing research, is now firmly established
in the area of medical research. However, there is still much debate as to the best
statistical approach to the analysis and, furthermore, there are unresolved statistical
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problems relating to both the standard fixed effect and random effects models which
require investigation. This thesis addresses a number of these statistical issues from
both a methodological and a practical perspective.
The standard fixed effect and random effects models are each considered criti-
cally and are compared with each other and with more novel methods, using illustra-
tive practical examples. It is accepted that neither model forms a realistic basis for
an overall estimate of treatment effect, as the assumptions underlying each cannot be
met. The validity of certain of these assumptions are investigated and the robustness
to deviations from them are discussed.
A further aim of the research is to extend the use of meta-analysis methods
to other types of data. It is shown how meta-analysis models may be useful in the
analysis of multicentre trials where there is heterogeneity between centres. It is also
shown how the random effects meta-analysis model can be used to analyse a single
trial which has a paired cluster randomised design.
Although the basis of much of the research is methodological, the practical
implications of the findings are always discussed and practical examples used where
possible to illustrate the points. The main data set used to illustrate the analysis of a
paired cluster randomised design is also used to exemplify the techniques in practice
and in order to pursue a practical data set in greater detail. Two other data sets
are used regularly as examples and these are introduced in Section 1.3 and will be
referred to at various stages throughout the thesis.
The rest of the current Chapter reviews the present state of statistical methods
for meta-analysis in medical research. The standard methods for both testing and
estimation are described and numerical examples are used to compare the results
obtained. Chapter 2 extends the estimation ideas presented in the introduction,
focusing on the random effects model and particularly on the issue of the estimation
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of the between-study component of variance. An approximate likelihood method is
proposed which produces both a confidence interval for the between-study variance
and also a confidence interval for the overall treatment effect which takes into account
the fact that the between-study variance is estimated. This approximate method,
based on the marginal likelihood, is found to be very comparable to a method based
on the full likelihood for binary data under most circumstances.
Both the standard fixed effect model and random effects model must make
distributional assumptions of normality if confidence intervals are to be obtained.
Chapter 3 proposes the use of q-q plots of the residuals, obtained for each trial in
the meta-analysis, in order to investigate these assumptions. The issue of testing for
normality is also considered.
Chapter 4 considers the power of the test for heterogeneity, which is known
to be low. The test is investigated using simulation in an attempt to quantify the
power and to identify situations where the power will be particularly poor. The
standard test is also compared with an alternative, supposedly more powerful test.
Chapter 5 extends the simulation work of Chapter 4 to investigate the effect that
estimating the individual within-study variances has on the power of the test, since
the null distribution of the test statistic is conditional on the assumption that they
are known. The work is then developed to look at the effect of this estimation on
the overall fixed effect and random effects estimates and their confidence intervals.
Analytic work is carried out to try to obtain improved estimates which allow, at least
to some extent, for the estimation of the weights.
Chapters 6 and 7 deal with the analysis of paired cluster randomised trials.
Chapter 6 describes a more detailed analysis of a single data set, namely the British
family heart study, thus illustrating how the ideas and methods previously described
are useful in practice. It also provides an opportunity for an investigation into and
a discussion of sources of heterogeneity as well as a chance to consider the analy-
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sis of multiple endpoints in meta-analysis. Chapter 7 compares the meta-analysis
techniques, for both testing and estimation, with previously published methods for
paired cluster randomised trials. Meta-analysis estimation techniques were found to
be preferable to those developed specifically for the analysis of paired cluster ran-
domised designs, which were shown to produce biased results. Finally, the findings
are summarised and the overall conclusions drawn in Chapter 8.
13 Introduction to Data Sets
1.3.1 A meta-analysis of nine clinical trials looking at the effect of taking
diuretics during pregnancy
A nieta-analysis of nine randomised controlled clinical trials which was published
by Coffins, Yusuf and Peto [46] is used throughout the thesis as an example. One
aim of this meta-analysis was to look at the effect of diuretics during pregnancy on
the incidence of pre-eclampsia. The term pre-eclanipsia is used to describe the de-
velopment of hypertension with proteinuria or oedema, or both, during pregnancy.
Pre-eclampsia is known to increase the risk of a perinatal death, which is the out-
come of ultimate importance. Perinatal mortality is, however, a difficult outcome
to study in a clinical trial as only a few pregnancies end in a death and only a few
of these are associated with pre-eclanipsia [46]. Since perinatal death is such a rare
occurrence, all the single clinical trials looking at this issue have been too small to
detect any differences in mortality and so have tended to concentrate on the effect of
the treatment on pre-eclampsia. Even using a meta-analysis, there were still too few
deaths to achieve adequate power to detect any treatment effect. Hence, the outcome
generally used in this thesis, when looking at the diuretics trials data, is the presence
or absence of pre-eclampsia, although the number of stillbirths is considered in one
instance.
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Reliable data wez available for nine out of the eleven trials published on di-
uretics during pregnancy since 1960, and the meta-analysis of these nine trials lead
to a total sample size of 7 000 women and over 600 cases of pre-eclampsia (Table 1).
It can be seen that the number of women and the number of cases vary considerably
across the trials. Furthermore, the individual study odds ratios vary with six of the
trials showing a positive effect of diuretics, but the other three showing an adverse
effect. The variation in estimates of treatment effect is not surprising, since the trials
differed from each other in many respects. The entry criteria for patients varied, as
did the treatment regimens and the definition of pre-eclampsia. Some trials also had
greater problems with withdrawals and non-compliance.
Table 1: Results and odds ratios for the nine trials included in the meta-analysis
looking at the effects of diuretics on the occurrence of pre-eclampsia during pregnancy
Trial First author Cases of pre-eclampsia/Total number of patients
number of paper	 Treated	 Control	 Odds Ratio
1	 Weseley	 14/131(10.7%)
	
14/136(10.3%)	 1.04
2	 Flowers	 21/385(5.5%)
	
17/134(12.7%)	 0.40
3	 Menzies	 14/57(24.6%)	 24/48(50.0%)	 0.33
4	 Falls	 6/38(15.8%)	 18/40(45.0%)	 0.23
5	 Cuadros	 12/1011(1.2%)
	
35/760(4.6%)	 0.25
6	 Landesman 138/1370(10.1%)
	
175/1336(13.1%)	 0.74
7	 Krans	 15/506(3.0%)	 20/524(3.8%)	 0.77
8	 Tervila	 6/108(5.6%)	 2/103(1.9%)	 2.97
9	 Campbell	 65/153(42.5%)	 40/102(39.2%)	 1.14
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1.3.2 A multicentre trial looking at the treatment of mild hypertension
Meta-analysis methods can also be used in the analysis of multicentre clinical trials,
as each centre can be considered as being equivalent to a separate trial. Although
the protocol followed should be the same in each centre, meaning therefore that there
is less scope for clinical heterogeneity to exist, there may still be differences due to
geographical location and demographic characteristics of the patients. There may
also be differences in the centres' interpretation of the protocol, the additional care
given and the skill with which the treatment is administered. Hence, the possibil-
ity of between-centre differences should at least be considered in the analysis of a
multicentre trial.
The main aim of the Medical Research Council (MRC) mild hypertension trial
was to determine whether drug treatment of mild hypertension (phase V diastolic
pressure 90-109 mmHg) reduces the rates of stroke, of death due to hypertension and
of coronary events in men and women aged 35-64 years [47]. A subsidiary aim was
to compare the blood pressure in two groups of patients on active treatment, those
taking bendrofluazide and those taking propranolol. The outcome considered most
often in this thesis is the blood pressure reduction (both diastolic and systolic) over
the first year of the trial in the combined treatment group compared to the control
group, as this provides the opportunity to analyse a continuous outcome measure.
The measurement of treatment effect used is a difference in two means, that is the
difference between the mean reduction in blood pressure in the treatment group and
the mean reduction in blood pressure in the control group.
In total, 17 354 patients were randomly allocated at entry to the trial to take
bendrofluazide or propranolol or placebo tablets. The patients were recruited from
190 centres (mostly general practices) distributed throughout England, Scotland and
Wales. The original analysis [47J made no allowance for possible differences across
these centres, analysing the whole set of data without stratification for centre. All
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analyses are by 'intention to treat', that is patients were analysed as belonging to the
group to which they were randomised, irrespective of what treatment they actually
received.
The number of patients in each centre varied greatly, with some centres re-
cntiting less than 10 patients and others recruiting over 100. Most analyses had to
be carried out using 189, rather than 190, centres, since centre number 1 recruited
only one patient to the placebo group, meaning that a variance for the reduction in
blood pressure could not be calculated for that centre. The total number of strokes
observed was 169 and the total number of coronary events was 456. The overall av-
erage reduction in diastolic blood pressure over the first year in the treatment group
was 11.7mmHg, while for systolic blood pressure it was 23.7mmHg. The average
blood pressure was also reduced over the trial period in the placebo group. Diastolic
blood pressure was reduced on average by 6.6mmllg and systolic blood pressure by
13.3mmHg. This may be as a result of the so called 'placebo effect'.
1.4 Hypothesis Tests in Meta-Analysis
In a meta-analysis of k trials, a hypothesis test may be carried out in order to see
whether the k differences from a zero treatment effect observed are greater than would
be expected by chance. The null hypothesis is, therefore, that the true treatment effect
O in each trial i, i = 1,...,k,is equal tozero, that is H0 :O = ... = O, =0. Hence,
if there is sufficient evidence that any one of the individual trial estimates deviates
from zero, then the null hypothesis will be rejected.
if it is assumed, at least asymptotically, that the estimate of O has a normal
distribution with mean O and variance v then under the null hypothesis, this estimate
(, has a normal distribution with zero mean and variance v. When the interest
lies in the absolute values of the departure of the O from no treatment effect, an
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appropriate test is based on the squares of the individual observed treatment effects,
thus not accounting for the direction of the effect. Standardising these squared effects
by dividing by the variance v, means that = w,ô, where w = 1/va, has a x
distribution if O=O [121. Hence, assuming that all trials are independent, summing
over all k trials gives a test statistic for H0
E=1 w0k	
2	 (1)
which has a distribution under H0 . However, the use of the squares of the treatment
effects means that this test is 'general' in that it has no specific alternative hypothesis
against which it is particularly powerful [121. The general alternative hypothesis is
H1 : 0, 0 for at least one i, i = 1, ..., k. This test therefore lacks power against
certain alternative hypotheses of particular interest, such as Hi : 0 < 0 (or 0, > 0)
for all i.
One appropriate test which is powerful against these directional alternatives is
again based on the asymptotic normality of each trial estimate, but does account for
the direction of each estimate. For each study, if 0=0, w,0 has a normal distribution
with zero mean and variance given by 1/va = w, [4]. Hence, for the null hypothesis,
H0 : 01 = ... = 0 = 0, the sum w,è, has a normal distribution with zero mean
and variance E w [4]. Therefore the test statistic
:1 Wô
	
(2)
Wi
has a standard normal distribution under the null hypothesis [48]. Equivalently, the
square of the statistic given in (2) follows a x distribution [4, 12]. The rejection of
the null hypothesis can still, however, only be interpreted as being evidence that at
least one treatment effect is different from zero.
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The Mantel-Haenszel test is a particular example of a test, although not di-
rectly equivalent to (2), which is powerful against the directional alternative hypothe-
ses [49]. It can only be used in situations where the outcome measure is binary, unlike
test statistics (1) and (2) which may be used for both binary and continuous data.
The null hypothesis is, once more, that the treatment effect in every study is zero.
Then, under H0, and using the notation given in Table 2, for each trial i, i = 1, ...,
the number of observed events in the treatment group a, conditional on the total
number of patients in the treatment group a + b1 = n11 , has a hypergeometric distri-
bution with a mean given by n i m i/N and a variance of - 1)
where N = n11 + n 2 , m11 = a, + cj and m12 = b, + d1 (Table 2). Furthermore, since
in a meta-analysis, the strata are k independent trials, the total observed number of
events	 I a1 , simply has a mean of 	 E(a) and a variance of	 var(a1). The
variance of the sum of the differences between the observed and the expected number
of events E.1 (a1 - E(a)) is therefore equal to the sum of the individual variances
of the (a 1 - E(a)) terms [50]. Hence, the test statistic is given by
I
- E(a1))]2
L.i=1 var(a,)
which, it may be shown, has an asymptotic x distribution.
A continuity correction for (3) may be necessary, particularly when the num-
bers involved are small and hence the test becomes
[I E(a - E(aj) _0.5]2 (4)
L.s;1 var(a1)
A test which is identical to the Mantel-Haenszel test, but which uses different
notation, is known as Peto's test [51]. Peto considers the differences between the
observed O and the expected E number of events in the treatment group. The
(3)
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Table 2: Notation for the frequency table of the results of the i study from which
the odds ratio is calculated
Number of
	 Event	 Total
patients	 Yes	 No
Treatment	 a,	 a, + b, =
Group
Control	 c	 d	 Cj + d, n2
Total	 a + Cj = rn, 1 b + d = rn,2
	N
sum of these differences is squared and divided by the total variance under the null
hypothesis V, and hence the statistic is written,
- E)]2
TI
L=i t
However, by noting that 0, = a, E = n i rn i /N and V =	 - 1)
it can be seen that this test is exactly the same as the Mantel-Haenszel test.
Examples which illustrate the use of the above tests are presented in Sec-
tion 1.5.5, after the standard methods of estimation in meta-analysis have been de-
scribed.
1.5 Fixed Effect Methods
The principle for estimating an overall treatment effect is that the observed treatment
effect within each trial should be averaged over all trials [36]. In order to carry
out such a procedure, however, assumptions are required. Initially the main issue
in the fixed effect approach, where homogeneity of treatment effects across studies,
01 = 02 = ... = 0k = 0, is assumed, is how to weight the individual trial estimates.
(5)
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The general idea is to give the greatest weight to those studies with the most precise
individual estimates Ô, = 1, .., k, and then the weighted average, given by Woolf
[52], takes the general form,
o
	
(6)
Wi
where w is the weight associated with trial i. If each O is an estimate of a common
0, then the expected value of the weighted average, assuming that the weights are
fixed constants (although the effects of relaxing this assumption will be considered in
Chapter 5) will be,
	
' °'E(O1 ) = 0'	 = 0	 (7)
This means that any choice of w, i = 1, ..., k, will lead to an unbiased estimate of the
true treatment effect. However, the most precise estimate of the overall treatment
effect 0, that is the one with the minimum variance, is obtained by calculating the
weighted average (6) and taking the weight for the study to be the inverse of the
variance v, that is w= 1/v1
 [53].
The general estimate given in (6) may be applied to various outcome measures.
For example, the difference in means between a treatment and a control group could
be the measure used if a continuous outcome measure were to be analysed. However,
the odds ratio is used here as a convenient measure to consider, as a comparison
may then be made of several estimation methods. Four methods of estimating an
overall treatment effect are now described in Sections 1.5.1 to 1.5.4. These methods,
together with the hypothesis tests described in Section 1.4, are then illustrated with
an example in Section 1.5.5.
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1.5.1 Inverse-variance method
It follows, that by weighting according to the inverse of the variance, larger trials
which have estimates with smaller variances are given most weight, while small studies
with large variances are given less weight. It is actually the logarithm of the odds
ratio that is taken as 0 here, since such a transformation improves the normality
of the distribution of estimated treatment effects. Hence, taking the log odds ratio
ln(ad/bcj) (Table 2) as Ô1 , the variance v can then be estimated by (1/a1 ) + (1/b1 ) +
(1/ce) + (1/d) [50].
Furthermore, assuming that Ô 1 is approximately distributed as N(0, v) and
that the w,=l/v1 are known, then the variance of the overall log odds ratio is 1/E1 w1.
This allows a 95% confidence interval for the estimate to be obtained,
Oj ± l.96i/var(,)	 (8)
The estimate of the overall odds ratio and its corresponding conildence interval may
then be found by exponentiating the relevant values calculated for the log odds ratio.
1.5.2 Mantel-Haenszel method
The Mantel-Haenszel estimate [49] is well established and much used for the purpose
of combining information across a set of 2x2 tables. The result can be used in the
context of a meta-analysis by considering each study as a separate stratwn producing
an individual estimate of the odds ratio a2 dj/b1 cj. A weighted average is again used,
but the weight w in stratum i is now taken to be bc/N, (Table 2). These weights
are approximately inversely proportional to the variance of the log odds ratio under
the condition that the stratum-specific odds ratios are near unity [53], thus implying
that a,d1 = b14. By substituting the relevant values, ö,=ad/bcj and w, = b1c/N1,
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into the general formula (6), the overall Mantel-Haenszel estimate of the odds ratio
is obtained:
dRMH - E= ad,/N
-	
b1c/N	
(9)
Robins, Breslow and Greenland [54] obtained an approximation to the variance of
the logarithm of the Mantel-Haenszel estimate. By letting P = (a1 + d)/N, Q =
(b + cj)/N, Rj = ad1 /N and S = bcj/N, the variance is given by the formula,
P1 R1	 >. 1 (P1S + QR) E1 Q1Svar(logdRMH ) = ________ ____________ _______Pq)2 + 2
	 Ri E=1 S + 2 (E . 1 S1)2	
(10)
This variance may then be used to calculate the confidence interval for the overall
odds ratio in a similar way to that shown in (8).
1.5.3 Peto method
Peto's method [5, 51], which is the estimation procedure related to the Peto test
described in Section 1.4, produces an approximate estimate of the overall odds ratio
through a comparison of the number of events observed with the number expected
under the null hypothesis of no treatment effect in each particular trial. For each
trial the observed minus the expected number of events (O - E) is calculated, where
0, = a, and E, = n1i m1i/N (Table 2). Peto's argument [5] for using this measure is
that if there were no treatment effect, then (O —E1 ) for each trial would have an equal
chance of being either negative or positive, and hence the total of all the (O - E1)
would be close to zero. However, if a beneficial treatment effect were present then the
(O - E1 ) terms would tend to be negative (since 0, would tend to be less than E)
and, although this trend may not be noticeable in individual studies, it may stand
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out when the total is calculated. Furthermore, by dividing (O - E,) by its variance,
a good approximation to the log odds ratio results, providing the odds ratio is not
too far away from unity [55]. This stems from the fact that such an approximation is
the first Newton-Raphson step from zero towards the maximum likelihood estimate
[51, 56] and in general a parameter may be estimated by Z/V1 , where Z2 is the
efficient score and V is Fisher's information [4]. In this specific situation, (O - E,)
is the efficient score statistic for the log odds ratio and its variance V, given by
= - 1) (Table 2), is Fisher's information [4]. The overall log
odds ratio can then be estimated by simply adding up the differences (O - E1 ) and
dividing the resulting total by the sum of the individual variances , to give
	
logdRp -	 - E1)
	
-	
(11)
It can also be shown that by taking O1 equal to (O - Ej/V1 and w equal to
be V = 1/var(Ô) and substituting into the formula for the general weighted mean
(6), the same overall estimate as shown in equation (11) is obtained. The variance
of this estimator is, therefore, again given by 1/E w, which in this case is equal
to 1/E . A confidence interval may be calculated in the usual way using this
variance term.
1.5.4 Logistic regression
Logistic regression may be used to carry out a meta-analysis where the outcome
measure is an odds ratio [28, 57]. A variable representing 'trial' is treated as a factor
with k levels, so that each level of the factor corresponds to an individual trial in the
meta-analysis. After including such a factor in the model, together with a second
factored variable with two levels representing treatment group, the required log odds
ratio of treated patients compared to control patients is obtained. The log odds
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ratio of interest is then the regression coefficient relating to the variable representing
treatment group. In this model, it is again the case that results from larger trials are
given greater weight in estimating the overall treatment effect than those from smaller
trials, but the weighting is implicit in the model fitting procedure. In fact, logistic
regression is asymptotically equivalent to the 'inverse-variance' method for log odds
ratios. Logistic regression becomes advantageous, however, when it is necessary to
adjust for additional covariates while still looking at an overall treatment effect. The
confidence interval can easily be obtained using the variance of the estimate of the
overall log odds ratio. 	 .'
/	
,
1.5.5 Example
The diuretics trials meta-analysis (Section 1.3.1) is used as an example data set to
compare the four methods of estimation described in the previous sections. Further-
more, the 'general' and 'directional' tests and the Mantel-Haenszel test described in
Section 1.4 are also used to analyse these data and the results of the tests compared.
Considering the issue of testing first, the odds ratio ad1/bc1 or the relative
risk (RR) a1 n 2 /cn 1 are both possible measurements of treatment effect. Both are
considered here and hence the null hypothesis is that the odds ratio (or relative risk) is
1 in each study. Equivalently, since O is taken as the log odds ratio in practice, this is
a test of the null hypothesis that the log odds ratio (or log relative risk) is zero in each
study. It also follows that the weights w = 1/var(ôj) are taken as the reciprocal of the
variance of the log odds ratio, var(logdR) = (1/a 1 ) + (1/b) + (1/ci ) + (1/d), or the
reciprocal of the variance of the log relative risk, var(logFiR) = (b1/a1n1i)+(d/cjn12).
Since no assumptions are made, in any test, regarding the distribution of the
different treatment effects under the alternative hypothesis H1 , the tests are always
valid for the null hypothesis H0 : = ... = 0, = 0. However, they do not test the null
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Table 3: Test results for the diuretics trials data for the null hypothesis that there is
no treatment effect in any of the trials
Test	 Outcome Test statistic
	 Degrees of
	
p-value
measure	 observed	 freedom for x2	 '1
General	 logOR	 47.11	 9	 <0.001
General	 logR.R	 45.90	 9	 <0.001
Specific	 logOR	 19.85	 1	 <0.001
Specific	 logRR	 17.28	 1	 <0.001
Mantel-Haenszel	 21.63	 1	 <0.001
OR=odds ratio
RR=relative risk
hypothesis that the overall treatment effect is zero. In order to test H0 : 0 = 0, the
assumption of homogeneity of the treatment effects must hold, and only then may
the alternative hypothesis be defined as H1 : 0 0.
All tests carried out gave highly significant test statistics (Table 3), thus pro-
viding evidence against the null hypothesis. The tests using relative risk instead of
odds ratio produced the same conclusions with the test statistic in each case being
slightly smaller. The results indicate that there is strong evidence in the diuretics
trials that at least one trial has a log odds ratio which is different from zero. Hence,
the conclusions to be drawn regarding a meta-analysis from these tests are rather
limited and so it can be seen why it is usually desirable to produce an estimate of an
overall treatment effect.
The inverse-variance estimate, Mantel-Haenszel estimate and the Peto esti-
mate are easily calculated, but computer software is required to carry out logistic re-
gression. Hence, the statistical modelling package GLIM was used in order to obtain
the logistic regression results [58]. For each of the 18 (9 trials x 2 treatment groups)
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subgroups, the number of events of pre-eclampsia (r) was entered into the program,
together with the number of patients (n). The dependent variable was therefore r, the
error structure binomial with denominator n, and the link was logit. Factor variables
were created for trial (levels 1-9) and for treatment group (1=control, 2=treatment).
An additive model was then fitted induding both trial and treatment group variables
so that the estimate of overall treatment effect was obtained.
Table 4: Estimates of the overall odds ratio and its confidence interval for the diuretics
trials data from the four different fixed effect methods
Method	 Estimate of overall 95% C.I. for
odds ratio	 odds ratio
Inverse-variance	 0.67	 (0.56,0.80)
Mantel-Haenszel	 0.67	 (0.56,0.80)
Peto method	 0.66	 (0.56,0.79)
Logistic regression	 0.66	 (0.56,0.79)
The results from all four methods produce almost exactly the same estimate of
the overall odds ratio and almost the same 95% confidence interval (Table 4). This will
not be the case for every set of data, however, since some estimators perform better
than others under specific conditions. The inverse-variance method is generally to
be preferred as it is asymptotically unbiased and consistent for all values of 0 [591.
However, this method has a disadvantage in that it cannot be used if at least one of
the studies in the meta-analysis has an event rate of zero. Furthermore, if the sample
sizes are small, then the asymptotic normality assumptions will not hold [60, 61].
The same is true for small sample sizes with the Peto estimation method, where the
validity of the confidence interval relies on the approximate normality of the score
statistic under the null hypothesis of no overall treatment effect [40]. It has also been
observed that the Peto estimate can yield extremely biased results when applied to
sets of data where there is a large imbalance between the number of patients in the
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treatment group and the number in the control group and also when the odds ratio is
far from unity [55]. The Mantel-Haenszel estimate, in contrast, is robust when there
are small frequencies and it can cope easily with zero cells [50, 62]. It does become
unreliable, however, like the Peto method, when the true odds ratio is a long way from
unity, but also when there is severe heterogeneity, although it is reasonably robust to
moderate heterogeneity [62]. The confidence limits proposed for the Mantel-Haenszel
estimator are also approximations, but have been found to perform well, even when
the counts in individual strata are very small, provided the method does not break
down with too many zeros [61, 63]. A better alternative, when frequencies are small,
may be to use exact methods (Section 2.5) which are based on exact distribution
theory [61]. It should also be noted that the choice of method will be limited when
the outcome of interest is other than the odds ratio.
Although the consistency of the results in Table 4 might appear to suggest that
the estimate obtained is a reliable indication of the true treatment effect, the choice
between the different fixed effect estimates is not the real issue here. The problem is
whether a fixed effect model is appropriate for this set of data at all, or whether the
assumption of homogeneity is unrealistic.
1.6 Heterogeneity Across Studies
For the assumption of homogeneity to be valid, the assumption that 0. is equal to 0
for every study i (i=1,...,k) must be satisfied. If this condition does not hold then
heterogeneity is present. Due to the fact that in the majority of meta-analyses there
will be differences in study protocol, type of patient, and treatment duration and
regimen between the trials, it would not be surprising if each study were to have a
different underlying treatment effect. Hence, in practice, this clinical heterogeneity is
likely to lead to statistical heterogeneity and therefore the breaking of the assumption
underlying the fixed effect model.
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A formal test of heterogeneity [38J may be performed using a statistic which
is derived by considering the squared deviation of each study estimate from the true
overall mean, (O - 0)2, and then standardising by dividing by the study variance
v=1/w. Then assuming that the in1 are fixed, w1 (O - 0) 2 has a x12 distribution and
hence summing over all k studies produces a statistic w(i - 9)2 which has a
x distribution under the null hypothesis of homogeneity. However, the true value 0
is, of course, unknown and must be replaced by the weighted mean estimate O (6).
This means that 1 degree of freedom is lost from the null distribution and the actual
test statistic used is given by
= k	
- 0)2	 (12)
where 0i=E.1 w1 Oj/E.1 w, which is then compared to a xL distribution. It is
assumed in the calculation of Q that the weights are known, when in practice they
are estimated, and this issue is addressed in Chapter 5.
A non-significant result for the test of heterogeneity does not prove homogene-
ity, particularly since the test is not very powerful [35]. (The issue of power of the
test will be investigated further in Chapter 4.) Therefore, even when a non-significant
result is obtained, interpretation should still bear in mind the possibility of hetero-
geneity across the studies. In the example of the diuretics trials, however, it is clear
that heterogeneity exists, since calculation of the test statistic given in (12) produces
the value Q=27.27, which is highly significant (p < 0.001) when compared to the x
distribution.
Peto presents a "natural approximate chi-square test" of the homogeneity
assumption. The test is based on the use of the efficient statistic Z and Fisher's
information V as defined in Section 1.5.3, substituted into the formula for Q (12)
[4]. The statistic becomes simply the overall x test minus the x specific test and is
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given by
(Oi - E)2 [E=1(O - EI)J2	 13)
i=1
which has an approximate x2 distribution with k - 1 degrees of freedom, where
k* is the number of non-zero variances (k* is usually equal to k). In the diuretics
trials example, the results for this test agree with Q, with Qp being equal to 29.3
(p <0.001).
The results of the logistic regression, obtained from the fit of the model in
GLIM, also yield a test of heterogeneity by way of the deviance. The deviance is a
measure of the fit of the model, and so if a significant 'trial by group' interaction (or
equivalently heterogeneity) exists, there will be a lack of fit of the model, indicated
by a large deviance in comparison to a x2 distribution. Again in the diuretics trials
example, heterogeneity was found to be present since the deviance (29.4) indicated a
significant lack of fit (p <0.001). However, when small frequencies are present in the
data, caution in the interpretation of the deviance is required, since the approximation
to a x2 distribution may then be poor [58].
Thus, the results obtained from the fixed effect methods must be interpreted
cautiously in the case of the diuretics trials data, since the homogeneity assumption
on which they are founded is obviously not valid. Hence, the fixed effect estimates
are of little value by themselves and in such circumstances should certainly not be
presented without any reference to the heterogeneity which is present.
If heterogeneity is found to be present in a meta-analysis, which is common
in medical research situations, then there are two options available. The first, which
is generally to be preferred, is to look at the reasons behind the heterogeneity. This
may involve consideration of the various characteristics of the original studies and an
investigation of trial and patient differences [55, 64, 65]. It may thus be possible to
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explain and, therefore, effectively to eliminate heterogeneity from the meta-analysis
by identifying homogeneous subgroups of trials. However, it should be noted that
such procedures are always post-hoc and must therefore be carried out with care
[12]. If not all the variation can be explained in this way, or if an investigation is
impossible due to the required data being unavailable, then an alternative approach is
to incorporate the heterogeneity into the meta-analysis model by, for example, using
the so called random effects model presented in the next section.
1.7 The Random Effects Method of Meta-Analysis
A standard random effects method based on the calculation of a moment estimator
of the between-study variance is described in Section 1.7.1. An example is presented
in Section 1.7.2 where the random effects results are compared with the fixed effect
results, while Section 1.7.3 contains a discussion.
1.7.1 Standard random effects method
In situations where there is heterogeneity present, the random effects method for
meta-analysis provides a way of incorporating between-study variability into the
overall estimate. However, assumptions different from that of homogeneity must
be made instead, and these are that the true treatment effect of each individual trial
O, i = 1, ..., k, is distributed with mean 0 and a between-study variance o. This
implies that trials included in the meta-analysis are a random sample from an overall
population of all such trials. Then each separate trial estimate 0, i = 1, ..., k, is as-
sumed to have a distribution with mean 0 and variance v. By setting up this model,
an estimate of the between-study variance may be obtained, which can then be used
in the calculation of a random effects estimate of the overall treatment effect 0.
One formula used to calculate ô [38J, similar to that used in the random
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effects one-way analysis of variance, is based on the Q statistic of heterogeneity (Sec-
tion 1.6) and is derived by consideration of the expectation of Q (12). Rewriting Q
as E.1 w(Ô - 9)2 - (E_ w)(à - 0)2 in order that the expectation may be easily
obtained gives
E(Q) =	 wvar(ôj) - (E...1 w)var(Ô)	 (14)
= (k-1)+4 ( E=1w—	 \)	 (15)
L4=1 W /
Then using the method of moments, equating Q with the expected value of Q (15),
and rearranging the resulting equation, an estimate of the between-study variance is
obtained:
2...	 Q—(k-1)
ç— k	 2	 ( )
L1=i i
L.=i s -
L=1 t
However, when Q is less than (k - 1), the estimate of 4 will be less than zero. Since
a variance cannot take a negative value, the actual estimate of 4 used in practice is
max{O, b}	 (17)
where & is given in (16).
The unbiased random effects estimate of 0, â, say, can then be found by
calculating a weighted average of the individual estimates, as in formula (6), but with
new weights w7. These weights incorporate the additional component of variance and
are given by 1/(v +4). Hence, once more assuming that the weights, and therefore
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4, are known (the issue of allowing for the estimation of 4 is considered in Chapter
2), the random effects estimate of the overall treatment effect is given by
- E=1w:ô
-k	 *
L11=i i
To obtain confidence intervals it is necessary to make further assumptions
about the form of the distribution of the treatment effects and the random effects,
that is Ô1 N(O, v1 ) and O N(O, 4) . (Chapter 3 addresses the problem of checking
these distributional assumptions). The approximate variance of Or is then given by
1
var(Or) = ckLjs=Ii
and hence confidence intervals for the log odds ratio may be obtained.
1.7.2 Example
The random effects estimate was calculated for the meta-analysis of the nine diuret-
ics trials and the results were compared with those from the fixed effect methods
(Section 1.5.5).
The random effects estimate of the overall odds ratio is smaller than the estimates
obtained using any of the fixed effect methods (Table 4). Table 5 compares the results
from the random effects method with those from the fixed effect inverse-variance
method, which is in fact the random effects model where è is taken equal to zero.
It can also be seen from the comparison of results on the odds ratio scale that the
95% confidence interval for the random effects estimate is substantially wider than
that for the fixed effect estimate.
(18)
(19)
The estimate of 0.230 for the between-study variance indicates that the van-
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Table 5: Comparison of the estimates of the overall treatment effect and its confidence
interval from the inverse-variance fixed effect and random effects methods for the
diuretics trials data
Method	 Estimate of	 Estimate of 95% C.!.
between-study variance overall OR	 for e°
____________________ ___________________	
(e0)	 _________
Fixed (inverse-variance) 	 0	 0.67	 (0.56,0.80)
Random	 0.230	 0.60	 (0.40,0.89)
or
ability between studies is large in comparison to the variation within individual stud-
ies. There are only two of the nine trials (trials 4 and 8) which have an individual
variance v greater than this between-study variance.
1.7.3 Discussion
The wider confidence interval associated with the random effects estimate is due to the
extra variability introduced into the model by the between-study variance. In order
to see why the random effects estimate is lower than the fixed effect estimate for these
data, it is necessary to consider the allocation of weight. The simplest way to achieve
this is to look at the percentage weight, defined as (w/ E..1 w) x 100% for trial i,
given to each of the individual estimates under the two models (Table 6). Including
a between-study component of variance in the model has the effect of levelling out
the weights. In the fixed effect method, where oj=0, the trial with the smallest
variance, that is the most precise study, is given over half of the weight (54.6%).
The next largest allocation, which is to trial 9, is much less at only 11.8%. Trial 8, in
which only a very small number of events occurred, is given hardly any weight (1.2%).
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These weights clearly contrast with those obtained from the random effects method.
The additional variation means that, although trial 6 still receives the largest amount
of weight, its share has been considerably reduced from 54.6% to 17.0%. The next
largest weight is now not much less, being 13.9%, and all the other trials have been
given the extra weight which has been taken away from trial 6. This means that
the overall estimate from the random effects method is not so dominated by just one
single trial, as it is in the fixed effect case. The fact that trial 6 has a odds ratio higher
than the overall fixed effect estimate and that it loses weight in the random effects
method pulls the overall estimate down. Also, this weight is redistributed primarily
between trials 1, 2, 3, 5, and 7, three of which have odds ratios much lower than the
fixed effect estimate, and this further explains why the estimate is lowered.
Table 6: Comparison of the percentage weights allocated to each of the diuretics trials
in the fixed effect and the random effects methods
Trial	 Percentage of total weight
(w/ E w) x 100
Fixed effect J_Random effects
6	 54.6	 17.0
7	 6.6	 11.8
8	 1.2	 4.5
9	 11.8	 13.9
w2 =weight allocated to study i, i = 1, ..., k
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The random effects estimate, like the fixed effect estimate, should not simply
be quoted without any questions regarding the validity of the model. The between-
study variance has been estimated and should, therefore, ideally have its own measure
of precision. The fact that in this example, as in many meta-analyses, 4 has only
been estimated from a small number of trials means that the estimate will not be
very precise. Furthermore, in calculating the confidence interval for 9, it has been
assumed that the value of the between-study variance is known rather than estimated.
This means that although the random effects confidence intervals, based on taking
the variance as 1/E w under the assumption of normality, are wider than the
fixed effect intervals, they are still likely to be too narrow, since they do not take into
account the variability in	 These points are pursued further in Chapter 2.
A further point which has already been briefly mentioned, which relates to both
the random effects and the fixed effect methods, is that they each assume that the
individual study variances v are known, whereas in reality they must be estimated
from the data. This problem was identified by DerSimonian and Laird [38] as an
aspect of their method which required further investigation and they suggested that
it may be preferable to use alternative estimators of the v to that proposed. The
problem of estimating weights is considered later in the thesis (Chapter 5).
1.8 Displays in Meta-Analysis
The presentation of a statistical analysis is generally enhanced by graphical displays
of the data. Meta-analysis is no exception in this respect, as a clear idea of all the
trial estimates in relation to each other is required. Displays can also be useful when
interpreting the amount of heterogeneity contained in a particular set of data. The
amount of heterogeneity in any given meta-analysis can be tested using the statistic Q
(Section 1.6). An estimate of the between-study variance can also be obtained which
is an indication of the amount of heterogeneity present (Section 1.7.1). However,
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what the value of the between-study variance means in terms of heterogeneity can be
difficult to comprehend. This section reviews ways in which graphical displays and
plots can be used when presenting a meta-analysis.
The standard way to represent a meta-analysis data set in a diagrammatic way
is to present each individual trial estimate of treatment effect ö,, together with its
95% confidence interval on a single plot [33]. The overall fixed effect estimate Ô 1 and
its 95% confidence interval are usually plotted as well (Figure 1). From such a plot it
can be seen whether there is much variation in the individual trial estimates , and,
by looking at the overlap of the confidence intervals, how compatible they are with
each other. Hence, some grasp of the amount of heterogeneity present in the data can
be gained from these simple displays. These diagrams also provide information as
to which trials produce a statistically significant treatment effect and which do not.
Furthermore, it may be seen that the confidence interval for the overall estimate of
treatment effect is much narrower than those of the individual trial estimates (Figure
1), indicating an increase in precision.
When odds ratios are the outcome measurement of interest, then it has been
suggested by Galbraith [66] that, for two reasons, a display on the log scale is to
be preferred to that on the linear scale. Firstly, the confidence intervals will be
symmetrical, rather than asymmetrical as on the linear scale, and secondly, a unit
change in the log odds ratio corresponds to a multiplication of the odds ratio by the
same factor at any point on the scale. This means that 0.5 and 2.0, for example,
are equidistant from 1. Also, the asymmetrical intervals on the linear scale may
not always fit onto a conveniently scaled diagram if the precision of the varies
considerably. Trials are often ordered chronologically [46] on these diagrams, but
may also be ordered by quality [361 or grouped such that trials with similar designs
or characteristics are displayed together [67, 68].
However, regardless of the outcome measure or scale used, a disadvantage of
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Figure 1: Standard meta-analysis diagram showing each md vidual trial estimate of
treatment effect together with its 95% C.I. for the diuretics trials data
trial
number
-3 -2.5 -2 -1.5 -1 -0.5 0	 0.5	 1	 1.5	 2	 2.5	 3
log odds ratio
this type of display has been identified. Trials which have more observations or events,
thus providing more reliable information to the meta-analysis, have the narrowest
confidence intervals. The visual impression of the plots can therefore be misleading
in that the trials which are least informative tend to dominate the diagram as they
have the widest confidence intervals. In order to get over this problem, a simple
improvement to the diagram may be to order the trials with the most informative
at the top and the least informative at the bottom, that is in increasing width of
confidence interval (Figure 2).
Alternatively, the idea of representing the percentage weight allocated to each
trial in the fixed effect model (or random effects model) by means of squares drawn
on the individual confidence interval has also been used [64, 69, 70, J41 (Figure 3).
The squares are such that their areas are proportional to the weight and so the
larger the square, the more informative the trial. It may clearly be seen that in the
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Figure 2: Standard meta-analysis diagram for the diuretics trials data with trials
ranked from the most to the least informative
trial
number
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diuretics trials meta-analysis, a single trial takes most of the weight in the fixed effect
model (Figure 3). The importance of looking at percentage weights has already been
discussed (Section 1.7). Ways of incorporating this information into the displays is
therefore to be encouraged.
A further adaption of the standard meta-analysis diagram suggested by Lau et
al. [23] is to display a 'cumulative' meta-analysis, whereby a new overall estimate and
new confidence interval is plotted as each new trial result is added in chronological
order. This may be done using a fixed effect (Figure 4) or a random effects method
(Figure 5). Typically the picture obtained will be of a series of increasingly narrow
confidence intervals centring around an increasingly stable point estimate [36]. These
plots, therefore, provide a continuous picture of the state of knowledge over the period
in which the full set of trials were being carried out. It can clearly be seen at which
stage the large trial (number 6) was incorporated into the analysis as there is a
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Figure 3: Standard meta analysis diagram where the squares have areas proportional
to the amount of information contributed to the fixed effect estimate
trial
number
-3 -2.5 -2 -1.5 -1 -0.5 0	 0.5	 1	 1.5	 2 2.5	 3
log odds ratio
substantial decrease in the confidence interval on the fixed effect plot (Figure 4)
at this point. The fact, however, that implicit multiple significance tests are being
carried out here, that is one for each study added, means that adjustment of the
p-values may be required, or alternatively that the display should not be interpreted
formally.
Although useful as an initial look at the data to be included in a meta-analysis,
these standard meta-analysis diagrams are not particularly informative for the pur-
pose of investigating heterogeneity [27]. A diagram proposed by Galbraith [66] is an
improvement in this respect and is discussed in Section 3.4.2.
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Figure 4: Cumulative fixed effect meta-analysis diagram for the diuretics trials data
year (tr al)
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log odds ratio
Figure 5: Cumulative random effects meta-analysis diagram for the diuretics trials
data
year (tria')
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1.9 Comparison of the Fixed Effect and the Random Effects
Methods of Meta-Analysis
To complete Chapter 1, the interpretation of the fixed effect and random effects
methods are discussed and differing views compared.
In the case where a group of studies have very similar protocols and study
populations and in the absence of any statistical heterogeneity, it is generally agreed
that the fixed effect estimate of an overall treatment effect is a valid way of sum-
marising the data [36]. However, there is less consensus as to the best approach when
clinical and statistical heterogeneity is present in a meta-analysis. Furthermore, there
continues to be disagreement as to the interpretation of the fixed effect results and
the value and appropriateness of the random effects model. Many researchers have
advocated that the best approach to a meta-analysis, when heterogeneity exists, is to
carry a full investigation of the sources of heterogeneity [21, 27].
The issue of hypothesis testing (Section 1.4) is much less controversial than
that of the estimation of the overall treatment effect, since fewer assumptions are re-
quired. The approach to meta-analysis advocated by Peto [5] uses the idea of hypoth-
esis testing rather than estimation. He favours the (0— E) methods (Section 1.4 and
1.5.3) because "one can get all the asymptotic efficiency of logistic regression,...while
avoiding the assumption that the relative risk is the same in each trial" and therefore
prefers to term this approach "assumption free". The overall log odds ratio obtained
using Peto's method is described as the "typical" log odds ratio, suggesting that it
is an average value of the treatment effect derived from a selection of true fixed ef-
fect values. Peto then suggests the use of three standard deviations away from zero
as being the reference standard for evidence of a treatment difference [ 51 . Hence,
as long as it is remembered that the null hypothesis being tested is merely that of
each treatment effect being equal to zero, then the approach outlined above is valid.
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However, Peto's approach to estimation is far less clear and no specific exposition of
these methods has been provided in the literature.
Various researchers [35, 72] have compared the fixed effect and the random
effects approaches. Berlin et al. [35], when looking at the results of 22 meta-analyses,
claimed that both methods often yield similar results, certainly at a qualitative (sta-
tistically signfficant versus non-significant) level. However, the variance estimates of
the overall treatment effect did differ, with the random effects analysis being slightly
more conservative. Although in the examples considered few qualitative differences
existed, it should be noted that this generalisation will not hold for all sets of meta-
analysis data. If the random effects model is more conservative, there will be cases
when the two methods will produce different results at a qualitative level too; that
is the fixed effect approach will produce a significant result and the random effects
method a non-significant one. Berlin et al. [35] conclude from the study that the
choice of methods may, therefore, depend on other more philosophical, rather than
statistical, considerations. The random effects model has been criticised as being
"a wholly wrong approach" [731, because it is answering the wrong and irrelevant
question of "what would happen if we chose another treatment at random from the
universe of treatments that we could choose and another population at random from
the universe of populations?" The fixed effect model, on the other hand, it is claimed
is addressing the question of interest [73]. Others express more doubt in the fixed
effect model in the presence of heterogeneity [33, 72, 74].
When estimating the overall treatment effect, all fixed effect methods are mak-
ing the same assumption of underlying homogeneity of the treatment effects, since
the weights only take account of within-study variation and ignore any between-study
variation. Rather than the point estimate being incorrect, the main problem with the
fixed effect methods when heterogeneity is present, is that the standard error is too
small thus meaning that the confidence interval is artificially narrow [12, 35, 38, 45].
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The results of a simulation study [75] considering the issue of between-centre vari-
ance in a multicentre trial can be directly applied to meta-analysis since the data is
simulated in exactly the same way in both cases using the same model. These results
showed that the between-centre (or between-study) variation leads to the confidence
intervals being inappropriately narrow. Peto has suggested the use of 99% instead of
95% confidence intervals [731, implying that greater evidence is required against the
null hypothesis in a meta-analysis than a single clinical trial. However, 99% and 95%
confidence intervals have different meanings and both will be spuriously narrow if cal-
culated from a fixed effect model. A 99% confidence interval cannot simply replace a
95% confidence interval and reflect extra variation.
It is generally accepted that a thorough investigation of heterogeneity is re-
quired in order to attempt to explain the variation in the treatment effects. In the
opinion of Greenland and Salvan [55], the choice between the two approaches is en-
tirely secondary to the examination of inter-study heterogeneity. Indeed, Greenland
[21] is sceptical of the random effects model in that he holds the view that it can
conceal the fact that the overall estimate is a poor suimrnary of the data. Similarly,
Jenicek [65] believes that the analysis of heterogeneity should not be sacrificed in or-
der to obtain some 'average' value. Large meta-analyses by those who favour the fixed
effect approach [64, 69, 70] have also included an investigation of heterogeneity in the
form of separate subgroup analyses. However, residual heterogeneity may remain un-
explained, even after such an investigation, possibly because of some unmeasured or
unreported study characteristic [36]. In such situations the random effects model may
be useful, but should not be viewed as a panacea for any situation in which hetero-
geneity is large [36]. However, the random effects model does gives more appropriate
confidence intervals than the fixed effect model [35].
The random effects model is certainly far from ideal as a method for obtaining
an overall estimate of treatment effect. Firstly, because of the widely criticised and
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unrealistic assumption that the trials in a meta-analysis are a random sample from a
broader universe of trials, particularly when a specific form, usually normality, must
be attached to this distribution. Furthermore, since the random effects method gives
greater weight to smaller studies, the results may be emphasising poor evidence at
the expense of good [33]. The estimate of the between-study variance is usually
imprecise, being estimated from only a few trials, and is susceptible to bias [76] and
hence this bias could affect the overall estimates. The random effects analysis is,
therefore, probably best thought of as a check on the robustness of the conclusions
from the fixed effect method to the failure in the assumption of homogeneity [76].
This sensitivity analysis will be of particular value when the sources of heterogeneity
are intangible. Peto holds the view that the random effects approach can lead to
the over cautious interpretation of results leading to a treatment being withheld
from patients who would find it beneficial. However, if there is much between-study
variation, then there may be uncertainty as to whether the treatment is of benefit,
with different trials showing different results. If the random effects analysis indicates
that the conclusions of the fixed effect analysis are valid then there will be additional
cause for confidence in these results. If, however, the conclusions are different then
it is likely that further information is required and no firm clinical conclusions can
be drawn as to the benefit of the treatment. Dickerson and Berlin [36] state that the
choice of the research question is critical in meta-analysis and a fairly general clinical
question is often preferable to a very specific one, due to the heterogeneous nature of
studies.
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2 Extensions to the Standard Meta-Analysis
Methods
The estimation methods for meta-analyses described in Chapter 1 are all commonly
used standard techniques. However, none are completely satisfactory, especially in
the presence of significant clinical and statistical heterogeneity. Chapter 2 considers
extensions to these basic techniques and in particular addresses problems related to
the estimation of the between-study component of variance in a random effects model.
The fact, that in a random effects model, the between-study variance is as-
sumed to be known in the calculation of var() when in practice it must be estimated
from the data, means that the standard random effects confidence interval is still too
narrow. The initial sections of the chapter address this problem. Section 2.1 shows
how a graphical method can be used as a sensitivity analysis to check the robustness of
the estimate of the overall treatment effect to changes in the between-study variance.
Section 2.2 proposes a likelihood method which produces both a confidence interval
for the between-study variance and a confidence interval for the overall treatment
effect which takes account of the fact that the between-study variance is estimated.
Three practical examples are considered in Section 2.3 in order to illustrate this new
methodology and this section also includes a discussion of the use of the information
matrix to obtain approximate results from the likelihood model. Section 2.4 consid-
ers an alternative likelihood approach proposed by van Houwelingen, Zwindermann
and Stijnen [45], based on the full conditional likelihood for binary outcomes and
Section 2.5 shows how this method may be particularly useful when dealing with
meta-analyses which include trials which have small numbers of, or even zero, events.
Section 2.6 considers a Bayesian approach to meta-analysis, reviewing both empirical
Bayes and fully Bayesian methods. Section 2.7 compares a proposed alternative mo-
ment estimator of the between-study variance with the standard DerSimonian and
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Laird moment estimator (Section 1.7.1) and finally Section 2.8 contains a concluding
discussion for Chapter 2.
21 Sensitivity Analysis
In the standard random effects model (Section 1.7.1) it is assumed that the weights
are known and therefore, that the value of the between-study variance is known.
In practice must obviously be estimated from the data, but the method does not
take this imprecision into account when estimating 0. The fact that °1 is estimated
means that there is an interest, when carrying out a meta-analysis, in the robustness
of the estimate of the overall treatment effect to changes in the value of the between-
study variance. Such an investigation gives an idea of the effect that an imprecise
estimate of 4 may have on the estimate of treatment effect.
Section 2.1.1 explains the methods and uses an example to explain how a sensi-
tivity plot may be produced. Section 2.1.2 discusses the resulting plot and investigates
the reasons for the observed shape.
2.1.1 Methods
A plot of the estimate of 0 against the between-study variance 4 may be used as a
form of sensitivity analysis to assess how the estimate of the overall treatment effect
0 varies across values of 4. Thus, when 4=0, the estimate of the treatment effect
is simply that obtained from the fixed effect model using the inverse-variance method
(Section 1.5.1). As 4 increases, the distribution of the weight between the trials
in the meta-analysis becomes increasingly even. As 4 tends to infinity, the weights
tend to equality and the overall estimate, therefore, tends to a simple unweighted
average.
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Using simple plots of 0 against 4 it is not possible to show the complete range
of variation on a single graph. Hence, plots of the odds ratio against 4/(ô1 +4),
where & is the non-zero DerSimonian and Laird (D&L) moment estimate of the
between-study variance (Section 1.7.1) were used, In the context of the meta-analysis
of the diuretics trials (Section 1.3.1), the estimate of 4 is 0.23. The sensitivity
plot of the estimated odds ratio, which is actually e°, is therefore plotted against
x = 41(0.23 + 4) in Figure 6, so that x = 0 corresponds to 4=0, z = 0.5 to
4=0.23 (the D&L moment estimator) and x=1 to 4=oo, and the whole range of
4 is reduced to a finite scale. The choice of the moment estimate of 4 in the term
4/(ô + 4) is rather arbitrary, as any constant number, such as 1 for example,
could have been used and is, in fact, necessary in the situation where ô is zero. The
use of & does however mean that for â>0, the random effects estimate is always
situated in the centre of the plot, that is at 0.5 on a scale of 0 to 1. This ensures
that attention is always focused on the most important part of the plot, irrespective
of the numerical value of the random effects estimate.
The diuretics trials data have an overall odds ratio (Figure 6) which decreases
from the fixed effect estimate to a minimum (which happens to be close to the random
effects estimate) and then increases again until it reaches the 'equal weighting' value.
This type of pattern is not necessarily produced by these sensitivity plots, and the
shape of a plot for any particular set of data is not easily predicted. The behaviour,
particularly for large 4, tends to depend on the treatment effects in the smallest
trials.
2.1.2 Discussion
In order to explain the shape of the plot which emerged for the diuretics trials data,
the percentage weighting allocated to each trial was obtained for a range of values of
4. The main interest lies in the explanation of the minimum value and subsequent
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Figure 6: Sensitivity plot showing how the overall odds ratio varies with the between-
study variance (o) for the diuretics trials meta-analysis
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O.23=random effects estimate of between-study variance 4
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increase in overall odds ratio. Hence, weightings corresponding to values of ti be-
tween 0 and 1 were studied since this range includes the area of the plot where the
minimum occurs.
Trial number 8 (Table 7), which has a large individual odds ratio (OR=2.971)
but is the most imprecise trial, gets allocated increasing weight as 4 increases and
it is this that raises the overall estimate after the minimum value has been reached.
Trial 8 has the lowest initial weighting and is consequently the last whose weight
levels out. At a 4 value of approximately 0.5-0.6, the weightings for all the other
trials are approximately equal (Table 7), and hence the major effect on the change
in the overall odds ratio after this point must be that of trial 8 receiving increased
weight.
Before the minimum is reached, the main influence which leads to a decrease in
the estimate of the overall treatment effect is the rapid loss of weight of the largest trial
(trial 6), which has an individual estimate higher than the overall fixed effect estimate.
In the fixed effect estimate (4=0), trial 6 is allotted over half of the total weight,
while in the random effects estimate much of this weight has been redistributed to
the other trials. Four (numbers 2, 3, 4 and 5) out of the other seven trials which
receive this weight in the initial redistribution (i.e. all trials except trial 8) have low
individual odds ratios (Table 7) and this would appear to explain the reduction in
the overall estimate. Furthermore, it is interesting to note that the overall odds ratio
begins to increase again soon after the random effects estimate and at a value of 4
which is far from extreme. Hence, the most imprecise trial would appear to have
some influence on the random effects estimate of the overall treatment effect.
The sensitivity analysis was repeated with the small trial (trial 8) being ex-
cluded in order to see whether, indeed, the influence of this trial was important. This
second analysis did produce a quite substantially different estimate of the overall
odds ratio under the random effects model (Table 8). The estimate of the between-
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Odds
ratio
0.8	 0.9	 1.0
(0.78) (0.80)	 (0.81)
11.2	 11.2	 11.2
	
1.04
11.7	 11.7
	
11.6	 0.40
11.0	 11.0	 11.0	 0.33
9.8	 9.9	 10.0	 0.23
11.8	 11.7	 11.7	 0.25
13.2	 13.0	 12.8	 0.74
11.8	 11.6	 11.6	 0.77
7.2	 7.5	 7.1'	 2.97
12.4	 12.3
	
12.2
	
1.15
Table 7: Percentage weights allocated to each trial for different values of the between-
study variance
Trial
0.0
	 0.1	 0.2
(0.0) (0.30) (0.47)
1
	 5.0	 9.7	 10.5
2
	 6.8	 11.6	 11.9
3
	 4.5	 9.1	 10.0
4
	 2.7
	
6.3	 7.6
5	 7.0
	
11.8	 12.1
6	 54.6 22.0	 17.6
7
	 6.6	 11.4	 11.8
8	 1.2	 3.2	 4.3
9
	 11.8	 15.0	 14.1
Weight allocated to trial (%)
Between-study variance (4)
(x = 4/(0.23 + 4))
0.3	 0.4	 0.5	 0.6	 0.7
(0.57) (0.64) (0.69) (0.72) (0.75)
10.9	 11 0	 11.1	 11.1	 11.2
12.0	 11.9	 11.7	 11.8	 11.8
10.4	 10.7	 10.8	 10.9	 11.0
8.3	 8.8	 9.2	 9.4	 9.6
12.1	 12.0	 11.9	 11.9	 11.8
15.9	 14.9	 14.2	 13.8	 13.5
11.9	 11.9	 11.8	 11.8	 11.7
5.1	 5.7	 6.2	 6.6	 6.9
13.6	 13.2	 12.9	 12.7	 12.5
study variance, however, remained almost the sä.me, being only slightly smaller at
0.21. Consequently, the associated confidence interval for the overall odds ratio was
marginally narrower and was shifted in position. The plot also differed in shape,
no longer increasing after reaching a minimum value, but decreasing monotonically
to the 'equal weighting' estimate (Figure 7). This was much lower than the 'equal
weighting' estimate obtained for the full set of data.
For the full data set, the range of possible values of is between 0.5956 and
0.6717 (Figure 6), and hence the variation in the point estimate is not particularly
large. However, as 4 increases, the certainty with which the value of 0 may be
estimated decreases and hence the 95% confidence interval for 0 gets wider as 4
increases. Confidence intervals may also be illustrated on the sensitivity plots. For
each value of 4, the variance from the random effects model may be calculated using
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Figure 7: Sensitivity plot showing how the overall odds ratio varies with the between-
study variance (4) comparing the full set of data with that excluding trial 8 for the
diuretics trials meta-analysis
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O.23=random effects estimate of between-study variance 4 for full data
O.21=random effects estimate of between-study variance 4 excluding trial 8
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Table 8: A comparison of the results for the full data with those from the data
excluding trial 8
Case	 Type of	 Estimate of
	
Estimate of	 95% Ci. Width of CI.
estimate between-study variance overall odds ratio 	 for
_____________ ________ 	 (&)	 ()	 _________ ___________
Full data	 Fixed	 0	 0.67	 (0.56,0.80)	 0.24
Random	 0.23	 0.60	 (0.40,0.89)	 0.49
Without trial 8 Fixed	 0	 0.66	 (0.55,0.79)	 0.24
Random	 0.21	 0.56	 (0.37,0.82)	 0.45
var(Ôr) = w and so the corresponding confidence interval can be obtained.
The plot (Figure 8) indicates how the initial increase in the width of the confidence
interval is gradual, but how for extreme values of 4, the interval increases in width
very rapidly, with the upper bound tending towards infinity.
The technique presented in this Section is useful for checking the robustness of
any conclusions drawn from a fixed effect or a random effects meta-analysis. Since 4
cannot be estimated very precisely, especially when there is only a small number of
trials in the analysis, the technique reveals whether this creates a problem in relation
to the conclusion being drawn. If the sensitivity plot shows very little change over a
range of different 4, then the greater the confidence in the conclusions. However,
if the plot shows that the estimate and confidence intervals change markedly, then
extra caution should be expressed in the results.
2.2 Maximum Likelihood Approach to Meta-Analysis Based
on Marginal Distributions
A likelihood approach to meta-analysis is proposed in this Section, which is shown to
offer certain improvements over the standard random effects method (Section 1.7.1).
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Figure 8: Sensitivity plot showing how the overall odds ratio and its 95% confi-
dence interval vary with the between-study variance (o) for the diuretics trials
meta-analysis
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The model is introduced in Section 2.2.1, while Section 2.2.2 describes how confidence
regions may be obtained and Section 2.2.3 derives confidence intervals for both 0 and
4 from the relevant profile likelihoods.
2.2.1 Introduction
The standard random effects confidence interval for 0 is too narrow as it makes no
allowance for the imprecision in the estimate of 4. Furthermore, there is no published
method for calculating a confidence interval for 4 itself. In meta-analyses, which
commonly include only a small number of trials, the estimate of 4 will not be very
precise and so any such confidence interval would be wide. Initially an analogy to
the one-way analysis of variance was pursued in order to obtain a confidence interval
for 4, but this approach could only be applied in certain situations and proved
problematic for the general case. Both the problems mentioned above can, however,
be solved by using a likelihood approach.
The random effects model was set up as described in Section 1.7.1 with the
distributional assumptions of normality. Under this model, the marginal distribution
of each individual estimated treatment effect Ô, j = 1, ..., k, is, therefore, normal with
mean 0 and variance (v+ 4) . Hence the contribution from study i to the likelihood
for 0 and 4 is,
1	
{ -(
Ô - 0)2 1	 (20)L(0, 4) = /2ir(v +4)	 2(v +4) 5
For a meta-analysis involving k independent studies, the full likelihood is the
product of the individual study likelihoods. The log-likelihood is, however, simpler
to work with, and is given by,
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(22)
(23)
k	 k
1(0,4) = -	 ln2ir(v + 4) -	
-9)2
. 
2(vH-4)	 (21)
To obtain maximum likelihood estimates (MLEs) of 0 and 4 that is and
bk,, the partial derivatives of equation (21), 81/80 and 01/04, are set to zero and
the resulting expressions rearranged [77]. The equations thus obtained, (22) and (23),
are then solved in an iterative manner, beginning by substituting an initial value of
in equation (23),
oi
A	 L.jj=1 (V+41)
k	 1
(v+41)
A A
'i-'k (0_0,)2_V
A	
L.41 (v.+b2)2
k	 I
(V.+b2)2
The actual form given in (23) is not the simplest expression possible for ô and is
obtained by subtracting	 v/(v + ô,)2 from either side of the initial equation,
but it is the most convenient form for the implementation of the iteration process.
Alternatively, the MLEs may be obtained directly from the log-likelihood given in
(21) using, for example, Splus [78J. This implements a routine which produces a
range of points from the joint likelihood 1(0,4) using a grid of values of 0 and 4.
The program then finds the maximum value of 1(0,4) and hence , and ô, also.
2.2.2 Confidence regions
The joint log-likelihood of 0 and 4 in (21) can be calculated and three-dimensional
plots obtained using Splus [78]. This same likelihood can also be displayed on a con-
tour plot where the contours join all the points which have the same log-likelihood
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and hence represent likelihood-based confidence regions. To obtain a joint confidence
region for both parameters 0 and 4 the fact that —2{l(0, 4) - l(O, &)} has an
asymptotic x distribution [79] is used. The approximate 95% likelihood-based con-
fidence region is thus given by all pairs of 0 and 4 which satisfy,
1(0, 4) > l(Ô1, o11) - 5.991/2	 (24)
where 5.991 is the 95% point of the x distribution.
2.2.3 Profile likelihoods
The profile log-likelihood can be used in order to find confidence intervals for each of 0
and 4. The profile log-likelihood is the log-likelihood for one parameter, which takes
into account the fact that the other parameter is unknown and must be estimated.
Hence, the profile log-likelihood for 4 is obtained by replacing 0 in equation (21) by
the maximum likelihood estimate O,,
-k _______
L1=i (V+7)
k	 i
(V+7)
for each given value of 4, that is proffle out 0. The profile log-likelihood, 1(4) =
l(0(4), 4), where â(4) is the MLE of 0 for a given 4, may then be plotted
against 4. It requires more work to obtain the profile likelihood for 0, since the
maximum likelihood estimate of 4 cannot be written in terms of 0 alone. The
maximum likelihood estimate of 4 for any given 0 satisfies the equation
(25)
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(O_0)2_V
=1 (V1+ô'1)2
	 (26)k	 1
(V+ô1)2
Hence, in this case, the profile log-likelihood has to be found numerically, whereby for
each given 0 equation (26) is solved to find ô. This maximum likelihood estimate is
then used to obtain the corresponding point of the log-likelihood, l*(9) = 1(0, ô,(0)),
using (21).
In order to obtain confidence intervals from the profile log-likelihoods, the fact
that —2{difference in profile log-likelihoods} has an asymptotic x2 distribution is
utilised. Hence, _2{l*(4) - l*(&)} and 2{l*(0) - l*(ô:)} each have approximately
a x distribution [79], the degrees of freedom being the difference between the number
of unknown parameters. It then follows that the 95% confidence intervals are given
by all values of the parameters which satisfy the equations
1*() > l*(b1) - 3.84/2	 (27)
and
l*(0) > 1(Ô,) - 3.84/2	 (28)
where 3.84 is the 95% point of the x distribution.
A test for heterogeneity may also be derived from these profile log-likelihoods,
since a null hypothesis of homogeneity is equivalent to H0 : = 0. The one-sided
alternative hypothesis is then H1 : 4 > 0, under the assumption of a normally
distributed random effects model. The relevant likelihood ratio statistic to test for
heterogeneity is therefore LRT = /2{l*(4) - 1(0)} which can be compared to the
standard normal distribution to obtain a one-sided p-value.
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2.3 Practical Considerations
Three contrasting examples will now be considered in Sections 2.3.1-2.3.3 to illustrate
how taking into account the imprecision in the estimate of 4 affects the confidence
interval for 0. Section 2.3.4 then considers use of the information matrix as a way of
approximating the confidence intervals for 0 and 4 and Section 2.3.5 is a discussion.
2.3.1 Example 1: Diuretics trials meta-analysis
For the diuretics trials meta-analysis (Section 1.3.1), it can be seen from the three-
dimensional likelihood plot (Figure 9), as well as from the profile log-likelihood (Figure
10), that the likelihood of the between-study variance is, as expected, very asym-
metric. The profile log-likelihood for the overall treatment effect indicates that the
likelihood of 0 is much more symmetric in shape (Figure 11). However, unlike the
standard methods (Sections 1.5 and 1.7), using the profile likelihood does not force
the confidence interval for either parameter to be symmetric.
The contour plot (Figure 12) is difficult to interpret and is best used to obtain
an idea of the shape of the joint log-likelihood surface. It does, however, indicate that
the possible ranges of 4 and 0 are very much wider than the individual confidence
intervals suggest. It can be seen that the 95% likelihood-based conildence region
includes values of 0 greater than 0 which indicates the possibility of no treatment
effect.
The estimates and their corresponding confidence intervals based on the like-
lihood model can be compared to those obtained from both the fixed effect method
and the standard random effects method using the D&L moment estimator of 4
(Table 9). The maximum likelihood estimates agree well with the standard random
effects estimates. The fixed effect estimate of the overall treatment effect is slightly
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Figure 9: Bivariate distribution of the overall log odds ratio and the between-study
variance for the diuretics trials meta-analysis
0	 -
larger than the two random effects estimates. However, the fact that a reasonably
large estimate of the between-study variance is obtained indicates a lack of homo-
geneity in this set of studies. The likelihood ratio test for heterogeneity produces
a highly significant result (LRT=2.53, N(O, 1) p=O.006). However, the Q statistics
for heterogeneity (Section 1.6) is even more significant (Q=27.27, x pO.00O7) and
therefore appears to be more powerful than the likelihood ratio test in this example.
The confidence interval for the between-study variance is wide, reflecting the
fact that only nine studies are included in this meta-analysis, meaning that the
between-study variance is imprecisely estimated. Allowing for the estimation of the
between-study variance means that the likelihood based confidence interval for the
overall treatment effect is wider than that obtained by the standard random effects
method. Nevertheless, bearing in mind the large imprecision in the estimate of 4,
the increase in the width of the confidence interval for 	 is relatively small.
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2Figure 10: Profile likelihood for the between-study variance for the diuretics trials
meta-analysis
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Table 9: Comparison of the results from three meta-analysis methods for the diuretics
trials data
Method	 Estimate of	 95% C.!.	 Estimate of	 95% C.!.
between-study variance (4)	 for 4	 overall odds ratio (e9 )	 for e0
Fixed effect	 0.00	 -	 0.67	 (0.56,0.80)
Random effects
Standard	 0.23	 -	 0.60	 (0.40,0.89)
Likelihood	 0.24	 (0.03,1.13)	 0.60	 (0.37,0.95)
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Figure 11: Profile likelihood for the overall log odds ratio for the diuretics trials
meta-analysis
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Figure 12: Contour plot for the bivariate distribution of the overall log odds ratio
and the between-study variance for the diuretics trials meta-analysis
0.6
0.4
0.2
0
0.0
-0.2
0)
.2 -0.4
-0.6
>
0
-0.8
-1.0
_1.211	 I	 I	 I	 I	 I	 I	 I	 I
0.0 0.2 0.4 0.6 0.8 1.0 1.2 1.4 1.6 1.8
between-study variance
Key
£ maximum likelihood
88
The sensitivity plots described in Section 2.1 provide a guide to the effect that
the imprecision in the estimate of 4 will have on 9 (or ê as ö1 =ô for a given 4) and
hence how much the likelihood based confidence interval will differ from the standard
random effects interval. The important characteristic of the sensitivity plots in this
respect is what happens to the estimate of 0 in the region of ô?. If the estimate
of 0 remains constant across the values of 4 contained in the 95% likelihood-based
confidence interval, then the likelihood-based confidence interval for 0 will be no
different to that obtained from the standard random effects method. However, the
greater the variation in O over this region of interest, the greater the increase in width
of the interval for 0. The imprecision of the estimation of 4 does not have a direct
influence on the width of the confidence interval for 0. However, the more imprecise
the estimate of 4, the larger the range of influential values and hence the greater
the chance of a variation in Ô in the range of interest.
Figure 6 shows that the estimate of the overall odds ratio e0 changes by only
0.03, approximately, in the region covered by the likelihood-based confidence interval
for 4. This suggests that the estimate of the between-study variance does not have
much influence on the overall estimate in this example, and hence a large increase in
the width of the confidence interval for 0 when using the likelihood method compared
to the standard random effects method would not be expected. The same information
may also be gained by considering the plot of the change in the MLE of the 'nuisance'
parameter for different values of the parameter of interest on a contour plot (Figure
13). The value of (=6) changes very little when looking at the profile likelihood
of 4, and it is only for very small values of 4 where there is a marked difference.
Hence, the profile log-likelihood is almost the same as a cross-section cut through the
joint likelihood at the maximum likelihood value of 0. This again suggests that the
estimate of the overall mean does not depend greatly on the value of 4. In contrast,
the value of è does change quite considerably over different values of 0 (Figure 13).
As 0 increases the value of ô, decreases to the maximum likelihood estimate and
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then increases again. This pattern is to be expected since & will obviously be larger
as 0 moves away from the maximum likelihood estimate.
Figure 13: Contour plot showing how the estimates of the log odds ratio and the
between-study variance change
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Contours as in Figure 12
In moving from the simple fixed effect model to the likelihood model, which
allows both for the heterogeneity and the estimation of the between-study variance,
the certainty with which conclusions may be drawn from this meta-analysis changes.
Although the point estimate of the overall treatment effect alters little, the increased
width of the related confidence interval reduces the certainty of the conclusions (Ta-
ble 9). The fixed effect interval is narrow and corresponds to a highly significant
treatment benefit. However, in the likelihood analysis where the interval has in-
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creased substantially from the fixed effect analysis, the treatment benefit of diuretics
is substantially less significant, with the upper limit of the 95% confidence interval
being only slightly below unity.
2.3.2 Example 2: A multicentre trial
The second example uses data from the Medical Research Council's multicentre trial
of the treatment of mild hypertension (Section 1.3.2). This allows an example with a
large number of 'trials' (i.e. centres in this example) to be considered. Furthermore,
since the outcome considered here is the reduction in diastolic blood pressure in
mmHg between entry to the trial and one year after entry, the outcome measure is
continuous, which also contrasts with the first example. The likelihood methodology,
however, carries through in an exactly similar way as for the log odds ratio.
Table 10: Comparison of the results from three meta-analysis methods for the mild
hypertension trial data
Method	 Estimate of
	 95% C.!.	 Estimate of	 95% C.!.
______________ between-study variance (oj)
	 for 4	 overall odds ratio (e 9 )	 for
Fixed effect	 0.00	 5.31	 (5.03,5.59)
Random effects
Standard	 1.81	 -	 5.29	 (4.94,5.63)
Likelihood	 1.78	 (0.83,3.05)	 5.29	 (4.94,5.63)
In this example, there is considerable evidence of heterogeneity between centres
(Q278.12, xi.ss p <0.0001), but there are no real differences between the standard
random effects results and the likelihood results (Table 10). In contrast to the pre-
vious example, the likelihood ratio test (LRT=19.8, N(0, 1) p <0.00005) produces
an even more extreme result than the Q statistic. The confidence interval for the
between-centre variance is fairly wide, especially when considering that & is based
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on a large number of centres. However, looking at the sensitivity plot of 9 against
4/(o1 1+4), changes in the value of 4 do not affect the estimate of 9 to any great
extent and certainly not in the region around b (Figure 14). As a consequence,
the likelihood-based confidence interval for 0 is apparently identical to the confidence
interval derived from the standard random effects method. The interval for 0 is ap-
proximately symmetric and that for 4 is also more symmetric than in the previous
example, resulting from the larger number of centres involved.
Figure 14: Sensitivity plot showing how the overall difference in mean diastolic blood
pressure reduction varies with the between-centre variance
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2.3.3 Example 3: An extreme case
The third example is an extreme, and perhaps rather artificial, meta-analysis where
there are only two studies to be combined. The two trials investigate the effect of
aspirin in the primary prevention of the incidence of stroke, myocardial infarction and
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other vascular diseases. Both trials were carried out in a population of male doctors,
with one taking place in the U.K. [71] and the other, which was a component of the
Physicians Health Survey, in the U.S.A. [80]. Both were randomised controlled trials
which compared aspirin (500mg/day in Britain and 325mg/day in U.S.A.) with a
placebo. The trial in the U.S.A. had 22,071 participants in the cardiovascular com-
ponent, whereas the British study was smaller with 5,139 participants. The endpoint
considered here is the incidence of non-fatal myocardial infarction (MI) (Table 11)
as this provides a situation where there is considerable heterogeneity between the
treatment effects (i.e. the log odds ratios) in the two trials. The results used here
are those published in the more recent overview of randomised trials of antiplatelet
therapy [64], rather than those in the original papers themselves. These two trials are
the only two low risk (primary prevention) trials for which the outcome of non-fatal
myocardial infarction was reported.
Table 11: Results for two trials of the effect of aspirin in the primary prevention of
non-fatal myocardial infarction (MI)
Trial	 Number of non-fatal MIs/Total number of patients Odds ratio 95% C.I.
Treated	 [	 Control	 (e°)	 for
[iii	 87/3429(2.5%)	 38/1710(2.2%)	 1.15	 (0.78,1.68)
________ 129/11037(1.2%) 	 211/11034(1.9%)	 0.61	 (0.49,0.76)
In a fixed effect analysis on these data, there is a significant treatment benefit
from taking aspirin (Table 12). However, when using either of the random effects
models, the effect observed is no longer significant at the 5% level as both intervals
are much wider and include unity. The confidence interval for the overall treatment
effect from the likelihood model is also considerably wider than that from the standard
random effects model. These results indicate that no conclusion can be reached from
these data alone concerning the benefit of aspirin in terms of the risk of non-fatal
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myocardial infarction.
As would be expected the confidence interval for 4, being based on only two
observations, is extremely wide. This is due to the gradual decrease of the profile
likelihood for values of 4 greater than the MLE (Figure 15). This uncertainty in
the estimate of 4, together with the fact that the range of values of 4 included in
the confidence interval lead to a large range of possible estimates of 0 (between 0.71
and 0.825 approximately) (Figure 16), results in the large increase in width in the
confidence interval for 9. This situation contrasts with that in the previous example
where, although the confidence interval for 4 is quite wide, the specific value that
4 takes does not influence the overall estimate of the treatment effect. This example
also contrasts with the diuretics trials example, since the value of O is rapidly changing
in the region around ôi (Figure 16).
The one-sided likelihood ratio test for the null hypothesis of homogeneity
H0 : 4 = 0, gives a p-value 0.034, while the test for heterogeneity using Q gives
p 0.005 (Q=7.86, xfl indicating strong evidence of heterogeneity. This, again, per-
haps surprisingly, suggests that Q has greater power than the likelihood ratio test.
Table 12: Comparison of the results from three meta-analysis methods for the aspirin
trials data
Method	 Estimate of
	 95% C.L	 Estimate of	 95% Cl.
_____________ between-study variance (4)	 for 4	 overall odds ratio (e0 )	 for e9
Fixed effect	 0.00	 -	 0.71	 (0.59,0.86)
Random effects
Standard	 0.18	 -	 0.82	 (0.44,1.52)
Likelihood	 0.07	 (0.00,1.73)	 0.80	 (0.39,1.78)
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Figure 15: Profile likelihood for the between-study variance for the aspirin trials
meta-analysis
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Figure 16: Sensitivity plot showing how the overall odds ratio varies with the between-
study variance for the aspirin trials meta-analysis
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2.3.4 Use of the information matrix
Approximations to the profile likelihoods may be obtained using quadratic curves
derived from the asymptotic variance-covariance matrix for = (8, 4)T. Tests,
based on this approximation, of the null hypothesis of no treatment effect may also
be derived as shown for the case of continuous outcome measures by Rosner [811. In
order to take some account of the fact that 4 is estimated from a finite number of
trials, Rosner [811 suggested that for finite sampies the test statistic may be better
approximated by a t-distribution than by the N(O,1) distribution. However, as has
been shown, the widening of the confidence interval depends more on the strength
of the relationship between 4 and Ô1 than it does on simply the number of trials
involved and the precision of ô. The method using quadratic curves is investigated
here so that the resulting intervals can be compared with the likelihood based ones
in order to see if the approximation is reasonable in the meta-analysis case.
For a single parameter, the asymptotic distribution of —2{clifference in log-
likelihood) tends to that of (0 - ô1 ) 21(0) [79]. But asymptotically the distribution
of 0 tends to N(0, 11(0)), where f'(0) is the information matrix which is given by
so [(0 - ê1)//1/I(0)]2 = (0— ô1)21(o) tends towards a x distribu-
tion. If the expectation cannot be taken algebraically, then 1(0) may be replaced by
the observed information J*(0), which is given by (_82l(0)/802) evaluated at
In the case of two parameters, the multivariable Taylor expansion is used to obtain
the equivalent result for '. It can be shown that the distribution of —2{l() -
tends asymptotically to that of -( - )TI()(1F - ) and that the distribution of
( - )Ti()( - ) tends to a x distribution [79]. This means that the likelihood
surface is approximated by a quadratic for both parameters of the model. The values
of which satisfy the equation
( - )TJ*()(4. -
	
= 5.991	 (29)
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where 5.991 is the 95% point on the x distribution, give the 95% confidence region
for the two parameters jointly, which may again be displayed on a contour plot. The
quadratic approximation would not appear to be very sensible, however, since by
approximating the distribution to an ellipse, negative values of 4 can be obtained
and the possible asymmetric nature of the likelihood surface is not taken into account.
This happens in the case of the diuretics trials data, where the region contains negative
values of 4, which have no meaning, and hence must be set to zero (Figure 17).
Figure 17: 95% contour of the bivariate distribution of the overall log odds ratio and
the between-study variance using the quadratic approximation to the likelihood for
the diuretics trials meta-analysis
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A further disadvantage is that equation (29) is fairly complicated to solve. By mul-
tiplying the matrices, (29) becomes
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kk	 1	 k (Ô-9,)	 _______________
1=1 
(v + oj,)2 +(ol _,)2 E 
2(9 - 9) - (v + 81)(9_Ü,)2	 (v + 2) +2(9 —9,)(4 —o11) 1=1	 2(v + o,)3
(30)
which is equal to 5.991. This expression is solved for 0 and 4 to obtain the 95%
confidence region for 0 and 4 . Hence it is actually more straightforward, as well as
more meaningful, to produce confidence intervals for each parameter individually.
If the surface of the log-likelihood is quadratic in both parameters, then the
interval for a single parameter may be obtained using the respective entry in the
observed formation matrix, J*.1() [821. Hence, for 0 for example, (0 -
where Ij.1(O1) is given by I - '12'22'21 and I,, is the entry (ij) in the 2x2
variance-covariance matrix, has a x distribution. Alternatively, but equivalently,
(0— 1)/Ij'(ô,) has a standard normal distribution and hence values of 0 satisfying
(0 -	 = 1.96	 (31)
provide an approximate 95% confidence interval. Similarly, a confidence interval for
4 can be obtained by using the relevant entry in the inverted information matrix,
that is 1j'1 . However, in the meta-anlysis case under consideration, the surface of
the log-likelihood is certainly not quadratic in both directions and so the result is not
strictly valid.
Comparing the two confidence intervals for the overall odds ratio estimate
for the diuretics trials data, it can be seen that the interval for e0 derived from
the profile likelihood is substantially wider than the approximate interval (Table 13,
Figure 18). The 95% confidence interval for 4 using the profile likelihood is much
wider than that obtained using the variance from the information matrix (Table 13).
That the approximation to the confidence interval for e° using the quadratic is no
different to the interval obtained when using the conventional random effects variance,
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Table 13: Confidence intervals for the two estimates comparing the profile likelihood
method and the quadratic approximation (diuretics trials data)
Method	 95% C.I. for the	 95% C.I. for the
between-study variance overall odds ratio
Profile likelihood	 (0.027,1.130)	 1 (0.374,0.953)
Information matrix
	 (0.000,0.623)	
J	
(0.398,0.893)
1/ 2.1 (v
 + 4)', may be explained by the fact that the covariance term in the
matrix, Cov(O 1 , o 1), is very small, and therefore has little impact on the value of
Ij.1(è). This implies that the variance for Ô is equal to 1/ E.1 (v + 4)-' if it is
assumed that the two off-diagonal elements of J*(i), that is the covariance terms,
are zero. Similarly, an approximate variance for 4 can then be obtained and is given
by 1/
	
(2(Ô1 - ô1)2 - (v + b i))/(2(v + o1,)).
It is possible to use a transformation of 4 in order to obtain a profile log-
likelihood which is a better approximation to a quadratic. In this example, the
transformation ln(4) does improve the quadratic nature of the profile log-likelihood,
but the problem with the log transformation is that it forces all values of 4 to be
greater than zero. The likelihood is certainly more quadratic in shape (Figure 19),
but the transformation skews it slightly in the other direction.
The information matrix must be recalculated for the parameters 0 and ln(4) to
obtain the results and hence the reparameterisation gives a log-likelihood of
1	 1	 (â._9)2
	
l('I') 
= -. ;;: 
ln2ir(v + e"°l) -	 (v2 + e''l)	 (32)
Then by making the simplifying substitution, e"4 Ca, l() in (32) can be rewritten
as
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Figure 18: Profile likelihood for the overall log odds ratio compared to the quadratic
approximation to the likelihood for the diuretics trials meta-analysis
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Figure 19: Profile likelihood for the log of the between-study variance compared to
the quadratic approximation to the likelihood for the diuretics trials meta-analysis
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I '1	 '% (_9)2
l()=	 ln21r(vj+ez) (33)
i=1 (v + Ca)
Since I() = _02l/&2,
En'
	 'ci
$ 1 (v,+o ) 	 Le=1 (Vj+O)2
= ( n _____ 1 n )	
(34)
E=, (v+)
and it follows that the expression for ( - 4)I*(ii)( - ) = 5.991, similar to (30)
can be obtained. Furthermore, confidence intervals for 0 and ln(4) can be calculated
(Table 14) in the same way as illustrated in (31).
Table 14: Information matrix-based confidence intervals using 0 and ln(4)
Parameter	 95% C.I. of parameter
Overall log odds ratio (0)	 (0.389,0.893)
Log between-study variance (ln(ol))
	
(-3.042,0.176)
Between-study variance (4)	 (0.048,1.193)
Comparing these results with those obtained without the transformation the
confidence interval for 0 remains unchanged, but the interval for 4 becomes wider
and does not include zero (which it cannot, because of the log transformation). This
approximation now happens to agree reasonably well with the interval obtained di-
rectly from the profile likelihood. This will not generally be true, but it may be that
in certain cases a transformation of the variable will improve the quadratic nature of
the log-likelihood. The transformation of one parameter will have no effect on the
interval of the other parameter. Hence, the interval for 0 remains the same after the
transformation of 4.
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For this particular set of data, and indeed in general, it is more sensible to use
the likelihood based intervals taken directly from the profile likelihood curve. The
quadratic approximations based on the use of the information matrix lead to confi-
dence intervals which are too narrow. Using the approximation was computationally
not much quicker than using the curve directly, especially since a data-dependent
transformation of 4 was required to obtain a reasonably sensible approximation.
The approximations would be rather better for the multicentre trial (Section 2.3.2),
since the joint log-likelihood of 0 and 4 is much more quadratic in shape because of
the large number of centres involved. However, it would be completely unrealistic for
the case of the aspirin trials meta-analysis (Section 2.3.3), as the likelihood for 4 is
far from quadratic.
2.3.5 Discussion
The fact that the likelihood based confidence intervals are based on the 95% confi-
dence level from the x distribution, which requires the quadratic approximation to
hold, means that they too are only approximate confidence intervals. They should
therefore not strictly be viewed as 95% confidence intervals in the usual sense, but
rather as likelihood support intervals. However, these likelihood support intervals
may be interpreted for practical purposes as being approximate confidence intervals,
as suggested by Clayton and Hills [83].
The likelihood method presented yields a confidence interval for 4, so that
the precision of can be directly judged. Obviously the fewer trials involved, the
less precise will be the estimate of 4. However, even in the second example with 189
'trials', the width of the confidence interval was large. Hence, in any meta-analysis in
practice there will be considerable imprecision in estimating 4. Whether the value
of 4 used substantially affects the overall estimated treatment effect is a separate
issue, and can easily be investigated using the sensitivity plot of (or Ô 1 ) against ol
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(Section 2.1). In practical terms, this issue is of importance when 4 is imprecisely
estimated and when the value of 4 affects the overall estimate of the treatment effect
in the region around the MLE.
It has been noted how in the first and third examples (Sections 2.3.1 and
2.3.3), the likelihood ratio test appears to have less power than the Q test to detect
heterogeneity. However in the second example, it has greater power. To understand
why this occurs, it is necessary to consider the hypotheses which are being tested. In
the case of the test for heterogeneity using Q the null hypothesis is that all individual
study estimates are equal H0 : = 0 for all 1. This is equivalent to the null hypothesis
in the likelihood ratio test which is that the between-study variance is zero H0 : 4 =
0. However, the alternative hypotheses differ between the two tests. The alternative
for the Q test is H1 : O 0 for at least one i, while that for the likelihood ratio
test is more specific, being not only that the between-study variance is greater than
zero, but also that the normal random effects model holds under this alternative.
Since it is the alternative hypothesis that determines the power of a test, it would not
necessarily be expected for these two tests to have the same power. Hence, differences
in the p-values obtained may not be that surprising.
It would be expected, that if a set of data does follow a normal random effects
model reasonably well, then the likelihood ratio test would be more powerful than
the general Q test. However, if the data was not of this form then the likelihood ratio
test would lose power due to the alternative hypothesis being inappropriate and the
Q test would perhaps be more powerful in such a situation. With only a few points
normality is difficult to check and is impossible with only two trials. Normal plots (see
Chapter 3) for the first example indicate that the normally distributed random effects
model may not be very suitable in this case. Hence, the alternative hypothesis of the
likelihood ratio test is inappropriate and so the test will lack power when compared
toQ.
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k 
ln2ir((o.2/nj) +4) -
k	 (0._0)2
i=1 
(o.h/n.)+4) (35)l(0,4,o 2) = -
Although the likelihood method proposed allows for the estimation of the
between-study variance, it still assumes that the individual study variances v are
known, when in practice they too must be estimated. For continuous outcome mea-
sures, a possible alternative approach would be to define each v as o 2/n, where o
is a common within-study standard deviation. This is a valid substitution if v is
approximately proportional to 1/n1 , that is if the variance of Ô is only dependent on
the number of observations on which it is based. The likelihood, based on the nor-
mally distributed random effects model, can then be obtained with o 2/n replacing
v. Hence, the log-likelihood for 0, 4 and o.2 is
which contains three unknown parameters, 8, 4 and o.2, and since n are known, this
eliminates the problem of having to assume that the v are known. The MLEs for 0,
4 and .2 may then be obtained by standard methodology.
The likelihood method using the marginal distributions of è, makes the as-
sumption that the data è, are normally distributed as well as the random effects.
Hence, for binary outcome measures it does not utilise the exact distribution of each
2x2 table. The approximation to the normal distribution may, therefore, be inade-
quate in some cases, particularly when the sample sizes are small. The full likelihood,
for binary data, includes the exact conditional distribution of each 2x2 frequency ta-
ble given its margins [45]. If a full likelihood method were pursued, the confidence
intervals for the overall treatment effect would be expected to be even wider. This
issue is explored in the next section.
The examples presented show that caution is required when interpreting results
from the standard meta-analysis methods. Even the confidence interval for the overall
treatment effect from the usual random effects model may be too narrow. Certainly,
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the confidence intervals from a fixed effect model will tend to be far too narrow when
heterogeneity exists. This issue is of practical importance since the increased width
of the confidence intervals can severely limit the conclusions that can be drawn from
a meta-analysis.
2.4 A Full Likelihood Approach For Binary Outcomes
In a paper considering a bivariate approach to meta-analysis, van Houwelingen, Zwin-
dermann and Stijnen used a likelihood based "Mantel-Haenszel-type" procedure for a
fixed effect model and extended this to a random effects model [45]. Section 2.4.1 de-
scribes the fixed effect model and Section 2.4.2 the random effects model. Section 2.4.3
then compares the results obtained using the full likelihood method with those ob-
tained using the inverse-variance fixed effect method (Section 1.5.1) and the random
effects likelihood method based on the marginal distributions of ôj (Section 2.2) for
two practical examples.
2.4.1 The fixed effect model
The likelihood used in [45], under the homogeneity assumption, was obtained by
considering the conditional distribution of the number of events in the control group
Cj, given the total number of events in that trial m11 (notation as in Table 2). However,
in order that the odds ratios obtained are in the same direction as those in the rest
of the thesis, the conditional distribution for the number of events in the treatment
group will actually be considered here. In each trial, the conditional distribution of the
number of events in the treatment group a given m 1 is a non-central hypergeometric
distribution of the 2x2 table given its marginals [45], and so the likelihood of 0, the
log odds ratio, is
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( nii) (ni2) 0a	
(36)
a,
L(0)=	
(') 
a+d—y
fl2	 )ei
where yj = max(O, rn,1 - n 2) ^ y ^ rnin(r&, i , rn,i) = Yu . The denominator of (36)
represents the sum over all possible tables where the total number of events is equal
to that observed.
The total log-likelihood is the sum of the individual trial likelihoods, so if
1(9) = lnL1 (0), then
1(0) 
= k 
l(0)
	 (37)
This total likelihood can therefore be plotted and the MLE of 0 obtained directly
from the curve, together with 1(ö) and the 95% confidence interval for 0. The 95%
confidence interval is obtained, as in Section 2.2, by taking as the confidence limits
the points at the intersection of the likelihood curve and the horizontal line drawn at
3.84/2 (3.84 is the 95% point on the distribution) units below the maximum.
2.4.2 The random effects model
This likelihood model was extended by van Houwelingen et al. [45] to incorporate
random effects. This was done by assuming 0 to be random with some distribution G
and so 0, i = 1, ..., k, is a random sample from C, the values of 0 being unobservable.
Then assuming that 0 is independent of the sample sizes, the likelihood for trial I is
given by
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L1(G(0)) 
= f L,(0)dG(0)	 (38)
and hence the parameters of the distribution G can be estimated by maximising the
total log-likelihood of G(0),
1(G(0)) =	 l(G(0))	 (39)
Either the nonparametric approach of Laird [84] or a parametric approach
may be used to estimate the distribution of C. The parametric approach leads to
a smoother estimate of C being obtained [45], and van Houwelingen et al. assume
a normal distribution as in the marginal likelihood model of Section 2.2. Hence
C N(jt, 4) where .t is now the overall treatment effect and 4 is the between-
study variance and so,
1	 f _(O_,․ )2
L(/L,4)=jLi(0),_exPl	 24	
}do	 (40)
where L1 (0) is given in (36). The MLEs of 
.t and 4 can then be obtained by
implementation of the EM algorithm [85]. The EM algorithm consists of two steps,
the estimation step (E-step) and the maximisation step (M-step), which are repeated
alternately until convergence is achieved. The E-step involves the computation of
the sufficient statistics of the O, which are E...1 9 and O f 0, ..., could be
observed. Hence, if f(O I p, 4) is the normal density function, then
f9L(0)f(O p,4)dO
	 (41)= E(O I data,parameters) 
= fL,(o)f(o I i4)dO
and
f92L,(0)f(O ,4)dO	 (42)= E(O I data,parameters) 
= fL1 (o)f(o I
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Numerical methods can be used in order to evaluate the integrals given in (41) and
(42).
The M-step then consists of calculating the mean and the variance of the
distribution as follows.
(43)
= 1 k -
	 (44)
A 95% confidence interval may be produced using the profile likelihood (defined
in Section 2.2.3) of . The EM algorithm can again be used in order to obtain the
maximum value of 4 for each value of . Hence, the procedure is exactly the same
as described above, except that the value of j is known in L(G). Once again the
horizontal line at 1.92 units below the maximum is used and so the 95% confidence
interval is defined as in equation (28).
Furthermore, a likelihood ratio test for heterogeneity may be formulated by
calculating the test statistic -2{l(Ô) - l(fA, ôt,)}, where 1(â) is the maximum likeli-
hood for the homogeneous model, that is where 4=0, and l(, ôi) is the maximum
likelihood for the random effects model. This is equivalent to the test described in
Section 2.2.3, except that the full likelihood as opposed to the marginal likelihood is
used.
2.4.3 Comparison of results
A Gauss program, provided by van Houwelingen et a!. [45], which carries out the
parametric likelihood analysis described above, was used in order to obtain results for
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both the diuretics trials data (Section 1.3.1) and the aspirin trials data (Section 2.3.3).
The results from the random effects methods were then compared with those obtained
from the marginal likelihood method (Section 2.2) and the results obtained under the
homogeneity assumption were compared with the inverse-variance fixed effect method
(Section 1.5.1).
The comparison of the results show that in the case of the diuretics trials
meta-analysis, the two fixed effect methods agree closely (Table 15). The differences
between the random effects Mantel-Haenszel-type likelihood results and the marginal
likelihood results are also very small (Table 16). The 95% confidence interval is
slightly wider and the estimate of o-? is slightly larger in the full likelihood method.
An increase in uncertainty is expected since the full likelihood does not make the
assumption that the variances of the individual studies are known. However, it is in
the smallest studies that the variances are most imprecisely estimated. Hence, such
studies take the least weight in a meta-analysis and also have their relative weight
determined more by the value of 4 than by v. This means that the additional
uncertainty would not be expected to have a great impact on the results, and so
pursuing the full likelihood approach may be unnecessarily sophisticated for most
purposes.
Table 15: Comparison of results from the fixed effect likelihood based Mantel-
Haenszel-type procedure with those from the inverse-variance fixed effect method
for the diuretics trials data
Method	 Estimate of overall
	 95 % C.I. for
odds ratio	 overall odds ratio
M-H likelihood 
f	 0.66	 (0.56,0.79)
Inverse-variance	 0.67	 (0.56,0.80)
The results for the meta-analysis of the two aspirin trials are also very corn-
111
Table 16: Comparison of results from the random effects likelihood based Mantel-
Haenszel-type procedure with those from the marginal likelihood random effects
method for the diuretics trials data
Method	 Estimate of overall
	 95 % C.I. for	 Estimate of between-
odds ratio	 overall odds ratio	 study variance
M-H likelihood	 0.60	 (0.37,0.97)	 0.26
Marginal likelihood	 0.60	 (0.37,0.95)	 0.24
parable (Tables 17 and 18). However, surprisingly, the confidence interval for the
overall odds ratio is narrower in the case where the full Likelihood is used. This may
be due to the fact that only two trials are being analysed leading to a peculiarly
shaped likelihood curve, particularly away from the maximum. Furthermore, the two
likelihood based confidence intervals are both much wider than that obtained using
the standard random effects model (Table 12). It is also noticeable that the two
likelihood estimates of 4 agree with each other (0.07 and 0.08), whereas the D&L
moment estimate is much larger at 0.18 (Table 12)
Table 17: Comparison of results from the fixed effect likelihood based Mantel-
Haenszel-type procedure with those from the inverse-variance fixed effect method
for the aspirin trials data
Method	 Estimate of overall	 95 % C.I. for
odds ratio	 overall odds ratio
M-H likelihood	 0.71	 (0.60,0.86)
Inverse-variance	 0.71	 (0.59,0.86)
The likelihood ratio tests based on the full likelihood give a p-value of 0.0025
for the diuretics trials data and one of 0.038 for the aspirin trials data. Both are
less powerful than the corresponding test using Q, as were the tests derived from the
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Table 18: Comparison of results from the random effects likelihood based Mantel-
Haenszel-type procedure with those from the marginal likelihood random effects
method for the aspirin trials data
Method	 Estimate of overall	 95 % C.I. for	 Estimate of between-
odds ratio	 overall odds ratio	 study varaince
M-H likelihood	 0.80	 (0.40,1.71)	 0.08
Marginal likelihood jj_0.80
	 (0.39,1.78)	 0.07
marginal likelihood model. However, the p-value for the diuretics trials data using
the full likelihood is substantially smaller than that using the marginal likelihood.
This may be due to the fact that the alternative hypothesis takes a different form,
which may, in this example, better represent the actual data.
Hence, in the examples considered so far, there is no clear advantage to be
gained from using a Mantel-Haenszel-type procedure as opposed to the marginal
likelihood model. Certainly the likelihood method based on the marginal distributions
of öj provides a good approximation to the full likelihood in circumstances where the
number of events in each trial is fairly large. Furthermore, the marginal likelihood
approach may also be used to analyse continuous outcome measures as well as binary.
However, the great advantage of the full likelihood is when there are studies which
have small and, most particularly, zero event rates. This issue is pursued in the next
section.
2.5 Dealing with Small Event Rates in Meta-Analyses
The problem of dealing with small event rates and zero event rates in trials included
in meta-analyses using binary outcome measures is introduced in Section 2.5.1. Exact
methods which are not prone to such problems and are based on the exact conditional
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likelihood are described in Section 2.5.2, while a comparison of the methods, using
two practical examples, is carried out in Section 2.5.3.
2.5.1 Introduction
When dealing with binary outcomes, if there is a trial included in the meta-analysis
which has a zero cell in the 2x2 table, then certain of the standard methods fail,
since it becomes impossible to calculate an individual odds ratio öj and variance v1.
Individual trial odds ratios and variances must be calculated explicitly in the inverse-
variance fixed effect method (Section 1.5.1), the standard random effects method
(Section 1.7.1) and the marginal likelihood method (Section 2.2), and hence it is
these methods that break down. Even if there are no zero event rates, but the event
rates are small, then the asymptotic conditions underlying the standard meta-analysis
methods will not hold [60].
One way around the problem is to add 0.5 to each cell of each 2x2 table in the
meta-a.nalysis and thus obtain empirical logits [86]. The use of empirical logits ensures
that both odds ratio and variance estimates may be obtained in all trials, and will
also reduce the bias for small sample sizes [50, 86]. Alternatively, estimation can be
based on the exact conditional distribution of the number of events in the treatment
group (Section 2.4). It was shown in Section 2.4 how van Houwelingen et a!. [45]
used the exact distribution of ö, and likelihood methodology to obtain estimates of
the overall treatment effect under both a fixed effect and a random effects model.
2.5.2 Conditional likelihood model
Similarly, although only for homogeneous data, the computer package StatXact [87]
uses the conditional likelihood of the sucient statistic S = A 1
 + A2 + ... + Ak, where
is the true number of events in the treatment group of study 1, to produce exact
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estimates and confidence limits [87]. The total log-likelihood for all k tables is given
by the sum of the k individual log-likelihoods and so the conditional distribution
of the total number of events S is considered. Hence, if the observed value of S is
3 = a, then the conditional distribution of S, that is the probability of observing
a total of S events given all possible combinations of the k tables with the observed
marginals, can be written as follows [881
c,tli'P(S=sIb)= (45)
EIP!VL 
c1b
where & =
I ni \ I flt2 \
C9 = ErEn(s) H= I4 a, ) 
¼	 )
fZ(s)={rEfl:yl+y2+...+yk=s}
YL = E=1 max(0, m 1 - n2)
Yu = E=1 min(n1 1, rn,i)
A test of 1' = e0=1 is based on this conditional distribution and an exact confI-
dence interval may be constructed by inverting this test [59]. Specifically, an exact
100 (1 -	 ) % confidence interval for 0 is given by	 where (s) is
such that
&(3)=0 if 3—YL	 (46)
P(S ^ S i&.(s)) = /2 if IlL <S <Yu	 (47)
P(S = s v5 (s)) =	 if 3 =	 (48)
and *() is such that
P(S = I i (s)) =	 if 3 = YL	 (49)
P(S^sI1/,*(s)) =/2 if IlL <3 <Yb	 (50)
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= oO if 3 =	 (51)
Hence, if the observed value of 3 is equal to the lower limit YL, then the data support
a lower confidence bound of zero, and so all of the error rate may be used computing
the upper bound. Similarly if Yu is observed the entire error rate can be used in
calculating the lower bound as the upper bound is oo. Mehta, Pate! and Gray [89]
developed a numerical algorithm for computing this exact confidence interval and
this is implemented by StatXact. The main problem is the time taken to compute
all the different possible values of c, and once this is done the confidence interval is
found easily using a binary search of all the probabilities calculated. However, due
to the discreteness of the distribution of 5, the above exact confidence interval is
conservative, with the probability usually being less than [87]. StatXact, therefore,
also produces mid-p adjusted intervals [87] which reduce the conservativeness. To
calculate these corrected intervals if YL <3 <Yu equation (47) is replaced by
P(S 3 1 (s)) + P(S>3 I .(s)) =	 (52)
and equation (50) is replaced by
P(S 3 1 f(s)) + P(S <3 I b(s)) = c/2	 (53)
2.5.3 Examples
The problem of analysing a meta-analysis when there are small numbers of events
was investigated in practical terms by means of two examples. In the diuretics trials
meta-analysis, the number of stillbirths was recorded in eight of the nine trials and
the total number of such events was small and was actually zero in some groups
(Table 19). There were no stillbirths in either group in trials 8 and 9 and as these
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trials contribute no information to the analysis the meta-analysis results are actually
based on six trials only.
Table 19: Number of stillbirths recorded for the six trials of diuretics taken during
pregnancy which contribute information to this outcome
Trial Stillbirths/Total number of patients Odds Ratio
Treated	 Control
1	 1/131(0.8%)
	
2/136(1.4%)	 0.52
2	 3/335(0.9%)	 2/110(1.8%)	 0.49
3	 1/57(1.8%)	 1/48(2.1%)
	
0.84
4	 0/34(0.0%)	 1/40(2.5%)	 0.00
5	 6/1011(0.6%)	 5/760(0.7%)	 0.90
7	 6/1370(1.2%)	 9/1336(0.7%)	 0.65
These data were analysed using the likelihood based Mantel-Haenszel-type
procedures, StatXact and also using the Peto and Mantel-Haenszel fixed effect meth-
ods. Results may be calculated by all these methods when there are zero event rates,
although the asymptotics of the Peto method may not be very good with small sam-
ple sizes. The Mantel-Haenszel estimator is known to be robust in cases where there
are small samples [50]. The results obtained from these methods were also compared
with those from the inverse-variance fixed effect method and the standard random
effects method based on empirical logits.
In this example è=0 and ô=0 and hence the fixed effect and random effects
methods produce the same results and so only the fixed effect results are presented
here (Table 20). The various confidence intervals do differ slightly (Table 20) and
it can be seen that the exact confidence interval from StatXact is wider than all
the others. This illustrates the conservative nature of the exact confidence interval,
while the corrected mid-p interval is in line with the other fixed effect intervals. The
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confidence interval for the inverse-variance method is slightly narrower than all the
others. However, in this example there is no evidence that the asymptotic methods
produce inappropriate or unreliable results.
Table 20: Results for the outcome of stillbirths in the diuretics trials meta-analysis
using several different fixed effect methods
Method	 Estimate of	 95% C.I. for
overall odds ratio overall odds ratio
Likelihood	 0.68	 (0.35,1.32)
StatXact (exact C.I.)	 0.68	 (0.33,1.38)
StatXact (mid-p C.I. *)	 (0.35,1.32)
Mantel-Haenszel	 0.68	 (0.35,1.31)
Peto	 0.68	 (0.35,1.31)
Inverse-variance (+0.5)
	
0.69	 (0.38,1.28)
* the mid-p method is only an adjustment to the confidence interval
An example with small numbers of events and statistically significant hetero-
geneity was then considered. The data are taken from a published meta-analysis of
the efficacy of BCG vaccine in the prevention of tuberculosis (TB) [90]. The results
of the 7 clinical trials which provided information on the number of TB deaths in the
vaccinated and unvaccinated groups were used, as the number of deaths was small
and there were two groups where no TB deaths occurred.
The results from each trial vary considerably, as can be seen from Table 21,
and this is probably due to the fact that the populations and geographical locations
in which the trials were carried out vary enormously. Hence, it is not surprising to
find that heterogeneity exists and ô=0.26 by the D&L moment estimator based on
the use of empirical logits, and ô,,=0.33 by the full likelihood method. All results,
using both fixed effect and random effects methods, show a significant reduction in
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Table 21: Results for 7 clinical trials looking at the efficacy of the BCG vaccine in
relation to TB deaths
Trial	 TB deaths/Total number of patients Odds Ratio
Vaccinated 1_Unvaccinated
Aronson, 1948
	 0/123(0.00%)
	
4/139(2.88%)	 0.00
Ferguson, 1949
	 2/136(1.47%)
	
9/303(2.97%)
	
0.50
Rosenthal, 1960
	 0/231(0.00%)
	
4/220(1.82%)
	 0.00
Rosenthal, 1961
	 1/1716(0.06%)	 6/1665(0.36%)
	
0.16
Comstock, 1974 8/50634(0.02%) 12/27338(0.04%)
	
0.36
Aronson, 1958
	 13/1541(0.84%)
	
68/1451(4.69%)
	
0.18
Levine, 1948
	 8/566(1.41%)
	
8/528(1.52%)
	
0.93
the number of TB deaths in the vaccinated groups (Table 22). The two random
effects methods of course provide confidence intervals which are wider than those for
the fixed effect methods. The conservativeness of the exact confidence interval from
StatXact is again evident.
It is noticeable that the three exact methods and the standard Mantel-Haenszel
estimate produce values for 0 which agree very well. However, the asymptotic meth-
ods, and particularly the methods based on empirical logits, produce larger estimates.
The use here of emirical logits does appear to slightly affect the results, as both the
inverse-variance fixed effect method and the standard random effects method pro-
duce the two largest estimates of treatment effect and are more similar to each other,
even though different models are being assumed, than they are to any of the other
estimates. However, use of empirical logits only produce a shift in the confidence
intervals, as a consequence of a different estimate, rather than a change in the width.
Overall, since there is some disagreement between estimates and heterogeneity is
present, the exact random effects likelihood estimate may be preferable in this case.
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However, the same conclusion of efficacy of the vaccine against TB would be drawn
from all methods.
Table 22: Results for the efficacy of BCG vaccine in the prevention of TB deaths
using different meta-analysis methods
Method	
H 
Estimate of overall	 95% C.L for	 Estimate of between-
odds ratio	 overall odds ratio	 study variance
Fixed effect methods
Likelihood	 0.24	 (0.16,0.35)
StatXact exact	 0.24	 (0.16,0.37)
StatXact mid-p	 (0.16,0.36)
Mantel-Haenszel	 0.24	 (0.16,0.36)
Peto	 0.27	 (0.20,0.38)
Inverse-variance (+0.5)
	
0.28	 (0.19,0.41)	 ____________________
Random effects methods
Likelihood	 0.23	 (0.07,0.46)	 0.33
Standard (+0.5)
	
0.29	 (0.16,0.54)	 0.26
Neither of the practical examples considered here has shown the asymptotic
methods to be completely unreliable. Hence, in most practical situations, this suggests
that any of the above methods may be adequate. However, it may be the case that
the asymptotic methods become less reliable when the total numbers in each trial,
as well as the event rates, become small. Further examples would be necessary to
investigate this issue more fully.
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2.6 Bayesian Approach to Meta-Analysis
As an alternative to the classical statistics approach, meta-analysis may be viewed
from a Bayesian perspective. Although a more detailed consideration of the latter
approach is outside the scope of this thesis, a brief review of Bayesian and empirical
Bayes methods is included here. Such Bayesian methods use ideas related to those
used in the likelihood based random effects approaches described in previous sections
of this chapter. Empirical Bayes methods are considered first, the concept being intro-
duced in Section 2.6.1 and the methodology described in Section 2.6.2. An example,
using the diuretics trials data, is presented in Section 2.6.3. The literature relating
to a fully Bayesian approach to meta-analysis is then reviewed in Section 2.6.4.
2.6.1 Introduction to empirical Bayes
If heterogeneity is present in a meta-analysis, then presenting only the overall estimate
of treatment effect and its variance may not be sensible from a clinical point of view,
since it does not provide an idea of the actual range of estimates that the trials
produce. However, it is difficult to compare the initial observations Ô as the precision
related to each estimate can vary quite considerably, as it does in the diuretics trials
data for example. The calculation of empirical Bayes estimates for each trial means
that the individual trial estimates become more directly comparable [31], as they will
be of a more similar precision.
The general idea behind empirical Bayes estimation is that of shrinkage, whereby
each individual observation is pulled in towards the overall mean value. This concept
is intuitively appealing because it means that the outlying estimates, and particularly
those with large variances, which appear unlikely in the context of the full set of data,
can be brought into line with the other evidence. Hence, in a meta-analysis, a new
estimate of treatment effect is obtained for each trial which also takes into account the
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combined information from all of the other trials. By incorporating these extra data,
the empirical Bayes estimates are more precise than the original observed estimates of
treatment effect. The ranking of the empirical Bayes estimates will on average more
resemble the ranldng of the true estimates more than the original observed values [311.
Furthermore, when considered as a whole, the initial observed treatment effects & will
be biased, even though they are individually unbiased [31]. For example, the largest
observation is likely to be an overestimate and the smallest an underestimate of the
true treatment effect, where the greater the sampling variability, the more likely the
under- or over-estimation. Hence, empirical Bayes estimates have certain advantages
over the simple observations of treatment effect in a meta-analysis.
Hedges and 01km [39] and Stijnen and van Houwelingen [31] proposed em-
pirical Bayes estimation for random effects models. Hedges and 01km made the
distributional assumption of normality for the random effects and used the EM al-
gorithm [85] in order to obtain estimates of 0, o and 9 for i-1,...,k simultaneously.
Stijnen and van Houwelingen [31] proposed methods where the distribution of the
random effects were both parametric and nonparametric. Furthermore, Morris [91]
used empirical Bayes inference to investigate the general problem of interpreting mul-
tiple estimates of the same quantity, but the methodology is easily adapted to the
case of meta-anlaysis.
2.6.2 Empirical Bayes methods
The setting considered here is that of the normally distributed random effects model.
In a Bayesian context, O can be thought of as having a prior distribution which is
normal with mean 0 and variance 4 [31], while the observed data Ô is also normal
with mean 0 and variance v. The Bayes estimates can therefore be considered as
those obtained from the posterior distribution of 0. The posterior distribution is
obtained using standard Bayes theory, which is straightforward in this case due to
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the normality assumption being made, and is found to be normal with mean öj, and
variance j, given by [31, 77, 91]:
o.—o.______	
vi
1	 t(vj+4)+O(vj+4) 	 (54)
2.
-
vi = (v+4)
In the empirical Bayes case 0 and 4 are then estimated from the data, rather than
their distributions being obtained through subjective judgement or prior knowledge
as they would be in the fully Bayesian case. The form of equation (54) may be
simplified by defining the 'shrinkage factor' B, where B = v/(v + 4) [91], that is
the proportion by which the estimate is shrunk towards the mean, and so
(56)
Obviously, estimates of 9 and 4 are required in order to obtain the empirical
Bayes estimates. Hence, the empirical Bayes estimate for the treatment effect in
each trial 0 consists of a linear combination of the individual observed estimate O
and the random effects estimate of the overall mean. The resulting empirical Bayes
estimate thus depends on the relative size of the within-study and the between-study
variance for each particular trial. Stijnen and van Houwelingen [31] suggest the use
of the weighted mean to estimate 0 and the D&L moment estimator of 4. The
estimates can also be obtained either using maximum likelihood methods, described in
Section 2.2.1, or by an alternative method of moments suggested by Maritz and Lwin
[77]. These alternative moment estimators are obtained by equating the estimates of
0 and var(0) with their expectations. Hence, the following expressions are produced:
(55)
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	c— k	 Ôi2.=i (V+O)
	
k	 1	 (57)
(V+O)
(58)L.e t ._O) 2vI
The moment estimator of the overall treatment effect 0 is the same as the MLE
and is again simply the weighted average taking 4 into account. By subtracting
E_ v/(v + b) from both sides of (58) and rearranging, a form is obtained which
is convenient for iteration,
(O1_O)2_V
=' (V+4)
	 (59)4= k	 1(v+4)
This expression for fr is very similar to that used for the maximum likelihood method,
given in (23), except that a squared term is missing in the denominator of each sum.
Equations (57) and (59) can now be solved iteratively in the same manner as the
maximum likelihood equations. Although equations (57) and (59) were derived using
the method given by Maritz and Lwin [77], the actual equations given in this text
were found to be incorrect and so the necessary corrections were made.
Both the maximum likelihood estimates and the alternative method of mo-
ments estimates of 0 and 4 were used in the analysis of the diuretics trials data as
an example. This then allowed the individual empirical Bayes estimates to be found
together with their variances and shrinkage factors. The two sets of results (using
different estimators of 4) were compared and the empirical Bayes estimates were
also compared with the original observed odds ratios.
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2.6.3 Results
The effect on the individual study estimates of using the empirical Bayes method can
clearly be seen, in that the individual log odds ratios are pulled towards the overall
weighted mean (Figures 20 and 21, Tables 23 and 24). The empirical Bayes estimates
based on the maximum likelihood estimates of 0 and 4 are all below zero (Figure
20), indicating that each trial produces an estimate which may be considered as being
consistent with a treatment benefit.
The moment estimate of 4 (Table 24) is larger than the corresponding MLE
(Table 23). This therefore has the effect of making the shrinkage factors smaller
which means that the estimates are not pulled towards the overall mean by such a
large amount (Figure 21). The two separate estimates of the 0 are, however, almost
equal.
Both sets of posterior variances are smaller than their corresponding v (Ta-
bles 23 and 24), which is an implicit characteristic of the empirical Bayes estimates.
This reduction is due to the extra data being incorporated into the estimates, thus
making them more precise. The variances of the estimates using the moment esti-
mators are larger than those obtained using maximum likelihood estimators. Again
this is because the moment estimate of the between-study variance is larger. A prob-
lem, however, with the empirical Bayes method is that the estimate of the variance
4 from the data will rarely be precise (Section 2.2) and hence there is a danger of
underestimating the uncertainty in the resulting inferences [40].
The amount by which the individual trial odds ratios move depends both on
the particular within-study variance v and the absolute distance, - ö,. , of the
individual estimate from the mean. The estimate from trial 8, which has a very
large variance in comparison to the MLE of the between-study variance (v = 3ô
approximately) is pulled in very considerably. This is because the large v causes B
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Figure 20: Comparison of the observed log odds ratios in each trial with the corre-
sponding empirical Bayes estimates for the diuretics trials meta-analysis using maxi-
mum likelihood methods to obtain 0 and c
ei	
estimator
Key
èj observed log odds ratio
U, empirical Bayes estimate of log odds ratio
- - Estimate of overall log odds ratio (0)=—O.5171
Estimate of between-study variance (&,) =0.2386
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Figure 21: Comparison of the observed log odds ratios in each trial with the corre-
sponding empirical Bayes estimates for the diuretics trials meta-analysis using mo-
ment estimators to obtain 0 and 4
&	
estimator	
oi
Key
0 observed log odds ratio
ã empirical Bayes estimate of log odds ratio
- - Estimate of overall log odds ratio ()=—O.5181
Estimate of between-study variance (4)=O.3170
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Table 23: Empirical Bayes estimates using maximum likelihood estimates of the
overall treatment effect 0 and the between-study variance o (diuretics trials meta-
analysis)
Estimate of overall treatment effect (Ô1)=-0.5171
Estimate of between-study variance (&i)=Q.2386
Trial Observed log Variance of Empirical Bayes Variance of Shrinkage
odds ratio (0) ___________ odds ratio (ö) ___________ factor (Be)
1	 0.04185	 0.159601	 -0.18218	 0.095632	 0.4008
2	 -0.92367	 0.117737	 -0.78934	 0.078836	 0.3304
3	 -1.12214	 0.178018	 -0.86361	 0.101952	 0.4273
4	 -1.47331	 0.298927	 -0.94155	 0.132689	 0.5561
5	 -1.39102	 0.114285	 -1.10800	 0.077273	 0.3239
6	 -0.29698	 0.014634	 -0.30961	 0.013788	 0.0579
7	 -0.26155	 0.120687	 -0.34739	 0.080148	 0.3359
8	 1.08876	 0.686372	 -0.10286	 0.177052	 0.7421
9	 0.13531	 0.067877	 -0.00919	 0.052844	 0.2215
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Table 24: Empirical Bayes estimates using moment estimates of the overall treatment
effect 0 and the between-study variance 4 (diuretics trials meta-analysis)
Estimate of overall treatment effect (è7)=-0.5181
Estimate of between-study variance (b)=0.3170
Trial Observed log Variance of Empirical Bayes Variance of Shrinkage
odds ratio (â) ___________ odds ratio (Os) ___________ factor (B1)
1	 0.04185	 0.159601	 -0.14566	 0.106163	 0.3349
2	 -0.82367	 0.117737	 -0.81382	 0.085844	 0.2708
3	 -1.12214	 0.178018	 -0.90491	 0.113993	 0.3596
4	 -1.47331	 0.298927	 -1.00972	 0.153840	 0.4853
5	 -1.39102	 0.114285	 -1.15970	 0.084005	 0.2650
6	 -0.29689	 0.014634	 -0.30665	 0.013980	 0.0441
7	 -0.26155	 0.120687	 -0.33229	 0.087409	 0.2757
8	 1.08876	 0.686372	 -0.01043	 0.216860	 0.6841
9	 0.13231	 0.067877	 0.02007	 0.055919	 0.1764
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(Table 23) to be large and hence Ô, to be dominant; in the case of trial 8, the random
effects weighted mean O is given 74% of the weight in the empirical Bayes estimate.
In contrast, trial 9 has a log odds ratio above 1, but a small variance which is well
below the between-study variance (Table 23) and ô only receives 22% of the weight
in the empirical Bayes estimate. Owing to this small shrinkage factor the estimate is
not pulled down as much as the estimate from trial 8 (Table 23). This results in the
empirical Bayes estimate for trial 9 being larger than that for trial 8 (Figure 20).
Empirical Bayes estimates are a useful way of summarising meta-analysis data
in the presence of heterogeneity. They allow the range of possible values of treatment
effect to be seen, and hence may aid decisions regarding for which sort of patients
the treatment is more (or less) effective. Furthermore, unlike the initial observed
estimates, they do take account of all the information available. The use of different
estimators of 4 may not have much impact on the empirical Bayes results. However,
it may be worth carrying out a sensitivity analysis on a variety of values of 4 as
none of the estimates of 4 are very precise and this imprecision is not taken into
account in the empirical Bayes methods.
2.6.4 A review of the Bayesian approach to meta-analysis
Most Bayesian methodology in meta-analysis has been based on the use of hierar-
chical models and is closely related to the likelihood based random effects models.
However, the approach is conceptually different and avoids the problem of having to
assume that there is some population of studies from which the studies included in
the meta-analysis are drawn at random. This is a great advantage of the Bayesian
approach as the notion of a universal population is a common criticism levelled at
the random effects meta-analysis models [33, 35]. DuMouch.l and Harris [92] and
Carlin [40] regard the studies in the meta-analysis as exchangeable. That is to say
that they are viewed as each bearing on the same general question, with some dif-
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ferences from study to study, but such that the differences cannot be anticipated a
priori [40]. Skene and Wakefield [41] also use the exchangeability assumption when
considering the analysis of multicentre trials with binary responses using Bayesian
hierarchical models. They point out that care is required over this assumption as
it is often the case that the investigators will have some prior idea of which centres
are likely to be most effective with regards to treatment. In such cases they sug-
gest the use of restricted exchangeability whereby the centres are split into groups by
some characteristic, such as country, and the centres within each group are considered
exchangeable. In general, the assumption of exchangeability means that an exchange-
able prior distribution for the effects in the different studies may be assumed, so that
the effects are independently and identically distributed conditional on the values of
certain hyperparameters [40].
The model proposed by Carlin [40] is typical of the Bayesian approach to
meta-analysis and is based on a normally distributed hierarchical model with three
stages. As with the standard normally distributed random effects model it is assumed
that the treatment effect in each trial has a normal distribution
I	 N(O,v)
	 (60)
and that the prior distribution [40, 421 is also normal and given by
0, 0,o	 N(0,4)	 (61)
Then for a Bayesian analysis, a third stage is required in which prior distributions
are specified for 0 and o. Carlin [40] assumes a non-informative prior for both
these parameters. The results for the overall mean treatment effect 0 are obtained
by writing down the likelihood and collecting terms so that the familiar standard
random effects estimate and variance is obtained (equations (18) and (19)). The
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posterior distribution for 0 conditional on 0 and 4 has mean and variance given by
E(0 I	 = (1—B8 ) Ô1 +B4 O	 (62)
Var(01 I Ôi ,	 0,4) = (1 - Bjv	 (63)
where B8 = v8/(v + 4), the shrinkage factor defined in Section 2.6.2.
The posterior distribution of the 0 conditional only on 4 may then be ob-
tamed by integrating the k independent normal distributions described by (62) and
(63) over the posterior for 0 described by (18) and (19) [401. The resulting moments
of this distribution are then
(64)
and
Var(08IÔl,...,k,4)=(1—B8)v+B
	 k	
- B8)
	 (65)
Formula (64) is the same as that used in the empirical Bayes situation. However, in
the empirical Bayes case, the point estimate of 4 calculated from the data would be
used to obtain B8 . However, Carlin [40] indicates that there is a danger of underesti-
mating the uncertainty in the resultant inferences since this prior variance can rarely
be precisely estimated from the data, as was seen by the wide confidence intervals
obtained for the estimate of between-study variance in Section 2.2.
A fully Bayesian solution, however, is computationally more complicated and
involves the integration of each of the conditional distributions described by (18),
(19), (62) and (63) over the posterior distribution of o. Carlin, therefore, adopts
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a Monte Carlo approach similar to that of Rubin [93] which provides approximate
solutions to these equations.
Malec and Sedransk [42] start from the same basic model, but then use a more
flexible prior for 0. This prior reflects the beliefs that there are subsets of 0 such
that the 0, within each subset are similar but that there is uncertainty about the
composition of such subsets. Gibbs sampling [94] may be used in order to obtain
the empirical posterior distributions of the ô which can then be used to obtain the
desired unconditional posterior moments. Similarly, DuMouchl and Harris [92] used
a series of hierarchical priors in a practical example to combine the results of cancer
studies.
Skene and Wakefield [41] also used a hierarchical model in the analysis of
multicentre trials, where they noted that the methodology is directly transferable to
meta-analysis. Again a three stage model is required, but in contrast to Carlin, was
based on the number of successes in each group given the underlying probabilities
of success Ps,, I = 1, ..., k and j = 1,2 (2 treatment groups), as the outcome with
which to work. The first stage assumes that the number of successes in each group
in each centre follow an independent binomial distribution. Hence, the first stage of
the model is a product of 2k binomial distributions. This is the model used by van
Houwelingen et al. [45] in their bivariate random effects model which is an extension
of the model described in Section 2.4.
At the second stage, a joint distribution for the Pj is specified and Skene and
Wakefield reparameterise the model so that
Pt2
i _log(1) (66)
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P'1 (67)
Hence,	 is the logistic transform of the rate in the placebo group and 9, is the
corresponding log odds ratio for centre i. It is often reasonable to assume that p(),, 9, I
j,E) is a bivariate normal distribution where = o) and E = (o, c, p).
Then assuming exchangeability, which thus allows inferences on mean values even
when the 0, are different, and a prior distribution p(t, E), the joint posterior density
p(\,0,,E I ) has the form
k	 k
,=i (1+ eAi+Oi)h1 (l + eAi)2 II I E j_1/2 exp{—([A . n.1T_)TE_1(r.	 E)I	 , sji=I
(68)
Evaluation of integrals involving the posterior density function (68) is required
in order to characterise the posterior distribution and make useful inferences. This
is computationally intensive, but may be done based on the repeated use of Gauss-
Hermite rules over a Cartesian grid [95]. For higher dimensional problems a method
based on the same iterative procedure in conjunction with importance sampling Monte
Carlo integration [96]. The marginal density of , given the data, then gives a
summary of the difference between the two treatments and that of reflects the
between-centre variability.
Eddy, Hasseiblad and Shachter [43, 97], proposed a Bayesian method for meta-
analysis which they named the confidence profile method. This method is very flexible
and may be used to adjust for different types of trials, different treatments and also
biases within the trials to be combined in a meta-analysis. The method requires prior
distributions, likelihood functions and functions describing biases to be specified.
Noninformative priors may be used, while a separate likelihood function is required
for each type of trial, each type of treatment and each type of outcome measure.
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The confidence profile method can also be extended to a hierarchical Bayes model
where there is no single overall treatment effect. Solutions to the problems basically
involve the combination of information according to Bayes formula, although the
mathematics gets increasingly complicated with increasingly complex models. Hence,
computer software has been developed along with this method [97].
Bayesian methods for meta-analysis avoid the conceptual problems of the stan-
dard random effects model and are very flexible in terms of the models which may be
set up. However, they are computationally intensive and, until fairly recently, there
have been technical difficulties arising in the calculation of the required marginal den-
sities. However, with new advances in methodology such as the development of Gibbs
sampling [98, 99], and the efficient implementations of the computer algorithms this
has ceased to be such a problem. In comparison to analytic approximation techniques
such as those proposed by Naylor and Smith [95] and Smith et a!. [96] which require
specialist software, the calculations for Gibbs sampling are much easier and hence
have become increasingly popular.
The advantage of the hierarchical Bayes model, which is equivalent to the
random effects model, is that by obtaining a distribution for o the variation in
this estimate is being taken into account. This is not the case in empirical Bayes
methods or the standard random effects methods, but it is the problem that the
likelihood models address by using profile likelihoods to obtain confidence intervals
for the parameters of interest (Sections 2.2 and 2.4).
Furthermore, Bayesian methods allow sensitivity studies to be undertaken to
assess the robustness of the inferences to the choice of model, prior and error distri-
butions [41]. For example, if one or two outlying studies are apparent, a heavy tailed
density, such as the bivariate t-distribution could be used in place of the bivariate nor-
mal density in the Skene and Wakefield model at the second stage. Carlin [40J uses a
weighted normal plot to assess the adequacy of the normal approximations, primarily
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the normality of the random effects distribution. He also uses plots which show the
dependence of the posterior mean on the value of 4 in a similar way to the sensitivity
plots described in Section 2.1. Hence, there has perhaps been a greater emphasis on
the checking of the assumptions underlying the models in a Bayesian context than
in the classical meta-analysis framework. Considerable work in this thesis, however,
is directed at applying model checking methods to standard meta-analysis methods
(Section 2.1, Chapter 3 and Chapter 5).
2.7 Comparison of alternative methods of estimating the
between-study variance
Four estimators of the between-study component of variance have been suggested
so far; the D&L moment estimator (Section 1.7.1), the Maritz and Lwin moment
estimator (Section 2.6.2) and the two maximum likelihood estimators (Sections 2.2
and 2.4). A further possible estimator of 4 is now considered, which has here been
adapted to the meta-analysis case from a related situation. This new estimate of
4 is introduced and described in Section 2.7.1. It is then compared with the D&L
estimate, to which it is closely related, in Section 2.7.2 using both simulated and
practical examples.
2.7.1 Introduction
Matthews [100] considered the problem of analysing repeated or serial measurements
of a continuous variable using summary measures. In this type of application, it is
important to consider both the within-subject variation over the repeated measures
as well as the between-subject variation. These two components of variance can be
considered as equivalent to the within-study and between-study variances in a meta-
analysis. The summary measure used for each subject is the regression coefficient
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and the precision attached to each of these slopes may vary considerably between
individuals. This leads to the consideration of a weighted analysis and hence the use
of the following model [100]:
Yij = +/31t, +6,	 (69)
where j'j is the th measurement, j = 1, .., n, on the i individual, i = 1, .., ic, taken
at time tj, and e..j i.i.d.N(0, c.). Now assuming 13i, ..., /3k are normally distributed
with mean 8o and variance 4, and may be estimated by the regression coefficients
= /3j +
	
	
(70)
E,=1
where t is t,j measured from the mean of the times of measurements for subject I
and var(b) = o + 4. Hence a weighted analysis can now be based on the weights
1/var(b). Assuming that b1 , ..., b, are independent, they have a marginal distribution
of N(/30, a +4) and hence an estimate of the between-subject variance is required.
Matthews obtains such an estimate by equating the sample variance S with its
expectation. Rearranging the resulting expression produces an unbiased estimate of
the between-subject variance which has the form
4M =S3=S—S?	 (71)
where s is the usual estimate of the variance of the slope. This expression (71) is
directly applicable to the meta-analysis situation, where S =	
- j, the
variance of the ô, where j is the simple unweighted mean of the ö, and s =	 V1.
The Matthews estimate (71) is equivalent to the D&L estimate of 4, except that S
is used as the basis for the method of moments instead of Q. In fact, when all weights
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are equal, then both these estimates of 4 are the same. As with the D&L estimator,
the unbiased nature of 4M is lost as all negative values must be set to zero. The
difference between the two estimators is that the D&L estimate takes into account the
different precisions of the individual study estimates, whereas the Matthews estimator
does not. Hence, intuitively, it would seem more sensible to use the D&L estimate. A
comparison, therefore, of the Matthews and the D&L estimators of the between-study
variance in a meta-analysis was undertaken.
2.7.2 Simulation results
Simulations were carried out in order to compare the Matthews estimate with
the closely related D&L estimate ô1 of the between-study variance in a meta-analysis
context. The D&L estimate was used as a comparison, since it is constructed in a
similar way to the Matthews estimate. Furthermore, both are simple to calculate, but
may be inferior to maximum likelihood estimates. All calculations in the simulations
were carried out using the true known values of v and the O generated from the
model (see Section 3.3.1 for details of the computer simulation methods used) in
order that any potential bias caused by the estimation of the v be avoided. In these
examples the number of studies in the meta-analysis Ic was taken to be 10 and 1000
repetitions were executed each time. The three initial simulated examples were such
that they represented cases with increasing amounts of variability in the precision of
the individual study estimates of treatment effect. Hence, the vj were taken to be
equal, slightly different and severely different; the details of the actual values used are
shown in Table 25. The sample mean and standard deviation of the 1000 simulated
values of each estimator were obtained for both the distribution of the raw estimates
of 4, that is including negative values, and the biased estimates, that is taking
max{0,ô} (Table 25). The true between-study variance 4 was set to 0.25 in all
simulations.
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Table 25: Simulation results comparing the performance of two moment estimators
of between-study variance under varying conditions
Example Estimator	 Raw results	 max{0,ô}
Mean	 Standard	 Mean	 Standard
of ô	 deviation of b	 of b	 deviation of &
1	 D&L	 0.2544	 0.6038	 0.3679	 0.4967
Matthews 0.2544	 0.6038	 0.3679	 0.4967
2	 D&L	 0.2518	 0.2686	 0.2647	 0.2528
Matthews 0.2481
	 0.3018	 0.2679	 0.2794
3	 D&L	 0.22561	 1.9060	 0.8459	 1.3861
Matthews 0.29526
	 3.1377	 1.3359	 2.3362
Key
The true values for all the simulations are:
Between-study variance 4=0.25
Overall treatment effect 0=5
Example 1: within-study variance vj=1 for all i
Example 2: v=0.6,0.55,0.50,...,0.15
Example 3: v=lO,9,8,...,l
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In the example where all the v are equal, both estimators produce exactly the
same results. This is due to the fact that in the equal weighting case, er M reduces
to & and, since the true values of v were used, equal weighting is assured for each
simulation. The result of equality can be shown algebraically, for if vj = v for all i
which implies that w = w for all i, then
2 __________________OB -
	 (kw -
	
(72)
Now since w = 1/v, then equation (72) becomes
(k_1)(9t0t)M	 (73)
As the v become increasingly more different, the performance of both the
estimators deteriorates, with the estimates becoming more biased and less precise,
but that of the Matthews estimator &M does so to a greater extent (Figure 22).
The two examples with unequal vj illustrate that when the v are different the D&L
estimator ô has a clear advantage over the Matthews estimator &M. In each of
these examples the standard deviation of the D&L estimator is less than that of
the Matthews estimator. Furthermore, when max{O,&} is taken, the fact that the
Matthews estimator is more variable than the D&L estimator means that more values
have to be set to zero. This leads to an increase in the sample mean of IM leading to
it becoming much larger than the true value of the between-study variance. Although
the same thing happens with the D&L estimator, the smaller variability means fewer
values being set to zero and hence a lesser effect on the mean (Figure 23). The
standard deviation for both estimators becomes smaller when max{O,o} is taken
due to the restriction in the possible values.
The diuretics trials data were used in order to provide a practical comparison
140
-5 -3 -1	 1	 3	 5	 7	 9 11 13
Figure 22: Distributions of the DerSimonian and Laird estimator and the Matthews
estimator of between-study variance from 1000 simulated meta-analyses for example
3 of Table 25
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Figure 23: Distributions of the DerSimonian and Laird estimator and the Matthews
estimator of between-study variance using rnax{0, &} from 1000 simulated meta-
analyses for example 3 of Table 25
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of the two estimators. The Matthews estimate Ô?JM was calculated to be 0.51, which is
very different to the D&L estimate which is only 0.23. Although this large difference
in the estimate of the between-study variance did not have a great impact on the
overall point estimate of treatment effect, the associated standard error was obviously
much larger reflecting the extra uncertainty suggested by 0BM• In the light of the
the simulations performed and since the precisions of the estimates in the diuretics
trials do vary, the D&L estimate of the between-study variance is to be preferred,
particularly since this estimate also closely agrees with the MLE.
The concern about whether an estimator should be based on a quantity which
does not take into account the varying precision of the estimates has been found
to be justified. The Matthews estimator of the between-study variance, at least in
the examples simulated, has been found to be inferior to the D&L estimator in the
meta-analysis context, and should not be used when precision of individual estimates
vary considerably. The problem of estimating 4 imprecisely is not helped by the
new estimator, as the simulations have shown it to be less precise and more biased.
In addition, the D&L estimator is as simple to calculate as the Matthews estimator
and so is still to be preferred. However, the DL estimator, it should be noted, did
not perform well in all cases and was still biased. Hence, it may be that none of the
moment estimators of the variance are very reliable and a likelihood estimate may be
a better alternative.
28 Conclusion
The sensitivity plots presented in Section 2.1 are a useful way of investigating the
robustness of the estimate of the overall treatment effect to changes in the value of
4. They provide information regarding the influence that an imprecise estimate of
4 may have on the estimate of treatment effect. Since in practice neither a fixed
effect or a random effects model is ideal, such a plot is valuable in assessing the
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validity of the results obtained from the meta-analysis. Furthermore, the plots may
be used to help determine whether the use of a likelihood meta-analysis model is
required.
Likelihood models, such as that proposed in Section 2.2, produce confidence
intervals for 9 which are wider than those obtained from the standard random effects
methodology, although this increase may be very negligible in many cases. Thus using
a likelihood approach may lead to a more cautious interpretation of the results. The
increase in the width of the confidence interval obtained from the likelihood model
in Section 2.2 is due to the fact that such a model overcomes one of the problems
with the standard random effects analysis, that is it allows for the estimation of o1
in the calculation of the confidence interval for 0. Furthermore, unlike the standard
random effects method, a likelihood approach allows a confidence interval for 4 to be
obtained. The examples presented in Section 2.3 suggest that caution is required when
interpreting results from the standard random effects methods, particularly when the
meta-analysis is based on only a small number of trials. However, when the numbers
of trials in a meta-analysis is large, then the standard method is often adequate. The
quadratic approximation to the likelihood method outlined in Section 2.3.4 is of little
practical use since the confidence intervals tend to be too narrow, and furthermore,
computationally it is no simpler than the method based on the profile likelihood.
In fact, more work is required when a transformation of the parameter of interest
is necessary to obtain reasonable quadratic approximations, as was the case in the
example presented. Hence, if a likelihood approach is to be pursued the confidence
interval should be obtained directly from the relevant profile log-likelihoods rather
than by quadratic approximation.
The Mantel-Haenszel-type random effects likelihood procedure for binary data
described in Section 2.4 offers further theoretical improvements over the marginal
likelihood method of Section 2.2. This is because such a model is based on the exact
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distribution of the 2x2 contingency table for each trial i, i = 1, ..., k, and thus the
estimation of the weights w is taken into account. This implies that the confidence
interval for 0 will, if anything, be even wider than that obtained from the marginal
likelihood model. In the examples considered (Section 2.4.3 and Section 2.5.3) both
likelihood models produced very comparable results and no clear practical advantage
was gained from the use of the Mantel-Ilaenszel-type procedure. The two methods
produced very similar confidence intervals for 0, even in cases where there were zero
event rates (Section 2.5.3), although, in general, the full likelihood approach should
probably be preferred when there are small numbers of observations in all or some
of the trials since it is based on the exact distribution as opposed to an asymptotic
approximation. Furthermore, the Mantel-Haenszel-type model may be adapted to
model the random effects using nonparametric methods in cases where the assumption
of normality is unreasonable. The marginal likelihood method does, however, have
certain advantages over the Mantel-Haenszel-type method. It is more flexible in that
it can be used to analyse continuous measures as well as binary. Such a model based on
continuous outcome measures is similar to an analysis based on a mixed model which
may be implemented in the computer software package SAS [1O1J. Furthermore,
for binary outcome measures the marginal likelihood method only requires öj and
v for each trial, whereas the Mantel-Haenszel-type procedure requires the full 2 <2
contingency table for each trial, which may not always be readily available in the
published literature. From the evidence provided by the examples in this chapter,
the choice between the two likelihood methods may depend more on the ease with
which the method can be implemented using a computer. A computer program is
available from van Houwelingen et a!. [45], written in Gauss, using the EM algorithm
to obtain the likelihood solutions for the Mantel-Haenszel-type model. The work
relating to the marginal likelihood model was carried out using GLIM where a macro
containing a simple cyclical iteration procedure was used to obtain the MLEs, and
also in Splus where standard Splus functions were used.
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A Bayesian approach to meta-analysis was briefly introduced in Section 2.6,
as the ideas are related to the likelihood approach previously considered. Empirical
Bayes estimates (Sections 2.6.1-2.6.3) were shown to be a useful alternative to a
single overall estimate of treatment effect for summarising the results from a meta-
analysis in the presence of heterogeneity. It was found that the use of alternative
estimators of 4 in the calculation of the empirical Bayes estimates öj is unlikely to
have a great deal of influence on the results. However, the robustness of each ö, to
different estimates of 4 may be worth checking, particularly if & is imprecise owing
to the meta-analysis being based on a small number of trials.
The hierarchical Bayes model (Section 2.6.4) is similar to the random effects
likelihood model, although by using the concept of exchangeability the controversial
assumption that the trials included in a meta-analysis are a random sample from
some global population of trials is avoided. Furthermore, the choice of the model,
prior and error distributions is flexible in the Bayesian framework. However, methods
tend to be computationally intensive and are perhaps conceptually more difficult for
the non-statistician than the standard meta-analysis methods. The existing Bayesian
meta-analysis literature also describes analyses to assess the robustness of the results
to various modelling assumptions. Plots similar to those of Section 2.1 have been
used in the Bayesian context, as have normal plots assessing the adequacy of the
distributional assumptions similar to those proposed in the next chapter of this thesis.
The emphasis on sensitivity analyses shown in the Bayesian context is valuable and
the ideas could be usefully translated to the classical framework. Hence, although it
is acknowledged that Bayesian methodology has much to offer meta-analysis it is not
pursued any further here. The focus of the thesis is to consider the more standard
and accessible approaches which are currently widely used in practice.
Various different estimators of the between-study variance 4 have been pro-
posed. However, none are very precise, particularly when k is small, and all become
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biased as negative values must be set to zero. Section 2.7 considered an alternative es-
timate of the between-study variance which was novelly applied to the meta-analysis
context. The estimate, based on that described by Matthews [100] when consider-
ing the problem of the analysis of repeated and serial measurements of a continuous
variable using summary measures, was adapted to the meta-analysis situation. The
estimator was found to be unsuitable for application to meta-analysis, and certainly
performed considerably worse than the D&L moment estimator of 4 in the sim-
ulation examples considered. It was less precise and more biased, particularly in
examples where the weight was unevenly distributed. However, these examples also
revealed that the D&L estimator was far from satisfactory in these unevenly weighted
situations too.
This chapter has shown that the estimation of the between-study variance in
a meta-analysis is problematic. Estimates tend to be imprecise, while allowing for
the estimation of 4 may affect the estimate of the overall treatment effect. However,
in many practical situations the use of the standard random effects method, which
incorrectly assumes that 4 is known, will produce reliable results in the presence of
heterogeneity as results can often be robust to changes in the value of 4. However,
the implications of varying 4 and allowing for its estimation by means of a likelihood
model should always be carefully considered. Furthermore, methods based on exact
distribution theory should be considered for use with sparse binary data.
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3 Checking Distributional Assumptions
To obtain confidence intervals for the fixed effect estimate of treatment effect the
assumption that the individual study estimates are normally distributed with mean
O and variance v, must be made. Additionally, in the random effects model for meta-
analysis, it is usual to make the assumption that as well as the individual study
estimates having a normal distribution the random effects have a normal distribution
too. Many of the results and methods in Chapters 1 and 2 are based on these
distributional assumptions. Section 3.1 describes the use of normal probability plots
to check the distributional assumptions of both the fixed effect and the random effects
model, while the issue of testing for normality is addressed in Section 3.2. Section 3.3
investigates the performances of the plots and tests using simulation techniques and
Section 3.4 provides some practical examples of the use of the methods. The chapter
is completed with a discussion in Section 35.
31 Normal Plots
The fixed effect version of the normal plot will firstly be described in Section 3.1.1,
followed by the corresponding random effects plot in Section 3.1.2.
3.1.1 Fixed effect plot
The contribution that study i makes to the test statistic for heterogeneity Q can be
written as q1 = (ô - öj)//, where q = Q. Tinder a normally distributed fixed
effect model, the (a, - O)/.Ji will have a standard normal distribution. Hence, the
distribution of qj, where 9 is replaced by , will be approximately standard normal,
provided that k is large. The q are ordered such that q(l) ^ q(2) ^ ... ^ q(k), and
then a normal plot, or 'q-q plot', is a display of q(i) against	 '(Fk (q)) where (q)
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and Fk (q) are the standard normal and empirical cumulative distributional functions
(cdf), that is
Fk(q) 
= >: I(q - q())/k	 (74)
where I(x)=1 for x
	 0 and 0 otherwise. It should be noted that in practice ad-
.justments must be made at the endpoints, since	 (Fk(q)) cannot be calculated for
q ^ qi or q ^ q. Blom scores [102] which are written as = (1— 3/8)/(k + 1/4)
may be used for this purpose. A q-q plot of q will produce, approximately, a straight
line through the origin with unit gradient if the specified distributional assumptions
hold. Hence, the plot can be used to provide a visual inspection of the validity of the
normality assumption that Oj '- N(0, v) in a fixed effect model.
3.1.2 Random effects plot
A plot, corresponding to that described in the Section 3.1.1 for the fixed effect model,
may be produced to check the normality assumptions underlying the random effects
model, that is 0 N(O, v) and O N(O, oj). A similar statistic to qj can be used,
except that the fixed effect estimate Oj is replaced by the random effects estimate
Ô and the additional component of variance 4 is incorporated. The statistic used
is therefore q = (O - O)/J(v + 4). Under the normality assumptions, the q
follow an approximate standard normal distribution. Therefore, under a normally
distributed random effects model, a q-q plot of the ordered q will produce, approxi-
mately, a straight line through the origin with unit gradient.
Since 4 is always greater than or equal to zero, then /(v +4), the denom-
inator of q, is always greater than or equal to 	 the denominator of q 1 . Hence,
because Oj is usually very close in value to 0,., q will be less than or equal to IqI.
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This means that each point will be shrunk towards zero in transferring from the fixed
effect plot to the random effects plot.
In addition, if v = v for all i, then under the normally distributed random
effects model, q1 will have an approximate normal distribution with a mean of zero
and a variance given by (v + ô')/v. Hence, using q, when the data actually follow the
normally distributed random effects model will produce a plot which is a straight line
going through the origin and which has a gradient which is steeper than one. In this
situation, where all within-study variances are equal, each point is pulled in towards
zero by the same proportionate amount when comparing the random effects plot to
the fixed effect plot. In fact, q can be written as cqj, where c is a constant which takes
the value v/(v + ô). However, it becomes much more difficult to predict how the
points will be transformed on the random effects plot, in comparison to the fixed effect
plot, when the variances are different. The proportion by which a point moves then
depends on the ratio of each individual within-study variance to the between-study
variance. A point with a small within-study variance v in relation to between-study
variance & will change by a greater extent in proportionate terms than a point with
a larger within-study variance, since q is now equal to (Jv/(v + ôflq. However,
in absolute terms a trial which is in the tails of the distribution of q1 , and thus with
large (Ô - will tend to change more than one in the centre of the distribution.
The points may also have different normal score values in the two plots meaning,
therefore, that the ordering of the points changes.
Examples of both types of normal plots are presented later in this chapter.
3.2 Testing for Normality
Since it may be difficult to judge from an informal visual inspection of the q-q plots
whether the data is compatible with a standard normal distribution, a test of the
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(75)
(76)
normality would be of use. The following sections (Section 3.2.1 and 3.2.2) describe
two possible tests for this purpose.
3.2.1 The Shapiro-Francia W' test
The Shapiro-Francia W' test [103] is a powerful test of departure from normality
[104] which is straightforward to carry out. Using the ordered q1 , the test is of the
hypothesis that the sample of interest is from a normal distribution with an unknown
mean and an unknown variance 2• These unknown parameters may be estimated
as follows,
I='q(i)
and
mTq
mTm
where q is the vector of the q and m is the expectation vector of the order statistics
of a sample of standard normal random variables. The Shapiro-Francia W' test
statistic is then defined by,
k	 Ic
W1 
= (> a()q(1)) 2/	 (q(i) - )2
	 (77)
i=1
where a = (mTm)h/2m. In practice, m may be approximated by the Blom scores
ñi, where
rn() =	 {(i - 3/8)/(k + 1/4))
	 (78)
Royston [104J provides a method for transformation of the null distribution of W' to
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normality so that the p-value for the test may be obtained.
It should be noted that	 (q - )2=S2 is the usual unbiased estimate of
(k - 1)o.2 where c2 is the variance of the q(i). When the sample comes from a normal
distribution, then both the numerator of (77), (E a(j) q(j) )2 , and the denominator
S2 , are, apart from a constant, estimating the same quantity, namely a 2
 [105]. Hence,
W' will be approximately equal to (k - 1)' If the sample comes from a non-normal
population then these two quantities are not, in general, estimating the same thing
and so W' will not be equal to (k - 1):'Since this test is only concerned with whether
the sample is from a normal distribution it actually tests only the linearity of the
plot. However, the hypothesis of interest here is that the observed sample is from a
standard normal distribution. Hence, the interest lies in the deviation of the points
from the line of identity, not simply in the deviation from linearity. This means that
a more useful test would be one which looked at the gradient of the plot as well as
the linearity.
An estimate of the slope of the plot may be obtained using the formula given
in (76) and hence this will give some indication of whether the slope is consistent with
unity. This implies that a calculation of the slope of the regression line of the ordered
values together with the test for linearity may indicate whether the assumption of
standard normality is reasonable. However, a single test of standard normality N(O, 1)
would be preferable.
3.2.2 The Anderson-Darling A2 test
Empirical distribution function (EDF) statistics for goodness-of-fit offer the possi-
bility of an improvement over the Shapiro-Francia W' test as they do allow for the
complete specification of the distribution of the null hypothesis. The most commonly
used EDF goodness-of-fit test is the Kolmogorov test, which looks at the maximum
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distance between the hypothesised distribution and the empirical distribution. How-
ever, due to the fact that it is only considering a maximum difference, this test is not
the most powerful EDF test. From a comparison study of 5 EDF tests, Stephens [106]
suggested that it was always worthwhile considering the Cramer-von Mises statistic
W2 , the Watson statistic U2 and the Anderson-Darling statistic A2. Sinclair and
Spurr [107] indicate that the Anderson-Darling test is designed to be more sensitive
to discrepancies between Fk(q) (74) and F(q) = (q), the standard normal function,
in the tails of the distribution, a feature which would be useful for the particular case
of meta-analysis under consideration. Hence, the Anderson-Darling statistic is the
EDF test considered here. Letting F(q()) = Z(), the Anderson-Darling statistic is
given by
_E=i(2i - 1)[ln(z()) + ln(l - Z(k+1_))] - k	 (79)A2=	 k
This statistic is based on the idea that the distribution of F(q()) is symmetric under
the null hypothesis, that is Z() = Z(k+1_i). Hence, under the null hypothesis
{E_i(2i - 1)ln(z))} - 
Ic	 (80)A2 =— k
Furthermore, under the null hypothesis Z() will take the value of the midpoint of
Fk (q( _ l) ) and Fk (q() ) so that Z() = ( + ')/2 = 2! . Hence (80) can be written as
A2=_fl E
=i (2i-1)ln( 1 ) }_i	 (81)
Then as Ic becomes reasonably large, it can be shown that - { E...i (2i - 1)ln(21) }
is approximately equal to k. This means that under the null hypothesis A2 k - k =
0. Therefore as Fk(q) becomes more different from F(q), A2 will get larger and it is
this characteristic that provides the basis for the test.
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Different versions of the Anderson-Darling test for normality are required for
different circumstances and the choice of test depends on what facts are specified
about the null distribution of the parameter of interest. There are four different
variants of the null hypothesis of normality:
(1)Mean (z) and variance (c 2) known
(2)Mean known and variance unknown
(3)Mean unknown and variance known
(4)Mean and variance unknown
Number (1) is the version of interest here, as in the present problem both the mean
and the variance of the null distribution of the q are assumed to be known, although
the estimation of Ô1
 or (3,. means that the results are only approximate. Now each Z()
is calculated by standardisation where Z(i) = (q(j) - p)/o , but in the situation under
consideration, however, u=0 and o=1 and so Z() = q(i). In the other three cases where
there are unknown parameters, estimates of jz and o.2 may be obtained from the ob-
served q(i), and then Z() can be calculated using and b 2 as required. The parameters
u and o may be estimated by à 
=	 q,j/k and 2 =	 f4)2/(k - 1) or
- /.L) 2 /k depending on what has been specified about the null distribution.
The resulting Z() are then used to calculate the test statistic A2 . Stephens [106] pro-
vides a separate table of critical values for each of the four different cases described
above. For the case where both the mean and the variance are estimated a modifica-
tion is made to A2 before it is looked up in a table, namely A2* = A2(1+4/k-25/k2).
After the necessary transformation of q(j) to a standard normal distribution
Z(), the hypothesised cumulative distribution function F(q() ) is completely specified
and the Z() should be uniformly distributed between 0 and 1. If the mean of the
sample is different to that specified then the points will tend to move towards 0 or 1.
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If the variance is different to that specified then the points will tend to move towards
each end or towards 0.5 [1061.
The performance of both the Shapiro-Francia W' and the Anderson-Darling
A2 tests are compared in Section 3.3 under different null and alternative hypotheses.
3.3 Simulation Studies
In order to compare the two tests for normality under different conditions, a series
of simulations were carried out using the methods described in Section 3.3.1. The
shape of both fixed effect q-q plots and random effects q-q plots were considered for
examples of data generated under different models in Section 3.3.2. The simulations
also presented an opportunity to investigate whether the estimation of 0 in the cal-
culation of qj, i = 1, ..., k, has an effect on the results of either test being compared.
This question is considered in Sections 3.3.3 and 3.3.4 in order that a valid and ap-
propriate test be identified (Section 3.3.5). The main aspect of the investigation,
addressed in Sections 3.3.6 and 3.3.7, is to see how well the Shapiro-Francia test and
the Anderson-Darling test are able to distinguish between correctly and incorrectly
specified meta-analysis models. Hence, the power of the two tests are investigated
and compared under various conditions.
3.3.1 Description of simulation methods
The computer program used to carry out the simulations, written in FORTRAN,
was designed to produce data points sampled from either a normally distributed
fixed effect model or a normally distributed random effects model. The routines
for generating the data were used for the investigations in Section 2.7 and Chapters
4 and 5, as well as for the work in the current chapter. Two different situations
were considered which involved the simulation of different models. Firstly, the v1 , i =
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1, ..., k were assumed known, that is the true values from which the data are generated
are used in any subsequent calculations. Such examples involve the generation of
values of such that
O P*dN(9,v,)	 (82)
where each O is generated from the distribution
0, '-'N(0,o)	 (83)
These values of 0,, together with the known v, are then used in the calculation
of Oj , b and O by standard meta-analysis methods. The data, both 0, and O,
were obtained using a random number generator, followed by a transformation to
normality. In the case where the known parameters are used, it is not necessary
to generate individual data points within each study. Hence, the results from such
simulations may apply to either a binary or a continuous outcome measure. However,
the conclusions drawn cannot be directly applied to a practicaJ situation, since the
estimation of the parameters may affect the results.
In order to investigate what happens in practice where v, as well as 0, must be
estimated from the data within each study, individual data points must be generated
in the simulations. The results presented in this Section are based on a continuous
outcome measure, as this data is less problematic to work with than simulated binary
data, and it also relates to the major practical example used to illustrate the ideas in
this chapter (Section 3.4.1). For treatment group j (j=l,2) in trial i, an individual
observation ye,,, l=1,...,n,, could be generated and the difference in means between
groups calculated. However, in order to simplify the simulations, each data point YiI,
l=l,...,n, and I = l,...,k, is generated using
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(84)
so that ö, N(O,v), where v = ô/n1 and b? =
	 —L.)2/(n.i —1), and as
before 0 N(O, 4) . The öj and v, used in the subsequent calculation of , & and
are obtained from the data yjj within each study using the standard techniques.
For this, as well as the previous situation, data following a fixed effect model may also
be produced from the same generating procedure. If ô, is from a fixed effect model,
4 may be set to zero and each O is equal to 0 and so -s N(0,vj.
For the particular issue being investigated in this chapter, subroutines were
written for the purpose of calculating q(i),
 q(j) and the Shapiro-Francia and Anderson-
Darling test statistics, and 1000 data sets were generated for each example to obtain
the required results. The number of observations n1 in each trial was set to be 50 for
all the simulations in this section.
3.3.2 Examples of the plots
Before pursuing the main simulations, examples of the type of plots, both fixed effect
(Section 3.1.1) and random effects (Section 3.1.2), that may be obtained from different
types of data are presented. A single simulated example was taken from a selection
of models where k was set at 50 and where all parameters were assumed known.
This is simply as an introduction to provide a guide to the sort of plots that may be
expected from different types of data. The number of points available was deliberately
chosen to be large to enable the shape of the plots to be seen clearly. Furthermore,
at this stage the parameters were assumed to be known, and the models generated
using (82) and (83), as there is then no problem with the validity of the assumptions
regarding the distribution of the q 1 or the validity of the tests. Initially, data sets
which conform to the two standard meta-analysis models are considered, being
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Model (1) Fixed effect model with v = v-0.1 for i = 1,..., k, k=50
Model (2) Random effects model with 4=0.5 and v = v=0.1 for i = 1, ..., k, k=50
Model (3) Random effects model with 4=0.5 and different v,
v1 - v5=0.05, v6 - v10=O.10,...,v45 - v50 = 0.5
When the data is sampled from a homogeneous normal distribution with equal within-
study variances (Model (1)), both the fixed effect plot (Figure 24) and the random
effects plot (Figure 25) follow the line of identity with any deviations being compatible
with chance. The random effects plot is very similar, although actually not identical,
to the fixed effect plot. The plots would be identical if 4=0. However, in the
example 4 must be slightly greater than 0 meaning that = cq() for all i where
c = ,/'ifçv + 4) (Section 3.1.2) is marginally less than 1.
Figure 2s: fZandni effecb normal plot of qj from a normally distributed fixed effect
model (k=50) compared with the N(0, 1) line
-3	 -2	 -1	 0	 1	 2	 3
norma scores
correlationO.996
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Figure 24-: /
	
effect normal plot of q from a normally distributed fixed effect
model (k=50) compared with the N(O, 1) line
-3	 -2	 -1	 0	 1	 2	 3
normal acorea
correlationO .996
The test results for both the Shapiro Francia W' test and the Anderson-Darling
A2 test in this example indicate that there is no evidence against normality in either
plot (Table 26). It is noticeable that the value of the statistic W' is the same for
both plots. This will in fact always be the case in examples where v=v for all i since
the within-study variances are all equal, and j is approximately equal to ô,., and q)
has been shown to be equal to cq() . Furthermore, since ñ is the same for both
q(i) and q) in the Shapiro-Francia test, then a() is the same for both the fixed effect
and the random effects version of the test. For the random effects test using the q),
therefore,
W' 
=	
a(t)cq(i))2/	 (cq(1) - c)2 = c2(	 a(1)q())2/c2 >(q(1) - ) 2	 (85)
and hence it can be seen that the c's cancel out, thus giving the test for the q ,.
Hence, the test statistic W' is equivalent in the two &tuations, and only the linearity
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of the plot is being tested.
Table 26: Results of two tests for normality for the simulated examples from models
(1)—(5) shown in Figures 24-24
Model Type of plot 	 Shapiro-Francia p-value Anderson-Darling p-value
W' statistic	 for W'	 A2 statistic	 for A2
(1) Fixed effect	 0.992	 0.95	 0.331	 >0.10
Random effects	 0.992	 0.95	 0.179	 >0.10
(2) Fixed effect	 0.977	 0.36	 14.663	 <0.01
Random effects	 0.977	 0.36	 0.315	 >0.10
(3) Fixed effect	 0.733	 <0.001	 8.375	 <0.01
Random effects	 0.965	 0.13	 1.369	 <0.025
(4) Fixed effect	 0.942	 0.02	 1.199	 <0.05
Random effects	 0.942	 0.02	 1.250	 <0.05
(5) Fixed effect	 0.921	 0.004	 1.462	 <0.025
Random effects	 0.953	 0.045	 1.186	 <0.05
5eepI3
If the data follow a random effects model with each study estimate having
the same variance v (Model (2)), the fixed effect plot (Figure 26) produces a straight
line through the origin with a gradient steeper than 1. This gradient will actually
be approximately equal to (v + 4)/v ((v + 4)/v=6 here) and the gradient of the
regression line can be estimated using equation (76). The random effects plot (Figure
27) suggests that the model fits the data with only chance deviations from the line
of identity. In this instance, it can be seen from the random effects plot that the
distribution of the q) is approximately standard normal and from the fixed effect
plot that the distribution of the q(i) is not. The estimated gradient of the line, using
(76), on the fixed effect plot is 5.6 (compared to the theoretical value of 6), which is
clearly greater than one, while the estimated gradient of that on the random effects
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plot is approximately one.
Figure 26: Fixed effect normal plot of q, from a normally distributed random effects
model with equal within-study variances (k=50) compared with the N(O, 1) line
-8 -6 -4 -2	 0	 2	 4	 6	 8
normal scores
correlationO.988
The Shapiro-Francia test applied to both the fixed effect and random effects
plots find no evidence against normality (Table 26), and the test is again necessarily
the same in both cases. The same argument as above (85) shows that this will
always be the case when all the within-study variances are equal for random effects
models as well as fixed effect models. The Anderson-Darling statistic is, however,
able to detect that the q are not standard normal and consequently does produce a
significant result (Table 26). Furthermore, the result of A2 using the random effects
q(;) is non-significant as expected.
When the within-study variances are different under a random effects model
(Model (3)), the fixed effect plot (Figure 28) still tends to produce a line with a
gradient steeper than unity going through the origin. However, this line tends to
be curved as opposed to straight, with the gradient becoming steeper towards the
tails as v, becomes larger for outlying points. The random effects plot (Figure 29)
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Figure 27: Random effects normal plot of q from a normally distributed random
effects model with equal within-study variances (k=50) compared with the N(O, 1)
line
-3	 -2	 -1	 0	 1	 2	 3
normal scores
correlation=O.988
indicates that a normally distributed random effects model may reasonable. The
Shapiro-Francia test correctly rejects normality of the fixed effect qj, but finds the
data consistent with a random effects model using the random effects q", thus correctly
identifying the true model (Table 26). The Anderson-Darling test rejects the fixed
effect model correctly, but the result for the test of the random effects is a false
positive for this example.
As well as helping to decide between the two standard normally distributed
models, these plots can also be useful in identifying sets of data which do not conform
to either. For example, a data set which is a mixture of two distributions where most
of the studies are homogeneous but where a few follow a random effects model, may
be identified. Hence, two such examples were considered,
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Figure 28: Fixed effect normal plot of q, from a normally distributed random
effects model with unequal within-study variances (k=50) compared with the N(0, 1)
line
-15	 -10	 -5	 0	 5	 10	 15
normal scores
correlatjon=O.857
Model (4) Data a mixture of fixed effect and random effects models
Moderate between-study variance 4=0.5, v=v=O.1 for i = 1, ..., k k=50
Number of points from a random effects model is 10
Model (5) Data a mixture of fixed effect and random effects models
Moderate between-study variance 4=0.5, different v,
v varied from 0.05 to 0.5 as for Model (3), k=50
Number of points from a random effects model is 10
For a situation where 40 of the studies follow a normally distributed fixed effect
model and the remaining 10 follow a normally distributed random effects model and
where the v are all equal (Model (4)), the fixed effect plot (Figure 30) produce3 a
display where the majority of the points follow the line of identity, but where some
clear outliers, which fall well away from the line, can be observed in the tails of the
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Figure 29: Random effects normal plot of q from a normally distributed random
effects model with unequal within-study variances (k=50) compared with the N(O, 1)
line
-3	 -2	 -1	 0	 1	 2	 3
normal scores
correlationO .982
distribution. The corresponding random effects plot (Figure 31) appears to be more
linear since the outlying points are pulled in towards the line of identity. However,
the majority of the points, although still forming a relatively straight line have a
gradient which is slightly less than 1. In this example, where the study variances are
all equal, the Shapiro-Francia test will again produce the same result for both plots,
as the two differ only in scale. Both A2 and W' correctly identify this data set as
being neither a fixed effect or a random effects model (Table 26). W' is specifically
a test of linearity and hence is able to detect the deviations in the tails, while A2 is
also sensitive to deviations in the tails.
This evidence suggests that if a random effects plot is obtained where the
gradient of most of the data is only slightly less than one on visual inspection, then
caution over the normality of the plot should be expressed. Hence, a test for normality
in this instance is helpful in detecting the non-normality because naive interpretation
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Figure 30: Fixed effect normal plot of q1 from a data set which is a mixture of two
distributions with equal within-study variances (k=50) compared with the N(0, 1)
line
-6 -4 -3 -2 -1 0	 1	 2 3 4 6
normal ecores
correlation=0.97O
of the plots may be misleading. The estimate of the gradient of the line can also be
misleading in situations where outliers are present as the estimate is highly dependent
on these few influential points. For example, on the random effects plot (Figure 31),
the estimated gradient is 0.95, although it can be seen quite clearly that the gradient
for the majority of the points is considerably less. Similarly the estimate of the slope
of the fixed effect plot (Figure 30) is 2.06, due to the influence of the outliers.
In the more realistic situation where the within-study variances are different
(Model (5)), although the fixed effect plot (Figure 32) and related tests still indicate
quite clearly a deviation of the plot from normality, the message from the random
effects plot (Figure 33) is far less clear. The plot shows only slight evidence of having
a gradient less than one in the middle of the distribution, and in fact the estimated
slope is approximately one. The p-values obtained from the Shapiro-Francia test and
the Anderson-Darling test, although still detecting evidence against normality using
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Figure 31: Random effects normal plot of q from a data set which is a mixture
of two distributions with equal within-study variances (k=50) compared with the
N(0,1) line
-5 -4 -3 -2 -1 0	 1	 2 3 4 5
normal scores
correlationO .970
the random effects q() are far larger than when using the fixed effect q(i) (Table 26).
3.3.3 Investigation of the null distribution of the test statistics for a fixed
effect plot
A potential problem exists with respect to the validity of the tests, since the theory
behind the distributional result, that is that under the correct models q() N 0, 1)
and q(,) N(0, 1), assume that 0 is known. Hence, in practice where 0 is estimated,
the results are only approximate. In order to investigate the validity of the tests when
parameters are estimated in the calculation of each q(,) and q), attention was focused
on the null distributions of the test statistics. For the fixed effect q firstly, under
the null hypothesis the data follow a normally distfbuted fixed effect model, so that
N(0,v,) as Yti	 N(0,crfl, where v1 =	 ( Section 3.3.1). The FORTRAN
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Figure 32: Fixed effect normal plot of q, from a data set which is a mixture of two
distributions with unequal within-study variances (k=50) compared with the N(0, 1)
line
-4 -3 -2 -1	 0	 1	 2	 3	 4
normal scores
correlation=0.96O
routine used here calculated four versions of the Anderson-Darling A2 test statistic,
together with the Shapiro-Francia W' test statistic. The number of times in 1000
normally distributed fixed effect model simulated data sets that each test statistic
was observed to be more extreme than the 5% significance level was then counted, in
order to obtain the Type-I error rate. If the null distribution of standard normality
of the q were to hold, then 5% (± twice the standard error) of the 1000 tests would
be significant. The number of trials in each data set was taken to be 20 in order to
create a realistic meta-analysis situation.
There are then four different ways in which q1 can be calculated in the simula-
tions, depending on whether 0 or v, or both, are estimated, and these are as follows:
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Figure 33: Random effects normal plot of q from a data set which is a mixture of two
distributions with unequal within-study variances (k=50) compared with the N(O, 1)
line
-4 -3 -2 -1	 0	 1	 2	 3	 4
normal ecore,
correlation=O.976
(a) qi=(&—O)/'./
(b) qj= ('—O)/'/
(c) qj = ( Ô -
where v now refers to a known within-study variance o/n and j refers to an esti-
mated within-study variance. Although it is only case (d) that is of practical concern,
all four cases are considered in order to deduce whether the estimation of the param-
eters has any effect on the tests. Data from a correct model will strictly only produce
a straight line through the origin with unit slope if it is assumed that both 0 and v
are known, that is in case (a). For all other cases this result is approximate and henc'
case (a) is the standard to which the others, and particularly (d), will be compared.
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Furthermore, due to there being four different versions of the Anderson-Darling
test (Section 3.2.2), the z used to calculate the A2 statistic also take four different
forms:
(1) ;=(q,-0)/1
(2) z,=(q1—O)/ô
(3) z=(q1—)/1
(4) z=(q1—ji)/ô
Hence, there are actually sixteen different versions of the Anderson-Darling test to
be considered, together with four versions of the Shapiro-Francia test, that is one
for each of (a)—(d). The version of the Anderson-Darling test of real interest for
the situation under consideration is (1), since the interest lies in obtaining a test of
standard normality and so the mean and variance of the distribution under the null
hypothesis are both known.
Table 27: Results from the simulations under the null hypothesis that the data follow
a normally distributed fixed effect model (that is when q .- N(O, 1))
Version	 Parameter	 Type-I error (% significant from 1000 tests)
of qj
	
Overall Within-study Version of A2 test	 Shapiro-Francia
effect (0) variance (vi )	 (1) (2) (3) (4)	 W'test
(a) known	 known	 5.0 5.8 5.2 5.6	 5.4
(b) known	 estimated	 4.8 4.9 4.3 4.5	 4.3
(c) estimated known	 0.1 0.0 4.9 6.4	 6.6
(d) estimated estimated	 0.1 0.0 4.8 4.7	 4.7
It can be seen from the results that not all versions of the Anderson-Darling
test produce the desired 5% error rate (Table 27). Focusing firstly on the practical
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case where q is calculated using estimates of both 0 and v, that is case (d), it can
be seen that versions (1) and (2) of the Anderson-Darling test produce error rates
which are far below 5% and are in fact approximately zero. This means that the
test will be extremely conservative and, in practice, will be very low in power. The
same results occur for case (c), but not for cases (a) and (b). The common factor
linking cases (c) and (d) is that they are the two situations where 9 is estimated in
the calculation of q(t). Furthermore, the two versions of the test, (1) and (2), which
produce low error rates are those where the mean of the distribution of the qi under
the null distribution is assumed to be known. Hence, the estimation of 0 affects the
performance of version (1) of the Anderson-Darling statistic and prevents it being
of any practical use. The results for version (3) of the Anderson-Darling test are
compatible with the 5% significance level in all cases.
The fact that the error rates for case (b) are around 5% for all versions of the
Anderson-Darling test (Table 27) suggests that the estimation of the v does not cause
any serious problems, at least for the example considered. Furthermore, version (3)
of the Anderson-Darling test appears reasonable under case (d). Hence, version (3),
that is where the null hypothesis tested is that of H0 : 9 .- N(, 1), may be used in
practice. Although not being ideal, this version at least provides an improvement over
the Shapiro-Francia test, in that the value of the variance of the q(i), or equivalently
the gradient of the line on the fixed effect plot may be tested as well as the normality of
the distribution. Hence, such a test is at least able to distinguish between a normally
distributed fixed effect model and a normally distributed random effects model by
detecting the increase in slope on the fixed effect plot with the latter.
Further investigation of version (1) of the Anderson-Darling test using q 1 where
0 and u are estimated, the case of practical interest, revealed that it is not the null
hypothesis of standard normality of the q which is being tested . For an example
where v- = v for all i, the null hypothesis actually being tested is Ho :	 N(0, v),
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where 0 and v are unknown. By treating this as the null hypothesis, and therefore
calculating the Anderson-Darling statistic using z = (O -	 (i.e. using the qj
as the zj, the correct 5% significance level is obtained. In a case where v=v for all
i, this test of Ôr- N(0, v) does check the distributional assumptions of a fixed effect
model adequately. However, when the v are different each öj has its own normal
distribution Ô N(0, v,) and hence, the null hypothesis relating to the distribution
of the 3j cannot be tested.
Finally, it is observed that the null distribution for case (c) for both the
Shapiro-Francia test and version (4) of the Anderson-Darling test produce Type-I
errors which are significantly larger than 5%. This may just be by chance, but it
may also mean that the power of these tests is artificially increased. However, since
case (c) is not of practical relevance and the increase is only slight, this issue was
not investigated further. Also, the fact that the results for (d) are compatible with a
value of 5% lends support to the view that they have occurred by chance.
3.3.4 Investigation of the null distribution of the test statistics for a ran-
dom effects plot
Simulations similar to those described in Section 3.3.3 were used to consider the
performance of the tests using the random effects q)• This time, however, the data
were generated under the normally distributed random effects model ((83) and (84) of
Section 3.3.1) with 4=0.5. Only versions (3) and (4) of the Anderson-Darling test
were considered here, since the previous investigations (Section 3.3.3) showed that
versions (1) and (2) are obviously very conservative and lacking in power when 0 is
estimated, and are therefore of no practical use.
Confirmation of the validity of all of the tests when all parameters in q are
known was obtained (Table 28). However, when the parameters 0, v, I = 1, ..., k and
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Table 28: Results from the simulations under the null hypothesis that the data follow
a normally distributed random effects model (that is when q) N(0, 1))
Parameter	 Type-I error (% significant from 1000 tests)
Overall Variance	 Version	 Shapiro-Francia
effect (0) (v + 4) of A2 test	 W' test
__________ __________ (3) (4) ______________________________
known	 known	 5.6 5.6	 5.3
	
estimated estimated 0.7 5.8
	 5.9
4 are estimated in the calculation of q, even version (3) of the Anderson-Darling
statistic is affected. Results for the null distribution indicate a significance level of
under 1% rather than the required 5% (Table 28). This lowering of the type-I error
rate must be due to the estimation of the between-study variance 4 in q, since it
has been shown in Section 3.3.3 that the estimation of v alone does not apparently
affect the test. Hence for the random effects components q, the only valid test is one
of the null hypothesis H0 : q1 N(4u, oi) which is the same as that for the Shapiro-
Francia W' test. The Shapiro-Francia test is not affected noticeably, if at all, by the
estimation of the parameters in q (Table 28).
3.3.5 Conclusions from the simulations under the null hypothesis
The results obtained strictly only apply to normally distributed continuous outcome
measures, as this is the type of data that were generated in the simulations. However,
since 0 is estimated in exactly the same way, that is by a weighted average of the
individual estimates, for a binomial outcome, then it is likely that versions (1) and
(2) of the Anderson-Darling test will again loe- power. The simulations obviously
indicate that the test of the null hypothesis H0 :	 N(O, 1), that is where the null
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distribution is completely specified, using the tables proposed by Stephens [1061, is
of little use in the practical situation where 0 must be estimated in the calculation of
qj. An improvement over merely being able to test for normality is to test H0 q
N(, 1) and hence version (3) of the Anderson-Darling test is to be preferred when
considering the distribution of the q(,)• By testing this hypothesis, an advantage is
obtained over the Shapiro-Francia test in that it enables a distinction to be made
between a fixed effect model and a random effects model using the components q(i).
However, on a random effects plot using q(j), version (4) of the Anderson-Darling test
must be used, that is taking the null hypothesis to be H0 : q, N(c, o2), which is
exactly equivalent to the null hypothesis of the Shapiro-Francia test.
In the simulations considered, since n was set to 50 for each study v will have
been reasonably well estimated. Hence, further simulations for smaller values of n,
would be required to be able to make the generalisation that the estimation of v from
individual study data does not noticeably affect the performance of the test.
3.3.6 Power of the tests for normality for fixed effect and random effects
models
The power of the tests in relation to the fixed effect plots were investigated for mod-
els (1)—(3) (Section 3.3.2). Random effects plots were not considered since these
models are all compatible with random effects models. For each example, 1000 rep-
etitions were again simulated in order to investigate the performance of version (3)
of the Anderson-Darling test, as well as the Shapiro-Francia test. Version (3) of the
Anderson-Darling test was considered since it should be able to distinguish between
a fixed effect model and a random effects model based on calculations using the fixed
effect q(1). Thus, it should have a clear advantage over the Shapiro-Francia test for
the three examples to be looked at. Each simulation was repeated twice, firstly as a
standard for comparison against, taking the parameters 0 and v1 to be known in the
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calculation of qj, and secondly, taking them to be estimated.
Table 29: Results of simulations looking at the power of the tests of normality using
the fixed effect q for data which follow three standard models (Section 3.3.2) when
the overall treatment effect 0 and the within-study variances v1, i = 1, ..., 20, are
known
Model	 Power (% significant from 1000 tests)
Anderson-Darling A2 test Shapiro-Francia W' test
________	 (Version(3))	 _________________________
(1) 5.1	 5.5
(2) 99.9	 4.7
(3) 100.0	 12.4
Table 30: Results of simulations looking at the power of the tests of normality using
the fixed effect q(i) for data which follow the standard models (Section 3.3.2) when
the overall treatment effect 0 and the within-study variances v, i = 1, ..., 20, are
estimated
Power (% significant from 1000 tests)
Model Anderson-Darling A2 test Shapiro-Francia W1 test
_______	 (Version_(3))	 ________________________
(1) 5.3	 4.6
(2) 99.9	 5.5
(3) 100.0	 14.8
The results for the power of both tests under models (1), (2) and (3) are
very similar whether 0 and v, i = 1, ..., k are known or whether they are estimated
(Tables 29 and 30). Version (3) of the Anderson-Darling test exhibits good power
when it comes to detecting a data set which follows a random effects model (Models
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(2) and (3)) from the q of a fixed effect plot (Tables 29 and 30). This is because the
variance of the distribution of each set of simulated qj will be significantly greater
than 1 and H0 : N(1u, 1). The Shapiro-Francia test does find the random effects
model with equal variances, Model (2), consistent with the null hypothesis of general
normality. For Model (3), however, where the v are different, thus introducing some
non-linearity into the plot, the power of the Shapiro-Francia test increases from the
null level of 5%. However, the power is very low at only 12.4% for known parameters
(Table 29) and 14.8% for estimated parameters (Table 30), since the test only detects
deviations from linearity rather than the more obvious deviation of the variance from
unity.
The Shapiro-Francia test cannot therefore effectively distinguish between the
normally distributed fixed effect model and the normally distributed random effects
model, based on the q, from a fixed effect plot, whereas the Anderson-Darling test
can. The plots may be used together and a random effects plot can consolidate the
findings from a fixed effect plot. For example, a random effects plot which produces
an approximate straight line with a gradient equal to 1, and corresponds to a fixed
effect plot with a line with a gradient greater than 1, will support the conclusion that
the data is well represented by a normally distributed random effects model.
3.3.7 Power of the tests for normality for data which conform to neither
of the standard meta-analysis methods
As well as being able to distinguish between the two standard normally distributed
meta-analysis models, it is useful to be able to detect data for which neither of these
models is appropriate. However, there are many different alternative forms that such
data could take, and hence only a brief exploratory investigation is practical here. A
data set which consists of a mixture of observations obtained from both a fixed effect
model and a random effects model is considered.
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The mixed models (4) and (5) outlined in Section 3.3.2 were considered, but
further variations were introduced whereby the number of random effects points in
each set of data was varied. Hence for each model, (4) and (5), the number of points
from a random effects model was taken to be 10, 20 and then 40. Again, both
situations where 0 and v, i = 1, ..., k, are known and where they are estimated were
simulated. A further model (Model (6)) was also considered in order to investigate the
effect of increasing the size of the between-study variance 4 relative to the within-
study variances v1 . Model (6), therefore, uses the same value of v=v as model (4),
but 4 is increased from 0.5 to 1.0.
Model (6) Data a mixture of fixed effect and random effects models
Large between-study variance 4=1.0 and v=v=0.1 for i = 1, ..., k
Number of points from a random effects model is 10, 20 and 40
Although neither the Shapiro-Francia test or version (3) of the Anderson-
Darling test is affected by the estimation of 0 and v1 under the null distributions,
the power of both tests appears, in general, to increase slightly under the alternative
models simulated here (comparing Tables 31 and 32). This may be due to the fact
that additional variability is introduced into the qj by the estimation of the parame-
ters, thus meaning that there is an increase in the non-linearity of the normal plot.
However, the interpretation of the tests remains unchanged, since the 5% error rate is
maintained (Section 3.3.3). The Anderson .Darling test has consistently greater power
than the Shapiro-Francia test when the parameters are known, except in the case of
model 5) when the number of random effects points is 10. But even in this mdi-
vidual example, the powers are approximately the same (Table 31). In the realistic
situation when the parameters are estimated, the power of both tests increases and
so the Anderson-Darling test still remains more powerful than the Shapiro-Francia
test (Table 32).
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When there are only a few points from a random effects distribution, the power
of the two tests tends to be similar with neither test performing particularly impres-
sively (Tables 31 and 32). The power of the Anderson-Darling test does, however,
increase as the number of random effects points increases, and, when there are 40 out
of 50 points from a random effects model, the power is very high and approaches 100%
for the values of 4 and v considered here. In contrast, the power of the Shapiro-
Francia test generally decreases as the number of random effects points increases and
is low when there are 40 random effects points. This contrast in the results observed
may be easily explained by the fact that one test (W') is looking at only linearity
H0 : q 1	 N(1e, 0.2) while the other (A2 ) is concerned with the gradient of the slope
as well H0 : q(j) N(1i, 1). As the number of random effects points in the data
increases, the variance of the distribution of the q(i), and equivalently, therefore, the
gradient of the slope on the fixed effect normal plot, increases. Hence, version (3) of
the Anderson-Darling test gains power as the variance gets increasingly larger than
one. In contrast, particularly in the example where the within-study variances are
equal (Models (4) and (6)), the plots will be more linear when there are 40 random
effects points than when there are 10 such points. This is because 10 random effects
points are more clearly seen as outliers among 40 fixed effect points than are 10 fixed
effect points among 40 random effects points.
The power of both tests increases, in general, as the between-study variance of
the random effects distribution increases from 0.5 to 1.0. This is to be expected since
an increase in the between-study variance will lead to an increase in the variation
observed in the data. Also, the power of both tests, although particularly that of W',
tend to increase when the v are allowed to be different as opposed to being equal.
The increase in power of the Shapiro-Francia test is due to the fact that the differing
variances are an additional source of non-linearity on the fixed effect plot which may
be detected by the test.
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Table 31: Results of simulations looking at the power of the tests of normality using
the fixed effect q(i) for data which follow a mixed model when the overall treatment
effect 0 and the within-study variances v, i = 1, ..., 20, are known
Model Power (% significant from 1000 tests)
Number of random effects points
_____ A2_110_W' A2 
20	
A2 
40
(4) 29.9 22.9 77.1 20.2	 99.6	 7.8
(5) 34.8 34.9 80.8 41.0	 99.8 22.2
(6) 66.2 49.4 98.5 46.0 100.0 8.7
A2=Anderson-Darling test statistic
W'=Shapiro-Francia test statistic
When trying to detect in practice a set of data which is a mixture of the
two standard models, it is not completely clear as to what approach to take. The
Anderson-Darling test (version (3)) was shown to be a generally more powerful test
than the Shapiro-Francia test for the purpose of detecting such data. Furthermore, a
look at the plots may be helpful, although the random effects plots may sometimes
be misleading in that it may suggest that the random effects model is adequate when
in fact the test shows it not to be (Section 3.3.2).
3.4 Practical Examples
Data sets will now be considered to provide examples where the techniques described
in Sections 3.1 and 3.2 are used as an aid to the interpretation and investigation
of heterogeneity. Section 3.4.1 looks at the reduction in blood pressure in the mild
hypertension trial (Section 1.3.2), an example where the normal plots produce clear
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Table 32: Results of simulations looking at the power of the tests of normality using
the fixed effect q for data which follow a mixed model when the overall treatment
effect 0 and the within-study variances v, i = 1, ..., 20, are estimated
Model Power (% significant from 1000 tests)
Number of random effects points
10	 20	 40
A2 W' A2 W'	 A2 1. W'
(4) 38.4 27.1 80.3 24.1	 99.8	 9.3
(5) 43.2 37.1 79.6 41.0	 99.8	 23.1
(6) 68.2 52.3 98.4 46.7 100.0 13.2
A2=Anderson-Darling test statistic
W'=Shapiro-Francia test statistic
pictures owing to the large number of observations available. Section 3.4.2 considers
an example, the diuretics trials meta-analysis (Section 1.3.1), where the plots are
of less use for checking distributional assumptions because of the small number of
trials. However, the example does show how the plots may be useful for investigating
sources of heterogeneity, and the Gaibraith plot [66] is also presented as a further way
of displaying meta-analysis data.
3.4.1 Mild Hypertension Trial
The assumption of homogeneity of treatment effect across all centres in the mild
hypertension trial was tested formally using the Q statistic (Section 1.6). The test
was carried out for the reduction in both systolic blood pressure (SBP) and diastolic
blood pressure (DBP) on the results for the treatment and placebo groups separately,
and also for the difference in blood pressure reduction between these two groups.
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Centre 1 was excluded in these analyses for reasons given in Section 1.3.2.
Table 33: Results of the test for heterogeneity for diastolic blood pressure reduction
between entry to the MRC mild hypertension trial and a year after entry
Outcome	 Statistic for	 Degrees of Q/df p-value
___________________ heterogeneity (Q) freedom (df) ______ ________
Placebo group	 1131.51	 188	 6.0187 <0.0001
Treatment group
	 953.79	 188	 5.0734 <0.0001
Difference between	 278.12	 188	 1.4794 <0.0001
placebo and treatment
Table 34: Results of the test for heterogeneity for systolic blood pressure reduction
between entry to the MRC mild hypertension trial and a year after entry
Outcome	 Statistic for	 Degrees of	 Q/df p-value
___________________ heterogeneity (Q) freedom (df) ______ ________
Placebo group
	 1052.06	 188	 5.5961 <0.0001
Treatment group	 760.78	 188	 4.0467 <0.0001
Difference between
	 246.28	 189	 1.3031 <0.005
placebo and treatment
The results show strong evidence of a lack of homogeneity across centres in
all cases (Tables 33 and 34). However, there is far greater heterogeneity within each
group individually than there is when the two groups are compared by taking the
difference in means. The extent of the heterogeneity, summarised by Q/degrees of
freedom, in the results for DBP (Table 33) is somewhat greater than the evidence of
heterogeneity in those for SBP (Table 34).
The results for the q-q plots will now be discussed for DBP only, as those for
SBP provide an almost identical picture. When looking at the difference in reduction
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of blood pressure between treatment and control groups using a fixed effect q-q plot,
the majority of the data falls along the line of identity and it is only in the tails
of the distribution where there is any deviation from this line (Figure 34). This
plot is similar to those obtained from simulations of data from a mixture of two
distributions (Figures 30 and 32). The Shapiro-Francia W' test (p 0.01) and
the Anderson-Darling test (p<O.Ol) indicate that there is strong evidence against
normality. The estimated slope of the regression line of 1.47 is not very informative
in this example as it can clearly be seen that the plot is made up of two different
groups of points and the estimate is influenced by the points in the tails of the
distribution of q(j). When the corresponding random effects plot is looked at, there
is no great visual evidence of a lack of fit of the random effects model, although it
should be noted that the middle section of the plot does have a gradient less than one
(Figure 35). This plot may suggest that the random effects model with the normality
assumptions is a reasonable representation of the data. The estimate of the slope is
only slightly less than one (0.99) and therefore strengthens the view that the random
effects model is a reasonable fit to the data. However, as was seen with the simulated
examples, the estimate of the slope may be highly dependent on extreme and outlying
values. Rather surprisingly, the Shapiro-Francia test provides stronger evidence of
non-normality from the q) than it did from the q and produces a p-value of 0.007.
The explanation may be that there are greater deviations from linearity in the centre
of the distribution which the test is sensitive enough to detect, and, furthermore,
the change of scale on the random effects plot may be rather deceptive. Hence the
random effects plot does not show the model violation as clearly as the fixed effect
plot, but according to the test based on the q it provides stronger evidence against
normality than the test based on q1)•
The fixed effect plot for each individual group (treatment and placebo), in
contrast, both produce straight lines through the origin with gradients steeper than
one (Figure 36). The estimate of this slope for the treatment group is 5.04 and
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Figure 34: Fixed effect normal plot of qi for the difference in the reduction in diastolic
blood pressure between the treatment and control group in the mild hypertension trial
compared with the N(0, 1) line
.4	 -3	 -2	 -1	 0	 1	 2	 3	 4
normal scores
correlatjon0 .990
this evidence suggests that there is great heterogeneity present which is distributed
throughout the centres. The results of the Shapiro-Francia test (pO.008) and version
(3) of the Anderson-Darling test (p<O.Ol) suggest that the plot is not in fact linear
and that there is significant evidence against normality. These results, together with
the shape of the plot, indicate that the sample may be from a random effects model
with different within-study variances. The random effects plot (Figure 37) reinforces
this view as the points fall along the line representing the N(0,1) distribution. The W'
test (pO.08) and the Anderson-Darling test (p<O.l) provide some evidence of non-
normality, but this is not overwhelming. Also, the estimate of the gradient is very close
to unity and hence the random effects model may be an acceptable approximation to
the data obtained from the treatment group.
In the case of the difference in blood pressure reduction between the two
groups, it is possible to remove the heterogeneity from the data by omitting a small
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Figure 35: Random effect normal plot of q' for the difference in the reduction in dias-
tolic blood pressure between the treatment and control group in the mild hypertension
trial compared with the N(O, 1) line
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correlationO .989
Figure 36: Fixed effect normal plot of q for the reduction in diastolic blood pressure
in the treatment group in the mild hypertension trial compared with the N(O, 1) line
-8	 -6 -4 -2	 0	 2	 4	 6	 8
norma scores
correlatjon—O.990
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Figure 37: Random effects normal plot of q for the reduction in diastolic blood
pressure in the treatment group in the mild hypertension trial compared with the
N(O,1) line
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number of the outlying centres, that is those in the tails of the q-q plot. In contrast,
for the individual groups (treatment and placebo), the heterogeneity is distributed
throughout all the centres. In order to deduce the centres which are the source of the
heterogeneity for the difference between groups in the reduction of blood pressure,
'outlying' centres were excluded one at a time, in order of decreasing size of q. As
each centre was removed Q was recalculated, using a new estimate of 0 each time,
and this procedure continued until enough centres had been removed to produce a
value of Q which corresponded to a p-value of 0.1 or above. The value of the degrees
of freedom of the x2 distribution to which Q is compared is obviously reduced by one
each time a centre is removed.
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Table 35: Centres are removed in turn, starting with the most heterogeneous, until
p> 0.1 for the test for heterogeneity Q for the difference in the reduction in diastolic
blood pressure between the treatment and placebo groups
Centre	 q, for	 Statistic for	 Degrees of	 Xk....1)
removed centre removed heterogeneity (Q) freedom (k - 1) (p=O.1)
	
278.12	 188	 214
118	 15.94	 262.18	 187	 213
65	 13.35	 248.83	 186	 212
162	 12.82	 236.02	 185	 211
186	 11.97	 224.05	 184	 210
36	 10.96	 213.09	 183	 209
176	 8.73	 204.36	 182	 208
k=189=number of centres in study
Heterogeneity, for the difference in the reduction of blood pressure between
groups, can be removed by omitting only 6 centres for each of systolic and diastolic
blood pressure (Tables 35 and 36). It is not the same set of centres that contribute to
the heterogeneity for both systolic and diastolic blood pressure outcomes, although
there is some overlap. The reasons for the large contributions being made to Q by
these particular centres were identified and are recorded in Tables 37 and 38. The
possibility of investigating clinical reasons behind such results in these centres then
exists, but is not pursued here.
Plots of q(i) for DBP against q for SBP show a positive correlation (Figure
38). Hence, larger than average reductions in DBP tend to be accompanied, as would
be expected, by correspondingly larger than average reductions in SBP. The plots of
qj for the placebo group against the treatment group for both DBP (Figure 39) and
SBP clearly show how there is great variation across centres within each treatment
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Table 36: Centres are removed in turn, starting from the most heterogeneous, until
p> 0.1 for the test for heterogeneity Q for the difference in the reduction in systolic
blood pressure between the treatment and placebo groups
Centre	 qj for	 Statistic for	 degrees of	 Xk_1)
removed centre removed heterogeneity (Q) freedom (k - 1) (p=O.l)
	
246.28	 188	 213
3	 7.84	 238.43	 187	 212
18	 7.45	 230.99	 186	 211
48	 7.10	 223.88	 185	 210
118	 6.92	 216.96	 184	 209
186	 6.47	 210.49	 183	 208
30	 6.46	 204.03	 182	 207
k=189=number of centres in study
group, that is in the x and y direction on the plot. They also indicate that a strong
relationship exists between the blood pressure reduction in the placebo group and
that in the treatment group. Hence, centres with larger than average reductions in
the treatment group also tend to have large reductions in the placebo group.
Hence, this information indicates that there is an important 'centre effect' in
this set of data. The effect is seen in the individual groups, but when the difference
is taken this 'centre effect' is largely cancelled out, leaving the heterogeneity confined
to only a handful of centres. it is, furthermore, interesting to note the presence of
a 'placebo effect' in this study, whereby a mean reduction in blood pressure occurs
in the group of patients who received only a placebo rather than an active drug.
There is a large variation in the 'placebo effect' across centres, with observed average
reductions in blood pressure in some centres being extremely large. The 'placebo
effect' may result from the psychological effect on the patients of participation in a
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Table 37: Reasons for the large contributions to heterogeneity of the centres removed
for the difference in the reduction of diastolic blood pressure (DBP) between the
treatment and placebo groups
Centre No. patients Difference Variance of Mean reduction Mean reduction
in centre	 difference	 (placebo)	 (treatment)
118	 61	 14.47	 5.26	 3.94	 18.41
65	 146	 10.40	 1.92	 -1.00	 9.40
162	 29	 -7.47	 12.79	 8.89	 1.41
186	 142	 0.34	 2.06	 7.75	 7.86
36	 79	 12.07	 4.15	 -1.60	 10.47
176	 35	 15.50	 11.88	 -0.16	 15.34
Difference=difference in mean DBP reduction between treatment and placebo
groups
(Overall average difference in mean DBP reduction between groups=5.lmmHg)
Mean reduction=mean reduction in DBP in single group
Centre Reason for large q
118
	
Large treatment effect
65
	
Placebo group has negative difference and small variance
162 Placebo effect much larger than treatment effect
186 No difference in effect between groups and small variance
36
	
Placebo group has negative difference
176 Large difference between groups
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Table 38: Reasons for the large contributions to heterogeneity of the centres removed
for the difference in the reduction of systolic blood pressure (SBP) between the treat-
ment and placebo groups
Centre No. patients Difference Variance of Mean reduction Mean reduction
in centre	 difference	 (placebo)	 (treatment)
3	 104	 20.77	 13.00	 1.16	 21.39
18	 19	 -8.27	 48.23	 13.67	 5.40
48	 107	 1.96	 10.72	 25.00	 26.96
118	 61	 21.22	 16.02	 12.41	 33.63
186	 142	 3.27	 8.51	 22.32	 25.59
30	 105	 1.95	 11.84	 20.11	 22.05
Difference=difference in mean SBP reduction between treatment and placebo groups
(Overall average difference in mean SBP between groups=10.4mmHg)
Mean reduction=mean reduction in SBP in single group
Centre Reason for large q
3
	
Small placebo effect and quite large treatment effect
18
	
Placebo effect much larger than treatment effect
48
	
Small difference in effect between groups
118 Large treatment effect
186 Small difference in effect between groups
30 Small difference in effect between groups
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Figure 38: Plot of qj for diastolic blood pressure against systolic blood pressure for
the difference between the treatment and the placebo group (correlation=O.539)
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Figure 39: Plot of qj for placebo group against treatment group in the mild hyper-
tension trial (correlation=O.712)
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trial and their being put on a course of tablets, as well as 'regression to the mean'
and some patients being changed to an active treatment. The heterogeneity in the
treatment and the placebo groups could be partially explained by, for example, a
'nurse effect', where some centres may have had a particularly reassuring research
nurse. Additionally, the standard of further care may have varied between centres
and this could have lead to heterogeneity, or the characteristics of the patients may
have varied between centres too, with certain groups possibly being more responsive
to treatment than others.
In this example, the plots have provided information regarding the possible dis-
tribution of the data and hence, the suitability of the standard meta-analysis models.
Information was also gained about the location and distribution of the heterogeneity
and possible outlying centres could be identified for further investigation.
3.4.2 Diuretics Trials Meta-Analysis
In contrast to the multicentre trial of the previous section, where there were 189
observations on the q-q plot, actual meta-analyses tend to contain only a limited
number of trials. In such situations the q-q plots are not so informative with regards
to the distribution of the data. The diuretics trials meta-analysis (Section 1.3.1)
illustrates the problem that is likely to be encountered since it produces q-q plots
with only nine points. The fixed effect plot (Figure 40) clearly indicates the presence
of heterogeneity within the data and that the q(j) are not standard normal as the
gradient of the plot is steeper than one, with the actual estimate of the regression
line being 3.55. Furthermore, the plot suggests the possibility of there being two
separate groups of trials. The first group of trials, which have individual treatment
effect estimates greater than the overall mean (trials 1, 6, 7, 8, 9), fall closer to the line
of identity than the group of trials with estimates smaller than the overall mean (trials
2, 3, 4, 5). The information thus gained may then be helpful when investigating the
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reasons underlying the heterogeneity. For example, trial 5, which makes the largest
contribution to the statistic for heterogeneity can be identified as a possible outlier
because it produces one of the largest treatment effects. Investigation reveals that
this is the only trial which uses the drug Bendroflumethiazide for the treated group
and, furthermore, that the entry criterion is 30 weeks or more into the pregnancy,
which is later than in nearly all the other trials. Hence, it may be that the result
observed in this trial was due to its having these different characteristics in design.
Figure 40: Fixed effect normal plot of q, for the diuretics trials meta-analysis corn-
pared with the N(0, 1) line
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If an explanation for the two groups of trials observed were found, then it
might be more reasonable to carry out a separate meta-analysis on each subgroup
or to use regression modelling with an indicator for each subgroup to account for
the variation. However, no characteristic about which information could be gained
from the published paper, such as type of drug, drug regimen, type of patient, entry
criteria, was found to explain the apparent bisection of the trials. Hence, it may be
that the reasons for the extra variation are too complicated to sort out. Alternatively,
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further investigation, using information from the original trials, may be required.
The evidence from the random effects q-q plot (Figure 41) may suggest that
the random effects model is a more reasonable fit to these data as all points have
been pulled in towards the line of identity. It is particularly noticeable that the point
representing trial number 5 has been pulled in very considerably and now falls on the
line of identity. This is due to its having a small within-study variance compared to
the between-study variance and so being shrunk by a large proportionate amount. On
the other hand, the q(i) for trial 7, for example, stays approximately the same on both
plots, because it has a relatively large within-study variance and has an individual
estimate close to the estimate of overall treatment effect. However, because there are
so few points, it is still not clear whether the points do in fact form a line through
the origin or whether there are still two separate lines indicating that there are still
two separate groups of trials. The estimate of the gradient is, however, still greater
than unity at 1.45.
Figure 41: Random effects normal plot of q for the diuretics trials meta-analysis
compared with the N(O, 1) line
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The tests for normality, in this example with so few points, are less helpful,
since for neither q(;) or q(j) do either provide any evidence against normality. This is,
however, likely to be due to the lack of power of the test with only nine points.
With respect to identifying sources of heterogeneity and displaying them, the
q-q plot provides the same information as the 'radial plot' described by Caibraith
[66]. The Calbraith plot is a scatter plot of y O/Ji5 against x - l/ji where a
single point is plotted for each trial (Figure 42). A radial log odds ratio scale can
then be used to read off values represented by lines through the origin and the point
of interest, (xi , ye). The horizontal axis of the graph, therefore, corresponds to an
odds ratio of 1. Such a plot can be simplified and drawn without the radial scale,
although still providing the same useful information.
Figure 42: Gaibraith plot of the diuretics trials meta-analysis
0 1 2 3 4 5 5 7 $ 0 10
Trials having estimates of treatment effect with small standard errors, which
are therefore those which provide the most information, lie well away from the origin
due to their large x-coordinates. On the other hand, less informative studies produc-
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ing estimates with large standard errors cluster near to the origin. Hence, the points
falling away from the origin look naturally most informative [66], which indeed they
are. It can therefore easily be observed from where the largest amount of information
is derived.
Since the gradient x/y is equal to ôj/ .4JJ / 1/'W = ôj, a line going through
the origin with gradient O1 represents the fixed effect estimate of the overall log odds
ratio of the meta-analysis. If the studies are homogeneous, then the points will scatter
homoscedastically, with unit standard deviation, about this line. Furthermore, lines
representing two standardised units either side of the overall odds ratio line may also
be drawn on the diagram to aid interpretation. The further away the point is from
the line representing the overall odds ratio, the more heterogeneous it is. The vertical
distance from the point representing trial i to the line representing j is equal to qj
(Figure 42), the value plotted on the fixed effect normal plot for study i. The point,
for trial i, on the Gaibraith plot is öj/,/ and the corresponding point on the odds
ratio line is ôj// and so the distance between them is (Ô -
	 = q1.
It can be seen from the Gaibraith plot for the diuretics trials data (Figure
42) that there is substantial heterogeneity present, since most of the points lie well
away from the line representing ör. As with the normal plot, trial 5 is seen to be an
outlying observation with a highly negative estimate of the log odds ratio, together
with a relatively small variance, meaning that the point falls well away from the line
representing O.
In the discussion of DeMets [7J, Peto suggested an alternative but similar plot
to that of Gaibraith, based on the Peto method of meta-analysis, namely a scatter
plot of (0 - E) against V (notation in Section 1.5.3), in which small trials cluster
near to the origin and the informative trials are far to the right of the plot. Gaibraith
[66] points out that a close approximation to the 'radial' plot is actually a scatter
plot of (0 - E)/./V against s/V.
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Both the Gaibraith plots and the q-q plots can help to identify outliers and
subgroups of homogeneous trials, which may then lead to further investigations. How-
ever, it should always be remembered that any explanations derived from such obser-
vations are post-hoc and should be interpreted cautiously. Furthermore, there may
sometimes be more than one feasible explanation or none. Hence, a sensible way of
using the findings from such investigations may be to generate hypotheses for future
trials.
3.5 Conclusion
There is clearly no single superior method for checking the distributional assumptions
of meta-analysis models. A combination of q-q plots and both the Shapiro-Francia
and versions (3) and (4) of the Anderson-Darling tests for normality should usually
be adequate to check the distributional assumptions when a reasonably large number
of trials is available. The plots are perhaps more useful in the case of multicentre
trials when more data points tend to be available (Section 3.4.1), so the shape of the
plot is clearer. In many meta-analyses there will not be enough studies to make full
use of these techniques. However, the plots can still provide useful information for
identifying outlying studies and groupings within the studies and therefore aiding in
the interpretation of heterogeneity (Section 3.4.2).
It must be remembered that the version of the Andersoi-Darling statistic to
be used in practical circumstances for the q() relating to a fixed effects plot is that
assuming a null hypothesis of normality with unknown mean and variance equal
to 1. For the random effects plot no advantage over the Shapiro-Francia test is
gained by using the Anderson-Darling statistic as both only test the null hypothesis
of general normality. If it is assumed that the null distribution is completely specified
as standard normal, the test is lacking in power, and, if used, the power to detect
non-normality will be greatly reduced.
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Nevertheless, the random effects plots do provide a check of the normality
of the random effects as well as the data. Hence, if it is the distribution of the
random effects, that is O
	 N(O, o), which is of primary concern, then a random
effects plot will be useful. However, it has been noted [108] that the unweighted
random effects normal plot used here may be inefficient for such purposes. Dempster
and Ryan [108] suggest the use of weighted normal plots as an improvement to the
straightforward unweighted plots (Section 3.1.2) to check the normality assumptions
of the random effects in linear models. The method can easily be adapted to the case of
a random effects meta-analysis. It has been shown [108] that weighted plots are more
sensitive than unweighted plots to certain departures from the assumed distribution.
For example, it is more sensitive for detecting a misspecified variance, for detecting ,
outliers among the random effects and for detecting when the distribution has a long
tail. However, such plots do have greater pointwise variability than the unweighted
plots [108].
The standard unweighted plot gives equal weight to each trial, even though
some study estimates will contain more information about the random effects than
others [108]. Hence, the weighted method involves the assignment of greater weight
to those observations for which ol accounts for a larger portion of the overall variance
(v + 4) . A simple choice of weights is w = 1/(v + 4) and then
F(q) =	 I(q - q)w/.1
 wj	 (86)
In order to make these plots equivalent to the unweighted plots, where Blom's modi-
fication [102] is used, adjustments to F(q) must be made [108]. As with the previous
unweighted plots, under the correct model the q-q plot should be a straight line
through the origin with unit gradient.
Exploratory investigations were carried out regarding the weighted normal
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plot using simulated data of the kind for which the weighted plot should be more
sensitive, for example, where there are outliers among the random effects. However,
no obvious advantages were seen and furthermore the weighted plots were found to
be very similar to the unweighted random effects plots. Also, given that the weighted
plots involve more complex calculations to produce, little advantage was seen in the
meta-analysis situation.
If investigations into the distributional assumptions show that either a fixed
effect or a normally distributed random effects model is reasonable, then the confi-
dence in the results obtained from the standard methods will be increased, However,
a problem which requires further research is that of what to do if neither model is
found to be satisfactory. Investigation is required into the robustness of the stan-
dard results to deviations from the assumed models, and also into alternative ways of
modelling such data. One possibility is to use a non-parametric distribution for the
random effects component such as in the method proposed by van Houwelingen et al.
[45].
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4 Power of the Test for Heterogeneity in Meta-
Analysis
The test for heterogeneity of treatment effects across studies in a meta-analysis is often
said to have 'low power' [76], but the actual power is rarely quantified. However, a
simulation study was carried out, considering heterogeneity in k 2 x 2 tables, which
showed the low power of heterogeneity tests in general, particularly when data are
sparse [109]. Hence, this chapter investigates the power of the test for heterogeneity in
meta-analyses. The assessment is based on the usual test statistic for heterogeneity,
using Q (Section 1.6) which is referenced to a xLi distribution.
The statistic Q is based on the assumption that each weight w1 is known rather
than estimated and is equal to the reciprocal of the variance v of the individual trial
estimate. However, in a practical situation, estimated weights must be used, which
are usually derived from the estimated variances. The work in this chapter is carried
out under the assumption that the w1 are known, but the issue of estimating w will
be pursued in Chapter 5.
Section 4.1 describes the methods and the strategy used for this investigation
of the power of the test for heterogeneity and Section 4.2 presents and discusses the
results. It is illustrated how the power of the test varies with the between-study
variance 4, the number of trials !c in the meta-analysis and the weight allocation.
An alternative statistic to Q for testing heterogeneity is then considered in Section 4.3
and conclusions are drawn in Section 4.4.
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4.1 Methods
The power of the test for heterogeneity is dependent on the distribution of the values
of Q. The expectation of the test statistic Q may easily be obtained for any given
random effects meta-analysis model, providing it is assumed that the weights are
known. The expectation of Q [38] is given by
E(Q) = (k - 1) +4 (
	
-	 )	 (87)2.=i Wi
Analytic results for the power of the test are, however, not simple to produce. In
general, however, the larger the expected value of Q, for a given number of degrees
of freedom, the greater the power. However, differences in the distribution of Q
will mean that if two examples have the same expected value of Q, the power may
still be different. Therefore, the power of the test was investigated using computer
simulation methods; these were again written in FORTRAN and were based on the
models defined by (82) and (83) of Section 3.3.1. Hence, the results obtained in this
chapter are all based on assuming the parameters are known rather than estimated.
This chapter, therefore, concentrates on quantifying the theoretical power of the test,
while Chapter 5 extends this work to look at the effect that estimating the weights
has on the power of the test for heterogeneity.
In this chapter it is always assumed, for simplicity, that the heterogeneity to
be detected takes the form of a normally distributed random effects model. Hence,
all the results obtained relate to the power of the test in detecting such heterogeneity.
An extension of the work would be to look at the power of the test for detecting
heterogeneity which takes alternative forms, for example, heterogeneity caused by a
few outlying points.
There are then three characteristics of a meta-analysis data set which will
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have an effect on the expectation of Q and therefore on the power of the test for
heterogeneity. They are (a) the extent of heterogeneity present, that is the value
of the between-study variance 4, (b) the number of studies included in the meta-
analysis k, and (c) the weights w allocated to the individual studies. Factor (c) is
the most complicated to investigate, since there are endless different combinations
of weights that could be considered. However, by making certain simpiffications, the
behaviour of the test statistic, with respect to weight allocation, could be investigated
reasonably fully.
The strategy employed to investigate the three factors (a)—(c) is now de-
scribed. For each meta-analysis example considered, simulations were carried out
for a variety of values of the between-study variance and 1000 repetitions were per-
formed for each value of 4 (4=0, 0.05, 0.1, 0.15, 0.2, 0.3, 0.4, 0.5). Hence, both
the mean value of the simulated Q and the power of the test could be plotted against
the between-study variance 4. Under the null distribution 5% (± twice the stan-
dard error) of the 1000 tests should produce a statistic larger than xL1 10.. Initially,
the weights allocated to each trial within each meta-analysis were kept equal, w=w
for all 1, in order that the effect of the number of trials k and the total amount of
information w be investigated. Simulations were carried out with w=10, and
the effect of varying the number of trials (k=5, 10 and 20 were used), and hence
also the total weight, was observed. Further simulations to investigate the effect of
changing k (k=5, 10 and 20) were carried out where the total information was kept
fixed, w1=100 here. Hence, changing k implies that w changes. Similarly, to
investigate the effect of changing the amount of total information for a given k, the
number of studies was fixed at Ic=10 and the total weight was varied (E w=50,
100 and 200 were used), implying that w varied too.
The behaviour of the test statistic, in relation to the changing allocation of
weight, was then considered, without any loss of generality, by fixing the value of
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w, while letting the individual w vary. This is illustrated by noting from
equation (87) that E(Q) plotted against 4 produces a straight line with intercept
(k - 1) and gradient W = (>	 w - (E.1
	
wi)) and assuming that each w
is fixed, then if
	 w is multiplied by any factor z, the sums
	 =	 xw
and (zw,)2 = z2 are obtained. This means that when the expectation
of Q is calculated, the gradient of the plot of E(Q) against 4 is simply multiplied
by x,
E(Q)=(k_1)+4z( Ew —	 (88)
Hence, the results for any sum of weights E zw differ only in the scale of the plot
of E(Q), although how this relates to the results for the power of the test is not clear.
For the purpose of this investigation, k=10 was used and the total information
w was fixed at 100. A further simplification was made, that of restricting the
investigation to consider examples where all trial weights, apart from to1, are equal
to each other. Three cases were chosen to represent a large range of possible values
of w1 . These cases were: w1 = 10 (i.e. the situation with all w equal), w1 = 50 and
= 90 (i.e. an extreme situation with a single study dominating the meta-analysis).
The fact that, for the equal weighting case, w,=10 for i = 1, ..., k means that v=0.1
for i = 1, ..., k. Hence, the range of values of 4 investigated covers cases where the
between-study variation is smaller, equal to and larger than the variation within each
individual study.
The mean values of Q, from 1000 repetitions, were obtained from the simula-
tions together with the power of the test for heterogeneity, that is the number of times
in the 1000 repetitions where a test statistic was produced which was significant at
the 5% level. The true expected value of Q was also calculated analytically for every
example using formula (87), and this value was compared to the simulated mean of
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Q in order to provide a check on the validity of the simulations.
4.2 Results
The results relating to the three factors identified as affecting the power of the test,
outlined in Section 4.1, are each described in Sections 4.2.1-4.2.3. Alternative ways
of viewing the results for the power of the test, in order that the practical implications
be highlighted, are then considered in Section 4.2.4.
4.2.1 Power and the between-study variance
The value of E(Q), for a given k, increases as the extent of the heterogeneity increases,
that is as the between-study variance gets larger (Table 39). As has already been
noted, E(Q), when plotted against 4, will form a straight line with intercept (k - 1)
and gradient W = (E.1 w -
	
w/E.1 w) (Figure 43). Figure 43 provides
examples of the plots where the number of trials k varies, but where
	 w1 is fixed
and within each example the weights are equal.
The 95% confidence intervals, calculated for the simulated mean Q, may be
used to check the validity of the simulations. All such intervals contained the true
expected value of Q (Table 39), thus indicating that the simulated results obtained
for the power of the test should be reliable.
For the behaviour of the power of the test, it can be seen that, following
on from the pattern obtained from E(Q), the power also increases with increasing
heterogeneity. The plots of power against the between-study variance take the familiar
form of a power curve, starting from 5% when there is no heterogeneity and then
levelling out as 100% power is reached (Figure 44).
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Figure 43: Expectation of the Q statistic against the between-study variance for
different numbers of trials k when	 w=1OO and the weights are all equal
0	 0.1	 0.2	 0.3	 0.4	 0.5
b.tw.en-study vsrI.nc•
Key
• k=5, W=80
+ k=1O, W=90
k=20, W=95
1000 simulations at each point
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Table 39: Mean observed values of the test statistic for heterogeneity Q from the
simulations compared to the true expected values where the total sum of weight is
equal to 100
Weight allocated to trial 1 w 1 (w2 = ... = w1o)
10	 50	 90
w21 ..,w10=lO, W90
	 w2,..,wlo=&6, W72.2 	 w21..,w10=l.1, W=18.9
Analytic	 Observed	 Analytic	 Observed	 Analytic	 Observed
___	 E(Q)	 (95% C.I.)	 E(Q)	 (95% C.I.)	 E(Q)	 (95% C.L)
o	 9.00	 9.08 (8.82,9.35)	 9.00	 9.06 (8.78,9.33)	 9.00	 9.28 (9.01,9.56)
0.05	 13.50	 13.52 (13.12,13.93) 	 12.61	 12.58 (12.20,12.97) 	 9.94	 10.09 (9.80,10.37)
0.10	 18.00	 17.73 (17.23,18.22)	 16.22	 16.44 (15.94,16.95)	 10.89	 10.92 (10.59,11.24)
0.15	 22.50	 22.72 (22.11,23.44)	 19.83	 19.12 (18.52,19.72)	 11.83	 11.72 (11.37,12.07)
0.20	 27.00	 27.34 (26.54,28.14)	 23.44	 22.80 (22.01,23.58)	 12.78	 12.43 (12.05,12.81)
0.30	 36.00	 36.61 (35.55,37.69)	 30.67	 29.48 (28.45,30.52)	 14.67	 14.84 (14.34,15.35)
0.40	 45.00	 44.31 (42.96,45.65)	 37.89	 37.74 (36.49,39.04)	 16.56	 16.62 (16.05,17.18)
0.50	 54.00	 53.56 (51.99,55.13) 	 45.11	 44.99 (43.27,46.72)	 18.44	 18.46 (17.08,19.12)
W=Gradient of line of E(Q) against 4
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Figure 44: Power of the Q statistic against the between-study variance for different
numbers of trials k when	 w=1OO and the weights are all equal
0.
0	 0.1	 0.2	 0.3	 0.4	 0.5
b.tw.sn-study v.rI.nc.
Key
• k=5, equal weight w=20
+ k=1O, equal weight w=1O
k=20, equal weight w=5
1000 simulations at each point
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4.2.2 Power and the number of trials
It may further be deduced from equation (87) that the expectation of Q, under the
assumption of homogeneity (i.e. when o=0), increases as the number of trials in the
meta-analysis increases. This increase in test statistic is, however, accompanied by
an increase in the associated degrees of freedom. There are two ways of looking at
the effect of the number of trials on the power, since changing the number of trials
k in the meta-analysis necessarily implies that the weights change too. Firstly, if the
weight allocated to each trial remains constant, w=10, i=1,...,k, in this example, as
k increases (k=5, 10, and 20), so the total weight	 w will increase. On the other
hand, if the total sum of weight w is kept constant, at 100 in this example, and
the number of trials k is varied (k=5, 10, 20) then the individual weight for each trial
w1 will change.
When w is kept constant, implying that E w increases, the expectation of
Q is larger and increases at a greater rate for larger k. However, since the degrees
of freedom change as k changes, plots of E(Q) against o are difficult to interpret in
relation to the power of the test. From the simulations it can be seen that the power
of the test also increases with increasing k (Figure 45) and, therefore, with increasing
total information. Power of almost 100% is reached, for the example where k=20
(and w1=200) by the time o is equal to 0.3, while for the case where k=5 (and
E w=50), the power only just reaches 65% at this point.
When w remains constant and the individual w vary with k, the larger
the number of studies in the meta-analysis, the larger the value of E(Q) for a given
4 and the steeper the gradient of the plot of E(Q) against 4 (Figure 43). However,
the gradients of these plots, for the examples chosen, are only slightly different. The
corresponding power plots for each k (k=5, 10 and 20) are fairly similar to each
other (Figure 44) and there is no one example which consistently has the greatest
power over all values of 4. For small values of 4 the power is greatest in the case
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Figure 45: Power of the Q statistic against the between-study variance for different
numbers of trials k when each individual weight is equal to 10
0	 0.1	 0.2	 0.3	 0.4	 0.5
b.tween-study verlanc.
Key
x k=5, E=1 w1=50
+ k=10, =1w=ioo
k=20, E.1w=200
1000 simulations at each point
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where k=5, while for larger values the power is greatest in the case where k=20. In
mid-range where a crossing over appears to take place the test statistic for the meta-
analysis with 10 trials has greatest power. The confidence intervals for the simulated
power values do, however, suggest that the power is not exactly the same for all three
examples. Hence, it is difficult to summarise the relationship between the power of
the test and the number of trials when the total information remains constant.
4.2.3 Power and weight
The most interesting, as well as most complex, aspect of this investigation is to assess
the effect that changing the allocation of the weight has on the value of E(Q) and
thus on power. On the simplest level, for a given k and when all weights are equal
to one another, the expectation of the test statistic increases as the amount of total
information increases (Figure 46). Hence, the larger the total information, the steeper
the gradient of the plot of E(Q) against 4 and the faster the rate of increase in E(Q).
It may then be deduced, from (87), that as w1 increases, E(Q) decreases (Fig-
ure 47). If	 w remains fixed, then for a given 4 and a given number of trials
lc, E(Q) is a maximum when	 w is a minimum. Hence, by minimising E= w
under the constraint that
	 w is constant, it is found that the maximum E(Q) is
obtained when the weight allocated to each study in the meta-analysis is the same.
The maximum of the expected value of Q for a given	 w, 4 and k, is therefore
obtained by substituting	 wjk for w in (87),
k
(89)
t=1
The minimum value of E(Q), which is (k - 1), is approached as the gradient
W tends to zero. That is as
	 w—' (E w)2 , which occurs when one individual
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Figure 46: Expectation of the Q statistic against the between-study variance for
varying values of w. when the number of trials k is 10 and the weights are all
equal
0	 0.1	 0.2	 0.3	 0.4	 0.5
b.twe.n-.tudy v.rI.nc.
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• E1k=1 w=50
+	 1w=100
x1 w=200
1000 simulations at each point
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Figure 47: Expectation of the Q statistic against the between-study variance for
varying values of w1 when	 w=100 and the number of trials Ic is 10
0 0.1 0.2 0.3 0.4 0.5 0.S 0.7 o.e 0.9
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1000 simulations at each point
210
w tends to
	 w,. Hence, between the two extremes, the expected value of Q for
a meta-analysis with given information decreases as the weights (or equivalently the
variances) become more different (Figure 47). The same behaviour of E(Q), that is
decreasing E(Q) with increasing differences in w, is observed for any value of
except that as the sum increases, the corresponding gradlients become steeper.
Considering the equivalent results for power, the meta-analyses with more
information have generally greater power to detect heterogeneity. For a fixed number
of trials, k=10 in these examples, the total amount of information included in a meta-
analysis has a great effect on the power curve of the test, with greater power being
achieved, for all values of ol, with increasing total information (Figure 48). When w1
is varied for a fixed total amount of information, the power decreases as the weight
given to this single trial increases (Figure 49). When w1 = 90, the power is below 40%
even when oj=0.5. This may not be surprising, since the within-study variances for
trials 2 to 10 at 0.9 are still larger than the between-study variance. In contrast the
power for the two other examples is over 90% when c=O.5, and for the case where
all weights are equal the between-study variance is 5 times that of the individual
within-study variances.
4.2.4 Alternative ways of looking at power
Although the findings outlined in the previous three sections characterise the be-
haviour of the power of Q in relation to the factors of interest, it is perhaps difficult
to form an idea of the practical implications. Hence, this section considers power
in two alternative and more practically applicable ways. It can then be deduced for
what practical situations the power of the test for heterogeneity is particularly low
and therefore where extra caution may be required.
It is of practical relevance to investigate the power that the test for heterogene-
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Figure 48: Power of the Q statistic against the between-study variance for varying
values of	 to, when the number of trials k is 10 and the weights are all equal
o•
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+	 w1= 100, weight w=10
>	 w=200, weight w=20
1000 simulations at each point
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Figure 49: Power of the Q statistic against the between-study variance for varying
values of w1 when	 w= 100 and the number of trials k is 10
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1000 simulations at each point
213
ity has to detect a between-study variance 4 at least as large as the within-study
variances v. If a meta-analysis is such that the v are much smaller than the 4 then
the between-study component is of great importance, as its iafluence on the overall
results (treatment effect estimate and conlidence interval) will be substantial. On the
other hand, the between-study variance is far less inlluential if it is small in compar-
ison to the v. Considering the behaviour of E(Q) for a between-study variance 4
equal in size to an 'average within-study variance' will provide an insight into the
related power.
Firstly, assuming that all within-study variances are equal (v = v, I = 1, ...k),
the between-study variance of interest is then simply equal to v. Hence, substituting
v in equation (87) in place of 4 gives
E(Q)=(k_1)+V(EiW_=1)
	
(90)
But since equal variances imply equal weights and w = 1/u, equation (90) becomes
E(Q)=(k_l)+!(kw_!)=2(k_l) 	 (91)
Hence, the expectation of Q when 4=v depends only on the number of trials included
in the meta-analysis and is independent of the total weight. E(Q) is, in fact, always
twice the degrees of freedom in such a situation. Obvioualy as w changes, the
value of v changes and so different values of 4 are being detected each time. As the
number of studies in the meta-analysis increases, then the expectation of Q for 4=v
also increases. Furthermore, the value E(Q) = 2(k - 1) is also the maximum value
of E(Q) that can be obtained when trying to detect the particular between-study
variance 4=v, since the maximum always occurs when all trials receive the same
weight (Section 4.2.3).
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Looking at the results of power from this point of view, for a given number of
trials k, is more complicated. The power depends not only on E(Q), but also on the
distribution of Q, and hence it cannot be stated that the power to detect a value of
c equal to v remains constant for all values of w1. However, the power is likely
to be similar for all values of E_ w and, indeed, the simulations back this up. For
k=l0, the power was found to be between 45% and 50% for each
	 w (Figure
48).
Alternatively, for a given
	 w, it can be stated that the meta-analysis with
the largest number of trials has the greatest power because, although the power curves
follow similar paths, the meta-analysis with the most studies has the largest within-
study variance. In the example where E....1 w=100, when k=20 the power to detect
a between-study variance of v=0.2 is 70%, while the power to detect a between-study
variance of v=0.05 when k=5 is only 30% (Figure 44).
The approach outlined above may be extended, still assuming that one wishes
to detect the between-study variance equal to v of the previous example, by allowing
the individual variances to be different. Hence, for a given
	 w, a between-study
variance equal to the value of the within-study variance if all studies had the same
variance and therefore the same weight we/k (i.e °1 = 1 /(E ..1 wi/k) will be
detected. Substituting 1/(E.1 wi/k) into (87) gives the required expectation,
E(Q)=(k—i)-i-
	
2_iWi \k	 (Eiw r'k 2'Wi	 - E1	 )	 (92)
This can be simplified, and becomes
E(Q)=2k-1—k (E_1 w)2	 (93)
Then, for a given k, where the total weight is allocated such that the percentage
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weights ((w/E..1 w)xl00%) are the same, each trial weight w can be written as
x	 w for any	 w3, where x is the fraction of the total weight taken by trial
i and so	 x=1. This implies that
	 w?/(E1 w)2 is equal to	 x and
so is a constant, say c, for any	 w, given a fixed percentagewise allocation of
weights to k studies. Hence (93) becomes,
E(Q)=k(2—c)-1	 (94)
It can be seen from (94) that, where the weights are not all equal, E(Q) depends not
only on the number of trials k, but also on the percentage weights allocated to those k
trials which determine the value of c. However, the expectation is still independent of
the total information	 w. and therefore provides a useful way of summarising the
expectation of the test statistic since it eliminates the variables of 4 and w.
The dependence of E(Q) on the total sum of weights is effectively removed by fixing
the value of the between-study variance which it is deemed necessary to detect since
4 is derived from E1
Looking at the corresponding results for the power of the test, it is found that
the power to detect the particular value of 4 = 1/(E1 wi/k) for each value of
ini (wi =10, 50 and 90) is approximately constant for every value of w1. The
power, at around 45-50%, being greatest when all weights are equal (Figure 48)
and dropping to about 12% when in1 =	 (Figure 50). Alternatively, for a given
w and a fixed percentage allocation of weights, there is an increase in power
as k increases (Figure 44). However, the decreasing power with increasing in1 is still
evident for any allocation (Figures 44 and 51).
Hence, the simulations back up the analytical findings that, for a given number
of trials in a meta-analysis, the power to detect a between-study variance as large
as the within-study variance if all weights were equal, that is 4=1/(E...1 wi/k),
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Figure 50: Power of the Q statistic against the between-study variance for varying
values of =i w when the number of trials k is 10 and w1 takes 90% of the weight
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Figure 51: Power of the Q statistic against the between-study variance for varying
numbers of trials Ic when Ek=i w=1OO and w1 takes 90% of the weight
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remains approximately constant for all values of
	 w,.
The discussion here shows that for small k, and particularly when there is an
uneven distribution of weight, the power of the test, defined in terms of being able
to detect a between-study variance as large as the average within-study variance, is
rather low. Hence, a second way of looking at power from a practical perspective, is
to consider the 'effective sample size' necessary to maintain the same value of E(Q)
for a given 4, compared to the most powerful case, that of equal weighting. If k and
4 remain constant, then from (87) it may be seen that E(Q) depends solely on the
value of W =
	 - (E...1 w,/Ei wj. Then, for general 	 w, let We and
T be the value of W and the value of w under the condition of equal weighting
(w=w, for all i). Furthermore, assume that F is the multiplicative factor by which
T must be increased in order that the same expectation as that achieved under equal
weighting be maintained, and let each individual weight be written in terms of the
percentage of the new total weight, that is w = ZiFTe where x is the fraction of
the total weight taken by trial i. In order to maintain the same expectation with
alternative weights, the new W must be equal to W. Hence, setting the expression
for W obtained under the alternative unequal weighting, that is where w=x1FT,
equal to We gives
Ic	 F2T	 2We 
=FTe>J>1- (95)FT 
=i X1
where F is the factor to be calculated. Hence, rearranging (95) allows F to be found,
F-
- T(1—E.1x)	 (96)
As an example, let k=lO, then for any value of
	
in, (i.e. total information
or 'effective sample size'), 	 w=T obtained under equal weighting must be mul-
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tiplied by the factors given in Table 40 in order to maintain the same value of E(Q).
Hence, when trial 1 takes 50% of the total weight, the effective sample size must be
increased by a factor of 1.25 and when it takes 70%, the effective sample size must
be doubled.
Table 40: Multiplicative factors for the 'effective sample sizes' required to maintain
value of E(Q) equal to that obtained under equal weighting for any total weight,
where k=10 and o is fixed
Percentage weight 'Sample size' required
to trial 1	 to maintain E(Q)
10	 1
30	 1.05
50	 1.25
70	 2.00
90	 4.76
The diuretics trials data may be used as a practical illustration of this idea, but
where the procedure works in reverse. The total weight under the observed unequal
weighting scheme, T0 say, is known and the total weight under equal weighting Te
required to maintain the observed value of E(Q) may be calculated. Obviously in
this case Te will be less than the observed total T0. Again, since Ic and o are fixed,
the interest lies in the value of W only. For an equal weighting situation, the value
of W given in (95) may be simplified to (Te(k - 1))/k since x = (1/k) 2 . Then, since
T6 can be written in terms of T0, that is as FT0, this becomes
FT0(k-1)
Ic
(97)
Setting (97) equal to the observed W, W0 say, which must be maintained, the factor
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F can be found using
F	
kW0
- T0(k-1)
The within-study variances v in the diuretics trials meta-analysis vary quite consid-
erably from 0.014 to 0.686, with ô equal to 0.23. The total observed information
T0 is 125. If the weights were equal, then using (98) to calculate F, the same value
of Q as that observed would be obtained with 73.6% of the information T0 actually
observed. This means that a total weight of 92 (w=10.22) rather than 125 is required
and hence, it can be seen that there is a considerable drop from the maximum power
due to the unequal weighting of the trials and the test is less powerful.
4.3 Alternative Statistic for the Test of Heterogeneity
Due to the recognised low power of the test for heterogeneity using Q, an alternative
statistic Q' has been proposed by Ewertz, Duffy et a!. [110]. It includes a 'correction'
which allows for the correlation between each individual study estimate 9, and the
overall estimate Ô. The idea behind the statistic Q' is that the 'correction' will cause
the power of the test for heterogeneity to be increased. The statistic is given by
ic
= ;; (v _(Ek1WJ_1)	
(99)
It was stated that, under homogeneity, Q 1 has a chi-squared distribution on
(k - 1) degrees of freedom [110], that is it has the same null distribution as the test
statistic Q
.
 This claim was checked using the basic simulation programs used in the
previous applications. The distribution of the statistic Q' was obtained under the null
hypothesis of homogeneity, and this was compared with both the x and the xL
distributions and the results are given in Section 4.3.1. Furthermore, in Section 4.3.2
(98)
221
the results obtained for Q from the simulations are compared with those obtained for
Q' . Values of Q' and the associated power were obtained for a selection of examples
used in the previous investigation of Q.
4.3.1 Distribution of Q'
Initially, the null distribution, that is the distribution under the homogeneous fixed
effect model, of the test statistic was investigated. The type I error rates a (cr=0.0l,
0.05, 0.1, 0.2, 0.3, 0.4, 0.5) were obtained for Q' from the 1000 computer simulated
data sets, where w1=100 and k=10. The process of obtaining a was carried
out assuming a x2 distribution on both k=10 and (k - 1)=9 degrees of freedom.
The results (Table 41) show that for all three situations considered (w i =10, 50 and
90) the values of a obtained are substantially larger than the theoretical values for
a xL1 distribution. The values of a obtained assuming a x distribution are also
slightly larger then the theoretical values in all but one instance. Hence, these results
suggest that the statistic Q' does not have a xL1 distribution, as was suggested. The
distribution of the statistic would appear to be closer to a x distribution, although
this appears to be only approximate. As w1 increases, the discrepancy between the
theoretical value of a and that observed increases, indicating that the approximation
to a x distribution may be better when the weights are equal than when they are
very different.
The distribution of Q', for the case where w=w for all i, was investigated
further by means of chi-squared quantile plots of the simulated distribution of the
statistic Q'
.
 The points plotted were (q,Q)), where Q1) is the ith smallest value of
Q' and
qj = F 1 ((i - 3/8)/(N + 1/4))
where F is the cumulative distribution function of the x2 distribution and N is the
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Table 41: Distribution of the Q' test statistic for heterogeneity under the null hy-
pothesis of a homogeneous fixed effect model with
	 w=100 and k=10
True a	 Weight allocated to trial 1 w1
(w2=...=w10)
10	 50	 90
2	 2	 2	 2	 2	 2
________ Xg,	 Xi0,c	 X9,o,	 X1O,	 X9,ø,	 Xio,
	
0.01	 0.018 0.014 0.024 0.016 0.023 0.017
	
0.05	 0.085 0.059 0.097 0.061 0.102 0.074
	
0.10	 0.162 0.110 0.168 0.120 0.177 0.128
	
0.20	 0.280 0.216 0.280 0.225 0.293 0.236
	
0.30	 0.381 0.311 0.388 0.310 0.423 0.326
	
0.40	 0.512 0.401 0.491 0.401 0.524 0.434
	
0.50	 0.601 0.516 0.574 0.495 0.611 0.533
number of values of the statistic, which in this case is 1000. If the statistic has a
distribution with the correct degrees of freedom, such a plot will be a straight line
with a gradient of 1.
A xLi and a x quantile plot (Figures 52 and 53) were produced for the
distribution of Q', using the values obtained from the simulation of the situation with
equal weights (w,=lO). A xL1 plot for the usual test statistic Q was also produced
(Figure 54), in order to have a standard plot by which to compare the plots of Q'.
When the statistic Q is plotted against the quantiles of a xL distribution (Figure
54) the expected straight line is achieved. However, when Q' is plotted against the
quantiles of a xL1 distribution, the straight line has a gradient which is steeper than
1 (Figure 52). The plot of Q' against the quantiles from a x distribution (Figure
53), again produces a good straight line, and this time it is closer to a line with a
gradient of 1. However, the gradient still appears to be slightly steeper than 1, with
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aa greater deviation being noticeable for larger values of q 1 . Hence, when comparing
this plot with that for Q, which does have a xLi distribution, it suggests that the
distribution of Q' is only approximately x even when the weights are equal.
Figure 52: xL quantile plot for the distribution of Q'
0 5 10 15	 25 30 35 40
4.3.2 Power of Q'
The power of the alternative test for heterogeneity using Q' would certainly be greater
than that of Q, if it were compared to the xL distribution. However, it would
appear that this is not the correct null distribution for the test statistic. Hence, for
the simulations involving Q', the power was obtained under the assumption that the
null distribution was approximately x•
From a comparison of the results, it can be seen that in every case, the power
of the test for heterogeneity using Q' is greater than that using Q (Table 42). This
increase in power is, however, not very large in any of the three examples considered,
being very slight when all weights are equal and getting larger as wj increases. It is
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Figure 53: x quantile plot for the distribution of Q'
0 5 10 15 20 26 30 35 40
Figure 54: xL quantile plot for the distribution of Q
0	 5	 10 15 20 25 30 35
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Table 42: Comparison of the power of the two statistics for heterogeneity, Q and Q',
for three examples where k 10 and
	 w,=100
4 Power (% significant from 1000 tests)
Weight allocated to trial 1 w1
(w2=...=w10)
10	 50	 90
___ Q Q' Q Q' Q Q'
0	 5.3	 5.9	 5.2	 6.1	 5.9	 7.4
0.05 26.5 28.5 20.7 25.0 9.0 11.8
0.10 47.5 50.1 39.9 43.2 12.8 19.2
0.15 67.5 68.9 53.0 57.1 16.5 22.4
0.20 79.4 80.6 60.9 65.1 21.9 28.0
0.30 90.2 91.2 77.6 80.0 31.5 40.0
0.40 92.7 93.6 88.7 90.2 39.2 46.1
0.50 95.7 96.2 92.4 93.2 46.8 52.8
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only when w1 =90 that there is any materially useful improvement in power. However,
in this case, the type I error rate (power when o-=0) is also increased above the 5%
level, indicating the uncertainty about the null distribution. The standard errors for
Q' are larger than those of Q, causing the 95% confidence intervals for Q' to be wider
than those for Q
.
 This indicates that the statistic Q' has a greater variability than
Q.
It can be concluded from these simulations that the null distribution of the
alternative statistic for heterogeneity is not xL.1 and that the actual null distribution
is only approximately x• Furthermore, this approximation to the x distribution gets
less satisfactory as the weights become more uneven. Additional to this uncertainty
regarding the null distribution of Q', little gain in power is achieved over Q. Hence,
Q' cannot be recommended as a test of heterogeneity and so Q is still to be preferred.
4.4 Conclusions
The simulations in Section 4.2 have shown that the power of the test for heterogene-
ity using the test statistic Q will have low power in many practical situations. In
particular the power will be less when the total amount of information available is
small, either because k is small or because the individual trial estimates lack precision.
Furthermore, as the weighting becomes uneven, the power drops from the maximum
achievable for the total weight observed. Hence, in practice, care should be taken in
the interpretation of a non-significant result from Q, especially if the meta-analysis
has low observed total information or a highly uneven distribution of weight.
The simulated examples (Section 4.2) were chosen so that the behaviour of Q
was investigated reasonably fully. However, further examples, such as ones in which
all the weights are allowed to be different, may be required to obtain a complete
picture. Furthermore, the results obtained only apply to detecting heterogeneity of a
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specific form, that is heterogeneity that follows a normally distributed random effects
model. Hence, although the expectation of Q is the same for a given or irrespective of
the form of the heterogeneity, the results for power cannot necessarily be generalised
to all situations. The power is dependent on the distribution of Q, which will be
different under different alternative models. Hence, further work would be required
to look at the power of the test under alternative heterogeneous models, especially as
the random effects model may, in practice, be rather unrealistic.
It was shown in Section 4.3 that an alternative statistic Q', claimed to be more
powerful than Q, in fact offers no improvement, particularly due to the uncertainty
over the null distribution. However, it may be that other test statistics provide an
improvement over Q
.
 Indeed, based on the results of a simulation study, Jones et
al. [109] recommend the use of the Breslow and Day statistic [111], which is similar
to Q, but based on the Mantel-Haenszel estimate of overall odds ratio and used by
StatXact [87], for situations with non-sparse data.
The results obtained in this chapter refer to the theoretical situation in which
v are known. Hence, they cannot strictly be applied to the practical case, although
they may be good approximations. The effect that estimating the v1 has on E(Q)
and the power of the test is addressed in the next chapter for the case of a continuous
outcome measure.
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5 The Effect of Estimated Weights on the Results
of a Meta-Analysis
In all standard meta-analysis methods, it is assumed throughout that the weights are
known. However, in practice the weights given by w=1/v, are, of course, estimated
from the data. This chapter investigates the effect that the estimation of the weights
has on the results obtained by the standard inverse-variance fixed effect (Section 1.5.1)
and the standard random effects (Section 1.7.1) meta-analysis methods. The influence
on the results of prime practical importance, that is the fixed effect and the random
effects estimates of the overall treatment effect and their variances, are considered.
In addition, the test for heterogeneity using Q and the estimate of the between-study
variance are investigated. This work involved the use of quantitative data, as progress
could be made analytically for this case. Computer simulations, similar to those used
to investigate the power of the test for heterogeneity (Chapter 4) but with weights
estimated from individually generated trial data, were programmed using FORTRAN
(Section 3.3.1). Novel analytic methods were also pursued to try to obtain improved
estimates allowing for the estimation of the weights. While exact analytic results
proved difficult, approximations were obtained.
Section 5.1 describes the simulation methods and the theory behind the ana-
lytic work. The results from the simulations comparing both the standard estimates
and the alternative estimates are then described in Section 5.2 and conclusions are
drawn in Section 5.3.
5.1 Methods
The simulation procedure used is described in Section 5.1.1 and then the analytic
theory is introduced in Section 5.1.2.
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5.1.1 Simulation methods
The model used for the simulations in this chapter is described by (83) and (84)
of Section 3.3.1 so that n observations are generated within each of the k trials.
Then Ô1 , which is the mean of Vu, l=l,...,n, in trial i in this case y, has a N(O, v,)
distribution, where v,=o/n=1/w1. The computer generated data 	 1 = 1, ...,
and i = 1, ..., k, is used to calculate the individual trial estimate of treatment effect
and its variance i),. This means that the estimated weight, denoted by tbj in
this chapter and equal to 1/, can be found. This reproduces the more realistic
situation, where the estimated weights tl are used to calculate the various statistics
required. However, in practice, the measure of treatment effect would often be a
difference in means between two treatment groups, that is Yi2. where g11=mean
in the treatment group and ,2 =mean in the control group. Hence, assuming that the
2	 '	 (n1i+n,)Ovariance o is the same in both groups then var(0) 
=	
l and so the n1 in the
simulations is equivalent to here. Therefore, the situation simulated is still a
simplification of what usually occurs in reality, since only one group of observations,
rather than two, is generated, but this resembles the situation where the reduction in
blood pressure in an individual treatment group in the mild hypertension trial was
considered (Section 3.4.1).
The number of observations n was taken to be the same in each trial, n say,
and two different values of n were investigated. Firstly, n was set equal to 50, thus
allowing each w to be estimated reasonably precisely. To provide a contrasting and
extreme example n was then set equal to 5. The values of 4 (4=0, 0.05, 0.1, 0.15,
0.2, 0.3, 0.4, 0.5) used when investigating the power of the test (Chapter 4) were
again used, and 1000 repetitions were carried out at each point. The number of trials
k in these simulations was fixed at 10 in order to keep things as simple as possible.
Furthermore, the total information in the meta-analysis, w, was fixed at 100.
The examples from Chapter 4 where w1 was allowed to vary (i.e. w1 =10, 50 and 90)
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were repeated. For each repetition Oj, var(ô j), Q, b, Ô,. and var(O*r) were calculated
using standard estimates. However, for this chapter only, the subscript th will be
used to denote that the weights are estimated from the data when calculating the
estimates as opposed to being known. The mean values from the 1000 simulated data
sets of the estimates of interest were then obtained and are, therefore, denoted by
var(Ô j),
	
,	 and var(Ôth).
It should be mentioned that negative values of ô,, which are meaningless,
may be obtained from the simulations. Hence, in practice the estimate of the between-
study variance is taken to be max{ô, 0}. However, even when known weights are
used, this leads to a bias in the estimate of 4, and so for the simulation of the mean
of & negative values are included in order that the only bias occurring is caused by
the estimation of the weights. However, when the random effect estimates and their
variances are calculated max{b, O} is used.
5.1.2 Analytic methods
Analytic methods for quantifying the effect of estimating the weights are now pursued.
An exact result is obtained for the expectation of a single estimated weight for a fixed
effect model E(ib), and this is then used as the basis for further approximations. The
fact that
(n-1)ô?
.2	
''x-1 i=1,...,k	 (100)
can be taken as a starting point, since by using the probability density transformation
	
f(y)=f(z)'	 (101)
	
I	 v I
(fl1-i)O.	 2	 .	 .	 .with x =	 and y =	 n1/c, the probability density function of w may be
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2
var(iu,) = E(ti) - {E(ti)} 2 = 2 (
	 ) ( - 5) (104)
and
obtained:
1
f(t) = r(!!) [
-1)
2c	 ] 
(fl—i)/2 
exp { —n,(n-1) j	 1
2oth	 J 
j,(fli1)/2 (102)
where r(a) is the gamma function for a, and for integral a, r(a)=(a - 1)!. Hence,
the expectation and the variance of th can be calculated by integration methods, and
in fact, it can be shown that,
E(tt) 
= J tbf(tui)dth =
	 (103)
The result for E(tb) can now be used to consider the effect that estimating the weights
has on the expected values of the estimates and variances of the overall treatment
effect. The variance of tb (104), however, did not prove to be useful in this regard
since the exact analytic results became too complicated. The result that E(tb) = f1w
where f	 is now utilised to provide approximate adjusted estimates for both
fixed effect and random effects meta-analyses.
The notation to be used in this chapter is firstly explained. As defined above,
a standard estimate using estimated weights is identified with the subscript ti,, for
example Oj . Furthermore, a subscript f, for example denotes an approximate
analytic result based on the approximation that the weight ti) is known and equal
to f1w, while a subscript a, for example Ôfa denotes an approximate estimate of
the parameter which may be obtained in practice containing th and f, but not the
unknown w.
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- E
k
= fw0fj (107)
Fixed effect model: From the result in (103), one approach to obtaining improved
estimates is to assume that each estimated weight ti, is equal to lw. Hence, by
dividing each estimated weight tb calculated in practice from the data by ft a weight
is produced which is on average closer to the true value w,=1/v. Hence, an adjusted
estimate of the overall treatment effect from a fixed effect model is given by
1a
	
L_ailf1 I	 (105)
L..is1 /
with a variance, which if obtained by simple substitution of th/f for w, is
1
var(Ôja ) =
	
( 106)
L_a=1 f
However, in practice the fixed effect estimate of treatment effect is usually
._ 1 Wjj	 kestimated by 01 11, =	 and its variance by var(6j ) = 1/E, w. This
variance will not be the true variance of 0 , in practice since it does not allow for the
extra variation caused by the estimation of the weights; it is really the variance of
w not	 By making the assumption that tb is known and equal
to	 rather than tv, an approximation to ôj , may be obtained and is given by
The variance of Ô may then be derived and takes the form
var(j1) - 
2.=i f?w
-	 (108)
(2_= f1w)2
Then an approximate 'adjusted' variance of 	 which may be calculated in practice,
allowing, to some extent at least, for the estimation of the weights can be obtained
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from (108) by replacing f1 w1 by iI
E=1 fti,VGI'a(011) = (
E=1 uui)2	
(109)
where tl are the weights estimated from the data. The variance given in (109) can be
considered as an approximation to the variance of 0fd, too since Oj O. It might,
therefore, be anticipated that this expression will provide an improved estimate of
the variance of the standard fixed effect estimate of treatment effect Ô1 in a practical
situation.
If the number of observations in each study is equal, that is if f=f for all 1,
then ôj , becomes equal to O, the approximate adjusted variance vara(ôjj) ( 109)
simplifies to	 ul,j which is then equal to var(Oja ) (106). This variance appears
to be sensible in so far as it will give a variance greater than 1/E tb, since
f > 1, thus reflecting additional uncertainty included because of the estimation of
the w. However, in practice, using the standard methods, the variance of the overall
treatment effect is found using 1/E. th 1/f E...1 w. This is obviously incorrect
and the variance calculated in this way will in fact be too small since 1/f E...1 w is
even smaller than i/	 w.
Random effects model: The case of the random effects model is more complicated
than that of the fixed effect model since the between-study variance must be obtained
before the overall treatment effect can be estimated. The estimate of the between-
study variance is derived using the test statistic for heterogeneity Q. In practice, Q,
denoted by Q1b in this chapter, is given by Ek tt,,(ô - âj.)2. Hence, the expected
value of Q must first be obtained and
E(Q,1,) = E(E.1 tui( - 9)2) - E((E1 XI,h - 0)2)	 (110)
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The covariance term of ti' and (Ô111, - 0) 2
 will not be zero since the terms are not
independent owing to the fact that Ô1 involves tZ,. An evaluation of this covariance
term is difficult, and hence approximate results are again found by making the as-
sumption as before, that is that the true weights are known and can be obtained by
dividing each ti)j by f . Then calculating the test statistic, say Qa, gives
(111)
i=1 '
which has an expectation analogous to (12),
E(Qa)=(k1)+4" Ek	 _E'/f?i=1	
)	
( 112)
Then assuming the weights are known, using the method of moments and equating
E(Q6 ) (112) with Q3 and rearranging, in the manner for deriving the D&L estimate
of the between-study variance with known weights (Section 1.7.1), one expression for
the approximate adjusted value of the between-study variance ô may be obtained:
-	 Qa(k1)
-	
- ______
=' I•	 E1II
 )	
(113)
Alternatively, the expectation of the approximate test statistic
Q,e 
=	
f1w,(Ô1 - ö11)2, which is Q,, with tbj replaced by f2 v.,1 may be written as
E(Qj) = E(E.1 f1w(1 - ô)2) = L fw1var(Ô1 ) -	 fwvar(Ôj1) (114)
Expressing the variances in terms of w, and 4 produces the following formula
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(118)
(119)
E(Qj ) = (:= f. - E=1 fw ) 
+ ( 
E fw - =i f?w	 (115)
E_fsw1 1f,w, I
Using the method of moments produces an estimate of 4 expressed in terms of to,
and f,
- (	 í. 
-
E81 flw)
"2 -
0Bf -
	 k , - E=1 flw12
Z=1 J8to8	 '-k j,t1)
This can be rewritten as follows, by substituting tlj for fw1, so that an adjusted
estimate of 4, ô	 say, is obtained,
k(-k	 E=1 fiwiQ- L-ii=lf'	 -k
"2 -
-
 Ek "2=1 w1L..ji=l 8
However, using the standard D&L estimator, the between-study variance cal-
culated in practice is actually given by
"2 - E= tb(Ô1 - êj)2 - (k—i)
k	 2
._	
WI
LsI=1 1
L=iW,
which, assuming that ti) =	 is approximately equivalent to
Q1—(k-1)
f,w - E=1 flw12
(116)
(117)
This expression is a. biased estimate of 4.
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If n, = n for all 1, then from (111) Qa = Qiz'/f, where f = (n - 1)/(n - 3).
The estimate of the between-study variance ô 11 (113) becomes
(Qtblf) - (k - 1)	 (120)
(i
k______
=— E_11h )
which is equal to ô1 (117) when f = f for all 1. Hence, for equal n the adjusted
between-study variance estimator can be denoted by ô1.
Consideration of the random effects estimate and variance is problematic since
even the expectation of a single estimated weight ti, = l/( + b) is complicated to
obtain. The biased estimate of the between-study variance & usually obtained in
practice could be replaced by one of the adjusted estimates ôi, è or ôa• Then
the random effects estimate of the overall treatment effect would be given by
oi
=' (°+L)	 (121)k	 1
(O+ô2)
Furthermore, by simple substitution
1
var(Ôra) 
=	 Ic	 1	 (122)
(i+ôa)2
whereas in practice, the variance is calculated by 1/E tl = 1/	 l/( + bk),
which is incorrect. However, it is not clear in which direction the bias will be since
there is the effect of estimating both £' and ôj to consider.
The approximate 'adjusted' estimates, vara (Ôjj ) (109), Q (111) and ô (120)
for cases where n are all equal, since this is the simplest situation and in which
= Ôj , var(Ôjr) = var(Ôj a ) and	 =	 are compared with the equivalent
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standard estimates in the next section. The simulations also provide an idea of the
extent of the bias of the standard estimates.
5.2 Results
The results from the simulations for the fixed effect model are described and discussed
in Section 5.2.1. Similarly, Section 5.2.2 considers the results for Q and Section 5.2.3
those for orb. Finally the results for the random effects model are discussed in Sec-
tion 5.2.4. For ease of reference a table of the notation used in this chapter is provided
(Table 43).
Table 43: Table of notation for Chapter 5
Variable	 Usual estimate with Approximate analytic Adjusted estimate Mean from
estimated weights 	 result with w=f w	 with tb & f	 simulations
Fixed effect
estimate
Variance of fixed	 var(Oj)	 var(Off)	 vara(9jj)	 var(9j)
effect estimate	 vara (O )
	 ____________
Test statistic	 Q	 Qj'	 Qa
forheterogeneity	 ___________________ ______________________ __________________ ____________
Between-study
vaziance
Random effects	 -
estimate
Variance of random	 var(r,)	 -	 -	 var(9)
effects estimate
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5.2.1 Fixed Effect Model
In this section Ojr. = 11 1 Ô/ tui1 , that is the estimate of the overall treatment
effect which is usually calculated in practice using weights calculated from the sim-
ulated data, is checked to make sure that it is unbiased. In the examples considered
= Ôj1 since f=f for all i and so	 = }	 ii)Ô/3r	 = Ô1 . Further-
more, two methods for calculating the variance of Ô1,, that is using the standard
1/ E-1 tuij and also the adjusted variance vara (Ôjj) = vara (Ôj ,1,) = 1/ tb (109)
proposed in Section 5.1.2. This latter variance is also equal to the variance of ôj
(106) in the case where n=n for all i.
Initially, however, it is useful to check the behaviour of an individual estimated
weight tZ,. When the number of observations in a study is large, f is very close to one
and therefore the expectation of tb is approximately equal to w. However, when the
number of observations in a study is small, f is greater than one and in the extreme
case when n=5, fi=2. This characteristic may be illustrated using the values of w1
obtained from the simulations. The mean value of obtained from 1000 simulations
when w1 =90 and n is 5 was 0.01151, which compares well with the true value of
0.01111. However, the mean value of th1 was 169.20, which is reasonably close to the
expected value of 180, that is 2w1 , and is certainly much larger than the value of
w1 =90. Hence the simulations back up the analytic findings that the weights are, on
average, inflated by the estimation of the variances v,.
The results from the simulations indicate that there is no systematic bias
(Figure 55) caused by the estimation of the weights in the overall fixed effect estimate
of treatment effect. The plot displays (Ô11 , - 0), where Ô1 ,1, (=à jr) is the mean value
of the estimates of 0 from the 1000 simulated sets of data, and it can be seen that
the points are randomly distributed either side of zero, with the variation becoming
greater as 4 increases. The fact that no bias is seen is not surprising, since the
estimate is still a weighted average of O2 , but with weights other than the true w.
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However, it is with regards to variance that the estimation of the weights is likely to
have an impact, since the standard variance does not account for the estimation of
the weights.
Figure 55: Plot showing the bias in the fixed effect estimate of the overall treatment
effect (Oj - 0) against the between-study variance
0.
0.0
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-0.0
-0.
0
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between-study variance
Key
- w1 =1O, n=50	 w=10, n=5
+ w1 =50, n=50	 w=50, n=5
* w1 =90, n=50	 • w1 =90, n5
1000 simulations at each point
The average simulated variance var( j ), obtained using 1/	 ti, is smaller
than the theoretical analytic variance obtained under the assumption that all weights
are known and equal to w, that is l/	 wO.Ol, in all three examples (wi=10,
50 and 90) (Table 44). This is as expected since l/_ ii calculated in practice is
approximately equal to 1/ 	 few,, or 1/f.1 w when f = f for all i, and f, is
always greater than 1 (Section 5.1.2). In other words the variance will be calculated
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using the estimated weights which are, on average, larger than the theoretical weights.
Hence, the reciprocal of the sum of the estimated weights will tend to be smaller than
the reciprocal of the sum of the true weights. The variance when n=5 is smaller
than that when n=50. Hence, the simulated results are consistent with the analytic
finding that the weights are inflated to a greater extent in the former situation due
to the larger value of f. When n=5 the bias is clearly dependent on the allocation of
the weight, with a greater discrepancy occurring for an uneven allocation of weight
(Table% 44). However, the bias is not dependent on the value of 4.
Table 44: Standard estimated variance of the fixed effect estimate when
i/E.1 w2 =0.01 for different allocations of weight
Between-study	 Mean from simulations (var(Oij,))
variance	 number of observations in each trial (n)
(4)	 n=50	 n=5
_____________ wi=10 w1=50 wj=90 w1=l0 w1 =50 
J_
w1=90
0.00	 0.00963 0.00969 0.00986 0.00596 0.00660 0.00885
0.05	 0.00963 0.00969 0.00993 0.00604 0.00641 0.00855
0.10	 0.00960 0.00967 0.00991 0.00607 0.00651 0.00884
0.15	 0.00958 0.00968 0.01008 0.00597 0.00654 0.00859
0.20	 0.00965 0.00967 0.00985 0.00595 0.00650 0.00878
0.30	 0.00962 0.00969 0.01000 0.00597 0.00653 0.00861
0.40	 0.00963 0.00972 0.00991 0.00590 0.00654 0.00855
0.50	 0.00966 0.00967 0.00994 0.00606 0.00661 0.00879
wi =Weight allocated to trial 1
The true variance of Oj will, however, be larger even than 1/E w in prac-
tice, since the estimation of the weights introduces some additional variation. Hence,
the actual variance of the simulated means, that is v2zr(,d3, as opposed to the mean
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Table 45: Comparison of the mean standard estimated variance and the observed
variance of the fixed effect estimate when 1 /E . 1 w=0.01, for different allocations of
weight under homogeneity (i.e. 4=0)
Weight	 Number of observations in each trial (n)
given to	 50	 5
trial 1 (w1 ) var(Ôj,) vàr( j,) var(Oj,1,) vàr(Ô1)
10	 0.00963	 0.01014	 0.00596	 0.01885
50	 0.00969	 0.01122	 0.00660	 0.01957
90	 0.00986	 0.00935	 0.00885	 0.01751
of the 1000 simulated variances var(O1113, was calculated in order to obtain an esti-
mate of var( j ) allowing for the estimation of the weights. The variances vàr(Ôj),
obtained under the assumption of homogeneity (4=0), were generally found to be
greater than 1/E w=0.01 (Table 45), and the increases were greater when n=5
than n=50. Since under the fixed effect model the variance of 9 j , is calculated as-
suming homogeneity, whatever the value of the true 4, the mean variance should be
equal to that when 4=0. Hence, the mean variances for all values of 4 given in
Table 44 can be compared with var(ôj ) in Table 45. For all three values of w1 it
can be seen that the standard estimate of the variance w(Ia1ways be too small.
The alternative approximate expression derived for the variance of Ô1,, that
is vara(èfd,) = 1/	 th, was also used to calculate the variance for each repeti-
tion in each simulation example, and the mean of these was obtained. The results
for the mean of the adjusted variance vara (Ôj,) (Table 46) can then be compared to
var( j ,) obtained using 1/E tb (Table 44) and also to the true variances obtained
from the 1000 simulated values of Ôj,, (Table 45). For n=5 a clear improvement in
the estimation of var(Ô1 ) is shown when using f/	 as opposed to 1/
particularly for large w1. Where w1 =90, vàr(Ôj )=0.01751 and all the mean adjusted
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variances vara (Ôj,,) agree with this to three decimal places (Table 46). However, for
the equal weighting case, the adjustment is less good, although the adjusted mean
variances have at least increased from the unadjusted ones (Table 44). For n=50, the
error in the unadjusted variances are small anyway (Table 44), but the adjusted vari-
ance still causes the mean variance to increase towards vàr(Oj ,13. However, when w1
was equal to 90 (Table 45), var(ô1 ,) was, surprisingly, smaller then 1/E w,=0.01,
although the difference was small enough to be due to sampling error.
Table 46: Alternative estimated variance of the fixed effect estimate when
1/E w=0.01 for different allocations of weight
Between-study	 Mean from simulations (vara(/,b))
variance	 number of observations in each trial (n)
(4)	 n=50	 n=5
_____________ w 1 =10 w=50 w1=90 w1=10 w1 =50 w1=90
0.00	 0.01004 0.01011 0.01028 0.01193 0.01320 0.01770
0.05	 0.01004 0.01010 0.01035 0.01208 0.01282 0.01710
0.10	 0.01001 0.01009 0.01034 0.01214 0.01301 0.01769
0.15	 0.00998 0.01009 0.01050 0.01194 0.01309 0.01718
0.20	 0.01006 0.01008 0.01027 0.01190 0.01299 0.01757
0.30	 0.01003 0.01010 0.01043 0.01194 0.01306 0.01723
0.40	 0.01004 0.01013 0.01033 0.01181 0.01308 0.01710
0.50	 0.01007 0.01008 0.01036 0.01213 0.01321 0.01757
wi =Weight allocated to trial 1
It is clear from the simulations that when calculating a variance for an overall
fixed effect estimate in a practical situation, using the standard estimate 1/E 11j
is likely to produce a value which is too small. Using fth/(E1 tl)2 (or
f/E= tbj in the case where the nj are all equal) appears generally to be a better
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alternative, producing a value which is larger than 1/E w2.
5.2.2 Test statistic for heterogeneity
In this section Q,,, the test statistic for heterogeneity obtained in practice, is compared
to the theoretical value of E(Q) obtained under the assumption that the weights
are known. Then since the simulations are of examples where n=n for all i, an
approximate adjusted estimate of the true Q may be obtained by simply dividing Q,,
by f to give Q (111). The mean values of Q are then compared with E(Q) as well
as with Q.
When the weights are estimated from the simulated data, the mean value from
the simulations is larger than the expected value for each of the three choices of w1
for both values of n (Figures 56-58). This difference is small when n=50, but is much
larger when n=5. The increase is only slight when n=50 since f is approximately 1,
but much larger when n=5 when f is equal to 2.
The results of the simulations show that
	 provide better approximations to
E(Q) than Q,. Table 47 indicates that the adjustment to Q is particularly good when
= 50, but less so when n=5 where it tends to overcompensate for the large inflation
in the statistic. These results, therefore, show thai on average the statistic calculated
in practice is closer to fE(Q) than it is to E(Q). Hence, the null distribution of Q
will not be xL and so the test will be incorrect
Following on from the increase in the value of the expectation of Q caused by
the estimation of w, the power of the test is also increased (Figures 59-61). Again
this increase is small when n=50, but large whem n=5. It can also be seen that for
any given value of n, the absolute increase in power is always greatest when w1=90,
and hence the greatest difference overall occurs when n=5 and wj=90 (Figure 61).
The power of the test decreases as the weights allocated to the studies in the meta-
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Figure 56: Mean value of the test statistic Q from the simulations where the weights
are estimated from different sample sizes when w 1 =1O and >I_ w=1OO
0	 0.1	 0.2	 0.3	 0.4	 0.5
between-Mudy v.rlsnc.
Key
- expected value of Q
• true weights
+ estimated weights (n=50)
* estimated weights (n=5)
1000 simulations at each point
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Figure 57: Mean value of the test statistic Q from the simulations where the weights
are estimated from different sample sizes when w1 =50 and >Ii w1=100
0	 0.1	 0.2	 0.3	 0.4	 0.5
b.tw..n-.t%idy v.rlsnc.
Key
- expected value of Q
• true weights
+ estimated weights (n=5O)
* estimated weights (n=5)
1000 simulations at each point
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Figure 58: Mean value of the test statistic Q from the simulations where the weights
are estimated from different sample sizes when w 1 =9O and	 w=1OO
0	 0.1	 0.2	 0.3	 0.4	 0.5
b.tw..n.tudy v.rnc.
Key
- expected value of Q
• true weights
+ estimated weights (n=50)
estimated weights (n=5)
1000 simulations at each point
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Table 47: A comparison of the standard test statistic for heterogeneity Q calculated
in practice and the adjusted Qa with E(Q)
Weight 4	 Number of observations in each trial (ni)
givento	 50	 5
trial 1
	 Values from simulations Analytic Values from simulations Analytic
wj = ____ ________ E(Q) ____ _________ E(Q)
10	 0	 9.213	 8.837	 9.000	 15.262	 7.631	 9.000
0.05	 14.085	 13.510	 13.500	 22.936	 11.468	 13.500
0.10	 18.648	 17.887	 18.000	 28.501	 14.251	 18.000
	
0.15 23.426	 22.470	 22.500	 39.249	 19.625	 22.500
	
0.20 28.267	 27.113	 27.000	 46.729	 23.365	 27.000
	
0.30 37.890	 36.343	 36.000	 62.162	 31.081	 36.000
	
0.40 46.913	 44.999	 45.000	 78.618	 39.309	 45.000
	
0.50 55.269	 53.013	 54.000	 91.153	 45.577	 54.000
50	 0	 9.160	 8.786	 9.000	 15.503	 7.751	 9.000
0.05	 13.191	 12.653	 12.611	 21.835	 10.917	 12.611
0.10	 16.856	 16.168	 16.222	 29.172	 14.586	 16.222
	
0.15 21.138	 20.275	 19.833	 32.564	 16.282	 19.833
	
0.20 24.634	 23.629	 23.444	 39.374	 19.687	 23.444
	
0.30 32.155	 30.843	 30.667	 52.414	 26.207	 30.667
	
0.40 39.378	 37.771	 37.889	 64.567	 32.283	 37.889
	
0.50 47.218	 45.291	 45.111	 75.153	 37.577	 45.111
90	 0	 9.244	 8.867	 9.000	 17.381	 8.691	 9.000
	
0.05 10.527	 10.097	 9.944	 19.550	 9.775	 9.944
	
0.10 11.370	 10.906	 10.889	 20.600	 10.300	 10.889
0.15	 12.748	 12.228	 11.833	 22.697	 11.349	 11.833
	
0.20 13.431	 12.883	 12.778	 24.354	 12.571	 12.778
	
0.30 15.299	 14.675	 14.667	 29.052	 14.526	 14.667
	
0.40 18.176	 17.434	 16.556	 29.797	 14.899	 16.556
	
0.50 18.923	 18.151	 18.444	 34.652	 17.326	 18.444
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analysis become more different as was observed when investigating the power with
known weights (Chapter 4).
Figure 59: Power of the test statistic Q where the weights are estimated from different
sample sizes when w 1 =10 and E=1 w1=100
0	 0.1	 0.2	 0.3	 0.4	 0.5
b.tw..n-study ysrisno.
Key
• true weights
^ estimated weights (n=50)
estimated weights (n-5)
1000 simulations at each point
When n=5, there is a large increase in the number of tests producing significant
results when there is in fact no heterogeneity present, that is an increase in the Type-I
error. This value rises from 5%, when the true weights are used, to between 30% and
40%, when the weights are estimated from 5 observations (Figures 59-61). These
results indicate that the test for heterogeneity is not valid when n is small. This is
supported by the calculation of confidence intervals for the difference in power between
the case where f he weights are known and the case where weights are estimated
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Figure 60: Power of the test statistic Q where the weights are estimated from different
sample sizes when w 1 =50 and	 w=100
0	 0.1	 0.2	 0.9	 0.4	 0.5
b.tw..n..tudy v.rnc.
Key
• true weights
+ estimated weights (n=50)
estimated weights (n=5)
1000 simulations at each point
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Figure 61: Power of the test statistic Q where the weights are estimated from different
sample sizes when w1 =90 and	 w=1OO
0	 0.1	 02	 0.3	 0.4	 0.5
b.tw..n..tudy v.rIsnc.
Key
true weights
+ estimated weights (n-50)
estimated weights (n=5)
1000 simulations at each point
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(Table 48). The confidence intervals all indicate an increase in power when n=5.
In contrast, this difference in power is much smaller when n=50. Hence, it may
be sensible to use as the test statistic for heterogeneity as this has a null
distribution which is at least closer to the xL1 distribution. Although caution is
then necessary as the test is even lower in power due to the over correction for the
inflation, particularly when n is small.
5.2.3 Between-study variance
This section includes an investigation of the mean of the simulated between-study
variances calculated using the D&'L method of moments b and based on the as-
sumption that the weights are known with the true between-study variance. When
n=n for all i, as in the simulation examples, the adjusted estimate of the between-
study variance & which takes into account the estimation of the weights to some
extent at least is given in (120). For each example, the mean simulated value using
this alternative estimate ôj is then also compared with the true ol and with the
standard estimate ô in order to see whether it does in fact offer an improvement.
Since & is calculated using the value of Q obtained using estimated weights,
this causes è to be biased. In all six simulated examples and for all 4, the mean
of the simulated ô3 was larger than the true value (Figures 62-64). It may be
observed from these plots that the bias of the D&L estimator remains approximately
constant over all values of 4. This observed bias (i.e. (bk— 4)) was very large, at
around 0.2 for the case where w1 =90 and n=5, while in all the other five situations
the bias was below 0.05. The adjusted estimate ô does perform better than the
D&L estimator in that the average observed bias for each example is smaller (Figures
62-64). There is still some consistent deviation from the true value of 4 when n=5,
but the adjusted estimate consistently underestimates, rather than overestimates, the
between-study variance. This is due to the overcompensation for the inflation in Q
252
Table 48: Differences in power (%) between results from simulations where the true
weights were used and those where estimated weights were used
Weight	 4	 Number of observations in each trial (n)
givento	 50	 5
trial 1 (Wi)	 Difference (d) 95% C.I. of d Difference (d) 95% Ci. of d
10	 0	 0.2	 (-1.8,2.2)	 25.6	 (22.4,28.8)
0.05	 1.5	 (-2.4,5.4)	 27.7	 (23.6,31.8)
0.10	 2.5	 (-1.9,6.9)	 21.7	 (17.5,25.9)
0.15	 0.5	 (-3.6,4.6)	 15.2	 (11.5,18.9)
0.20	 1.5	 (-2.0,5.0)	 10.7	 (7.6,13 8)
0.30	 0.2	 (-2.4,2.8)	 4.6	 (2.3,6.9)
0.40	 2.8	 (0.8,4.9)	 4.1	 (2.2,6.0)
0.50	 1.5	 (-0.1,3.1)	 2.7	 (1.2,4.2)
50	 0	 0.5	 (-1.5,2.5)	 25.9	 (22.7,29.1)
0.05	 2.8	 (-0.8,6.4)	 29.9	 (25.9,33.9)
0.10	 1.1	 (-3.2,5.4)	 29.2	 (25.0,33.4)
0.15	 5.5	 (1.2,9.9)	 19.9	 (15.8,24.0)
0.20	 6.6	 (2.4,10.8)	 20.5	 (16.6,24.4)
0.30	 5.7	 (2.2,9.2)	 12.6	 (9.4,15 8)
0.40	 2.8	 (0.2,5.4)	 5.7	 (3.3,8.1)
0.50	 1.7	 (-0.5,3.9)	 4.5	 (2.6,65)
90	 0	 -0.5	 (-2.5,1.5)	 30.8	 (27.5,34.1)
0.05	 2.6	 (-0.1,5.3)	 30.5	 (27.0,34.0)
0.10	 3.1	 (0.0,6.2)	 34.9	 (31.2,38.6)
0.15	 5.8	 (2.3,9.3)	 32.8	 (29.0,36.7)
0.20	 3.4	 (-0.3,7.1)	 32.2	 (28.2,36.2)
0.30	 2.9	 (-1.2,7.0)	 29.7	 (25.5,33.9)
0.40	 5.7	 (1.4,10.0)	 27.2	 (23.3,31.7)
0.50	 1.6	 (-2.8,6.0)	 26.3	 (22.2,30.4)
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noted in the previous section (Section 5.2.2).
Figure 62: A comparison of the bias of the unadjusted estimates and adjusted esti-
mates of the between-study variance o when w1 =1O for n-50 and n=5
0	 0.1	 0.2	 0.3	 0.4	 0.5
b.twe.n-.tudy varlanc.
Key
• unadjusted estimate of the between-study variance & ( n=50)
* adjusted estimate of the between-study variance b (n-50)
+ unadjusted estimate of the between-study variance b (n5)
o adjusted estimate of the between-study variance 'a (r5)
1000 simulations at each point
Since it is noticeable from the results of the simulations that the bias in the
standard estimator is constant for all values of o and an analytical approximation
to this bias was found. The D&L estimate of the between-study variance ô, under
the assumption that t1 fw, is given by
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Figure 63: A comparison of the bias of the unadjusted estimates and adjusted esti-
mates of the between-study variance 4 when w1 =50 for n=50 and n=5
-u.vu
0	 0.1	 0.2	 0.3	 0.4	 0.5
b.tw.,neludy vrl.nc.
Key
• unadjusted estimate of the between-study variance 4 (n=50)
adjusted estimate of the between-study variance &a (n=50)
+ unadjusted estimate of the between-study variance 4 (n=5)
o adjusted estimate of the between-study variance ô (n=5)
1000 simulations at each point
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Figure 64: A comparison of the bias of the unadjusted estimates and adjusted esti-
mates of the between-study variance o when w 1 =90 for n=50 and n=5
0	 0.1	 0.2	 0.3	 0.4	 0.5
b.tw..n..tudy v.rI.nc.
Key
- unadjusted estimate of the between-study variance & (n=50)
adjusted estimate of the between-study variance &a (n=50)
+ unadjusted estimate of the between-study variance ô	 (n=5)
o adjusted estimate of the between-study variance ba (n=5)
1000 simulations at each point
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fQ - (k —1)
o291=	 Vk	 2	 (123)1dI1 if(E=1wi_Ec )
and the true between-study variance assuming that weights are known is 4 . Hence,
the approximate bias is
fQ—(k-1)	 Q—(k-1)	 -	 (f-1)(k-1)
	
f(E=w_r ) E = w_:i	i(rw_E=ib0? )
(124)
This analytical result shows that the bias is not dependent on the amount of hetero-
geneity and is therefore constant across all values of 4 (Table 49), as observed.
Table 49: Comparison of the observed bias of the standard D&L estimator and the
approximate analytic bias
Number in Weight given Observed Approximate
	
each group	 to trial	 1	 bias of &	 analytic bias
	
(n)	 (Wi)	 (o,-4) 
_________
	50	 10	 0.0038	 0.0041
	
50	 0.0067	 0.0051
	
90	 0.0190	 0.0195
	
5	 10	 0.0360	 0.0500
	
50	 0.0392	 0.0623
	90	 0.1989	 0.2382
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5.2.4 Random effects model
The random effects estimate of treatment effect Ô,.. obtained in practice is consid -
ered in order to check for unbiasedness. The standard variance 1/ E.I ti,* of this
estimate is then compared with the true sample variance obtained from the simu-
lations var(ô,). No satisfactory adjusted variance for the random effects estimate
was found to compare with these values. The calculation of the variance of a random
effects estimate is more complicated than that of the fixed effect estimate because the
expectation of a single weight l/tI proves difficult to obtain. The estimated weight
contains both the biased estimate w, and that of 4; these two different effects work-
ing on the variance cannot be separated.
As for the fixed effect method, the results from the simulations indicate that
estimating the weights causes no systematic bias in the estimate of the overall treat-
ment effect (Figure 65). This is again due to the fact that the random effects estimate
is still a weighted average of the O and the changes in the weights do not affect the
unbiasedness of the estimate.
The mean simulated variances var(O,j,) using the standard estimate of the vari-
ance are, in general, slightly larger than the theoretical variances 1/E w based
on the assumption of known weights in the examples where w1 =10 and w1 =50 (Ta-
bles 50 and 51). The cases where n=5 produce variances which are on the whole
larger than when n=50, with the increase when n=50 being very small indeed. In
the example where wj=90 (Table 52), the estimates are too erratic to enable any
firm conclusions to be drawn. The general increase in variance is due to the mean
between-study variance estimate being larger than the true value because there is a
constant positive bias over all values of 4. Since the variance is calculated using
1/ I 1/( + fr) and ( ,3 + ô) will be greater than (v + 4) due to the addi-
tional bias, then l/( + 4,b) will be less than 1/(v + 4). Hence, the reciprocal of
the sum of l/(t + ô1,,) will be greater than the reciprocal of the sum of 1/(v +4).
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Figure 65: Plot showing the bias in the random effects estimate of the overall treat-
ment effect (Ôr - 0) against the between-study variance
Key
	
• w1 =1O, n=50	 w1=1O, n=5
	+ w 1 =50, n=50	 w1=50, n5
	w1 =90, n=5O	 • w1 =90, n=5
1000 simulations at each point
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Table 50: Comparison of the standard estimated variance for the random effects
estimate of treatment effect with the mean from the simulations and the standard
analytic result when	 w=10O and w1=10
Number of observations in each trial (n)	 Standard
50	 5 _________	 analytic
_____ (var()) vàr(Ô) (var(0)) vr( j,) variance	 w?)
0	 0.01160	 0.01006	 0.01138	 0.01255	 0.010
0.05	 0.01572	 0.01638	 0.01647	 0.01541	 0.015
0.10	 0.02033	 0.02084	 0.02073	 0.02179	 0.020
0.15	 0.02525	 0.02464	 0.02739	 0.02801	 0.025
0.20	 0.03053	 0.03079	 0.03285	 0.03136	 0.030
0.30	 0.04075	 0.03707	 0.04281	 0.04005	 0.040
0.40	 0.05052	 0.05364	 0.05251	 0.05030	 0.050
0.50	 0.05967	 0.05758	 0.06314	 0.06201	 0.060
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Table 51: Comparison of the standard estimated variance for the random effects
estimate of treatment effect with the mean from the simulations and the standard
analytic result when E- w1 =100 and w1=50
Number of observations in each trial (n)	 Standard
50	 5	 analytic
____ (var(Ô 1,)) j vàr(,) (var(Ô,)) vàr(à,.,) variance (1/E...1 w)
0	 0.01350	 0.01251	 0.01485	 0.01704	 0.01000
	
0.05	 0.01905	 0.02130	 0.02039	 0.02300	 0.01872
	
0.10	 0.02431	 0.02755	 0.02729	 0.02757	 0.02471
	
0.15	 0.03047	 0.03381	 0.03057	 0.03467	 0.03016
	
0.20	 0.03539	 0.03612	 0.03640	 0.03940	 0.03542
	
0.30	 0.04583	 0.05468	 0.04770	 0.04850	 0.04571
	
0.40	 0.05594	 0.05928	 0.05887	 0.05590	 0.05587
	
0.50	 0.06641	 0.06685	 0.06790	 0.06659	 0.06597
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Table 52: Comparison of the standard estimated variance for the random effects
estimate of treatment effect with the mean from the simulations and the standard
analytic result and the when 	 w=100 and w1=90
Number of observations in each trial (n)	 Standard
50	 5	 analytic
____ (var(Ô)) var(ô) (var()) vàr(Ô) variance (1/	 wfl
0	 0.03599	 0.02872	 0.05665	 0.05601	 0.01000
0.05	 0.04722	 0.05414	 0.06079	 0.07336	 0.03870
0.10	 0.05343	 0.07288	 0.07022	 0.09356	 0.05556
0.15	 0.06422	 0.08625	 0.07676	 0.09092	 0.06767
0.20	 0.06931	 0.10170	 0.08340	 0.09623	 0.07741
0.30	 0.08301	 0.11530	 0.09858	 0.10805	 0.09333
0.40	 0.10204	 0.12545	 0.10600	 0.12383	 0.10689
0.50	 0.10778	 0.12227	 0.12243	 0.13701	 0.19926
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The estimates of the true variance obtained from the 1000 simulated
values of Ô are nearly all larger than 1/E w (Tables 50-52). There are tiree
individual exceptions, however, in the example where n=50 and w j =l0 (Table 50),
but these differences are small enough to be regarded as being due to sampling error.
Hence, assuming that 1/E.1 w underrepresents the variation in Ôr, then the results
show that the variance obtained in practice 1/ tl may often be closer to vàr(Ô,j,)
than to 1/E w. However, no more definite conclusions can be drawn since there
is no theory to support the findings and furthermore, the results are rather erratic.
5.3 Conclusions
The investigations outlined in this chapter have shown that for qualitative outcome
measures the fact that the weights are being estimated can affect the results of the
meta-analysis. This is due to some extent to the fact that the expectation of a single
estimated weight th1 does not equal w, but rather f1w1.
The fixed effect estimate of the overall treatment effect remains unbiased, but
the corresponding variance term used in practice, that is 1/ e1, is too small. This
is not a problem when the number of observations in each trial n, is large since in
such circumstances the decrease is negligible. However, it does become an issue when
n in each trial is very small and the decrease in the variance could cause too definite
conclusions to be drawn about the true treatment effect. The adjusted estimate
derived in this chapter, vara (Ôj ), is a better approximation of the true variance,
although it performs better in certain cases than in others. However, it does always
produce a value which is larger than l/E to,1 which is at least an improvement over
1/	 th,. Using the adjusted variance of the fixed effect treatment effect will lead
appropriately to a more cautious interpretation of the data.
The test statistic calculated in practice, that is Q,,, is inflated due to the
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estimation of the weights. As for the variance of the fixed effect estimate, the effect is
very small for large n, but is very large when n are small. For the case where n=n
for all i, an adjusted test statistic may be obtained by dividing Q, by f. This brings
the test statistic towards E(Q). Certainly Q, is closer to E(Q) than Q,j,, although for
small n the adjustment overcompensates for the inflation and the test statistic is too
small. In practice using Q, means that the power of the test is artificially increased;
the null distribution of the test statistic is not xL1 and the test is not valid. This is
again a particular concern when n is small. Furthermore, the inflation increases as
w1 increases. Qa offers some improvement since it brings the null distribution of the
test statistic closer to xL although the possibility of underestimating the extent of
the heterogeneity is then a danger when n2 is small.
The results observed for Q then follow through to influence the estimate of
the between-study variance. Using the standard D&L moment estimate leads to an
overestimation of the between-study variation. This bias is constant over all values of
the between-study variance for any given example. However, the extent of the bias is
dependent on the allocation of the weight, where the more uneven the allocation of the
weight the greater the bias. The adjusted estimate proposed in this chapter L for
the case where n=n for all i was again an improvement over the standard estimate,
although not ideal. The reduction in Q, when n is small leads to the underestimation
of 4.
The conclusions that can be drawn for the random effects model are rather
limited. The estimate of the treatment effect appears to remain unbiased, although
the variance clearly is larger than 1/E1 w due to the estimation of both v and 4.
The variance calculated in practice, that is 1/
	 t2i is also larger than l/E w
due to the influence of the inflated estimate of 4. However, there is no theory to
state that 1/
	 tb is a reasonable estimate of the true variance.
Hence, overall, in most practical situations where n, is large the standard es-
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timates perform adequately. However, in such cases, for example where n=50, the
adjusted estimates do perform even better, although the adjustments are so small
that they are most unlikely to make any real difference to the conclusions drawn.
The case where n1 is small is where problems occur and adjustments are more impor-
tant. Unfortunately, when n was equal to 5 the simulated results indicated that the
adjustments were less good. However, improvements were still seen with regards to
the var(Ô j), Q and â'.
As always with a simulation study, the results are not necessarily generalisable
to situations which were not investigated. Further simulation examples were carried
out in cases where n was allowed to vary within a meta-analysis. These showed that
where only some of the trials have small numbers of observations and others have
large numbers problems can still occur. Hence, if a meta-analysis includes just one
small study an impact on the results is possible. The results do not apply to binary
outcomes and hence, there is scope for this work to be extended, especially as it has
been shown that the estimation of the weights can affect the meta-analysis results.
However, this problem may, perhaps, be more usefully approached by consideration
of the full likelihood method of van Houwelingen et aL [451 (Section 2.4) which allows
for the estimation of the weights for binomial outcome measures. A comparison, using
simulated data, of the standard results with those obtained from the full likelihood
method when numbers of observations in each trial is small would be informative.
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6 Analysis of Data From the British Family Heart
Study
In this chapter the application of meta.-analysis techniques to the analysis of a paired
cluster randomised trial is described. Data from the British family heart study [112]
is then analysed using such methods. Section 6.1 describes the design and conduct
of the British family heart study, while Section 6.2 illustrates how the random ef-
fects meta-analysis methods can be applied to such studies. Section 6.3 then presents
the results for a selection of outcome measures and provides an in-depth considera-
tion and investigation of heterogeneity for one continuous outcome measure (level of
cholesterol) and one binary outcome measure (prevalence of smoking). Section 6.4
contains a discussion of the problems of analysing a multicentre trial and trying to
account for heterogeneity. Furthermore, due to the multiple endpoints recorded in
the British family heart study, Section 6.5 considers the problem of multiple testing
and briefly introduces the concept of a multivariate meta-analysis.
6.1 Introduction to the British Family Heart Study
The aim of the British family heart study was to measure the change in cardiovas-
cular risk factors achievable in families over one year by the implementation of a
cardiovascular screening and lifestyle intervention programme based in general prac-
tice [112]. The intervention programme was nurse led, with a different research nurse
being allocated to each intervention practice. Research nurses were recruited locally
and trained centrally before commencing the study.
Two general practices in each of 13 towns in Britain (10 in England, 1 in
Scotland and 2 in Wales) with a population of between 50 000 and 100 000 at the
1981 census were identified. The pair of practices within each town were matched so
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that they had similar sociodemographic characteristics. The two practices within each
town were then randomly allocated to be either the intervention practice or the control
practice (Figure 66). Families recruited to take part in the study were identified
through the male partner who, in order to be eligible, had to be aged between 40
and 59 years. In each intervention practice and each control practice, all men aged
40-59 years were randomly ordered within five year age bands. Furthermore, in the
intervention practices, each age band was randomly split into two equal sized groups,
one of which became the intervention group and the other the internal control group
(Figure 66). The families randomised to the intervention group were then contacted
by the practice research nurse in the order given by the five year age band lists.
Contacts were made at the same rate within each five year band. The families were
screened and subsequently offered lifestyle intervention and follow up.
All family members attending the initial visit were screened, but only men and
their partners were followed up. During the initial screening interview, demographic,
lifestyle, and medical information were collected. Measurements of height, weight,
body mass index (weight/height 2), carbon monoxide concentration in the breath,
blood pressure, and random blood concentration of total cholesterol and glucose in a
finger prick sample were also obtained.
A coronary risk score was then derived and participants were told in which
decile of the distribution of risk for coronary heart disease they were relative to other
men (or women) of the same age. The risk score was recorded and relevant lifestyle
changes were individually negotiated with the research nurse relating to smoking,
weight, healthy diet, alcohol consumption and exercise. The frequency of the follow-
up visits was determined by the overall coronary risk score and specific individual
factors. The greater the risk, then the more frequent the visits.
Rescreening of men and their partners in the intervention group then took
place one year after the initial screening. Identified families in both the external
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Figure 66: Design of the British family heart study showing the numbers of men and
women randomised and screened
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control practices and the internal control groups were unaware that they were par-
ticipating in a trial until they were called for screening at the end of the one year
intervention period. Hence their first screening coincided with the rescreening of the
intervention group. In total, 7 460 men and 5 012 women were included in the study
(Figure 66). The smaller numbers in the intervention and internal control groups are
due to the population in the intervention general practice being split between these
two groups.
6.2 Statistical Methods
The comparison of the intervention group with the internal control group in the
British family heart study is of a typical multicentre trial design, in which members
of a single population (patients at a single practice) are individually randomised to
one of two groups. Hence, meta-analysis methodology applies to this comparison in
the same way that it does to the MRC mild hypertension trial (Section 1.3.2). In such
situations there may be variability in the effect of the intervention between towns,
which may be due to the varying ability and effectiveness of each nurse, the differing
general practices and the differences in the patient populations and their attitudes
towards changing their lifestyle.
However, the comparison of the intervention group with the external control
group is of a paired cluster randomised design. The two general practices within each
town are randomised to be either the intervention or the control. Hence, within each
town (strata) there are two separate clusters of patients who are to be compared, one
being the intervention group and the other being the external control group. It is
now shown how this sort of design can also be analysed using meta-analysis methods.
The treatment effect in the i' town (i=1,...,k) is denoted by ö, which may be, for
example, a log odds ratio for a binary outcome measure or a difference in means for
a continuous outcome.
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For a continuous outcome, &= 1 - i2. where	 is the mean of the n, mdi-
vidual observations in strata i and treatment group j (j=1 for treatment and j=2 for
control). Then the variance of the mean is var() = (c/n) + 4, where o is the
within-cluster (within-practice in the case of the British family heart study) variance
and 4 is the between-cluster variance. Hence, the variance of this difference is given
by
2 \
var(Ô) = var(i i ) - var(y 2 ) = 2o1 + ( 2:1.. +
	
(125)
h1	 ;2 I
and so 24 can be considered as the between-stratum variance in a random effects
model, or a between-town variance with respect to the British family heart study.
This between-stratum variance may then be estimated using either the D&L moment
estimator (Section 1.7.1) or by likelihood methods (Section 2.2), assuming the model
N(O, (o 1 /n i) + (o/n 2 ))	 (126)
Oi N(O,24)
	 (127)
Hence, by taking a weighted average of the individual within-stratum estimates of
treatment effect, where the weights are equal to 1/var(0) and var( j) is given by
(125), the equivalent of a random effects meta-analysis is obtained (Section 1.7.1).
For a binary outcome, the log odds ratio may be used as a measure of treatment
effect (3, and so the variance of â may easily be obtained where the within-stratum
component is given in Section 1.5.1. Alternatively, using the difference in prevalence
rates, that is o=A1 - P, 2 where F, i = a,/n, 1 and P,2 = cj /n,2 and a and Cj are the
number of positive responses (or events) in treatment groups 1 and 2 respectively
(Table 2), means that the within-stratum variance is given by (ab,/n) + (cjd,/n).
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For either outcome measure the meta-analysis methods again follow through with
the estimate of the between-stratum variation being obtained either using the DL
moment estimator or using likelihood methods.
In this cluster randomised design there are, in addition to the previously men-
tioned differences between towns, differences between the two general practice popula-
tions within each town. Hence, a greater amount of heterogeneity would be expected
in the results for the external control group comparison than for the internal control
group comparison and so the internal control group comparison would be expected
to produce the more precise results. However, due to the possibility of a transfer of
the effect of the lifestyle advice from the intervention to the control group within the
practice, the magnitude of the intervention effect may be diluted. Thus, the main
statistical comparison laid down in the protocol of the study was that of the interven-
tion group with the external control. Both control group comparisons are considered
here and the results compared.
6.3 Results
6.3.1 Overall results
Four separate analyses were carried out in order to see if any further insight into the
results or the heterogeneity between towns could be achieved from doing 'parallel'
analyses on the same study. The four analyses came about by considering men and
women separately and also by looking at comparisons of the intervention group with
both the internal and external control groups.
The differences between the intervention and control groups at the one year
screening for five cardiovascular risk factors are presented in Table 53. The crude
summary measure (prevalence or mean) for each group is given, together with the
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estimate of the overall difference (difference in prevalence or difference in means)
between the intervention and the control groups obtained using the standard random
effects meta-analysis methods (Section 1.7.1) and the standard error of this difference.
It may be seen that both control groups give similar results and these indicate that,
in relation to the five risk factors considered, the intervention group were at less risk
than either of the control groups. For both men and women smoking prevalence was
lower in the intervention group than in either control group. For men the prevalence
was about 4% lower in the intervention group than in either of the control groups and
these differences were significant at the 5% level. For women the difference was smaller
(3% and 3.6%) and less conclusive owing to the larger standard errors associated with
the differences.
The mean cholesterol level was approximately O.lmmol/l on average lower in
the intervention group than in either control group for both men and women. How-
ever, the standard error associated with this difference for women was large enough
for the possibility to exist of there being no intervention effect. For both systolic
and diastolic blood pressure the means were lower in the intervention group than for
either control group for both men and women. This difference was on average around
7mmHg for systolic and 3mmHg for diastolic. The mean weight in the intervention
group was also lower, by about 1kg on average for both sexes, than that in either
control group.
The fact that all outcomes for all comparisons are in. the same direction, tends
to add support to the existence of a real intervention effect, even though some differ-
ences may not be very large or conclusive. However, the possibility of biases having
occurred and influenced the findings should be considered and was in fact discussed
in the paper presenting the principal results of the study [112]. For example, the low
smoking prevalence observed in the intervention group at the end of the intervention
period could have been biased by non-returners or by the under-reporting of current
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cigarette smoking in those who did return for rescreening. It was found [112] that the
non-returners had a higher smoking rate at baseline than the returners and hence this
would have exaggerated the intervention effect with regards to smoking prevalence.
The meta-analysis diagrams for both cholesterol level and smoking prevalence
indicate that there is little variation in the estimates of intervention effect across
towns for the internal control group comparison for both men and women (Figures
67 and 68). Estimates with approximately equal precisions, as observed in this study,
are more likely to occur in a multicentre trial than in a meta-analysis, since as well as
the same protocol being followed in each centre, the numbers of patients recruited in
each centre will often be roughly comparable. In a meta-analysis, however, the trials
may vary greatly with respect to protocol and sample size and thus precision.
Figure 67: Differences in mean cholesterol level (mmol/l) between the intervention
group and the internal control group together with the 95% confidence intervals
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As would be expected, there are greater differences in the estimate of the
intervention effect for both cholesterol level and smoking prevalence in both men and
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Table 53: Results for five cardiovascular risk factors for the British family heart study
Group	 Men	 Women
pooled	 pooled
crude value difference (SE) crude value difference (SE)
Smoking prevalence (% of subjects)
Intervention	 19.1	 17.7
External control	 22.8	 -4.1(1.8)	 21.2	 -3.60(2.1)
Internal control	 23.0	 -4.1(1.3)	 21.5	 -3.00(1.5)
Mean blood cholesterol (mmol/l)
Intervention	 5.58	 5.48
External control	 5.69	 -0.12(0.06)	 5.61	 -0.12(0.09)
Internal control 	 5.72	 -0.13(0.03)	 5.60	 -0.09(0.07)
Mean systolic blood pressure (mm Hg)
Intervention	 131.6	 123.2
External control	 138.8	 -7.5(1.2)	 130.8	 -7.7(1.4)
Internal control	 139.0	 -7.3(0.8)	 129.6	 -6.2(0.9)
Mean diastolic blood pressure (mm Hg)
Intervention	 83.3	 78.6
External control
	 85.5	 -2.5(1.0)	 80.7	 -2.5(0.9)
Internal control
	 86.6	 -3.5(0.4)	 81.3	 -3.0(0.4)
Mean weight (kg)
Intervention	 79.55	 66.06
External control
	 80.70	 -1.17(0.36)	 66.83	 -1.09(0.42)
Internal control
	 80.76	 -1.18(0.43)	 66.73	 -0.74(0.54)
274



1
13
6
men
1
13
women
1
13
2
1
13
Figure 71: Pie charts showing the percentage weight allocated to each town in the
random effects estimate of overall treatment effect for the difference in cholesterol
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NB. For both internal control group comparison b=0
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Figure 72: Pie charts showing the percentage weight allocated to each town in the
random effects estimate of overall treatment effect for the difference in smoking preva-
lence expressed as a log odds ratio
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The mean level of blood cholesterol concentration and the prevalence of cur-
rent cigarette smoking are now considered in greater detail in Sections 6.3.2 and 6.3.3
respectively. The two aims of these sections are to compare the results obtained using
three different meta-analyses, that is the standard inverse-variance fixed effect method
(Section 1.5.1), the DerSimonian and Laird random effecmethod (Section 1.7.1) and
the maximum likelihood approach with profile likelihoods used to obtain confidence
intervals (Section 2.2), and to investigate heterogeneity from a more practical per-
spective.
6.3.2 Analysis of cholesterol level
This section focuses on a continuous outcome measure from the family heart study,
that is blood cholesterol concentration measured in mmol/l. Differences at the end of
the intervention period in the cholesterol level between participants in the intervention
group and those in the control group, - UI (1=intervention, 2=control), were
considered as the measure of outcome for the analysis. A meta-analysis is carried out
followed by a discussion of heterogeneity.
Geographical variation in the level of cholesterol concentration may be ex-
pected across towns in this study, since rates of heart disease, and therefore cardlio-
vascular risk factors, are known to vary from region to region. It is also possible that
the effect of the lifestyle intervention programme in the British family heart study
may vary with baseline cholesterol level and hence with geographical location. Mean
cholesterol levels for each group as well as for the differences in mean cholesterol levels
were, therefore, plotted against latitude. The results obtained from this study do, at
least to some extent, provide evidence of a gradient of cholesterol levels from north
to south. For women in the internal control groups there is a particularly strong
relationship between mean cholesterol level and geographical location (Figure 73),
with a clear increase in mean cholesterol as towns become more northerly. However,
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there does not appear to be any relationship between treatment effect and latitude in
any of the four comparisons of interest (Figure 74). Hence, it is perhaps reasonable
to assume that any regional differences that do exist between centres have been can-
celled out when a difference between intervention and control groups is taken. This
implies that there is no clear variation according to latitude in the way that different
populations respond to intervention.
Figure 73: Mean cholesterol levels in each town for women in the internal control
groups plotted against the latitude of the town
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Although the concerns regarding the low power of the test for heterogeneity
(Chapter 4) and the bias in the estimates caused by the estimation of the weights
(Chapter 5) must be considered as potential problems, neither are likely to be impor-
tant in the analysis of the British family heart study. This is because the numbers of
observations in each town is large and the numbers are approximately equal. Hence,
the power of the test for heterogeneity will not be particularly low and the estimated
weights will only be slightly greater than the true weights on average. When compar-
ing the internal control group and the intervention group, there is no heterogeneity
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Figure 74: Differences in mean cholesterol levels in each town plotted against the
latitude of the town for all four comparisons
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present between towns for the men as measured by Q=1O.6 on 12 degrees of freedom.
Furthermore, the likelihood ratio test of 4 = 0 also indicates a lack of heterogene-
ity and hence, all three methods produce the same estimate of intervention effect of
—0.l33mmol/l, indicating a lower mean cholesterol level in the intervention group
(Table 54). The 95% confidence interval indicates that this difference is significant at
the 5% level. When comparing the intervention group with the external control group,
heterogeneity was found to be present (Table 54). Evidence of a significant differ-
ence in cholesterol levels (5% level) was detected by all three meta-analysis methods,
with the intervention group again having the lower levels. The estimates from the
two random effects models were slightly less negative (i.e. smaller difference between
groups) than the estimate from the fixed effect model. The confidence intervals were
also, of course, wider for the random effects estimates with the widest interval being
that calculated from the profile likelihood, whose upper bound was only marginally
less than zero (Table 54).
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Table 54: Comparison of the results from three different meta-analysis methods for
differences in mean blood cholesterol concentration between intervention and control
groups in men in the British family heart study
Comparison Method II Estimated between-
	 95% CL J Estimated overall 	 95% C.I.
group	 _________ study variance (o-)
	 for 4	 ]	 effect (U)	 for 0
Internal	 Fixed	 -	
-	 -0.133	 (-0.200,-0.066)
Random	 0.000	 -	 -0.133	 (-0.200,-0.066)
Likelihood	 0.000	 (0.000,0.0405)	 -0.133	 (-0.200,-0.066)
External	 Fixed	 -	
-	 -0.126	 (-0.190,-0.064)
Random	 0.029	 -	 -0.117	 (-0.229,-0.004)
Likelihood	 0.025	 (0.006,0.077)	 -0.117	 (-0.231,-0.001)
Table 55: Comparison of the results from three different meta-analysis methods for
differences in mean blood cholesterol concentration between intervention and control
groups in women in the British family heart study
Comparison Method	 Estimated between-	 95% C.I.	 Estimated overall	 95% C.I.
group	 study variance (&)
	 for 4	 effect (U)	 for 0
Internal	 Fixed	 -	
-	 -0.105	 (-0.193,-0.017)
Random	 0.043	 -	 -0.087	 (-0.232,0.057)
Likelihood	 0.037	 (0.006,0.130)	 -0.087	 (-0.299,0.064)
External	 Fixed	 -	 -	 -0.111	 (-0.199,-0.023)
Random	 0.087	 -	 -0.113	 (-0.297,0.071)
Likelihood	 0.075	 (0.026,0.217)	 -0.113	 (-0.300,0.076)
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The results for women (Table 55) are less convincing in favour of the interven-
tion. Although the estimated overall intervention effects were similar for both men
and women, the associated confidence intervals were much wider for women than for
men. For both comparisons (internal and external control groups) for women the
fixed effect analysis provides evidence of a difference in cholesterol levels, but once
heterogeneity is taken into account and the confidence intervals are widened, the re-
suits are compatible with the possibility of there being no intervention effect. There
is greater heterogeneity in the results between towns for women than for men, as
well as smaller numbers leading to the wider confidence intervals and less conclusive
results.
The q-q plots, both fixed effect (Section 3.1.1) and random effects (Section 3.1.2),
were then obtained in order to investigate the form and cause of the heterogeneity
observed in three out of the four examples. They were also used to check the va-
lidity of the modelling assumptions of normality in conjunction with version (3) of
the Anderson-Darling test (Section 3.2.2). However, the test proved of limited use
in the examples presented here, since it did not appear to have the power to detect
deviations from the model, presumably due to the relatively small number of points.
It may be seen from the fixed effect q-q plot (Figure 75) and from the result of the
Anderson-Darling test (A2 —0.239, p >0.15) that the intervention effect estimates in
each town for the comparison of the intervention group with the internal control
group for men are consistent with a normal distribution, that is ö, .- N(O, vi). There
is clearly no significant heterogeneity in this example and the distributional assump-
tions of the normally distributed fixed effect model appear to be adequate. However,
the corresponding plot (Figure 76) for the external control comparison shows that
there is one clear outlying town in these data, rather than the heterogeneity following
a random effects model. However, the Anderson-Darling test does not pick this up
and produces a nonsignificant result (A2=1.56, p >0.15). Since the variances, and
hence the weights, of each town estimate of intervention effect are fairly equal, then
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data following a random effects model plotted using fixed effect q1 would produce an
approximate straight line with a gradient steeper than one. It would not produce the
type of plot seen in this example, although again the Anderson-Darling test produces
a nonsignificant result. Hence, in this particular case, more information is picked up
from the plot than by the results of the Anderson-Darling test. By considering the
component q of the heterogeneity test statistic Q contributed by Carlisle (town num-
ber 4), it may be seen that the heterogeneity is due entirely to this single observation.
The contribution of this town to Q is (_4.824)2=23.27 and Q calculated without the
observation for Carlisle produces a p-value greater than 0.1 when compared to the
Xi distribution.
Figure 75: Fixed effect normal plot of q2 for the internal control group comparison of
cholesterol levels for men compared with the N(0, 1) line
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The group mean cholesterol levels for Carlisle (Table 56) show why the results
for this particular town deviate from the rest and why it produces an outlying ob-
servation in the comparison with the external control group. Both the intervention
group and the internal control group have low average cholesterol levels in comparison
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Figure 76: Fixed effect normal plot of q2 for the external control group comparison of
cholesterol levels for men compared with the N(O, 1) line
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Table 56: Mean levels of blood cholesterol concentration among men for the three
study groups in Carlisle
Group	 Mean Standard Number of
deviation	 men
Intervention	 5.438	 0.965	 180
External control 6.067	 1.450	 345
Internal control	 5.468	 1.020	 222
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to the overall mean level (Table 53), while on the other hand, the external control
group has a very high mean cholesterol level (largest individual group mean).
There is heterogeneity present in both comparisons for the cholesterol levels
in women but, as would be expected, there is more for the external control group
comparison. For the internal control group comparison, there are apparently two
outlying points and the rest follow the fixed effect normal model reasonably well
(Figure 77). The plot, although not the test (A2=l.28, p >0.15), suggests that the
normally distributed random effects model is not a particularly good fit to the data
due to the heterogeneity present.
Figure 77: Fixed effect normal plot of q2 for the internal control group comparison of
cholesterol levels for women compared with the N(0, 1) line
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For the external control group comparison there is a greater amount of het-
erogeneity which is spread throughout the 13 towns (Figure 78). There is a group of
4 towns (Gloucester, Lincoln, Dunfermline and Newport) which are similar to each
other but noticeably different from the rest of the observed q2 (Figure 78). They all
have large positive q, thus indicating that 0, > 0. In fact, in all these towns the
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cholesterol level is lower in the external control group than in the intervention group.
There is also a clear outlying point with a large negative value of qj, and, as was the
case for the cholesterol level results for men for the external control group compari-
son, this outlier was Carlisle. Again this is due to a high mean cholesterol level in the
control group (largest individual group mean) and a relatively small mean cholesterol
level in the intervention group (Table 57). A normally distributed random effects
model would also appear to be inappropriate as the groupings observed on the fixed
effect plot are still apparent on the random effects plot (Figure 79) and the test for
normality is significant (A2=6.71, p <0.01).
Figure 78: Fixed effect normal plot of qj for the external control group comparison of
cholesterol levels for women compared with the N(0, 1) line
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The heterogeneity in two out of the three examples displaying a significant
amount of heterogeneity appears to be due to a few outlying observations rather
than being spread throughout the data. The external control group in Carlisle can
be singled out as a possibly 'odd' observation contributing to heterogeneity for the
results for both men and women. This finding was discussed with the research nurse
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Figure 79: Random effects normal plot of q for the external control group comparison
of cholesterol levels for women compared with the N(O, 1) line
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coordinator of the British family heart study, who was familiar with all the partici-
pating general practices. It transpired that both practices in Carlisle were situated
in the town centre, drawing on similar populations and hence a difference in popu-
lation characteristics would seem an unlikely explanation for the difference observed.
Furthermore, since there was little difference between the mean levels in the inter-
nal control group and those in the intervention group, it would not appear that the
finding was the result of a particularly effective intervention. A feasible explanation,
resulting from the discussion, was that there could be some consistent measurement
difference between the intervention and control practice. It is possible that the cali-
bration of the refiotron machines used to measure cholesterol could have been different
in each practice, despite a centrally coordinated quality control program [112], so that
consistently high readings were obtained in the control practice. It is also possible
that the nurse in the external control practice could have made systematically higher
readings than the nurse in the intervention group. These theories could be checked
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to some degree if the relevant data regarding the calibration of the instrument and
measurement of cholesterol were available.
Table 57: Mean levels of blood cholesterol concentration among women for the three
study groups in Carlisle
Group	 Mean Standard Number of
deviation	 women
Intervention	 5.249	 1.045	 109
External control 6.078
	 1.465	 186
Internal control
	 5.645	 1.300	 118
Discussion of the large amount of heterogeneity for the results for women in the
external control group comparison produced no conclusions. There is no obvious com-
mon factor linking the four towns of Gloucester, Lincoln, Newport and Dunfermline,
which produce similar residuals in this example. It was only possible to identify two
of these towns as possessing unusual characteristics which could explain the results
observed, that is the control groups having lower mean cholesterol levels than the
intervention groups in these particular town. In one of these towns the two practices
were serving populations with difference characteristics, and in the other there were
problems with the implementation of the intervention programme. However, these
are not convincing as explanations for the heterogeneity since each is related to only
one particular town. Furthermore, the two towns have not been identified consis-
tently across different risk factor outcomes (smoking, SBP, DBP and BMI) as having
a particularly poor intervention effect and, if there were a true population effect, it
would be expected to influence more than one outcome measure.
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6.3.3 Analysis of current cigarette smoking
The difference in the prevalence of current cigarette smoking between the intervention
group and the control group is now expressed in terms of the log odds ratio, rather
than the difference in prevalence rates as in Table 53, and an analysis of this outcome
measure is carried out. This is so that the analysis of a binary outcome remains
consistent with the measure used throughout the rest of the thesis.
For the internal control group comparisons for both men and women (Tables 58
and 59) all three methods produce the same results since the estimate of the between-
town variance for the two random effects methods is zero. For both sexes the results
indicate a significantly lower rate of smoking in the intervention group than in the
control group, again indicating a benefit from the intervention process.
For both men and women for the external control group comparison, the ran-
dom effects estimate, using the D&L moment estimator of the between-town variance,
of the log odds ratio for the overall intervention effect is smaller than the fixed effect
estimate, indicating a slightly greater effect due to intervention (Tables 58 and 59).
However, the corresponding widening of the confidence interval for 9 indicates the
reduced certainty in the intervention effect. For men there still remains a significant
difference in the smoking rates between the two groups when the heterogeneity is
taken into account, with the intervention group having a lower rate than the control
group (Table 58). However, for women the confidence interval for the random effects
model includes zero whereas for the fixed effect model it does not (Table 59). Hence,
the choice of model here affects the conclusions which may be drawn from the analysis
with regards to the benefit of intervention on reduction in smoking rates. The random
effects likelihood model produces a similar estimate to the standard method of 9 for
both men and women, but the estimate of the between-town variance is smaller in
both cases than the D&L moment estimator. Furthermore, the confidence intervals
for 9 are, as expected, slightly wider than those derived from the standard random
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effects method (Tables 58 and 59), thus further reinforcing the possibility of there
being no intervention effect on the prevalence of cigarette smoking among women in
the study.
Table 58: Comparison of the results from three different meta-analysis methods for
log odds ratios of the prevalence of cigarette smoking comparing intervention and
control groups in men in the British family heart study
Comparison Method	 Estimated between-	 95% C.I.	 Estimated overall	 95% C.I.
group	 __________ study variance (4)	 for 4	 effect (Ô)	 for 0
Internal	 Fixed	 -	 -	 -0.242	 (-0.399,-0.085)
Random	 0.000	 -	 -0.242	 (-0.399,-0.085)
Likelihood	 0.000	 (0.000,0.020)	 -0.242	 (-0.399,-0.085)
External	 Fixed	 -	 -	 -0.197	 (-0.342,-0.051)
Random	 0.079	 -	 -0.228	 (-0.442,-0.014)
Likelihood	 0.064	 (0.000,0.272)	 -0.225	 (-0.456,-0.013)
Table 59: Comparison of the results from three different meta-analysis methods for
log odds ratios of the prevalence of cigarette smoking comparing intervention and
control groups in women in the British family heart study
Comparison Method	 Estimated between-	 95% CI.	 Estimated overall	 95% CL
group	 _________ study variance (4)	 for 4	 effect (Ô)	 for 0
Internal	 Fixed	 -	 -	 -0.227	 (-0.427,-0.027)
Random	 0.000	 -	 -0.227	 (-0.427,-0.027)
Likelihood	 0.000	 (0.000,0.291)	 -0.227	 (-0.427,-0.027)
External	 Fixed	 -	 -	 -0.198	 (-0.382,-0.014)
Random	 0.098	 -	 -0.213	 (-0.469,0.043)
Likelihood	 0.082	 (0.000,0.386)	 -0.211	 (-0.485,0.050)
Fixed effect q-q plots (Section 3.1.1) for the internal control group comparison
for both men and women confirm that the results for smoking status are homogeneous
across towns as there are no large absolute values of q 1 (Figures 80 and 81). For men
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the line has a gradient which is less than one, suggesting that there is, in fact, less
variation in the estimates than would be expected, while for women the line is not
particularly straight. However, a normal fixed effect model would seem satisfactory,
although perhaps not ideal, for both these sets of data, as there is certainly no evidence
of heterogeneity. Furthermore, the results of the Anderson-Darling test produce test
statistics A2 corresponding to p >0.15 for both men and women.
Figure 80: Fixed effect normal plot of q for the internal control group comparison of
smoking prevalence for men compared with the N(0, 1) line
-2	 -1	 0	 1	 2
floltn& icot.,
correlatjonO. 977
The two fixed effect plots for the external control group comparisons (Figures
82 and 83) do indicate the presence of heterogeneity. The plots for men and women
are, however, different in that the heterogeneity takes different forms. For men the
plot is a straight line through the origin, but with a gradient slightly steeper than
unity (Figure 82). Hence, this is consistent with a normally distributed random effects
model with reasonably equal variances. Since it is known that the variances of the
individual town estimates are fairly similar for this outcome in men (Figure 72), such
an interpretation of the plot seems reasonable. The conclusion is further backed up
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Figure 81: Fixed effect normal plot of q, for the internal control group comparison of
smoking prevalence for women compared with the N(0, 1) line
-2	 -1	 0	 1	 2
flotm& sr..
correlation =0.954
by the corresponding random effects plot (Figure 84), which produces a reasonable
straight line with a gradient of one. The tests are again of little use here as they appear
to lack power in that they find the data consistent with both the fixed effect model
and the random effects model. In contrast, for women the fixed effect plot indicates
that there is a single very clear outlier which is the sole cause of heterogeneity (Figure
83). All the other points lie along the line of identity indicating that the majority
of the town estimates are consistent with each other. On the random effects plot
(Figure 85) the outlier has been pulled in, since it has a relatively small within-town
variance, but a normally distributed random effects model is less convincing in this
situation as backed up by the result of the Anderson-Darling test (A2=2.29, p <0.1).
Bury (town number 9) is the town which is identified as a clear outlier in the
external control group comparison for women. This town appears to be different with
respect to cigarette smoking to all th other towns, especially since it also produces
one of the large residuals on the plot for men (Figure 83). As Bury is not noticeably
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Figure 82: Fixed effect normal plot of qi for the external control group comparison of
smoking prevalence for men compared with the N(O, 1) line
-3
-3	 -2	 -1	 0	 1	 2	 3
noimel icor..
correlationO. 994
Figure 83: Fixed effect normal plot of q 2 for the external control group comparison of
smoking prevalence for women compared with the JV(O, 1) line
4 -3	 -2	 -1	 0	 1	 2	 3	 4
nutm.I scot..
orrelationO.937
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Figure 84: Random effects normal plot of q1* for the external control group comparison
of smoking prevalence for men compared with the N(O, 1) line
3	 2	 -1	 0	 1	 2	 3
naimal .cor.s
correlatjon=O.983
Figure 85: Random effects normal plot of q for the external control group comparison
of smoking prevalence for women compared with the N(O, 1) line
-4	 -3	 -2	 -1	 0	 1	 2	 3	 4
noimal scor..
correlation—O.930
296
outlying for the internal control group comparisons (Figure 80 and 81), the suggestion
is that the external control group produces the unusual observation. In the external
control group in Bury, there were a high proportion of current cigarette smokers,
particularly among women (33%), but also among men (30%). Hence, the differences
between the smoking rate in the external control group and the intervention group
are large, being 17% for men and 23% for women. This is also partly due to the
smoking prevalence being rather on the low side in the intervention group, as it is
in the internal control group. It should be noted that 30% is actually closer to the
national average smoking rate, and hence, it may actually be the other groups where
the rates are unusually low and may be as a consequence of a general under reporting
of cigarette smoking in the study or of bias caused by the non-randomness of non-
respondents.
In relation to the apparently unusually large intervention effect observed in
Bury, there are several possible explanations that could be investigated and these were
also discussed in the meeting with the research nurse coordinator. Although prac-
tices within each town were matched for sociodemographic factors, in some towns the
practices were still situated in different areas with differing characteristics and thus
drawing on different populations. Bury was, in fact, one such town where there was a
substantial geographic difference between the intervention and the control practices,
with the intervention practice being in a more advantaged and affluent area than the
control practice. Hence, this could explain the difference seen in that a more advan-
taged population would be expected to have a lower smoking rate. However, greater
faith would be placed in this explanation if the same effect were seen in all other
towns where there was a population difference between the practices (i.e. that the
practice with the more advantaged population always had the lower smoking rate in
the control group). This theory could be checked if the relevant data regarding social
differences in the practices in each town were available, although such information
would be based on rather subjective judgement.
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The fact that the cigarette smoking prevalence was low in the internal control
group as well as the intervention group in Bury suggests that the large difference
in rates is not due to a particularly effective intervention with regards to smoking.
However, it is possible that it is due to a difference in reporting rates. Since it is highly
unlikely that smoking rates will be overestimated, it may be that in the intervention
practice the smoking rates reported were lower than the true rates.
It was also considered possible that the response rate in the control practice
could have caused the high prevalence observed. If the response rate was particularly
high for the control practice in Bury, then it could be that more smokers responded
to the screening than in other centres. However, the response rate was actually about
average in this practice and so this would seem an unlikely explanation. Hence, again
no convincing explanation for the heterogeneity was found.
6.4 Discussion
Sources of heterogeneity in a meta-analysis require investigation and, therefore, so do
the sources of heterogeneity in a paired cluster randomised trial such as the British
family heart study. However, because there is more scope for variation between trial
protocols in a meta-analysis than in a single multicentre trial where all centres are
actually following the same protocol, there may often be more heterogeneity in a meta-
analysis than in a multicentre trial. This greater clinical homogeneity may mean that
it is more problematic to deduce the causes of heterogeneity in a multicentre trial
since there will be fewer and less obvious reasons for the heterogeneity than there
would be in a meta-analysis.
In the British family heart study the fact that two control groups were avail-
able, in addition to the results for both men and women, meant that there appeared
to be a greater chance of sorting out causes of heterogeneity, as all four analyses could
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be compared for consistency for each outcome. Hypothetically, if all four comparisons
were to show the same unusual effect in any particular town then it would seem likely
that this effect would be due to characteristics of that town. If, however, the effect
were only seen in one of the control group comparisons, but consistent for both sexes,
then the suggestion would be that there is a practice effect present in that town. If,
however, the effect were only seen in a single comparison in the town, then the reason
would be difficult to deduce, and would probably remain unexplained. Furthermore,
if a town were to be identified as unusual for more than one outcome measure then
more confidence could be placed in the possibility of a population or town effect.
As has been shown with the analysis of the British family heart study, how-
ever, there may not be any obvious or convincing explanations for the heterogeneity
observed or for outlying values. For the outcomes considered, that is smoking rates
and cholesterol level (Section 6.3) (but also SBP and DBP which are not presented
in detail here), no town revealed itself as a consistent outlier across more than one
outcome. Hence, this appears to provide evidence against the possibility of differences
in patient populations within towns causing different results.
It was only in the case of blood cholesterol levels where the external control
group in Carlisle produced outlying results that there was any possibility of a con-
vincing explanation being found, in that it is likely that a consistent calibration or
measurement difference was present. In all other cases speculative suggestions are all
that appear possible and these are all post-hoc and lacking in any sort of consistency.
Hence, in such situations a random effects analysis may be the best or only
solution, if an estimate of an overall intervention effect is required. A fixed effect
estimate is inappropriate since the narrow confidence intervals would not reflect the
additional uncertainty caused by the between-town variation. So, although investi-
gating sources of heterogeneity rather than resorting to random effects meta-analysis
may be commendable in principle, it is not practical in all circumstances, as exempli-
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fled here. Furthermore, in general, any such investigation of heterogeneity is post-hoc
and so explanations of heterogeneity are based on what is observed in the data. In-
vestigations of heterogeneity may be more problematic in a single multicentre trial
than in an actual meta-analysis since there are less clinical differences between cen-
tres than there are between separate trials. Separate trials may vary in terms of, for
example, patient characteristics, duration of trial and treatment regimen, which may
all offer explanations for the variation in individual trial estimates. The problem in a
meta-analysis, however, may be that there are too many possible explanations of the
variation in the individual trial estimates because the trials vary in many different
ways. Hence, there may be a danger that the process of looking too hard for an
explanation produces one which is incorrect. Explanations which were put forward
as possible causes of heterogeneity before the data were looked at are probably the
most reliable, particularly where they are based on sound clinical reasoning. However,
a further issue to consider is whether a normally distributed random effects model,
such as those used in this analysis, is appropriate. Certainly the normal plots for
the examples from the British family heart study do not generally support normality.
Hence, there should be some concern over the validity of the results since it is not
known how robust the analysis is to deviations from the assumed model.
6.5 Multivariate Models For Meta-Analysis
In a meta-analysis or a paired cluster randomised trial there will often be more than
one outcome of interest to be considered, as there is in the British family heart study
(Section 6.3). Therefore, as with any single clinical trial with more than one endpoint,
the problem of multiple testing and estimation exists and this, therefore, implies that
there will be an increase in the overall Type-I error rate. Furthermore, endpoints
will usually be correlated with each other and therefore will not be independent. The
issue of multiple testing has been considered in the context of meta-analysis by Hedges
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and 01km [39] and Raudenbush et al. [113]. Several possible ways of dealing with
multiple endpoints have thus been proposed and discussed. Section 6.5.1 considers
simple solutions to the problem by looking at ways of maintaining the correct Type-I
error rate. Section 6.5.2 introduces a multivariate approach to meta-analysis and
Section 6.5.3 considers the construction of a global test statistic for a multivariate
model. The British family heart study is then used as an example in Section 6.5.4 to
illustrate the multivariate methods and Section 6.5.5 contains a discussion.
6.5.1 Simple solutions
Hedges and 01km [39] suggest as one possibility the analysis of only a single end-
point. However, they do acknowledge that this procedure is obviously wasteful of
information. This approach is also discussed by Pocock et al. [114] when considering
multiple endpoints in a single clinical trial. They suggest the specification of a single
primary endpoint in the study protocol which is to be tested formally, with all other
endpoints being considered as secondary with the interpretation being exploratory.
Such a statement of the primary endpoint of interest could also be made before a
meta-analysis is carried out, so that emphasis of the results is focused on the one
pre-specified outcome, as opposed to the one which provides the apparently most in-
teresting result. However, there may be situations in which there are several outcomes
of equal importance and the discarding or down-weighting of important information
is not reasonable.
An alternative suggested by Hedges and 01km [39] is that each outcome be
treated as independent and then the significance levels be adjusted. This is precisely
what is sometimes practised in the context of a single clinical trial with multiple
endpoints where the individual p-values are modified in order that the overall Type-I
error remains at the desired level of . For example, the Bonferroni inequality can
be used for significance tests on p endpoints [115, 116], although this adjustment is
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always conservative. The adjustment leads to a nominal significance level for each
test being taken as a where a' = a/p. However, when endpoints are correlated, as
they tend to be in practice, the Bonferroni correction becomes even more conservative
[114]. Furthermore, this solution only applies to hypothesis testing but does not help
with regards to estimation.
Raudenbush et al. [113] refer to another strategy for dealing with studies that
consider multiple continuous outcome measures in terms of effect sizes. The effect
size for study i is given by 6, = (jsi - j2)/O ip, where ajj (j = 1,2) is the mean in
treatment group j and c,, is the pooled standard deviation. The effect size 6, is used
extensively in psychological research and may be estimated using
gi = (Li. - Y,2.)/P	 (128)
where Lj is the mean of the individual observations in treatment group j in trial i
and
- 1)3 + (n 2 - 1)s?2
	 (129)
V	 n,1+n,2-2
where njj is the number of observations and s is the standard deviation in treatment
group j in trial i. However, g, = (v1 Y2.)/ap has been found to be a biased estimate
of the true effect size [39] and
'5i
E(g) =
	
	 (130)
J(n,i + fl,2 - 2)
where J(n,i
 + n12 —2) may be tabulated [39]. J(n,i + n,2 —2) may be closely approx-
imated by 1 - ( 3/(4(n, i + n,2) - 9) and so
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Si	 36i
	
__________	
(131)=
	
1 - 4(n+n)9	 4(n11 + n22) - 9
Hence it can be seen from (131) that, as the sample size becomes large, the bias tends
towards zero and so for large trials g, will be approximately unbiased. The bias may
be removed by redefining the estimated effect size so that
= J(n1 + n2 - 2)g	 (132)
or approximately
d• '	 4(nil+n2)-12'\- I 4(ni+naa)-9) gj	 (133)
Therefore, as the sample size increases, the adjustment factor tends to unity.
Hedges and 01km [39] state that the asymptotic distribution of d is normal
with mean Sj and variance
nil + n2 ___________
var(d) =	 +	 (134)
i1i2	 2(n1i + fli2)
The variance may be estimated by replacing in equation (134) by the estimated
effect size d..
Effect sizes are therefore standardised measures with no dimensions, which
means that endpoints can be combined by taking, for example, a mean or median [117,
118]. This approach is not always possible in. medical situations if, for example, the
odds ratio is the measurement of treatment effect used, or where an effect size would
be difficult to interpret. In many medical trials some sort of combined treatment effect
measurement would be meaningless, although it could be used for some psychological
or quality of life outcomes.
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6.5.2 Multivariate meta-analysis using generalised least squares
An obvious solution to the problem of multiple endpoints is to use multivariate meth-
ods in which all outcomes are analysed simultaneously, taking into account the cor-
relations between each pair of outcome measures. Raudenbush et al. [113] propose
the use of a generalised least squares (GLS) approach which builds on earlier work
by Hedges and 01km [39] and Rosenthal and Rubin [1191. The model is specified in
terms of effect sizes.
Assuming that each trial i, i = 1, ..., k included in the meta-analysis produces
results for r = 1, ..., r, of the total number of p endpoints being considered, the model
is of the form
6=X$	 (135)
where 5 is the vector of effect sizes 5' =	 £12, ..., Sifl,..., £kl, £k2, ..., £Icrii ) SO	 is
the effect size for the endpoint r for trial 1, X is the required design matrix and 3 is
the vector of parameters which are to be estimated. The matrix X has R =
rows, one corresponding to each outcome in each study, with the number of columns
being equal to the number of parameters fitted in any particular model. If a single
effect is being modelled for all the endpoints then X is a vector containing R l's. If
a different estimate is being obtained for each endpoint, then X has p columns of
indicator variables, one for each outcome.
The parameter estimates, together with their variances, may then be obtained
using standard GLS techniques. Writing equation (135) in terms of unbiased esti-
mated effect sizes given in (133), the model becomes
d=Xt3+e	 (136)
304
where e is assumed to be approximately normal with an RxR estimated variance-
covariance matrix S. The structure of S is such that it contains the individual trial
variance-covariance matrices S, i = 1, .., k, stacked along the diagonal with all other
elements being zero, that is
Si0 ... 0
o 52 •.. 0
5=	 (137)
oo	 ...
Each S contains the variance of each effect size in trial i on the diagonal and the
covariances of each pair of outcomes elsewhere. The effect sizes for outcomes p and
p' have the same asymptotic correlation as the original observations yj, and yj [39].
Hence, the covariance between the effect sizes relating to the two correlated outcome
measures Yip and yip' is
cov(d,,,, d1) = p,,,iJvar(d p)var(d pi) 	 (138)
where p,1' is the population correlation between Yip and Yip'. In large samples Pipe,'
may be estimated from the sample data within each study.
If e is assumed to have a zero mean vector and a known variance-covariance
matrix E, then the best linear unbiased estimator of 3 [113] is
/ = (X'E'X)X'E1d	 (139)
and the variance of /3 is
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var(f3) = (X'E 1 X) 1	(140)
However, since E is not known in practice, it must be replaced in equations (139) and
(140) by S.
The fit of the model may then be tested by considering the null hypothesis
that the predictors included in the model completely explain the variability in effect
sizes. The test statistic is given by
HE = (d - X/)'S'(d - Xj)	 (141)
assuming normality for d, and HE has a x2 distribution with R - q degrees of freedom,
where q is the number of parameters estimated in the model.
As is usual with regression analysis, the significance of each individual effect
can be tested by considering the null hypothesis H0 :	 = 0 and the familiar
z-statistic
= var()
	 (142)
is used. Raudenbush et al. [113] then suggest that since each parameter is being
considered separately, the p-values associated with each test should be adjusted to
avoid an inflated Type-I error probability.
In addition to these individual tests, an overall test of the significance of the
model may be carried out. This is a test of whether any of the parameters in the
model have a non-zero effect on the outcome and thus is a test of the null hypothesis
H0 /3 = 0. The test statistic is given by [391
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HR = d'Sd - HE	 (143)
which has a x distribution.
This test HR is similar to the Hotelling's T2 test for comparing two multivariate
samples and whose test statistic takes the form
T2 = z'A 1 z	 (144)
where z is a vector of z statistics for each of the p endpoints and A is the covariance
matrix which allows for correlations between the standardised normal deviates. The
correlations between the are the same as the correlations between the raw obser-
vations. Like Hotelling's T2 (144) statistic HR (143) will lack power against certain
important alternative hypotheses, since it is a general test of significance looking at
whether one or more of the treatment effects are different [120]. The alternative of
particular interest is that one treatment performs consistently better than the other
for all, or nearly all, of the endpoints. Without the power to detect such an alter-
native, all the evidence must be weighed up subjectively to deduce which treatment
is better overall, rather than being able to give a single probability statement on
efficacy. This issue is addressed in Section 6.5.3.
The main problem, however, with this multivariate model is that it is of a
fixed effect type and, hence, if any extra variation exists, then the model may not be
adequate. In certain circumstances, heterogeneity may be explained by the addition
into the model of trial-specific covariates, represented by the addition of a further
column to the design matrix. This allows the effect size estimates for each outcome
to have a slope, which may be common to all endpoints or different for each endpoint.
However, it may sometimes be the case that no covariate can be found which offers
a plausible explanation for the heterogeneity. Also, since any such investigation of
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covariates is generally post-hoc, caution needs to be expressed. Hence, in some sit-
uations the model will be a poor representation of the data and so this approach is
limited in its usefulness.
6.5.3 Global test statistic
Addressing the question of a global test statistic which is powerful against specific
alternatives, in the context of a single clinical trial, Pocock et al. [114] state that
the prime interest is often in an alteraive hypothesis with all (or some) endpoints
showing treatment differences in the same direction. An alternative to Hotelling's
T2 statistic, which is more powerful for this alternative of interest, was proposed by
O'Brien [120]. Assuming J' = (1, ..., 1), A is again the covariance matrix for the
multiple endpoints r = 1, ..., p, and z is the vector of test statistics for each individual
outcome measure, then, for any p asymptotic normal statistics with known covariance
matrix, J'A 1 z is the optimal linear combination for the alternative hypothesis that
the p standardised treatment differences are all of equal magnitude and in the same
direction [114], that is H1 :z1 = ... = z 0. The test statistic is therefore of the form
J'A1z
N(O,1)	 (145)(JA-1J)1/2
The weighting factors J'A' are column sums for each variable, indicating their total
correlation with all other endpoints. Hence, because A is inverted, the endpoints
which are less highly correlated with any of the other variables have greater weight.
Further work has been carried out which shows how the global test statistic (145)
may be extended to any set of asymptotically normal test statistics whose covariance
matrix it is possible to estimate [114].
If the same effect size were being assumed for each endpoint in the multivariate
meta-analysis model, then the test statistic HR is equivalent to Hotelling's T2 since
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X becomes 3, that is a vector of l's, and each dir is a standardised difference. The
difference with the meta-analysis case is that the null hypothesis being tested is
H0 : = 0 for all trials i = 1, ..., k and all outcomes r = 1, ..., r, rather than
H0 : z, = 0 for all outcomes r = 1, ...,p in a single trial.
The same null hypothesis as for the T2 test is being tested using the O'Brien
type test. The z test (142) in the case where a common treatment effect is being
fitted to all outcomes produces a global statistic equivalent to the O'Brien statistic,
using (139) and (140) to define and var(3). The statistic is given by
- X'Ed (146)
a1/var(f3) - (X'E-'X)1/2
where X is equivalent to 3 and E is also a covariance matrix like A and d is a vector of
asymptotically normal test statistics. This test is more powerful than HR against the
alternative hypothesis of H1 :	 = S12	 = 5lri = = 8k1 = 5k2 = ... =	 0
and therefore for alternative hypotheses where the effect sizes tend to go in the same
direction.
6.5.4 Example of multivariate meta-analysis
The British family heart study is used as an example to illustrate the multivariate
methods described in Section 6.5.2. The outcomes considered are diastolic blood
pressure (DBP) and systolic blood pressure (SBP). These outcomes were chosen since
the value of SBP and DBP for each person will obviously be correlated, and it may also
be of interest to make an efficacy statement about the treatment of blood pressure in
general, rather than about the two components separately. The correlations could be
estimated from the data within each centre and here the correlations for this analysis
were actually calculated using both intervention and control observations combined.
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The methods have been carried out for the results for men, using both the internal and
external control group comparisons. By looking at both control group comparisons,
models representing data with differing amounts of heterogeneity may be considered.
Firstly, for each analysis a common difference was fitted for DBP and SBP.
Such a model is only reasonable when dealing with effect sizes since it would be
meaningless to try and fit the same effect to the mean differences for DBP and SB?,
as the differences in SBP are much larger than those in DBP. Secondly, a separate
effect was fitted for each blood pressure outcome separately. The fit of both these
models was assessed using HE as defined in (141). The results obtained from such a
model could then be compared with the standard individual fixed effect meta-analysis
results.
In the univariate analyses, there is less heterogeneity present in the SBP es-
timates for the internal control group comparison than for the external. However,
perhaps surprisingly, there is no evidence of heterogeneity in the DBP estimates for
the external control group comparison, but there is some for the internal control group
comparison. However, there is overall far less variation in DBP than in SB? and so
the multivariate model, being a fixed effect method, is therefore more reasonable for
the internal control group comparison. Results for the multivariate model (Table 60)
indicate that both blood pressure measurements cannot be adequately estimated by a
common effect size for either the internal control group or the external control group
comparison. Fitting a separate effect for each outcome does improve the fit of the
model significantly in both cases, although neither explains an adequate amount of
the variation.
The effect size estimates for both outcomes in both comparisons are very
comparable to those obtained from separate univariate fixed effect meta-analyses
using effect sizes (Table 61). The standard errors of the two sets of estimates are
almost exactly the same in the two cases for both outcomes as well. Hence, nothing
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has apparently been gained in this example by carrying out a multivariate meta-
analysis
Since in the external control group comparison there is unexplained variation
present, because the model is still not a good fit to the data as indicated by the large
deviance HE, one option is to add covariates to the model to try and improve the
fit. As an example, purely to illustrate the methodology, a covariate indicating the
location of each study centre in Britain was constructed. Since there was one inter-
vention and one control practice situated in 13 towns distributed throughout Britain,
a covariate was constructed having two categories indicating a location in either the
north (Scotland, north of England and Midlands) or south (south of England, Wales
and East Anglia) of the country. A model was then fitted with a common slope
for both outcomes and then extended to allow the slope to differ for each of SBP
and DBP. In neither of the examples did geographical location explain a significant
amount of the variation (Table 60). Hence, there was no geographical variation in the
difference in blood pressure between intervention and control groups. It may be the
case that any geographical variations have been cancelled by considering differences
within towns.
6.5.5 Discussion
In terms of estimation there is little to be gained from the multivariate analysis of
the blood pressure outcomes in the British family heart study. However, in other
situations where the multiple outcomes of interest may be of equal magnitude the
analysis may be worthwhile, as an estimate of a single overall effect size, representing
a general treatment effect, could be obtained. The fact that there is no improvement
in the precision of the estimates of treatment effect with the multivariate model in
the example considered, as opposed to the individual univariate analyses, is because
the data is complete, that is there is a measurement recorded for each of DBP and
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Table 60: Multivariate generalised least squares models for effect sizes for the differ-
ence in blood pressure (both DBP and SBP) between the intervention and control
groups in men in the British family heart study
Model	 Parameter	 Internal control	 External control
Estimate S.E._J Hg(df) Estimate S.E.
	 HE(df)
Common	 3	 -0.369	 0.0297 42.66(25)	 -0.292	 0.0274 189.10(25)
effect size
Separate	 -0.336	 0.0322 36.05(24)	 -0.205	 0.0299 135.95(24)
effect sizes	 /32	 -0.403	 0.0326	 -0.380	 0.0298
Common	 /3	 -0.369	 0.0435 34.82(23)	 -0.195	 0.0398 135.81(23)
slope	 /32	 -0.435	 0.0438	 -0.369	 0.0397
__________	 7	 0.066	 0.0594	 -0.369	 0.0548
Different	 /9i	 -0.355	 0.0451 33.49(22)	 -0.249	 0.0415 125.46(22)
slopes	 /92	 -0.450	 0.0456	 -0.350	 0.0410
	
l'i	 0.037	 0.0646	 0.091	 0.0598
__________	 12	 0.096	 0.0650	 -0.063	 0.0597
/3=common effect size for both DBP and SBP
/9i=effect size for DBP
/32=effect size for SBP
-y=common slope for both DBP and SBP
71 =slope for DBP
'2 =slope for SBP
HE=Test of fit of the model given in (141) compared with X%_q distribution
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Table 61: Fixed effect meta-analysis results for the difference in blood pressure (both
DBP and SBP) between the intervention and control groups in men in the family
heart study
Measurement Control	 DBP	 SBP
____________ group 	 Estimate S.E. Estimate S.E.
Effect size	 Internal	 -0.336	 0.0323	 -0.404	 0.0324
External	 -0.386	 0.0297	 -0.207	 0.0296
Difference	 Internal	 -3.501	 0.514	 -7.255	 0.568
in means	 External	 -2.477	 0.568	 -7.285	 0.514
SBP in each individual and in each town. The multivariate model can cope with
different numbers of outcomes being measured in different trials in a meta-analysis.
Hence, multivariate methods would provide improvements in precision when different
trials measure different outcomes, since such methods make up for missing data in one
variable by using the information regarding the others and the correlations between
them. This may be useful in certain meta-analyses, where different trials on the same
treatment may consider different measures of outcome. It is likely to be less useful
for the analysis of multicentre trials because all centres should be measuring the same
outcomes as they are following the same protocol. In a meta-analysis these methods
would allow the results of more trials to be included, since in order to perform a
univariate meta-analysis, all outcome measures must be the same.
Furthermore, the model does, however, provide a global test of treatment ef-
fectiveness on all outcomes of interest, which is of some use in that it provides a
test of the general impact of the treatment. The test given in (146) may be partic-
ularly useful in testing for a consistent treatment effect across all outcomes. Hence,
a significant result from such a test provides strong evidence of an overall benefit of
treatment.
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The fact that the method pursued here is restricted to the use with effect
sizes means that interpretation in practice is difficult. With further work it may be
possible to adapt the model to cope with alternative measures of treatment effect.
Furthermore, although other covariates may explain the heterogeneity present in the
blood pressure data, a random effects model may be required to model the additional
variation which was evident after the fixed effect model was fitted. Further research
is again needed into the issue of fitting a multivariate model which allows for random
effects, with a possible way of proceeding being to follow a multilevel modelling ap-
proach [121]. This sort of approach is an improvement over the model used here as it
allows the covariance structure of the data to be estimated simultaneously with the
treatment effect. In the method applied to the blood pressure outcome, the covari-
ance matrix is obtained by estimating the relevant variances and correlations from the
data set and then substituting them in to the model as if they were known values. In
general, the work illustrated here provides an explanation of the problem of multiple
testing in meta-analyses and an introduction to methods which could be pursued and
the problems which need to be solved, but do not provide satisfactory solutions for
the analysis of the British family heart study.
314
7 A Comparison of Meta-Analysis and Paired
Cluster Randomised Methods
The comparison of the intervention group with the external control group in the
British family heart study involves the analysis of a paired cluster randomised design
and Section 6.2 illustrated how these data could be analysed using meta-analysis
techniques. However, there is also some existing literature which proposes methods
specifically for the analysis of paired cluster randomised trials. Hence, in this chapter
a comparison of meta-analysis methods and these other paired cluster randomised
methods will be made. Both testing and estimation are considered.
Section 7.1 introduces the concept of the intracluster correlation, which is
central to paired cluster randomised trial methods. The issue of testing for an overall
treatment effect is then considered and existing methods for dichotomous outcomes
are described in Section 7.2 and for continuous outcomes in Section 7.3. A discussion
of findings in published papers in Section 7.4 is then followed by a comparison of the
tests using data from the British family heart study in Section 7.5. Estimation of an
overall treatment effect is the focus for the remainder of the chapter, with published
methods being described for dichotomous outcomes in Section 7.6 and continuous
outcomes in Section 7.7. Again the British family heart study provides an example
for the comparison of the different methods and Section 7.8 also compares these
methods with the standard meta-analysis methods of Chapter 1. The chapter is
rounded off with a discussion and comparison of the different methods (Section 7.9)
and a conclusion (Section 7.10).
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CBC
= cr, + c
(147)
7.1 Intracluster Correlation
Paired cluster randomised methods use the concept of intracluster correlation. If
clusters, rather than individuals, have been randomised, then individuals within a
cluster will tend to be more like each other than like individuals from other clusters.
This means that the measurements within a cluster are likely to be dependent. The
intracluster correlation is a measure of the association between the observations within
a cluster compared to between clusters. It may be expressed in terms of the proportion
of the total variance due to the between-cluster differences,
where is the between-cluster variance and o is some average within-cluster
variance (see Section 7.2). A suitable estimate of this intracluster correlation must be
obtained in order to proceed with the methods. The expression for the intracluster
correlation is such that if p=l, then all the observations in each cluster are exactly
the same, that is there is no within-cluster variation. On the other hand if p=O, there
is no clustering, that is there is no between-cluster variation, and so the observations
within a cluster are no more like each other than observations from different clusters.
The latter situation is simply a case of straightforward random sampling.
The intracluster correlation links up with the meta-analysis concept as both
are concerned with the appropriate use of the between-cluster and within-cluster
components of variance. However, the two methods actually estimate the variation
differently. In the meta-analysis case, oj is estimated after taking out a common
treatment effect, whereas in the cluster randomised method the estimate of between-
cluster variation ô is confounded with the treatment effect. This will be explained
further in following sections.
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7.2 Published Methods For Testing in Paired Cluster
Randomised Trials When the Outcome is
Dichotomous
In the case of testing for a treatment effect from a meta-analysis point of view, there is
no distinction made between the test used for both homogeneous and heterogeneous
data. The Mantel-Hacnszel test, and its equivalent tests, test the null hypothesis that
each individual treatment effect 0 is zero against the alternative that at least one
such effect is non-zero (Section 1.4). They do not test the hypothesis that the overall
treatment effect 0 is zero, unless homogeneity can be assumed. If homogeneity can
be assumed then the Mantel-Haenszel test is not only valid but is also optimal for
such a null hypothesis [38].
From the perspective of a paired cluster randomised design, however, the desire
to test the null hypothesis that the overall treatment effect is zero when heterogeneity
is present, that is H0 : 0 = 0 against the alternative H1 : 0 0, has led to the
development of a range of alternative tests. When positive intracluster correlation
is observed in a set of data, individuals within each cluster cannot be regarded as
independent and the statistical importance of any one response is decreased. This
means that the effective sample size is less than the total number of individuals in the
trial, but greater than the total number of clusters (unless there is total dependence
within clusters). Hence, due to this effective reduction in sample size, the variance
of the treatment effect in each pair of clusters is too small [122]. Consequently, the
Mantel-Haenszel test, even when there is no treatment difference, gives significance
levels much more extreme than 0.05 when there is a large amount of correlation
between the observations in the same cluster [123]. Thus the use of the Mantel-
Haenszel test can result in obtaining spurious statistical significance.
The design of a paired cluster randomised trial means that each strataoøi (i =
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1, ..., k) includes a pair of matched clusters, one randomly allocated to treatment
and the other to control or placebo. This section considers dichotomous outcome
measures, and the proportions of patients exhibiting a positive outcome are denoted
by Pi = a1/n i and P12 = cj/n12 where i = 1, ..., k (1=intervention, 2=control). Five
different tests of the hypothesis H0 : 9 = 0 for dichotomous outcome measures, which
have been published in the literature, will now be presented in Sections 7.2.1 to 7.2.5.
An example illustrating the use of and a comparison of the results of these tests is
presented in Section 7.5.
7.2.1 Unweighted t-test
The simple unweighted paired t-test, applied to dichotomous outcome measures, is
given by,
tt4 =	 ( 148)
- ô)2/(k - 1)
where Ô = E.1 Ô2 /k and ô, =P1 - P,3 is the estimate of the treatment effect in
strata i. Here each cluster mean is treated as if it were a single observation. Hence,
this test assumes that all the variation is between-clusters and no account is taken
of the variation within each cluster or of the different cluster sizes. Under the null
hypothesis and assuming normality of öj, this statistic has a t distribution with (k—i)
degrees of freedom.
7.2.2 Weighted t-test for proportions
Donner and Donald [123] present two alternative approaches for dichotomous data
based on a t-statistic which allow for both within-cluster and between-cluster varia-
tion. The first method is based on a weighting of the differences O=P 1 - P 2 . The
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weighted average is , =
	
wO/ E w1 , where an appropriate choice of weights
is found by considering the variance of under the null hypothesis H0 0 = 0. If ni
and n12 are reasonably large in all strata, then the variance is approximated by
var(Ô1 ) =	 - P) I 1+(,1),3 + 1+(n2-1) 1	 (149)I 'hi	 tI3	 J
where P = (a + cj)/(n11 + n 2 ) is the estimated event rate in stratum i under the
null hypothesis and 3 is an estimate of the intracluster correlation (Section 7.1). As
each n tends to infinity, then var(Ô) reduces to 2,3P(1 - P,) approximately. Hence,
an estimate of p is required to proceed and the derivation of such an estimate is now
provided.
Analysis of variance methods are used to obtain ô. Unbiased estimates of the
average within-cluster correlation o, and the between-cluster variation 4 are given
by [124],
=MSE
	 (150)
= (MSC - MSE)/flA 	(151)
where MSE is the error mean square, MSC is the cluster mean square and A is
an adjusted average sample size and is given by [N - nj/n,)]/k. The
derivation of the required analysis of variance table for the example of particular
interest is provided later. Hence, for now, it is simply stated that the estimate of p
is given by
- 4	 (MSC - MSE)/nA	 MSC - MSE
- 
+4 = MSE + (MSC - MSE)/nA MSC + ( flA - 1)MSE (152)
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If MSC < MSE then 3 must be set to zero as the intracluster correlation cannot
sensibly take a negative value. Once an estimate of the intracluster correlation has
been obtained, the weights wi,,, which are the reciprocal of the variances (equation
(149)) which take account of the clustering, can be calculated. The estimate of the
overall treatment effect is therefore given by
=	 (153)
The test statistic for looking at the treatment effect over all strata, allowing for
clustering given by Donner and Donald [123] takes the form
= 3d%/El w2
	 (154)
where s = w,,(O - ô,,,,)2/ Under H0 , i has an approximate t-
distribution with (k —1) degrees of freedom. If the number of strata is small, Donner
and Donald [123] indicate that it is desirable to introduce a continuity correction.
This involves replacing Ô, by On,, - 0.5/ E_1 n1 - 0.5/ E n2.
No details regarding the derivation of the statistic are, however, provided by
Donner and Donald [123]. Hence, to understand the reasoning behind the method a
derivation is now provided which has been deduced through reference to other papers.
The estimate is derived from the analysis of variance table used in the analysis
of intraclass correlation in multiple samples for survey data [124]. In this multiple
sample situation there are Cj clusters within each stratum i, but there are no different
'treatments' within each stratum. The model can therefore be written as
YiJl = + cx, + /3jj + e1 i 	 (155)
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where /3jj	 N(O, oj) and e1 j 	 N(O, o-,) with i = 1, ..., k,j = 1, ..., cj and 1 =
1, ..., n 1,. The strats.n effects c, are considered to be fixed, while the cluster effect f3jj
and the individual effect e13 : are both random. The intracluster correlation is assumed
to be constant across all strata, which implies that the variation in the response y
from cluster to cluster is the same in each stratum [124].
In adapting this approach to a paired cluster randomised design, a treatment
effect is introduced within each stratum, which, however, the model does not account
for. When constructing the analysis of variance table required for the model given in
equation (155) a stratum mean square and a cluster (within stratum) mean square are
obtained, together with the error mean square. Hence, the variation between clusters
within each stratum will be due in part to a treatment effect, if one exists. Hence,
due to the fact that ,3 is based on the variation between clusters within a stratum
[125], an unbiased estimate of p may only be obtained under the null hypothesis of
no treatment effect.
To derive the relevant analysis of variance table for such binary outcomes it
must initially be assumed that each observation is on a continuous scale but can take
one of only two values, either 0 or 1. The value 1 is recorded if an individual exhibits
the outcome of interest and otherwise 0 is recorded. Then letting y,j be the observed
value (0 or 1) for individual 1 (l=l,...,n,) in cluster j (j=1,2) of strata i (i=1,...k),
the analysis of variance table (Table 62) may be constructed [124].
Then since y,, can only take the values 0 and 1, then	 yij: is equal to the
number of positive responses,	 say, in cluster j of stratum I (a1i = a, and a12 = ci).
Hence, the sums of squares in Table 62 may be simplified because,
fl,3
Yijl =
	 (156)
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-Yi. 
=	
= Pu (159)
and
Table 62: Analysis of variance table for a paired cluster randomised design
Source of Degrees of	 Sums of squares	 Mean square
variation freedom
Strata	 k - 1	 SSS = E .I 	 -	 MSS = SSS/k —1
Cluster	 k	 SSC =	 n1(1 -	 MSC = SSC/k
Error	 N —2k SSE 
=	 I	
- 
v1) 2 MSE = SSE/N —2k
Total	 N - 1	 SST =	 E=i E' ( i -
=	 yijz/ni,=mean of all individuals belonging to the th cluster in strata i.
= E_i	 ytjz/n=mean of all individuals in strata i.
=	 y,11/N=mean of all individuals in the study.
and
Yji = a,,	 (157)
= fl i + i2	
a j =	 (158)
Hence,
SSC =	 n,,(P, - u) 2	(160)
t=1 2=1
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SSE = E1 E=1 IE'1 (i: - )2]
= E	 -	 + L)]
= EiE=i[ai-2,+,]	 (161)
- çk ç-2 a(1_LL-s=1 Lij=1 '2'
-k	 — 2	 jl
- L..,j=1 L.s3=i a,,i - i
Hence, the values for the relevant mean squares calculated using the expressions
in (160) and (161) can be substituted into the expression for the estimate of the
intracluster correlation (152). The variance of each Ô (149) may then be estimated in
order to obtain the weights wv,. These weights are then used to obtain the estimate
of the overall treatment effect Ô u,,, (153), although they are assumed known rather
than estimated.
The test statistic is then given by this overall estimate divided by its standard
error, that is tu, = ô,/iJvar(&,,). Now equating this expression with that in (154)
implies that
22
var(Ôu,3,) =	 wi,, sd/(E ..i w3,)2	 (162)
rk	 2
= _s=1 w 1, var(Ô)/(E. 1 w3,)2
Hence, Donner and Donald appear to be estimating var(Ô) by
=	 w3,(Ô - ôu,, )2/	 w3, for all i, rather than estimating each variance
separately using (149). Hence, a pooled between-stratum estimate of the variance is
used, which would appear incorrect since it is being assumed that all the individual
strat.c.estimates are equal when they are not under clustering.
Donner and Donald [123] do acknowledge a drawback with this method in that
the way the model is defined leads to the variation between clusters being combined
with the treatment effect. Hence, "as the treatment effect increases, ,ô will also
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increase and will provide an increasingly biased estimate of the true p" [1261. Thus
the intracluster correlation attributable purely to the design of the study cannot be
obtained. This issue is discussed and investigated further in following sections of this
chapter.
7.2.3 Empirical logistic weighted t-test
An analogous procedure to the test described in Section 7.2.2 was also presented by
Donner and Donald [123] based on the empirical logistic transform,
= log ( (a+O.5)(d+O.5) )
' (4+o.․)(b1+o.5)
The variance of O may be approximated by [123]
= (n i + 1)(n i
 + 2)[1 + (n i - 1)] + (2 + 1)(na + 2)[1 + (n 2 - 1),31
var(Oa)
ni(a + 1)(b + 1)	 n22(ci + 1)(d + 1)
(163)
Again, taking a weighted average with the weights wj being equal to the reciprocal
of the variance of each estimate (163), a test statistic is obtained in the same way as
for the weighted t-test.
The weighted average is therefore Oj =	 wj and in order to
test the null hypothesis that there is no overall treatment effect, the test statistic
wit
Lw1 = 	 _________	 (164)
sly'E=1 wi2
where s = - O:)2/ 1I w1 , can be compared to the t-distribution with
(k - 1) degrees of freedom. Hence, similar to the weighted t-test of Section 7.2.2,
this leads to the conclusion that var(O,) = E= w1s?/(E1 w,)2 which means that
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var(ö) = ?, that is a pooled estimate of the variance of &.
7.2.4 Wilcoxon signed rank test
The straightforward non-parametric Wilcoxon signed-rank test may also be used in
the analysis of a paired cluster randomised trial. Such a test considers the null
hypothesis that the overall median treatment difference is zero. It uses both the
direction of the difference between a pair of clusters as well as the ranks of these
differences, but not their magnitude or precisions. In the situation under discussion
this test may be applied to the difference in proportions t3 =	 - P 2 for i = 1, ..., k.
The Ô1 are ranked without regard to their signs. Rank 1 is therefore assigned to
the smallest absolute difference and rank k to the largest absolute difference. The test
is then based on the value T+, the sum of the ranks of the positive differences. For
small k, the exact distribution of T, which is symmetrical about k(k + 1)/4 can be
tabulated. However, for large k (k ^ 15) it can be assumed that T is approximately
normal. It may be shown [127] that
E(T) = k(k+ 1)
	
(165)
var(T)	 + 1)(2k + 1) (166)
-	 24
Hence, the test statistic
- /var(T+)
	 (167)
can be compared to a standard normal distribution.
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'7.2.5 Permutation test
An alternative non-parametric approach is to use a permutation test which uses the
magnitudes, rather than simply the directions, of the differences ô=F 1
 - as well
as their ranks, but not their precisions. The rationale behind such a test, is that
under the null hypothesis H0 : 0 = 0, the event rates would remain the same if the
labels 'treatment' and 'control' within a pair of clusters were interchanged. This is
equivalent to regarding the assignment of labels within a pair of clusters as random.
This means that, for each strata, the observed difference may be regarded as either
positive or negative with equal probability. There are thus 2" equally likely possible
combinations of these signs under the null hypothesis conditional on the magnitudes
of the differences actually observed. Hence, 2" separate differences D = can
be calculated from the observed data. Therefore a one-sided test rejects at the 5%
level if the observed total falls among the largest 0.05x2' values. If k is too small,
then 0.05x2" could be less than 1, hence this method would not be very sensible.
On the other hand, unless k is reasonably small, this process will be time consuming
and, since the distribution of D depends on the difference actually observed, it is
not practical to tabulate D. Hence, in practice, approximate forms of the test are
used. Donner and Donald [123] use an approximation based on the fact that under
H0 : 0 = 0, the mean difference L =	 Ôjk has a normal distribution with zero
mean and variance E...1(& - 0) 2 /k2 
=	
Ô12/k. Hence the test is based on the
statistic
-k	
•
z = L,=i ' - =	 (168)
V5=i Ô2/k2	 /E=1 2
which has an approximate standard normal distribution under the null hypothesis
H0 : 0 = 0.
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Gail et al. [128], use an equivalent test based on an approximation of the test
statistic to the t-distribution [129]. The test statistic is the same as that above (168)
apart from the fact that a different estimate of the variance is used. The variance of
â, suggested is given by E-1( — ö,j 2 /(k — 1)k = s2/k and so the test statistic is
'ç-k a/L	 A	 -k ,
T— L1 =l vsI I — u —	 169
7.3 Published Methods For Testing in Paired Cluster
Randomised Trials When the Outcome Variable is
Continuous
In the case of a continuous outcome measure Donner and Kiar [1301 propose the
use of either an unweighted paired t-test (Section 7.3.1) or a weighted paired t-
test (Section 7.3.2). Their paper refers to estimation and confidence intervals, but
obviously tests may also be derived and it is these that are presented here. In the case
of a continuous outcome variable the estimated treatment effect in strata I is given by
the difference in means, = - A generalisation of the paired t-test, proposed
by Rosner [81], which allows for heterogeneity between strata, is then described in
Section 7.3.3.
7.3.1 Unweighted paired t-test
The same straightforward unweighted paired t-test, not taking account of the within-
cluster variance, that was used for a dichotomous outcome (Section 7.2.1) may also be
used for a continuous outcome. Hence, the overall treatment effect may be estimated
as
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_ EÔ2
k
(170)
which has an estimated variance given by
2_ E1(ö _)2 (171)
-	 (k—i)
The test statistic therefore takes the form
d	 (172)
which has a t-distribution with (k - 1) degrees of freedom.
The unweighted paired t-test is only strictly valid if n,1 =	 = n for
i = 1, ..., k, because variance homogeneity must be assumed [1301. Hence, when
cluster sizes are moderately or severely imbalanced Donner and Kiar [130] state that
a weighted procedure would be preferable.
v.3.2 Weighted t-test
The weighted t-test uses a weighted average of the individual strata estimates of the
treatment effect,
- - E=1
t	 k
wiw
The estimated variance given by Donner and Klar [130] is
(173)
- ________ (174)var(4) -
[2_,=i Ww]2
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where s, =	 -	 wa,,, again implying that the variance of the
individual stratum effects have been obtained using a between-strata estimate, rather
than within-strata estimates. Hence a test statistic is given by
(175)tw= 	 =
E=1
	 3 vf=i wL
A reasonable, but simple, choice of weights, according to Donner and KIar [130], is
given by w,, = n11 n12 /(n1i + n12 ). These weights are based solely on sample sizes and
therefore do not depend upon the individual cluster variances.
7.3.3 Rosner's generalisation of the paired t-test
Rosner [81] proposed a generalised paired t-test for continuous outcome measures.
It is an extension of the standard paired t-test to a situation where there are vari-
able numbers of cases and controls per pairing. This situation is therefore directly
applicable to meta-analysis and to the case where each pairing is made up of two
clusters.
It is assumed that the within-strata differences between the treatment group
and the control group means follow a one-way random effects analysis of variance
model,
—Y1i.	 = O+cx;+ e1 ,	 = 1,...,k	 (176)
where 0 is the overall within-strata difference in means, a, is the random effect rep-
resenting a stratum specific change in difference and a; 	 N(0, 4). Then e; is
the variation within group for strata i and e1 	 N(0, v1 ) where v; = r2(. +
This is exactly the model for the normally distributed random effects meta-analysis
329
(Section 1.7.1).
Once again the aim is to test the null hypothesis H0 : 0 = 0 against the
alternative H1 : 0 0. As in Section 2.2.1, the marginal distribution of each stratum
estimate has a normal distribution with mean 0 and variance (4 + v1) and so the
full likelihood for all the strata may be obtained (Section 2.2.1)
k
L(0, 4) = II	 exp { _9_9)2 }
=i /2ir(4 + v)	 2(OB+V)	 (177)
The variances of the individual estimates are then estimated using the following un-
biased estimator for or2,
k	 2 flu
=	
- .)/(N - k)	 (178)
s=1 J=1 1=1
Then conditional on c 2 , the maximum likelihood estimates of 9 and 4 are calculated.
Two equations are obtained which must be solved iteratively to produce the estimates
(Section 2.2.1).
The variance-covariance matrix for the vector = (s,., è)", given by I*_1(),
can be found where J*() is the observed information matrix for 0 and & as defined
in Section 2.3.4 and w1 =1/var(ô) where 1/var(Ô) is estimated individually for each
2
- E=1 w	 w(Ô -
E_1 w(ê - a,. )	 w(Ô - ö,.)2 -
	
w/2
This is exactly the matrix used in Section 2.3.4 to provide approximate confidence
intervals for the maximum likelihood estimates of 9 and 4.
Rosner [81] uses the variance-covariance matrix to obtain an asymptotic test
procedure for the null hypothesis of no overall treatment effect. The test statistic is
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given by
A 
=
	 or	 (179)
where I 1 (0) is entry (1, 1) in the 2x2 variance-covariance matrix, and the test
compares this with the standard normal distribution.
7.4 Discussion of Existing Methods
Donner and Donald [123] carried out a Monte Carlo investigation to look at the
powers and significance levels of tests described in Sections 7.2.1 to 7.2.4 and to
compare them with the Mantel-Haenszel test. The quantities k, n j and P were
varied under a paired cluster randomised design. The number of strata Ic was taken
to be 6 and then 12. The odds ratio & = P11 (1 - P 2)/P,2 (1 - P 1 ) was fixed at 1
for the null procedure used to obtain significance levels and at 1.5 for the procedure
used to compare powers. By fixing and varying the value of P 2 , the value of
P 1 is automatically assigned. For k=6, P12 (i=1,...,6) were taken to be 0.3, 0.5,
0.7, 0.3, 0.5, 0.7 respectively, while for k=12, this pattern was repeated twice. The
simplification that n = n 2 = n was then made and three levels of imbalance in
numbers from stratum to stratum (balanced - n=120 (i=1,...,k), mildly imbalanced
- n 1 =60, 120, 180, 60, 120,..., severely imbalanced - n=20, 120, 220, 20, 120,...)
were considered. For each combination of k and balance of design, various values of
the intracluster correlation, ranging from 0 to 0.15, were investigated. This was done
both for significance level (=1) and for power (=l.5) simulations.
The Mantel-Haenszel procedure gave significance levels much more extreme
than 0.05 in situations where p was greater than zero, thus indicating the inappro-
priateness of this test for clustered data when testing H0 : 0 0. As the intracluster
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correlation increased, the significance level became more extreme.
The standard unweighted paired t-test assumes that there is no within-cluster
variability as it considers the rate from each cluster as a single observation. Hence, this
test is also strictly inappropriate in the situation where clustering is present. However,
the Monte Carlo study found that the paired t-test t, (148) provided satisfactory
significance levels in general for all factor combinations. Donner and Donald therefore
suggest that this illustrates "the robustness of this procedure to departures from
normality and homogeneity of variance". The homogeneity of variance being referred
to is that of the variances of t3,.
The paired t-test may also be applied to a continuous outcome measure for
a paired cluster randomised design (Section 7.3.1). However, Rosner [81] indicates
that the standard paired t-test is not valid unless there is no within-cluster variation
(or the numbers in each cluster are the same). He therefore advocates the use of the
generalised paired t-test (Section 7.3.3), but notes that, if o1/o is large, then the
result will be almost exactly that of the standard paired t-test. This is because when
the variation within each cluster is very small, compared to the differences between
clusters, then the within cluster variation can effectively be ignored and each cluster
can be treated as if it provides only a single observation.
Donner and Donald, in the 1987 paper [123], suggest that the standard paired
t-test is adequate for all situations where continuous outcomes are involved. This
assertion stems from investigations carried out by Korn [131] which indicate that the
standard paired t-test can be recommended for most practical situations. Korn shows
that the asymptotic relative efficiency of the paired t-test is very high (>0.89 for all
cases considered). By a simulation study he also shows that the rejection probabilities
of the standard test are around 0.05 even when there is clustering. However, this
investigation by Korn is limited and only considers the case where there are small
sized clusters, as the specific application under discussion is for a paired case-control
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design with differing numbers of cases and controls per strata. Hence, a generalisation
to all designs regarding the robustness of the paired t-test from this evidence alone
may not be valid. Moreover, Donner appears to have revised his view, as a later
paper [130] suggests that the use of a weighted paired t-test is preferable in situations
where the cluster sizes are moderately or severely imbalanced.
From the Monte Carlo study [123], Donner and Donald found that for cases
where the intracluster correlation was greater than 0.05, the weighted paired t-test
and the logistic weighted t-test were generally more powerful than the unweighted
test. This was particularly noticeable where the numbers of individuals between
strata were severely imbalanced. The weighted logistic t-test was also found to be
useful if there was considerable variation in the event rates from stratum to stratum.
The non-parametric test was found to be less powerful in every case than all the
parametric tests, although the difference was less when k=12 than when k=6.
In conclusion, Donner and Donald suggest the use of a weighted procedure
when a design involves a few strata each of a fairly large size and where the intracluster
correlation is likely to be small but significant. The weighted logistic test is slightly
favoured over the weighted t-test as it produced nominal significance levels closer to
0.05 in the simulation study, while both tests are approximately equal with regards to
power. For studies involving a large number of small strata, the standard paired t-test
or a non-parametric test is recommended. The advantage in power of the weighted
tests over the unweighted test becomes minimal for larger values of k, particularly
when the numbers per cluster are reasonably balanced. Donner and Donald state that
they do not expect weighted tests to perform well for designs with many small strata.
However, they give no argument as to why this should be so, and the results from the
simulation study do not back up this view. Presumably, problems may be caused by
the necessity of estimating many weights imprecisely (as exemplified in Chapter 5).
It is clear that the advantage in power of the weighted procedures is diminished in
333
such a situation and so the paired t-test, being easier to compute, may be preferable.
Choosing an appropriate test may, therefore, depend on the amount of intra-
cluster correlation present. If the intracluster correlation is small, the weighted tests
are more powerful, since they take both the within-cluster and between-cluster varia-
tion into account. When the intracluster correlation is larger, the advantage in power
of the weighted procedures becomes less since the between-cluster variation becomes
more important and so an unweighted paired t-test is adequate.
The consequences of the effect of the variation between clusters and the treat-
ment effect being combined in the model used for the weighted t-test was explained in
a personal communication from Donner [126]. He explains that since 3 is spuriously
large when a treatment effect exists, the estimate of vcr(Ô,) using (149) will also be
spuriously large for each stratum. Hence, a potential decrease in the power of the
t-test would result. Donner states [126] that any choice of weights will lead to a valid
test, but the efficiency is increased by estimating var(0) between, rather than within,
strata when obtaining the variance of the estimate of the overall treatment effect. A
reduction in power would occur if a within-stratum estimate of var(ã,) were used,
due to the bias in the estimate of p in all the weighted procedures described where
an estimate of the intracluster correlation is required. The use of a between-stratum
estimate in these tests appears to be a means of correcting for this bias.
The generalisation of the paired t-test proposed by Rosner [81] is very similar
to the random effects likelihood method in Section 2.2. In both these methods a
consistent treatment effect is estimated separately from the between cluster variation,
whereas in Donner's weighted methods the between cluster variation is confounded
with the treatment effect. Since the estimate of p will be unbiased under the null
hypothesis of no treatment effect, but under the alternative hypothesis it will be
biased, the tests will still be valid although perhaps less powerful.
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7.5 Results of a Comparison of the Tests
hi order to compare the tests for binary outcomes described in Section 7.2 with each
other and with the standard meta-analysis type tests, data from the British family
heart study were used. A test derived from the quadratic approximation to the
likelihood in Section 2.3.4, which is equivalent to Rosner's test for continuous outcome
measures (Section 7.3.3), was also considered. This test is given by o1/I'(ê1)
where Ô1 is the MLE of 0, which is, in most cases, approximately equal to Ôj/s/var(0*l)
since the covariance of 1 and ô will usually be negligible. This test statistic is
then compared with a standard normal distribution, although it may be better to
compare it with a t(k_1) distribution as suggested by Rosner [81]. The purpose of
this practical example is to see whether the tests produce similar or different results
and conclusions, and to consider the effect of differing amounts of heterogeneity. The
unweighted procedures are expected to perform less well than the weighted procedures
or the random effects procedure under conditions of moderate heterogeneity, while
the standard Woolf and Mantel-Haenszel tests for H0 : 0 = 0 may be expected to
produce spuriously significant results.
The difference in prevalence of current cigarette smoking between the inter-
vention and control group at the one year screening was the outcome chosen. Test
results were obtained for both men and women using both the internal and external
control group comparisons (Tables 63-66). The comparisons with the internal con-
trol group are not of a paired cluster randomised design, since within each practice
individuals were randomised to one of two groups. However, there will still exist a
component of between-town variation which may be estimated, unless the treatment
effects in all towns are homogeneous.
For the comparison of the intervention group with the external control group,
heterogeneity is present in the estimates for both sexes (Tables 63 and 64). The results
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Table 63: Comparison of results of six different tests for the difference in the preva-
lence of cigarette smoking between the intervention and the external control group in
men in the British family heart study
Test	 Observed value Distribution p-value
of statistic	 under H0
Woolf	 2.654	 N(0, 1)	 0.008
Mantel-Haenszel	 2.950	 N(0, 1)	 0.003
Tinweighted t	 2.216	 tk.....1	 0.047
Weighted t	 2.054	 tk...1	 0.063
Weighted logistic	 2.027	 0.066
Permutation	 2.05 1	 N(0, 1)	 0.040
Rosner	 2.054	 N(0, 1)	 0.040
Test statistic for heterogeneity Q=25.224
Estimated between-study variance &=0.079
Estimated intracluster correlation 3=0.010
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Table 64: Comparison of results of six different tests for the difference in the preva-
lence of cigarette smoking between the intervention and the external control group in
women in the British family heart study
Test	 Observed value Distribution p-value
of statistic	 under H0 ________
Woolf	 2.105	 N(0, 1)	 0.035
Mantel-Haenszel	 2.529	 N(0, 1)	 0.011
Unweighted t	 1.696	 tk.....1	 0.116
Weighted t
	 1.568	 ik_1
	
0.143
Weighted logistic	 1.538	 tk_1
	
0.150
Permutation	 1.585	 N(0, 1)	 0.113
Rosner	 1.618	 N(0,1)	 0.106
Test statistic for heterogeneity Q=22.114
Estimated between-study variance ô=0.098
Estimated intracluster correlation p=O .012
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of the tests for women (Table 64) provide a clear example of what can happen when a
positive intracluster correlation is present and a Mantel-Haenszel type procedure used
to test the inappropriate null hypothesis H0 : 0 = 0. Both the Woolf and the Mantel-
Haenszel test, that is the tests which assume homogeneity of treatment effects across
strata, give highly significant p-values, indicating evidence against the null hypothesis
of no overall intervention effect. However, since there is heterogeneity present, the null
hypothesis being investigated is H0 : 0 = 0 for all i rather than H0 : 0 = 0. The other
five tests produce p-values greater than 0.1, providing much less evidence against the
null hypothesis H0 : 0 = 0. A similar effect, although not so clear because all tests
produce apparent evidence against H0 : 0 = 0, can be seen in the results of the tests
for men (Table 63). All three t-tests, in this instance, produce similar results, with
the permutation test and the Rosner type test appearing to be slightly more powerful
in this example. Hence, it can be seen why the Mantel-Haenszel test and the Woolf
test cannot be interpreted as tests of H0 : 0 = 0 in cases where heterogeneity exists,
whereas all the other tests appear to be adequate for such purposes.
There is no significant statistical heterogeneity when comparing the interven-
tion group with the internal control group for either sex (Tables 65 and 66). Hence,
even the Woolf and the Mantel-Haenszel test should be valid for the null hypothesis
of H0 : 0 = 0 in these cases and, furthermore, the Rosner type test based on the
random effects model will be equivalent to the Woolf test. All tests provide evidence
of a difference in the prevalence of cigarette smoking between the two groups for
men and only the weighted t-test fails to detect a significant difference for women. 7
The results indicate that the reported prevalence of cigarette smoking is lower in the
intervention than in the control group. The result of the weighted t-test for women
is rather odd as it is markedly different from the other results, including the other
weighted procedure and no plausible explanation has been determined. There is only
a small intracluster correlation and so the weighted procedures would, in fact, be
expected to have greater power than the unweighted.
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Table 65: Comparison of results of six different tests for the difference in the preva-
lence of cigarette smoking between the intervention and the internal control group in
men in the British family heart study
Test	 Observed value Distribution p-value
of statistic	 under H0 ________
Woolf	 3.021	 N(0, 1)	 0.003
Mantel-Haenszel	 3.057	 N(0, 1)	 0.002
Unweighted t	 4.473	 0.001
Weighted t	 4.738	 t...1	 0.000
Weighted logistic	 4.418	 tk-1	 0.001
Permutation	 2.851	 N(0, 1)	 0.004
Rosner	 3.021	 N(0, 1)	 0.003
Test statistic for heterogeneity Q=5.414
Estimated between-study variance ô=0
Estimated intracluster correlation ?=0.001
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Table 66: Comparison of results of six different tests for the difference in the preva-
lence of cigarette smoking between the intervention and the internal control group in
women in the British family heart study
Test	 Observed value Distribution p-value
of statistic	 under H0
Woolf	 2.229	 N(O,1)	 0.026
Mantel-Haenszel	 2.299	 N(0, 1)	 0.026
Unweighted t 	 2.480	 0.029
Weighted t	 1.777	 tk.....1	 0.101
Weighted logistic 	 2.416	 tk_.1
	
0.033
Permutation	 2.099	 N(0, 1)	 0.036
Rosner	 2.229	 N(0, 1)	 0.026
Test statistic for heterogeneity Q=l0.482
Estimated between-study variance ô=0
Estimated intracluster correlation 3=0.003
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From these results, the unweighted paired t-test does appear to be robust and
produces adequate results even when there is substantial intracluster correlation. It
performs comparably with the weighted logistic t-test in the examples considered.
The weighted t-test also gives similar results to the other two versions of the t-test
apart from in one case in Table 66. The permutation test and the Rosner type test
also produce results which are compatible with the t-tests. However, for this outcome,
the intervention effect was small (Table 53) and so the estimate of the intracluster
correlation will not be greatly inflated. In examples where there is a larger treatment
effect, a fall in power of the weighted procedures would be expected, and hence the
Rosner type test may be preferable in general.
7.6 Published Methods For Estimation in Paired Cluster
Randomised Trials When the Outcome Variable is
Dichotomous
When dealing with estimation of the overall treatment effect for dichotomous out-
come variables, Donner and Klar [130] distinguish between two types of pair-matched
cluster designs. Type (i) designs are those in which the cluster sizes may be relatively
small, such as families, but the number of strata is reasonably large. Type (ii) designs
are those in which the cluster sizes are fairly large, such as general practices, but the
number of strata may be small. The reason for distinguishing between these two
types of design is that they correspond to two different sets of asymptotic conditions.
For type (i) designs, the asymptotic conditions assume that the stratum sizes are
fixed but that the number of strata becomes large. In contrast, for type (ii) designs,
they assume that the number of strata is fixed but that the sample sizes within each
stratum become large. Since the type of design considered from a meta-analysis per-
spective will be of the type (ii) design, only the type (ii) designs will be considered
here. This is the design where there are more problems in the analysis and where
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modifications must be made to the standard methods.
Section 7.6.1 describes a modified Mantel-Haenszel estimator, while Section 7.6.2
describes a modification to the Woolf estimator.
7.6.1 Modified Mantel-Haenszel estimator
The standard Mantel-Haenszel estimator (Section 1.5.2) may be written in the fol-
lowing way
E
k
=1 wOi
t7MH =
L1=i i
where Ô, is the odds ratio in stratum i and w, = b1cj/N (notation in Table 2). The
weight can be rewritten in terms of the numbers of individuals in stratum i, n 1 and
n,2, and the estimated proportions P11 = a1 /n,,, P 2 = cj/n12 and tjj = 1 -
0=1,2),
nilni2
=	 ,1P12	 (181)
nil + n2
The standard Mantel-Haenszel estimator of the overall odds ratio is unbiased
in large samples, even when clustering is present, but not in small samples [122].
However, the unmodified confidence limits, such as those given by Robins et al. [132],
are not valid in type (ii) designs since the variance of the Mantel-Haenszel estimate
requires that the number of strata be large (Robins et a!. suggested as a practical
criterion that the number of strata be at least 20).
Donner and Hauck [125] propose alternatives to these weights by considering
the inflation in the variance of an individual cluster due to the clustering as a shrinking
of the effective sample size. The actual sample size n1; is replaced by the effective
(180)
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sample size n,c, = n 1 /[1 + (n 1 
- 
l)p] when calculating the weights (181). The effective
sample size is such that when p=0, n, = n j and when p=l, n,=1. For values of
p between these two extremes, n, will take a value somewhere between one and
the true sample size where the larger the intracluster correlation, the smaller the
effective sample size. The intracluster correlation coefficient may be estimated as in
Section 7.2.2 and hence the modified Mantel-Haenszel estimate of the overall odds
ratio is given by
0cMH =
	
WjmOj	 (182)
Wm
where Wirn = nn j1 P12/(n + n). The weights w are most suitable when 0=1
and depart from optimality as 0 becomes large or small since 5 is only a consistent
estimator of p if there is no treatment effect (Section 7.4). Hence, as in the case of
hypothesis testing, when a treatment effect exists, ,3 will be spuriously increased and
so the effective sample sizes will be decreased and hence the weights w will be larger
than they should be. Hence, although the estimate will still be unbiased on average,
it may be far from the true value in each specific case. There is no published method
for obtaining the confidence interval of this modified Mantel-Haenszel estimate and
so it is of very limited use.
7.6.2 Modified Woolf estimator
Donner and Klar [130] suggest as an alternative using the 'studentised Woolf method'.
The estimate of the overall log odds ratio Ô is exactly that given in Section 1.5.1, where
var(ö,) = (1/as) +(1/b) + (1/cj)+ (1/d), which may be rewritten as [1/(n i Pii )] +
[1/(n2P12()12)]. However, when calculating the variance of this estimate , instead
of taking the variance of each individual study separately to be v=1/w, as in Sec-
tion 1.5.1, a pooled between-stratum estimate of the variance of ö, is obtained. Hence
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2k
(183)var(0) - 
[E=1 wJ2
where 32 = E'- w1 (o_e) 2/E 1 w1 , thus taking the form common to all the weighted
techniques proposed by Donner (Sections 7.2.2, 7.2.3 and 7.3.2). In the usual Woolf
method (Section 1.5.1), when any clustering (or heterogeneity) is not taken in to
account, the individual within stratum variances v are used as opposed to a weighted
pooled estimate of the variance 	 In this way the variance of the overall treatment
effect reduces to 1/E..1 w1.
The confidence intervals constructed using this standard variance may, how-
ever, be spuriously narrow when clustering is present and thus exaggerate the preci-
sion with which treatment effects are estimated. This leads to the modification of the
estimator to produce the 'clustered Woolf estimator' which does allow for the effect
of clustering both in the point estimate and confidence interval. The intracluster
correlation coefficient p must again be estimated as shown in Section 7.2.2. Hence
the 'clustered Woolf estimator' is still a weighted average of the individual study
estimates, but with alternative weights,
-
 E
k
= wicO
CW	 k
tDic
(184)
where ô is the log odds ratio for stratum i and	 =
that is the reciprocal of the variance of Ô, with njj replaced by n,1 (Section 7.6.1).
The estimate of the variance of L can then be used to obtain the confidence limits
for this estimate and is given by
-	 (185)var(9) - 
[E=1 w•]2
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where s = E	 - L)2/ Ek 1 w,.. Again a between-stratum estimate of
var(Ô) is used rather than estimating it for each stratum separately. A simulation
study carried out by Donner and Hauck [125] with binary data suggests that the
Woolf method can be recommended for designs having six or more strata and at least
40 subjects per cluster. However, in general, the modified estimator has been found
to be more precise, that is to have a smaller mean square error, than the unmodified
estimator in the type (ii) paired cluster designs [1251.
7.7 Published Methods For Estimation in Paired Cluster
Randomised Trials When the Outcome Measure is
Continuous
Donner and Kiar [130] propose the use of either an approach based on an unweighted
paired t-test or one based on a weighted paired t-test. In the situation of a con-
tinuous outcome variable, the measure of treatment effect is the difference in means
between the two treatment groups. Using the notation and the ideas presented in
Section 7.7, estimates, variances and, therefore, confidence limits may be obtained.
For the unweighted paired t-test (Section 7.3.1), the overall estimate of treatment
effect is obviously given by =
	
;/k and then the variance of is given by
k
	 (186)
Furthermore, the weighted estimate of the overall difference is
= E w,A/	 (Section 7.3.2) and the corresponding variance is given
by (174)
As in the case of testing and estimation for dichotomous outcomes in methods where
the intracluster correlation is used, both methods outlined in this section are affected
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by the bias in the estimate of p when a treatment effect exists.
7.8 Results
The example outcome variable from the British family heart study of prevalence of
current cigarette smoking which was used when considering testing (Section 7.5) will
also be used to compare the different methods of estimation in order to see whether
the clustering must be taken into account. The three methods (modified Mantel-
Haenszel, unmodified and modified Woolf) described in Section 7.6 were considered
and compared with the Woolf method where var(Ô) = 1/wi , instead of 2, is used
to obtain var(Ô) (Section 1.5.1) and the random effects meta-analysis method using
the D&L moment estimator of o. A 'clustered Woolf method' was also considered
taking var(Ô) to be 1/wj, rather than .s, thus implying that the variance of the
estimate of the overall treatment effect would be 1/ Wj, since this would appear
to be the natural estimator for the variance of the clustered estimator.
The modified Mantel-Haenszel estimates are fairly similar to the unmodified
ones (Table 67), but the real difference would be in the precision of the two estimates.
However, since there is no apparent method of obtaining the confidence interval for
the modified estimate, then a real comparison is not possible. Furthermore, this lack
of a measure of precision on the modified estimate severely limits its usefulness.
Since there is very little intracluster correlation for the internal control group
comparison in men, all methods, both Mantel-Haenszel type and Woolf type, produce
very similar estimates as would be expected (Tables 67 and 68). However, the two
Donner and Klar Woolf methods, that is those where var(Ô1 ) is estimated by a pooled
between-stratum variance 2, produce much smaller variances of the overall estimate
than the methods using individually estimated variances (Table 68). This behaviour
is also evident in the internal control group comparison for the women, although
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Table 67: Comparison of two Mantel-Haenszel type estimates of the overall odds
ratio comparing the prevalence of cigarette smoking in the intervention group and
the control groups in the British family heart study
Mantel-Haenszel 	 Estimate of overall odds ratio
estimator	 (variance)
Men	 Women
Internal External Internal External
Unmodified	 0.784	 0.807	 0.793	 0.793
(0.0068) (0.0058) (0.0109) (0.0091)
Modified (*)	 0.784	 0.787	 0.784	 0.797
* No method for obtaining the variance
the difference in the variances between the two types of method are less noticeable
(Table 68). Hence, in the examples where there is no heterogeneity present, the
variances for the clustered estimate obtained using the between-stratum estimate of
var(Ô1) are too small, while those obtained using within-stratum estimates are too
large. Therefore, when there is no significant clustering, a standard Woolf method is
preferable to a clustered method, since the associated variance will be more reliable.
The clustered variance proposed in the literature will produce a variance which is too
small, thus providing stronger evidence of a treatment effect than actually exists.
It is in the case of the two external control group comparisons that the modified
estimates are really required since substantial clustering is present for both men and
women. For men, the clustered estimate agrees well with the random effects estimate,
with the meta-analysis estimator producing a slightly smaller overall log odds ratio
(Table 68). All variances are similar with the exception of the standard Woolf method
using individually estimated weights for each strata, which is too small. This is to be
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Table 68: Comparison of Woolf type estimates of the overall odds ratio comparing
the prevalence of cigarette smoking in the intervention group and the control groups,
together with variances, in the British family heart study
Estimator
	
	 Estimate of overall odds ratio
(variance)
Men	 Women
Internal External Internal [External
standard var(Ô) = 32	 -0.242	 -0.197	 -0.228	 -0.198
(0.0030) (0.0 119) (0.0 100) (0.0179)
standard var(Ô) = 1/wi	-0.242	 -0.197	 -0.228	 -0.198
(0.0064) (0.0055) (0.0104) (0.0088)
clustered var(à) =	 -0.242	 -0.226	 -0.240	 -0.203
(0.0030) (0.0120) (0.0099) (0.0164)
clustered var(ö) = 1/wj	 -0.242	 -0.226	 -0.240	 -0.203
(0.0072) (0.0 152) (0.0134) (0.0220)
random effects 	 -0.242	 -0.228	 -0.227	 -0.213
________________________ (0.0064) (0.0119) (0.0104) (0.0171)
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expected, since this is a fixed effect model that does not take into account the extra
random variation. It is not clear, however, why the variance for the standard fixed
effect estimate derived using 2 is so much larger than that using 1/wi , as this method
does not take account of clustering either. This point is raised in the discussion section
(Section 7.9).
When using var(ô1 ) = 1/w, the variance of the estimate of overall treatment
effect is spuriously increased in cases where heterogeneity is present due to the pre-
viously discussed bias in the estimation of p (Table 68). Although estimating var(&)
using the between-stratum variance would not appear to be based on sound statisti-
cal theory since it assumes that the variance for each strata estimate is the same, it
does appear to produce more reliable estimates for the variance of L by causing a
decrease in var(L). The variances obtained in this way are close to those obtained
from the random effects meta-analysis when heterogeneity is present. Therefore, it
appears to correct approximately for the bias in the estimate of p, although it is not
obvious how or why. This is investigated further in Section 7.9. Hence, a random
effects meta-analysis method would appear preferable when heterogeneity is present.
7.9 Discussion
Due to the fact that when a large treatment effect exists, the estimate of p is biased,
then the estimate of each weight w will also be biased downwards. The examples in
Section 7.8 show how the results obtained from the paired cluster randomised meth-
ods could be misleading, as the estimates and variances from the cluster randomised
methods do not always agree with those from the random effects methods (Table 67).
When a treatment effect is present, but there is no evidence of heterogeneity, ,3 will
be biased thus introducing extra variation which does not exist. Hence, it causes
the variance associated with the estimate of overall treatment effect, as calculated
by Donner and Kiar [130], to be too small. This additional variance will also mean
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that although the estimator of the overall treatment effect is still unbiased, the es-
timate obtained in practice may be a long way from the true value. When there
is heterogeneity present, the variance of the estimate of the overall treatment effect
may still be incorrect as the extra variation will be overestimated when a treatment
effect exists. However, by using a between-stratum estimate of var(Ô) a reasonable
estimate of the variance of 	 appears to be obtained.
In the example from the British family heart study, the treatment effect is
fairly small and hence the estimate of p will not be greatly biased. A hypothetical
trial was therefore created in order to illustrate more clearly the failings of the paired
cluster randomised methods. In this example the treatment effects, in terms of a log
odds ratio, were large (varying between -0.8 and -0.4) in each of the 13 strata, but
were also homogeneous. The Q statistic for heterogeneity was only 3.858 and so the
between-stratum variance was set to 0.
However, due to the large treatment effect, the estimate of & was 0.0041 and
so the estimate of the intracluster correlation was greater than 0. The fixed effect (or
equivalently in this example the random effects) meta-analysis estimate of the overall
log odds ratio was larger than the clustered Woolf estimate (Table 70). The reduction
in the overall odds ratio is due to the different allocation of weight between the strata
in the standard fixed effect meta-analysis method and the clustered Woolf method
(Table 71). The clustered Woolf method, because of the extra spurious variation it
introduces, gives more weight to the smaller imprecise stratum estimates, all of which
happen to be smaller than —0.5, and so the overall estimate is decreased. This exam -
ple backs up the findings from the British family heart study example (Section 7.8)
regarding var(L) as defined by Donner and Kiar [130], since var(L) obtained using
a between-stratum estimate of var(Ô) produces a value which is smaller than that
obtained using the standard fixed effect meta-analysis method. Hence, when there
is homogeneous data, using the between-stratum estimate of var(â,) produces an es-
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Table 69: Data for a hypothetical example with 13 centres where the treatment effect
is large but where there is no heterogeneity
Centre	 Events/total number of patients Odds Ratio
number	 Treated	 Control
1	 25/100(25%)
	
50/100(50%)	 0.500
2	 2/40(5%)	 5/50(10%)
	
0.500
3	 60/250(24%)	 80/200(40%)	 0.600
4	 20/200(10%)	 45/200(22.5%)	 0.440
5	 6/50(12%)	 6/25(24%)
	
0.500
6	 25/150(16.7%)	 40/150(26.7%)	 0.625
7	 55/500(11%)	 100/500(20%)	 0.550
8	 75/300(25%)
	
150/400(37.5%)	 0.667
9	 2/50(4%)	 4/50(8%)	 0.500
10	 100/600(16.7%) 150/600(25%)	 0.667
11	 12/100(12%)	 25/100(25%)	 0.480
12	 14/200(7%)	 30/200(15%)	 0.467
13	 75/800(9.4%)	 75/500(15%)	 0.625
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timate of var(Ô,,) which is too small. However, it is a better estimate of var(L)
than that which would be obtained if the within-strata variance estimates were used
leading to var(L) being equal to 1/ w. This estimate would be too large, and
in this particular example would be far too large, taking the value 0.74 (Table 70).
Table 70: Comparison of Woolf type estimates of the overall odds ratio in the hypo-
thetical example and the diuretics trials example
Estimator	 Estimate of overall log odds ratio (Ô)
(variance)
_______________________ Hypothetical 	 Diuretics trials
standard var() =	 -0.52	 -0.40
(0.036)	 (0.072)
standard var(Ô) = 1/wi	-0.52	 -0.40
(0.004)	 (0.008)
clustered var() =	 -0.60	 -0.57
(0.002)	 (0.082)
clustered var() = 1/wj	 -0.60	 -0.57
(0.74)	 (1.308)
random effects	 -0.52	 -0.51
_________________________	
(0.004)	 (0.042)
standard estimate=...1 wã/E.1 w
clustered estimate=...1
The diuretics trial data (Section 1.3.1) (even though it is not of a paired cluster
randomised design) may be used as a second example, by considering each group to
be a cluster, to illustrate what occurs when there is both a large treatment effect and
a large amount of heterogeneity in the data. In this case, therefore, a trial represents
a stratum and a treatment group a cluster. Due to the large amount of heterogeneity
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Table 71: A comparison of the percentage weight allocated to each centre in the
random effects meta-analysis method and the paired cluster randomised method for
the hypothetical example and the diuretics trials example
Centre	 Percentage of total weight
number	 (w/.1 w) x 100
	
Hypothetical example	 Diuretics trials
Random effects Cluster Random effects Cluster
estimate (*)	 estimate	 estimate	 estimate
1	 5.3	 12.0	 10.7	 9.7
2	 0.6	 3.7	 11.9	 7.3
3	 11.0	 11.4	 10.2	 21.9
4	 5.1	 6.9	 7.9	 17.7
5	 1.1	 7.6	 12.1	 1.9
6	 5.4	 9.1	 17.0	 10.4
7	 13.1	 7.0	 11.8	 3.3
8	 16.3	 11.4	 4.5	 2.9
9	 0.5	 3.1	 13.9	 24.9
10	 21.0	 9.0
11	 2.9	 7.7
12	 3.7	 5.1
13	 14.0	 6.0
* Since the estimate of the between-study variance is 0 the random effects model
is the same as the fixed effect model in this example
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both the meta-analysis estimate of the between-stratum variance and the intracluster
correlation are greater than zero. The estimates of the overall log odds ratio and their
variances are different using the different methods. As for the previous example it may
be seen that the weights are allocated in different ways in the two different methods
(Table 71) with the clustered method appearing to allocate higher weights to the
trials with the largest event rates, that is the largest P,, rather than those with the
greatest precision. The clustered method produces a point estimate which is between
the fixed effect and the random effects estimates. The variance of Ô calculated as
proposed by Donner and Kiar [130] is considerably larger than the variance obtained
from the random effects model (Table 70). However, if 1/ w were to be used
instead, the variance would be far too large because of the large inflation in the value
of 3. This example shows that in the presence of a large amount of heterogeneity
and a large treatment effect the clustered Woolf method, even with the adjustment
to the var(L) of using s, may produce a variance for the overall estimate which is
too large (Table 70).
This effect of an underestimation of the variance when there is no hetero-
geneity but an overestimation when there is heterogeneity is due to the use of a
between-stratum estimate of var(Ôj. This appears to be an approximate way of
correcting for the bias in the estimate of p, since without this adjustment the vari-
ances using 1/ w would be far too large. This correction may be adequate
when there is a small treatment effect, as in the example from the British family
heart study (Section 6.3.3), but is obviously poor when a large treatment effect ex-
ists, irrespective of the amount of heterogeneity. The reason for the differences in the
variances of Ô using 2 compared to the individual v, is the difference in the values
that an average within-stratum variance and a between-stratum variance estimate
takes. When there is no heterogeneity a between-stratum estimate will be smaller
than the average within-stratum estimate. However, when there is heterogeneity, the
between-stratum estimate will tend to be large and will produce an estimate which is
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larger than the average within-stratum estimate (Table 72). It should be noted that
for the hypothetical example the mean variance is simply as oj=O.
Table 72: Comparison of the mean within-cluster estimate and the pooled estimate
of var(Ô)
Example	 Average within-study	 Pooled
variance (v + o)	 variance (s)
Hypothetical	 0.19793	 0.01912
Diuretics trials	 0.42505	 0.48354
7.10 Conclusion
For estimation of an overall treatment effect, meta-analysis methods applied to paired
cluster randomised designs have a clear advantage over the methods supposedly de-
signed specifically for such trials discussed in this chapter. It has been shown that the
estimation methods relying on the estimation of an intracluster correlation are biased
when a large treatment effect exists. The adjustment to the variance which is appar-
ently made to correct for the bias in is not founded on solid statistical theory and,
is in any case, unreliable when the treatment effect is large and there is considerable
heterogeneity. Hence, as was shown in the two examples of Section 7.9, conclusions
drawn from the analysis can be misleading. Under conditions of homogeneity, the
variances used by Donner and Kiar [130] will produce confidence intervals which are
too narrow and hence the possibility of obtaining a spurious significant result exists.
On the other hand, if heterogeneity is present, then the increased variance may lead
to a conservative interpretation of the findings. The random effects meta-analysis
method does not have the problem that the random variation is influenced by the
size of the treatment effect, because the treatment effect and the between-study vari-
ance are estimated separately. Hence, meta-analysis methods are an improvement on
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the standard methods in the analysis of paired cluster randomised trials.
With respect to testing the null hypothesis H0 : 0 = 0, then depending on the
amount of heterogeneity present, different tests are more suitable than others under
different conditions. If homogeneity can be assumed, then the Mantel-Haenszel test
is optimal [38], while at the other extreme, if there is considerably larger between-
cluster than within-cluster variation, a simple unweighted t-test is adequate. Due to
the small amount of variation within each cluster such a case is effectively equivalent to
obtaining a single observation from each cluster. Between these two contrasting cases,
where there is some heterogeneity, a weighted procedure is perhaps most suitable,
since it takes account of both types of variation, which is what is required when
neither dominates. However, due to the bias in the estimate of p and the inadequacy
of the correction to the variance of the overall treatment effect using a between-cluster
estimate of uar(è), the tests will lack power when heterogeneity exists. Hence, a test
based on the random effects model of Section 2.2), and similar to that proposed by
Rosner, is probably more reliable for all situations and will reduce to the standard
fixed effect test under homogeneity.
Hence, overall for both testing and estimation, the use of meta-analysis tech-
niques in the analysis of paired cluster randomised trials provides a clear improvement
over the method currently proposed in the literature. There is a fundamental flaw
in the procedure for the estimation of the intracluster correlation. Although such
methods may be adequate in certain cases, they are in general unreliable and may
produce misleading results in many circumstances.
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8 Conclusions
The research outlined in this thesis has covered various different statistical issues
relating to meta-analysis in medical research, and has also shown how a meta-analysis
approach is useful in the analysis of multicentre trials and paired cluster randomised
trials. This final chapter contains a summary of the conclusions from each of the
previous chapters and brings some of the ideas together in a more general discussion
and also highlights the practical implications.
In Chapter 1 the two standard meta-analysis models were introduced, that is
the fixed effect and the random effects models, and the drawbacks of each of these ap-
proaches was highlighted. This served as a starting point for the development of much
of the research in the following four chapters. Chapter 2 focused on the random effects
model and introduced a likelihood approach to meta-analysis based on the marginal
likelihood of each trial. It is concluded that such an approach may be required in
practice, particularly in situations where the between-study variance is imprecisely
estimated and if changes in the between-study variance have an effect on the estimate
of the overall treatment effect. Sensitivity plots, described in Section 2.1, are useful
not only in their own right for the purpose of investigating the robustness of the con-
clusions drawn from the standard meta-analysis models to changes in 4 but also for
investigating whether a likelihood method may be required. It is necessary to carry
out such checks as the use of the likelihood model may lead to a more conservative
interpretation of the effectiveness of the treatment due to a wider confidence interval
for 9 being obtained. Unlike the standard random effects model, this likelihood model
also allows a confidence interval to be obtained for the between-study variance so that
the precision of this estimate may be summarised directly. In practice, ô was often
found to be imprecise, thus reinforcing the need for a sensitivity analysis.
This marginal likelihood approach was also compared with the Mantel-Haenszel-
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type likelihood approach of van Houwelingen et al. [45] which is based on the exact
distribution of each triafs 2x2 contingency table (Section 2.4). Although this full
likelihood model is a better representation of the data than the marginal likelihood,
and furthermore does not make the assumption about weights being known, the re.
suits from the two methods have, for the examples considered, been found to be
comparable. However, the Mantel-Haenszel-type method does have the advantage of
being able to deal with zero event rates and small frequencies (Section 2.5) unlike the
marginal likelihood method where empirical logits would be required in the presence
of small frequencies. On the other hand, the marginal likelihood method is more flex-
ible in that it can be used to analyse continuous as well as binary outcome measures.
Overall, in most situations where either method could be used, the two likelihood pro-
cedures will produce very similar results. Hence, in general the choice between the
methods may depend more on the practical concerns regarding the implementation
of the procedures (Section 2.8).
Empirical Bayes or fully Bayesian approaches offer alternative ways for con-
sidering the meta-analysis problem. Empirical Bayes estimates may be more useful
in practical terms than an estimate of the overall treatment effect when a range of
estimates that could be obtained is required to make clinical judgements about the
appropriateness of treatment. A fully Bayesian approach has the advantage that it
overcomes the need for having to make the controversial assumption that the trials
included in a meta-analysis are a random sample from a large population of trials. A
Bayesian approach, however, is considerably more computer intensive than either the
standard fixed effect or random effects approaches, or even the likelihood methods.
The Bayesian meta-analysis literature does provide discussion on ways of looking at
the robustness of the conclusions from the meta-analysis. Indeed, sensitivity analyses
and the checking of assumptions have been discussed more in the Bayesian than the
classical framework, but work in this thesis has shown ways in which the conclusions
may be checked for robustness and the modelling assumptions in a classical statistical
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approach.
Part of this work was described in Chapter 3 which set out to provide ways
in which to check the assumption of normality, an assumption necessary to produce
confidence intervals for both the fixed effect and random effects estimate of the overall
treatment effect. The use of q-q plots of the q1 and of the q components of Q were
proposed to check these assumptions. Furthermore, a test of the null hypothesis
qi N(1a, 1) using an Anderson-Darling statistic was found to be the best test of the
normality assumptions. It can test the gradient of the plot as well as the linearity, thus
enabling it to distinguish between a fixed effect and a random effects model on a fixed
effect plot as well as being able to detect non-normality. In general, consideration of
both plots and the results of the Anderson-Darling test for normality is adequate to
establish whether the data follow either of the standard normally distributed models.
However, if it has been established that a set of data does not follow either of the
standard normally distributed models, the question of how to proceed then arises.
Further research, which could build on that presented in Chapter 3, is required to
investigate whether the invalidity of the normal assumptions can affect the results of a
meta-analysis. This could take the form of an investigation into the robustness of the
results to deviations from the standard models using simulation methods such as those
used in Chapter 3. Alternatively, the results from a non-parametric approach, such as
that of van Houwelingen et al. [45J could be compared to those from standard methods
under various alternative models. Further investigation into the use of alternative
distributions for the random effects is also required.
Both plots and tests were found to be of limited use when the number of trials
in the meta-analysis was small, for example when k=9 in the diuretics trials data.
The q-q plots may still be useful, however, in identifying sources of heterogeneity
which can then be investigated, although the same information may also be derived
from a Gaibraith plot [661. In practice, a meta-analysis should always be accompanied
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by investigations of the modelling assumptions and sources of heterogeneity, as well
as by sensitivity analyses. Once heterogeneity has been identified work should be
undertaken to try to explain the reasons behind the observed variation in terms of, for
example, trial characteristics, population differences and geographic differences. By
identifying trial-specific characteristics which explain the variation in treatment effect
the analysis can be reduced to an analysis of homogeneous sets of data. Although
the explanation of heterogeneity may be a commendable aim in principle, however, it
can be difficult to accomplish satisfactorily in practice as exemplified by the analysis
of the British family heart study in Chapter 6. Furthermore, it should be borne
in mind that such investigations are always post-hoc and any resulting explanations
will usually have been motivated by the observation of the data themselves. Hence,
caution should be expressed in any conclusions drawn, particularly when there may
be several alternative but equally feasible explanations. The findings from these
investigations may be useful for motivating future research by identifying subgroups
of patients for whom the treatment may be more, or less, effective. Ideally factors
which are possible causes of heterogeneity should be identified prior to the actual
analysis and prior to observation of the data, although this is not always realistic
in practice. This is in line with the suggestion that a protocol should be drawn up
before a meta-analysis is carried out [61, in a similar way to a protocol for a clinical
trial, outlining how the meta-analysis is to proceed.
The choice between a fixed effect or a random effects approach, is often based
on the result of the test, using Q, of heterogeneity of the Ô 1 . However, it was shown
in Chapter 4 how the power of the test may be particularly low in certain conditions.
It was also shown that a test proposed as an improvement to Q [110] was found to
provide no substantial increase in power. Furthermore, the null distribution of this
alternative statistic remained unclear, and hence the test using Q was still regarded
as preferable. The power of the test for heterogeneity Q was found to be poor when
the total amount of information available in the meta-analysis 	 w was small, due
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to either k being small or the trial estimates being imprecise, that is having large v.
However, situations where extra care in the interpretation of the test result , required
arewhere there is an uneven distribution of the weight between trials. This is because
the power of the test was found to be particularly poor, for a given total amount of
information and a given amount of between-study variation, when one trial took most
of the weight and the other trials all produced very imprecise estimates of treatment
effect. Hence, investigation of heterogeneity should be considered, particularly in such
cases as that outlined above, even in the presence of a non-significant result for the
overall test of heterogeneity.
Chapter 5 served to illustrate, in the context of continuous outcome mea-
sures, that problems may be caused by the assumption made in both the standard
meta-analysis methods that the weights are known as opposed to estimated. It was
concluded that the variances of both fixed effect and random effects estimates of
overall treatment effect are incorrect when w are estimated. This may lead to a
false certainty in the conclusions drawn from the fixed effect method in that the
confidence interval obtained will be spuriously narrow. The confidence interval for
the random effects model tends to be spuriously large due to the overestimation of
the between-study variance. In practice, the effect will often be negligible, although
caution is required when all or some of the n are small. It may be better to use the
alternative methods for calculating the results which are based on the assumption
that ti)j is known and is equal to fw, that is the expectation of thj where f is a
correction factor for the estimation equal to (n - 1)/(n - 3), rather than equal to
simply w1 . In certain circumstances, that is when n1 are reasonably large the adjusted
approximate results presented in Chapter 5 offer improvements in the performance.
Further work is, however, required to refine the estimates to allow exactly rather than
approximately for the estimation of w, and also to investigate the effect of the esti-
mation of w on meta-analyses with binary outcome measures. However, this problem
may perhaps more usefully be investigated further by a comparison of the standard
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ineta-analysis results with those from the Mantel-Haenszel-type likelihood model of
van Houwelingen et a!. [45J.
It has been shown in this thesis how meta-analysis methods may be used to
analyse single clinical trials with multiple centres, thus allowing for the possibility
of variations in treatment effect across centres. Individually randomised trials may
obviously be analysed in such a way by considering each centre as a 'trial', but so
may paired cluster randomised trials as shown in Chapter 6 in relation to the British
family heart study. It has been shown how difficult it may be to understand the
reasons for any heterogeneity observed, particularly in multicentre trials where any
practical differences between centres are less obvious due to the fact that all centres
follow the same protocol. Hence, it may be concluded that in certain cases, such as
the British family heart study, the variation can reasonably be considered as random,
and a random effects model will provide the most satisfactory approach to analysis.
Analysing such trials as the British family heart study also raises the problem
of multiple outcome measures. This issue was briefly considered in relation to the
analysis of the British family heart study, in Section 6.5. A directional test of the null
hypothesis that each outcome in each trial is zero may be useful in certain circum-
stances (Section 6.5.3) as it produces a test of the overall impact of the treatment.
A generalised least squares model based on effect sizes (Section 6.5.2) may also be
of some use in homogeneous sets of data, particularly where different outcomes are
measured in different studies. However, further research is required on this topic to
provide satisfactory solutions by extending the procedure to cope with random effects
and different measures of treatment effect.
A random effects meta-analysis approach to the analysis of paired cluster ran-
domised trials is certainly to be recommended over other methods which have been
specifically designed for the analysis of such trials (Chapter 7). Approaches to both
testing (Sections 7.2 and 7.3) and estimation (Sections 7.6 and 7.7) using the concept
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of the intracluster correlation p (Section 7.1) were found to be biased in circum-
stances where a large treatment effect exists. This bias is due to the estimate of p
being confounded by the estimate of the treatment effect, and hence such procedures
may produce very misleading results. Although the corresponding tests are still valid
under the null hypothesis of no treatment effect, they will be of low power. In terms
of estimation, the confidence intervals for the estimate of the overall treatment effect
can be incorrect (Section 7.6). In homogeneous sets of data, heterogeneity may be
introduced due to the bias in and confidence intervals which are too wide may be ob-
tained, thus leading to the increased possibility of a misleading nonsignificant result.
The opposite effect occurs when heterogeneity is present in that the confidence inter-
val obtained is too narrow due to an overcorrection in the calculation of the variance
of the estimate of the overall treatment effect for the bias in . The random ef-
fects meta-analysis approach has no such problems as it estimates the between-centre
component of variation separately from the treatment effect. The generalisation of
the paired t-test proposed by Rosner (Section 7.3.3) is more reliable since it is not
based on the intracluster correlation. In fact, the model on which the test is based
is that of the marginal likelihood of Section 2.2, where the quadratic approximation
(Section 2.3.4) is made.
Meta-analysis methodology is useful for both combining information from dif-
ferent centres in a single trial as well as from different trials in a true meta-analysis. It
is likely that the need for meta-analyses will grow in the future, partly because smaller
treatment benefits will require detection, and also because carrying out single trials
which are large and powerful enough may not be practical. Development of computer
software for meta-analyses should not obscure the need for careful consideration in
every specific analysis as to which trials to include, and also whether the trials can
meaningfully be combined to produce an overall estimated treatment effect. Further-
more, an investigation of heterogeneity should always be included in any analysis. If
no feasible explanation of heterogeneity is possible then a random effects analysis may
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be the best practical alternative when heterogeneity exists, certainly more appropri-
ate than a fixed effect estimate, since it does produce more appropriate confidence
intervals, providing the distributional assumptions are valid. However, standard re-
sults are best accompanied by a sensitivity analysis indicating how the conclusions
change as the between-study variance changes. Hence, meta-analyses cannot simply
be reduced to the following of a set formula, whereby an overall estimate is obtained
without cautionary investigations and discussion relevant to the individual case. Both
the fixed effect and the random effects models are not ideal, but they will, in gen-
eral, produce reliable results provided they are used in conjunction with appropriate
supporting investigations and interpreted with the required degree of caution.
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